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Background: Perianal fistulae are common and cause significant symptoms and 
psychosocial morbidity. Current theory suggests two distinct types: idiopathic (no 
established cause) and secondary, which usually arise from Crohn’s disease. 
Research to date has assumed that idiopathic and Crohn’s perianal fistulae differ in 
their pathogenesis and pathophysiology. This fundamental hypothesis has not yet 
been adequately tested. We therefore aimed to test the broad hypothesis that 
idiopathic and Crohn’s perianal fistulae differ in their pathogenesis and 
pathophysiology. 
Methods: We prospectively recruited a cohort of 61 participants (48 idiopathic, 13 
Crohn’s disease) and phenotyped them in detail using clinical assessment, Perineal 
Disease Activity Index, EQ-5D-5L, dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI), operative assessment, biopsy, and clinical follow-up. We 
interrogated the biopsy samples in the laboratory to characterize their profiles for 30 
cytokines and 39 phosphoproteins. Over 12,000 clinical and 23,500 laboratory 
measurements were made. 
Results: We found no clear differences in the clinical characteristics or the overall 
cytokine or phosphoprotein profiles between idiopathic and Crohn’s perianal fistulae. 
We also found no differences in the DCE-MRI measurements between the groups.  
Conclusions: We did not find good evidence to support our hypothesis. The 
alternative hypothesis offers a shift in the current research paradigm: idiopathic and 
Crohn’s perianal fistulae are the same pathology on a spectrum across which the 
pathogenic and pathophysiological features are distributed in a skewed manner. This 
may be the key to unravelling our understanding of the disease’s aetiology. It would 
also be a construct within which trials of biological therapy, such as infliximab, 
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Figure 41 DCE-MRI measurements sub-grouped by Parks’ classification. Max 
enhancement mean difference 449 (95% CI = 36–863; p = 0.04), max relative 
enhancement mean difference 0.522 (0.056–0.988; p = 0.03), area under TIC mean 
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1.1 History of Perianal Fistula Disease 
A perianal fistula is an abnormal tract that communicates between an internal 
opening in the anal canal and an external opening on the perianal skin. This tract 
penetrates through intervening structures, which importantly include the anal 
sphincters. It is a condition that has troubled Mankind for millennia. Indeed, in 400 
BC, Hippocrates described two strategies for treating perianal fistula: 
“Taking a very slender thread of raw lint, and uniting it into five folds of the length 
of a span, and wrapping them round with a horse hair; then having made a director 
(specillum) of tin, with an eye at its extremity, and having passed through it the end 
of raw lint wrapped round as above described, introduce the director into the fistula, 
and, at the same time, introduce the index finger of the left hand per anum; and when 
the director touches the finger, bring it out with the finger, bending the extremity of 
the director and the end of the threads in it, and the director is to be withdrawn, but 
the ends of the threads are to be knotted twice or thrice, and the rest of the raw 
threads is to be twisted around and fastened into a knot… 
“When the fistula does not get eaten through, having first examined it with a sound, 
cut down as far as it passes, and sprinkle with the flos aeris, and let it remain for five 
days…But it does not heal unless it be cut open.” (Hippocrates 400 BC) 
Despite intervening millennia with advances in knowledge and technology, these two 
operations remain essentially unchanged and are still the mainstay of modern-day 
perianal fistula management: the insertion of a seton* and the fistulotomy. This fact 
is testament to the incredible insight of Hippocrates, the father of modern medicine. 
                                               
 
* Apparently from Latin seta meaning ‘bristle’ (Pearsall 1998, p.1702) 
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It is also an indictment of our collective failure to discover better alternative 
treatments. 
In 1376, the English surgeon John Arderne (1307–1390) wrote systematically and in 
depth on the subject in Treatises of Fistula in Ano, Haemmorhoids, and Clysters 
(Arderne and Power 1910) and is credited for describing the modern fistulotomy for 
the first time. In 1686, Louis XIV developed a perianal fistula. This was treated by 
fistulotomy by barber-surgeon Charles-François Felix, who took six months (and 
several unethical trials on prisoners and peasants, many of whom died) to prepare for 
the operation. In his preparatory experiments he also invented an anal retractor and a 
curved scalpel to use (Figure 1). The operation was a success and many of the king’s 
subjects took to wearing swathes of bandages around their buttocks, known as le 
royale, in homage to his bandaged bottom (Littman 2014). 
 
Figure 1 Anal retractor (left) and curved scalpel invented by Charles-François Felix in 1686. 
Much of our current knowledge and theories on perianal fistula disease is owed to 
several prominent surgeons at the turn of the 20th century. Goodsall and Miles, 
Milligan and Morgan, Thompson, and Lockhart-Mummery all contributed to theories 
on pathogenesis and classification, and standardized surgical treatment. Later in the 
1960s and 70s, Parks, a consultant surgeon at the Royal London and St Mark’s 
Hospitals, contributed a large body of work to improving our ideas around 
pathogenesis and classification. 
However, despite the weight of history, which even includes the establishment in 
1835 of a whole hospital devoted to the study and treatment of fistula-in-ano namely 
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St Mark’s Hospital, the aetiology of perianal fistulae is still not clear, and for many 
patients, a cure has not yet been found. 
1.2 Anatomy 
A detailed knowledge of the pelvic floor, anal sphincters and perineum is essential to 
understanding the nature of perianal fistula disease. It is useful to think of the anal 
canal as the terminal part of the intestine, with all its layers present: mucosa, 
muscularis mucosae, circular muscle, and longitudinal muscle (Figure 2). As the 
rectal tube descends in the pelvis it encounters the pelvic floor, which is a bowl-
shaped sheet of muscle, comprising the levator ani and puborectalis, slung across the 
pelvic outlet. Below the pelvic floor is ischioanal fat and perineal skin. The rectal 
tube penetrates the pelvic floor and in doing so carries some of the pelvic floor 
muscle with it, traversing down through the ischioanal fat to the perineum. Thus a 2–
5 cm cylinder of muscle encircles the tract from the pelvic floor to the anal verge. 
This is defined as the surgical anal canal. 
 
Figure 2 Coronal section of the pelvic floor, demonstrating the origin of the anal canal as a continuation of 
the rectum above and its relationship with the pelvic floor and external sphincter, with the inter-
sphincteric plane existing between these two embryologically separate entities. For simplification, the 
longitudinal layer has been omitted. Source: Parks et al. 1976. 
The circular muscle in the anal canal is hypertrophied and is called the internal 
sphincter. It comprises involuntary smooth muscle and exerts a constant pressure to 
maintain continence. The longitudinal muscle surrounding this is in most cases a thin 
layer of smooth muscle. The cylindrical projection of pelvic floor muscle that 
There are two large paravisceral compartments 
separated by the levator muscles (Fig. 4). Above is 
the pararectal space, and below, the ischiorectal 
fossa; both contain fat. Once a fistula has penetrated 




Fig. 4. Coronal section of the pelvic floor demonstrates 
once more the dual origin of the structures and, in particular, 
i t  illustrates the intersphincteric plane, the ischiorectal fossa 
and the pararectal space. The longitudinal layer of the 
rectal wall and anal canal has been deliberately omitted for 
the sake of simplification. 
Fig. 5. Photograph of a thick slice of the anorectal ring 
which shows the internal sphincter, external sphincter and 
intersphincteric plane particularly well. The fat of the 
ischiorectal fossa is also clearly visible. 
Classification of fistula-in-an0 
the wall of the viscus (i.e. the anal canal) it can 
ramify extensively in these spaces. Spread in the ischio- 
rectal fat is common, but occasionally a track will 
pass upwards through the levator plate into the 
pararectal compartment. It is not generally appeciated 
that the ischiorectal fossa extends higher than the 
upper border of the anal canal because of the upward 
direction of the levator funnel. A fistula extension in 
the top of the ischiorectal fossa will cause induration 
which can be felt digitally above the anorectal ring 
through the rectal wall (Fig. 2). This high para- 
visceral extension is often the cause of some, usually 
unwarranted, apprehension. 
The two muscle cylinders, visceral and somatic, are 
separated by the intersphincteric plane (Fig. 5) .  This 
plane is a layer of embryonic fusion containing mostly 
areolar tissue and blood vessels. Infection spreads in 
it with great ease and an understanding of its relation- 
ships is essential in the operative treatment of fistulas. 
Pathogenesis 
It is difficult to understand the paths taken by anal 
fistulas without a brief consideration of present 
concepts of pathogenesis. In 1878 Chiari first described 
the anal ducts or glands which discharge at the muco- 
cutaneous junction of the anal canal into the anal 
crypts (Fig. 6). Since then much discussion has taken 
Fig. 6. Photograph of a thick section t h r o G h T e  anal canal 
showing an anal duct penetrating the internal sphincter to 




encircles the anal canal is called the external sphincter. It comprises striated muscle 
also exerts a pressure to support continence, and provides reflex and voluntary 
sphincter control. The inter-sphincteric plane separates the longitudinal muscle and 
the external sphincter. It is a potential space that acts as a conduit, allowing pus to 
track cranially, caudally and circum-anally, and explains why we observe a wide 
variation in the anatomical configurations of perianal fistulae. This pathophysiology 
is detailed later on. 
The anal canal mucosa contains longitudinal folds. These give rise to ridges and 
grooves called the columns of Morgagni and the anal crypts respectively. The lower 
border of this mucosal feature appears as a scalloped white line called the dentate 
line.  
The mucosa within the anal canal contains the fusion of the endoderm-derived 
simple columnar epithelium of the gut above with the ectoderm-derived stratified 
squamous epithelium of the perineal skin below. Descriptions of the structure of the 
epithelium within the anal canal vary in textbooks. Most anatomists are of the 
opinion that there is an intervening transition zone that consists of either transitional 
epithelium, stratified columnar, or cuboidal epithelium, and that the dentate line 
represents the embryological site of transition. However, a recent study involving 
intact parts of the rectum and anus from 13 patients who underwent resection for 
carcinoma elegantly demonstrated the true histology of the anal canal using scanning 
electron microscopy. Tanaka et al. (2012) found that the anal canal epithelium starts 
at the anorectal line, which can be seen macroscopically and lies below the level of 
the pelvic floor (the anorectal ring), and terminates at the same level as the 
termination of the internal sphincter (the anal inter-sphincteric groove). Above the 
anorectal line, the epithelium is clearly continuous with the simple columnar 
epithelium of the rectum. Below the anal inter-sphincteric groove, the epithelium 
contains skin appendages such as hair follicles. Between these two landmarks exists 
the anatomical anal canal. Tanaka et al. did not demonstrate a transition zone. Rather 
they clearly showed stratified squamous epithelium devoid of appendages, with 




Figure 3 Coronal section of the anal canal and rectum, showing the distribution of the different types of 
epithelium found. Source: Tanaka et al. 2012. 
Parks (1961) used light microscopy to study the structure of the anal glands in 44 
operative specimens retrieved after resection for various nearby diseases that did not 
involve the anus (e.g. radical excision for carcinoma of the rectum). He found 
between 6–10 anal glands within the internal sphincter around the anal 
circumference. Each gland was lined by stratified columnar epithelium and 
discharged into an anal crypt, also lined by stratified columnar epithelium. The 
glands also branched immediately into a racemose structure of widely ramifying 
ducts. These branches could extend into the internal sphincter and sometimes 
through it into the longitudinal layer. 
1.3 Classification 
Parks’ Classification 
Again it fell to Parks to devise the classification of perianal fistulae that we use 
today. Prior to this, classification focused on the relationship of the tract to the 
puborectalis muscle. However this was ill defined and ambiguous. Parks et al. (1976) 
a b
Fig. 11. Stratifi ed columnar 
epithelium (SEM). Bars 6 µm
Fig. 12. A simplifi ed schema 
showing the epithelium of the 
surgical anal canal based on LM 
and SEM
Fig. 13. Endoscopic fi ndings 
of the anal canal. a Infl ated 
rectum fi lled with feces or gas. 




embarked on a large cohort study involving 400 consecutive patients with perianal 
fistulae. His previous work brought the understanding that the primary focus of the 
disease starts in the anal glands and therefore at the level of the dentate line. With 
this in mind, he carefully documented in each patient the relationship of the primary 
tract to the external sphincter. He found that all fistulae could be classified into four 
main types: inter-sphincteric, trans-sphincteric, supra-sphincteric and extra-
sphincteric (Figure 4). Superficial fistulae were excluded as he thought they did not 
arise from the anal gland. 
 
Figure 4 Four main anatomical types of perianal fistula with their prevalence (%). Type 1, Inter-
sphincteric; type 2, trans-sphincteric; type 3, supra-sphincteric; type 4, extra-sphincteric. Source: Parks et 
al. 1976. 
Inter-sphincteric. This was the commonest type (45%). An inter-sphincteric fistula 
traverses the internal sphincter only. It does not extend outside the inter-sphincteric 
plane. In most patients the tract descends straight downwards in the inter-sphincteric 
plane to the anal verge. However there is considerable variation in its course: it can 
extend upwards towards the rectum and the para-rectal space, or it can horseshoe 
around in a circum-anal direction, or it can branch to give rise to secondary tracts. 
Trans-sphincteric. This was the second commonest type (30%). Here the primary 
tract crosses both sphincters. The level where the tract crosses the internal sphincter 
is relatively constant (i.e. the dentate line) because it arises from the anal gland and 
its duct. However, once the tract is in the inter-sphincteric plane it courses in any 
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the track to the anal sphincter muscles for the reason 
that current treatment involves section of a varying 
part of these structures, preservation of some of which 
is essential for the maintenance of rectal continence. 
Both internal and external sphincters play a part in 
this mechanism, but in practice when dealing with 
fistulas the more important is the external sphincter 
and puborectalis. In the following classification, 
therefore, the external sphincter is taken as the key- 
stone. For example, the term ‘trans-sphincteric’ (Fig. 
9, type 2 )  refers to a track passing through the 
external sphincter group below the level of the pubo- 
rectalis (after Steltzner, 1959). If in such a case the 
classic treatment of surgical lay-open is performed, 
only part of the muscle group need be cut, as it is only 
the muscle distal to the track which is divided, while 
the portion above it can be left intact. A ‘supra- 
sphincteric’ track (Fig. 9, type 3) passes over the 
entire external sphincter group including the pubo- 
rectalis muscle before turning downwards between 
the puborectalis and levator ani muscles into the 
ischiorectal fossa. Laying open this type of fistula 
will result in division of all the muscles of con- 
tinence. 
It was found that all fistulas could be classified into 
four main groups (Fig. 9): 
I .  Intersphincteric in which the fistula ramifies only 
i n  the intersphincteric plane; i t  is the commonest of 
all types (and is sometimes known as the ‘low anal’ 
fistula). 
2.  Truns-sphincteric. Here the track passes from the 
intersphincteric plane through the external sphincter 
complex at varying levels into the ischiorectal fossa. 
3.  Suprasphincteric. In this group the track passes 
in  the intersphincteric plane over the top of the pubo- 
rectalis, then downwards again through the levator 
plate to the ischiorectal fossa and finally to the 
skin. 
4. Extrasphincteric. A track passes from the 
perineal skin, through the ischiorectal fat and levator 
muscles into the rectum. I t  is outside the external 
sphincter complex altogether. 
The first of these does not involve the external 
sphincter at all since the fistula runs between the 
internal and external sphincters in the intersphinc- 
teric plane. Treatment involves cutting the internal 
sphincter only, the external sphincter remaining 
untouched. In the other three categories the fistula 
passes through, over or outside the external sphincter 
and puborectalis muscle and the classic method of 
treatment involves cutting part of this muscle mass. 
All the fistulas pass through the internal sphincter, 
except certain extrasphincteric varieties to be discussed 
later. * 
Detailed analysis of results 
The incidence of the four main types is shown i n  
Fig. 9. These will now be discussed in more detail. 
* The shallow subcutaneous fistula, which is sometimes 
associated with the lower border of an anal fissure and which 
requires no treatment, is not included in this analysis. 
Type 3 
Fig. 9. The four main anatomical typcs of fistula. The 
external sphincter mass is regardcd as the keystone and the 
terms ‘trans-’, ‘supra-’ and ‘extra-’ refer to it. Type I ,  
Intersphinteric; fype 2, trans-sphincteric; fype 3, 
suprasphincteric; rypc 4. extrasphincteric. 
Fig. 10. The simple intcrsphincteric fistula, the commonest 
of all types. In the acute phase it presents as a perianal 
abscess. It does not cross the external sphincter a t  any part 
of its course. 
Type I : Intersphincteric jistulu 
There were 183 cases (45 per cent) which can be sub- 
classified into seven varieties. 
a. Simple intersphincteric Jistulu (137 cases): In this 
variety a track passes from the primary abscess in the 
intersphincteric plane straight downwards to the anal 
verge (Fig. 10). It is the commonest of all types of 
fistula and is usually referred to as ‘low anal’ in 
standard British surgical textbooks. In treating it by 
current methods only the lower half of the internal 
sphincter has to be divided and this seldom gives rise 
to any disturbance of function. In the acute phase this 




direction (up, down or around). Thus the level where the tract perforates the external 
sphincter is variable. Most commonly this is at a low level but it can also be as high 
as the proximal external sphincter, just below the puborectalis. Again secondary 
tracts can branch off in the inter-sphincteric plane, giving rise to inter-sphincteric 
tracts, para-rectal tracts and secondary external openings anywhere on the anal verge. 
Secondary tracts can also branch off after the fistula has traversed the external 
sphincter, which result in ischio-rectal abscesses, infra-levator tracts, trans-levator 
tracts and secondary external openings anywhere on the perineum, including the 
scrotum or labia. 
Supra-sphincteric. These accounted for 20% of fistulae. Supra-sphincteric fistula 
similarly start by crossing the internal sphincter at the level of the dentate line. Upon 
reaching the inter-sphincteric plane, they course upwards above the level of the 
puborectalis. This part of the fistula may form a horseshoe around the rectum before 
perforating the levator plate and descending down through the ischio-rectal fossa to 
exit on the perineum. Again secondary tracts can ramify from the primary tract in the 
inter-sphincteric plane, para-rectal space and ischio-rectal fossa. 
Extra-sphincteric. These were the least common fistulae (5%). In affected patients, a 
trans-sphincteric fistula gives rise to a secondary tract in the ischio-rectal fossa, 
which then courses upwards, perforating the levator ani and the rectal wall to re-enter 
the intestinal lumen. However, iatrogenic trauma can also give rise to this 
morphology, whereby the operating surgeon probes a trans-sphincteric fistula with a 
high secondary extension, and mistakenly forces a false passage upwards into the 
rectum. Caution also needs to be given to the extra-sphincteric fistula that arises from 
a primary ischio-rectal or para-rectal abscess e.g. as a consequence of perforated 
diverticular disease or tumour. These are considered a separate entity because the 
anal glands are not implicated. 
Subsequent case series have largely agreed with the prevalence of the four main 
types (Table 1). 
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Table 1 Prevalence of the different anatomical types of perianal fistulae. 
 Parks et al. 1976 Marks and Ritchie 1977 Vasilevsky and Gordon 1985 
N 400 666 160 
Inter-sphincteric 45% 66% 42% 
Trans-sphincteric 30% 26% 52% 
Supra-sphincteric 20% 4% 1% 
Extra-sphincteric 5% 4% 0% 
 
Low versus High 
Surgeons often describe perianal fistulae as high or low based on the nature of the 
primary track. There are, however, no accepted definitions for this classification. It is 
used to convey the relative risk of incontinence from lay open, i.e. a low fistula 
carries an acceptably low risk of incontinence if laid open, with the converse being 
the case for high fistulae.  
The St Mark’s Hospital group define a low perianal fistula as subcutaneous, inter-
sphincteric or trans-sphincteric involving no more than 1 cm of external anal 
sphincter (Atkin et al. 2011). Göttgens et al.(2015) in their case series of 537 patients 
defined a low perianal fistula as one traversing the lower one third of the anal 
sphincter complex or a superficial fistula not involving the striated sphincter 
complex. Jordán et al. (2010) defined a high fistula as one crossing more than 50% 
of the external sphincter.  
1.4 Grading 
There is no accepted grading system for perianal fistulae. Previous authors have 
arbitrarily graded fistulae as simple or complex based on their morphology according 
to the Parks classification. Marks and Richie (1977) found that two-thirds of the 
patients they treated had simple fistulae. The vast majority of these responded 
adequately to surgery. The most common type of complex fistula they treated was 
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trans-sphincteric with an ischio-rectal extension. These patients were more likely to 
have had previous operations, particularly drainage of an abscess. The majority of 
these were treated in stages and stayed in hospital for 4 weeks – a ‘major undertaking 
for both the surgeon and the patient.’ 
Jordán et al. (2010) defined a complex fistula as a tract crossing more than 50% of 
the external sphincter, presence of secondary tracks or chronic abscess cavities, or 
pre-existing faecal incontinence. Presence of a complex fistula was associated with a 
higher recurrence rate (16% versus 1.3% in simple fistulae; p < 0.001). Simpson et 
al. (2012) included complexity of management in their grading. Thus, their definition 
of complex fistulae included those with secondary tracks and cavities that extend 
above the levator muscles, supra-levator or supra-sphincteric extensions, horseshoe 
extensions, and a history of Crohn’s disease, cancer, previous surgery or 
radiotherapy, and pre-existing impairment of continence. In a recent prospective 
study, Sileri et al. (2011) defined fistulae as complex if any of the following 
conditions were present: tract crossing more than 30% of the external sphincter, 
anterior fistula in a woman, recurrent fistula, or pre-existing incontinence. 
The St James’s University Hospital Classification was developed to grade fistulae 
using conventional magnetic resonance imaging (MRI) (Morris et al. 2000). This 
system arranges fistulae into five grades of increasing severity: grade 1, simple linear 
inter-sphincteric fistula; grade 2, inter-sphincteric with abscess or secondary tract; 
grade 3, trans-sphincteric; grade 4, trans-sphincteric with abscess or secondary tract 
in ischio-rectal or ischio-anal fossa; and grade 5, supra-levator and trans-levator. 
Spencer et al. (1998) studied outcome according to these grades. They considered 
grades 1 and 2 as simple, and grades 3 to 5 as complex, and showed that complex 
fistulae were associated with an unsatisfactory surgical outcome, meaning that 
further intervention was necessary. 
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1.5 Clinical Features 
Epidemiology 
Perianal fistulae occur in 1.84 per 10,000 people per annum in England (Zanotti et al. 
2007), are commoner in males up to a ratio of 2:1 and usually present in mid-life. 
However, despite being a relatively uncommon disease, a perianal fistula carries 
significant physical and psychosocial morbidity, with an average of three operations 
being necessary to achieve cure or palliation. 
Aetiology 
Primary perianal fistulae, otherwise known as idiopathic, account for 90% of cases 
(Sainio 1984). Other perianal fistulae occur secondary to Crohn’s disease (1.3%), 
ulcerative colitis (1.5%), tuberculosis (TB, 0.2%), perianal operations or trauma 
(3.3%), anal fissure (3.3%). Human immunodeficiency virus (HIV) infection has also 
been implicated in previous cases (Rivera et al. 2009). 
Symptoms 
Common complaints include perianal pain, swelling, discharge and or bleeding from 
the perineum or anus, skin excoriation or pruritus and a perineal external opening or 
subcutaneous lump. These can lead to a psychosocial restriction of lifestyle and 
sexual activity. 
A thorough history includes a documentation of the symptomatology, the resultant 
psychosocial morbidity, and also questions on current sphincter function. This allows 
the clinician to estimate of the total burden of disease and the risk of sphincter 





Clinical examination gives valuable diagnostic and prognostic information. 
Inspection of the perineum and careful palpation with lubrication usually reveals the 
site of the external opening and the path of a subcutaneous tract. If the external 
opening is medial to the border of the pigmented perianal skin (the border of the 
external sphincter), it is likely that the primary tract is inter-sphincteric. The converse 
indicates a trans-sphincteric tract. Absence of an external opening is an indication for 
imaging. An impalpable subcutaneous tract suggests that the tract descends more 
vertically to the perineum either through the inter-sphincteric plane or the ischio-anal 
fossa. In these cases the fistula is more likely to be high. Digital rectal examination 
where only the tip of the finger is admitted into the anal canal can demonstrate the 
internal opening, which is a subtle sensation of a ‘grain of rice’ against the otherwise 
silky smooth anal mucosa. The height of the internal opening in relation to the 
anorectal junction is best estimated in the awake patient, when anal tone is not 
altered by anaesthesia. This estimation is important in judging the length and 
function of the uninvolved sphincter that would remain behind if a lay open were 
performed. Deeper palpation of the anorectal junction and the pelvic floor from 
within the rectum can demonstrate areas of high sepsis, which is felt as ‘woodiness’ 
instead of the usual soft springy musculature. However, it is impossible to 
differentiate whether the underlying sepsis is either in an infra- or supra-levator 
location. 
1.6 Imaging 
The role of imaging in perianal fistula disease is to reach a diagnosis when the 
clinical features are atypical, map out the full pathoanatomy to direct surgical 
treatment and monitor progress following treatment. The best modalities in common 
use today are anal endo-ultrasonography (ultrasound) and MRI, which have now 
superseded fistulography and computed tomography (Williams et al. 2007). 
Buchannan et al. (2004) compared ultrasound with digital rectal examination and 
MRI in 108 perianal fistulae. They found that classification of the fistula was correct 
 
29 
after digital rectal examination in 61%, ultrasound in 81%, and MRI in 90%, when 
compared against an outcome-derived outcome standard (which was determined post 
hoc by considering the findings of all the modalities with the clinical course after 
surgery). 
Ultrasound is well tolerated and is able to demonstrate the internal opening, the 
primary tract traversing the sphincters and any associated collections or secondary 
tracts. However, insufficient penetration means that the ischio-anal fossa and supra-
levator space are not demonstrated clearly, and extensions into these areas may be 
missed. In recurrent disease, scars of previous surgery pose a problem as they have 
the same appearance as active fistula tracts. In addition, the technique is operator 
dependent and therefore studies have reported both superiority (Orsoni et al. 1999) 
and inferiority (Chew et al. 2003) to MRI. 
MRI is now the gold standard modality for imaging perianal fistula disease. A meta-
analysis comparing ultrasound with MRI in 481 fistulae found that their sensitivity 
was similar (87%), but that MRI had a higher specificity (69% versus 43%) (Siddiqui 
et al. 2012). 
MRI provides accurate morphology of the disease entities and their exact anatomical 
relationship with the perianal structures in multiple planes. It is also well tolerated, 
being non-invasive (unless an endo-anal coil is inserted, which is not common) and 
non-ionising. The technician should first perform an overview scan to plan the 
sequences. Crucially these sequences need to be orientated to the axis of the anal 
canal, which is approximately 45° in the sagittal plane. Both T1 and T2 weighted fast 
spin-echo (FSE) sequences are important. Fat-suppressed T2-weighted sequences 
such as short tau inversion-recovery (STIR) or frequency-selective fat-saturated T2-
weighted FSE, are also valuable in demonstrating the fluid-filled tracts, and 
gadolinium-enhanced fat-suppressed T1 images are good at demonstrating the tracts 




The ultimate goal of treatment of perianal fistulae is cure. However, this gives rise to 
a paradox as curative surgery can come at the cost of impaired continence. The more 
radical the surgery, the higher the chance of cure, but also higher the chance of life-
changing faecal incontinence. Thus one set of chronic symptoms may be replaced by 
another, and the net benefit to the patient’s quality of life may not be favourable. 
Therefore, treatment needs to be tailored to the patient, balancing the desire for 
fistula eradication against the need to preserve continence (Figure 5). 
The general strategy for treating perianal fistulae involves (1) draining, controlling or 
resolving any acute sepsis; and (2) controlling or eradicating the primary tract, which 
includes the offending anal glands. If these principles are followed, secondary tracts 
usually resolve without direct intervention. 
 
Figure 5 Balance of priorities when selecting treatment for a perianal fistula. 
Fistulotomy 
The most effective surgical treatment is fistulotomy, which involves laying open the 
fistula tract from the internal to the external opening. The intervening skin, fat and 
sphincter are divided, meaning that only the sphincter above the level of the fistula 







Fistulotomy can achieve success in about 95% of patients (Vasilevsky and Gordon 
1984). In a retrospective study involving 461 patients with simple perianal fistulae, 
6.5% developed recurrent fistulae within a mean follow-up of 34 months (Sangwan 
et al. 1994). Van Tets and Kuijpers (1994) retrospectively surveyed 281 patients who 
had had fistulotomy and reported minor continence disorders in 26%. Garcia-Aguilar 
et al. (1996) retrospectively surveyed 375 patients. Mean follow-up was 29 months. 
Procedures included fistulotomy (N = 300), seton placement (63), endo-rectal 
advancement flap (3), and other (9). Fistula recurrence occurred in 8% and post-
operative incontinence was experienced by 45% of patients. Westerterp et al. (2003) 
surveyed 60 patients who underwent fistulotomy for inter-sphincteric and trans-
sphincteric fistulae. Within the follow-up of 1–4 years, none experienced a 
recurrence; 50% had impaired incontinence. Jordán et al. (2010) analysed 132 
patients who had undergone fistulotomy. Minimum follow-up was 1 year. 
Recurrence occurred in 1.5% at a median of 4 months post-operatively and post-
operative faecal incontinence in 10% of patients. 
However, most studies struggled to accurately measure post-operative faecal 
incontinence and perhaps more importantly, its impact on quality of life. In an 
attempt to address this, Cavanaugh et al. (2002) measured the Faecal Incontinence 
Severity Index (FISI) in 110 patients after fistulotomy. Some degree of incontinence 
was reported in 64% and the use of a pad, lifestyle restriction, depression, and 
embarrassment after fistulotomy were unusual occurrences. No patient reported a 
severe restriction in lifestyle or severe depression as a result of fistulotomy, but one 
did report severe embarrassment. 
Loose Seton 
The purpose of a loose seton is to allow drainage of the fistula. This relies on the 
premise that acute symptoms are related to superficial closure of the fistula opening 
causing build up of transudate or exudate within the tract and abscess formation. A 
seton is a fibre (usually now a synthetic suture material such as non-absorbable 
braided Ethibond) that is passed into the external opening of the fistula, along the 
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primary tract, through the internal opening and drawn down out of the anus and tied 
upon itself to form a loop that remains in situ. It therefore allows drainage along the 
fibre by means of wicking, and prevents the openings from closing over. 
A loose seton is often used as a bridge to definitive surgery. In these situations, the 
seton is deployed to drain the primary tract, resolve the acute sepsis and heal the 
secondary tracts prior to a fistulotomy (or other surgical approach). In a retrospective 
case series, the outcomes of 41 consecutive patients with high trans-sphincteric, 
supra-sphincteric, or extra-sphincteric perianal Crohn’s fistulae were reported 
(Faucheron et al. 1996). Seven had a secondary fistulotomy and none experienced a 
recurrence. The authors concluded that this strategy was effective in treating sepsis 
and preserving anal sphincter function. 
A hybrid operation involving a loose seton can achieve a cure with a lower risk of 
incontinence compared with fistulotomy. In several small studies, all retrospective, 
surgeons performed a partial internal sphincterotomy, or a core fistulectomy without 
sphincteric division and then deployed a loose seton across the tract. Within the 
follow-up, which ranged from 16 to 142 months, recurrence or persistence occurred 
in 10–79%, minor incontinence in 0–58% and major incontinence in 0–8% of 
patients (Thomson and Ross 1989; Kennedy and Zegarra 1990; Williams et al. 1991; 
Lentner and Wienert 1996; Balogh 1999; Joy and Williams 2002; G. N. Buchanan et 
al. 2004). 
However, in approximately 50% of patients, fistulotomy is not feasible (Dudukgian 
and Abcarian 2011), because the risk of causing significant faecal incontinence is 
unacceptable. In these circumstances, a loose seton can be employed as a long-term 
non-curative strategy. In eleven patients with a mean follow-up of 75 weeks, a seton 
achieved resolution of septic episodes in eight (Joy and Williams 2002). 
Other Operations 
A cutting seton can treat trans-sphincteric fistulae (Williams et al. 2007). This 
method involves tying the seton tight in the fistula tract causing it to slowly cut-out 
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through the intervening sphincter. In theory the sphincter muscle is slowly divided 
and heals behind the seton without the muscle edges retracting apart. Recurrence is 
typically no more than 8% (Graf et al. 1995; Hämäläinen and Sainio 1997). 
However, authors have reported major incontinence as high as 20% after its use in 
low trans-sphincteric fistulae (Joy and Williams 2002). The cutting seton is also 
uncomfortable or even painful for patients. 
An advancement flap may also achieve a cure. The surgeon raises a flap of mucosa 
or skin, advances it and secures it over the internal opening. This avoids sphincter 
division. Several techniques including trans-anal rectal mucosal advancements and 
cutaneous flaps exist. However, authors have reported recurrence rates of 36% 
(Sonoda et al. 2002). 
Rojanasakul et al. (2007) first described ligation of the inter-sphincteric fistula tract 
(LIFT), another sphincter-sparing technique. Eighteen patients underwent the 
procedure, with only one (6%) recurrence reported. However, other groups in 
retrospective studies have since reported higher recurrence rates ranging from 8% 
(Mushaya et al. 2012) to 43% (Bleier et al. 2010). In a recent randomised controlled 
trial, 35 patients underwent LIFT for high trans-sphincteric fistulae (Madbouly et al. 
2014); recurrence at one year was 26%. 
Injecting fibrin glue into the fistula tract met with initial enthusiasm. Unfortunately 
subsequent authors reported disappointing long-term results, with recurrence rates of 
up to 100%  (Hammond et al. 2004). This therapy has therefore evolved into placing 
a plug within the fistula tract. In a case series of 45 patients, the fistula plug achieved 
complete healing in 44% (Thekkinkattil et al. 2009). A large (N = 500) UK 
randomised controlled trial, the Fistula–In–Ano Trial (FIAT) is currently underway 
to establish the efficacy of this treatment (University of Birmingham 2015). 
Other emerging techniques include fistula laser closure (FilaC) and video-assisted 
anal fistula treatment (VAAFT) with recurrence/failure rates of 29% and 26% 
respectively (Giamundo et al. 2014; Meinero and Mori 2011). Finally, researchers 
 
34 
are also exploring novel biomaterials such as adipose derived stem cells, human 
acellular dermal matrix and platelet rich plasma (Narang et al. 2016). See Table 2 for 
a comparison of these treatments. 
Table 2 Comparison of surgical treatments with curative intent for perianal fistulae. VAAFT, video-
assisted anal fistula treatment; LIFT, ligation of inter-sphincteric fistula tract; FiLaC, Fistula Laser 
Closure; ADM, acellular dermal matrix.  
 
Failure/recurrence rate Comments 
Fistulotomy 5% Incontinence 26–64% 
Cutting seton 8% Painful, incontinence 20% 
VAAFT 13% Single series, special equipment 
Platelet rich plasma 10-17% Limited data 
LIFT 26%  
FiLaC 18–29% Limited data, special equipment 
Advancement flaps 36% 
 
ADM 46% Single series 
Stem cells 29–48%  
Fistula plug 66%  
Fibrin glue 100%  
 
Crohn’s Perianal Fistulae 
The initial surgical strategy for treating Crohn’s perianal fistulae is the same as in 
idiopathic fistulae, namely drainage and control of the acute sepsis. The longer-term 
surgical strategy generally favours long-term drainage (seton) rather than fistulotomy 
or other potentially curative procedures due to issues of wound healing and also need 
for future operations that may cumulatively result in incontinence. In response to 
this, several pharmacological agents as primary treatments for fistulating Crohn’s 
disease have emerged. Long-term closure of Crohn's fistulae is rare in patients 
receiving therapies such as 5-aminosalicylates, corticosteroids, antibiotics, 
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methotrexate and cyclosporin (Klag et al. 2015). In a landmark randomised 
controlled trial, 94 adults with abdominal or perianal Crohn’s fistulae received 
placebo or the chimeric anti-TNF-α (tumour necrosis factor alpha) antibody, 
infliximab (Present et al. 1999). The primary endpoint was a reduction of at least 
50% in the number of draining fistulae. Sixty-eight per cent of the patients who 
received 5 mg/kg of infliximab and 56% of those who received 10 mg/kg achieved 
the primary endpoint, as compared with 26% of the patients in the placebo group (p 
= 0.002 and p = 0.02, respectively; Figure 6). A second trial then studied the 
efficacy of infliximab to maintain remission of fistulising disease in 306 patients 
with abdominal or perianal Crohn’s fistulae (Sands et al. 2004). This multicentre, 
double-blind, randomized, placebo-controlled trial found that time to loss of response 
was significantly longer for patients who received infliximab maintenance therapy 
than for those who received placebo maintenance (more than 40 weeks versus 14 
weeks, p < 0.001). Unfortunately, results for the perianal fistulae were not reported 
separately in either trial. 
Infliximab therapy however carries significant risk of adverse effects, which include 
hypersensitivity reactions, infections, demyelinating disorders, lymphoma and death. 
Infliximab is also immunogenic meaning that long holidays between infusions can 
give rise to antibodies that cause infusion reactions and loss of efficacy. Another 
fully-human anti-TNF-α antibody, adalimumab, has since been developed. In three 
randomized controlled trials, it showed similar efficacy to infliximab in the treatment 
of Crohn's disease, but was less immunogenic (Hanauer et al. 2006; Colombel et al. 





Figure 6 Results from treating a Crohn's perianal fistula with infliximab. Source: Present et al. (1999) 
1.8 Pathogenesis of Crohn’s Disease 
Before discussing the pathogenesis of perianal fistulae, a brief summary of the 
pathogenesis of Crohn’s disease in general is warranted.  
Crohn’s disease is a systemic inflammatory condition in which gastrointestinal 
manifestations predominate. The clinical picture is characterised by relapses of focal, 
asymmetric, transmural chronic inflammation involving any part of the 
gastrointestinal tract from the mouth to the anus. The commonest area involved is the 
terminal ileum, and perianal involvement is found in up to one third of patients. 
The aetiology of Crohn’s disease is unknown. Current research suggests that it arises 
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same was true for patients with multiple fistulas (71
percent vs. 39 percent, P=0.03). In addition, inflixi-
mab was consistently beneficial regardless of concom-
itant therapy (e.g., corticosteroids, mercaptopurine




All 94 patients were evaluated for safety. The per-
centage of patients with adverse events was the same
for the group assigned to receive 5 mg of infliximab
per kilogram and that assigned to placebo (65 per-
cent); there was a trend toward more adverse events
among the patients assigned to receive 10 mg of in-
fliximab per kilogram (84 percent, P=0.09). The
most frequently reported adverse events among pa-
tients treated with infliximab were headache, abscess,
upper re piratory tract infection, and fati ue (Table
4). One patient in the group receiving 10 mg of in-
fliximab per kilogram discontinued treatment because
of pneumonia, which developed 22 days after the sec-
ond infusion. The symptoms resolved within a week
with antibiotic treatment. Altogether, five patients had
The New England Journal of Medicine 
Downloaded from nejm.org at QUEEN MARY AND WESTFIELD COLLEGES on March 27, 2013. For personal use only. No other uses without permission. 
 Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
 
37 
innate and acquired immune response towards an altered gastrointestinal microbiome 
(Baumgart and Sandborn 2012). There is 35% concordance in monozygotic twins 
and siblings of affected individuals have a 30-fold increase in incidence. Genome 
wide association studies have identified 174 susceptibility loci for Crohn’s disease so 
far (Bianco et al. 2015). Key factors include mutations in NOD2 (nucleotide-binding 
oligomerization domain-containing protein 2), which codes for an intracellular 
sensor of bacterial molecules (see below), the autophagy genes ATG16L1 
(autophagy related 16-like 1) and IRGM (immunity-related GTP-ase M-protein), and 
IL-23 (interlukin 23) receptor gene. However, many mutations that confer 
susceptibility are also found in healthy individuals, highlighting the complexity of 
the disease’s aetiology. 
Differences in incidence across age, time, and geographic region suggest that 
environmental factors significantly modify the expression of Crohn’s disease (Loftus 
2004). Smokers are twice as likely to develop the disease. Other putative risk factors 
include oral contraceptives, high sugar diet, high fat diet and early childhood 
infections. 
In contrast to nearly all other tissues, the mucosa of the small and large intestine has 
continuous, low-grade (physiologic) inflammation, most likely because the intestine 
is exposed to a great antigenic load from luminal bacteria and a large variety of Toll-
like receptor (TLR) ligands (MacDonald et al. 2011). Crohn’s disease seems to be a 
disorder of this symbiosis (Baumgart and Sandborn 2012). A detailed review of the 
immunopathology is outside the scope of this thesis. In summary, the main 
mechanisms are: 
1. Diminished bacterial diversity 
2. Impaired mucosal barrier that increases permeability to bacterial antigens 
3. Stimulation of host pattern recognition receptors such as TLRs on the cell 
surface and intracellular NOD2 receptors 




5. Imbalance of effector T cells (predominantly Th1 and Th17), which secrete 
IFN-g (interferon-gamma), TNF-a, IL-17 and IL-22, and regulatory T cells, 
which secrete IL-10, TGF-b (transforming growth factor-beta) and IL-35 
6. Stimulation of macrophages to secrete pro-inflammatory cytokines such as 
TNF-a, IL-1 and IL-6 in large quantities 
7. Increased adhesion molecule expression on the intestinal vascular endothelium, 
recruitment of leucocytes, and tissue damage 
1.9 Pathogenesis of Perianal Fistulae 
Until Parks’ studies, the common pathogenic theory was that infection penetrated the 
mucosal surface through a fissure or other wound, creating a suppurative tract 
through the anal canal wall. Faecal contents entering the internal orifice then 
perpetuated the tract. Parks (1961) observed that the anatomical distribution of the 
anal glands and perianal fistulae was similar and thus hypothesized that the anal 
glands provide free channels for infection to pass from the anal lumen deep into the 
sphincter muscles: since termed the ‘cryptoglandular theory’. In 30 consecutive 
patients with idiopathic perianal fistulae, he excised the internal part of the fistula 
tract and examined them using light microscopy. In all but two, the fistula tracts were 
lined by stratified columnar epithelium, the same epithelium that was present within 
normal anal glands. The other commonly observed features were a gross cystic 
dilatation of the anal gland (with two also containing vegetable matter) and an inter-
sphincteric abscess lined by anal-gland epithelium. Parks concluded that infected 
anal glands caused the perianal fistulae in 28 (90%) patients.  
The cryptoglandular theory is now widely accepted for idiopathic disease. However, 
subsequent work to support and explain the theory has been sparse. Challenge came 
from Golligher et al. (1967) who found evidence of inter-sphincteric sepsis or tracts 
in only 14 of 32 patients with perianal fistula. However, critics argue that the 




Fundamental questions remain unanswered (Gosselink et al. 2015): why do perianal 
fistulae occur more commonly in males in the third decade of life? Why do only a 
minority of perianal abscesses progress to a fistula? Why do they more commonly 
arise in the posterior quadrant of the anal canal? What drives fistulae to persist and to 
recur?  
In Crohn’s perianal fistulae, the cryptoglandular theory may also apply. If this is the 
case then it follows that idiopathic and Crohn’s perianal fistula may share a common 
initial pathological process, which gives rise to further fundamental questions: is 
there an undescribed inflammatory disease or disease process similar to Crohn’s 
disease that underpins idiopathic perianal fistula pathogenesis? Do both idiopathic 
and Crohn’s perianal fistulae share risk factors that promote the initiation and 
progression of anal gland infection into a persistent perianal fistula?  
Unfortunately, Parks’ study excluded perianal fistulae secondary to Crohn’s disease 
and no one has published a similar study in Crohn’s perianal fistulae. Hughes (1978) 
offered an alternative pathogenic mechanism based on observations made during 
approximately 400 consecutive cases of perianal Crohn’s disease. He suggested that 
faeces become trapped within an anal fissure and then forced into the submucosal 
tissues by the pressure of defecation. However, no data were presented to support 
this theory and there were no follow-up studies. 
A third theory, again offered on the basis of weak evidence, proposed that the 
inflammatory tissue destruction observed in luminal Crohn’s disease occurs in the 
anal canal and leads to a transmural tissue-overarching defect in the gut wall. Wound 
healing does not take place. Instead, these fissure-like tissue defects are characterized 
by epithelialization as an alternative healing mechanism of the intestinal barrier 
(Klag et al. 2015). 
Working from these theories of pathogenesis, researchers have investigated genetic, 
microbiological and immunological factors implicated in the pathophysiology of 




Studies of the genetic factors contributing to the pathogenesis of perianal fistulae are 
predominantly in Crohn’s disease. As mentioned previously, Crohn’s disease has a 
strong genetic basis and genome wide association studies have identified 174 
susceptibility loci so far (Bianco et al. 2015). Some notable examples are 
highlighted.  
NOD2 (nucleotide-binding oligomerization domain-containing protein 2) 
Mutations in NOD2 account for approximately 15% of cases of Crohn’s disease. The 
gene is located on chromosome 16 (16q12) and codes for an intracellular receptor for 
muramyl dipeptide, a bacterial molecule (peptidoglycan). Mutations confer loss of 
function, although exactly how these mutations cause Crohn’s disease is still 
unknown (Hugot et al. 2001). In Crohn’s disease, NOD2 mutations do not appear to 
be associated with risk of developing perianal fistulae (Freire et al. 2011; Karban et 
al. 2007). However, they do seem to be associated with perianal disease severity. 
When treated with ciprofloxacin, complete fistula response was observed in 13 of 39 
patients with NOD2 wild-type (33%) compared with none in patients carrying NOD2 
variants (0%, p = 0.02; Angelberger et al. 2008). In a study of 203 consecutive 
patients, response of perianal fistulas to antibiotics (metronidazole alone or combined 
with ciprofloxacin) was significantly higher in patients without NOD2 mutations 
(7.7% versus 41%, p = 0.04; Freire et al. 2011). Carriers of the G908R variant of 
NOD2 need fistula surgery more frequently (32% versus 4.8%; p < 0.01; Barreiro et 
al. 2005). 
Yazdanyar and Nordestgaard (2010) extended the study of NOD2 polymorphisms to 
other common gastrointestinal diseases. Around 44,000 individuals from the Danish 
general population were genotyped. The age and sex adjusted hazard ratio for anal 
fissure, fistula and abscess amongst compound heterozygotes was 3.2 (95% CI 1.3–
7.8, p = 0.003) compared with non-carriers. This suggests that NOD2 mutations may 
be pathogenic non-Crohn’s perianal fistulae. 
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ATG16L1 (autophagy related 16-like 1) and IRGM (immunity-related GTP-ase M-
protein) 
Autophagy is a crucial defence mechanism against bacteria. Paneth cells found in the 
intestinal epithelium are crucial effectors of autophagy. They mediate host-microbe 
interactions, maintain a homeostatic balance with colonizing microbiota, provide 
innate immune protection from enteric pathogens and also modulate epithelial 
renewal (Clevers and Bevins 2013). NOD2 interacts with and recruits ATG16L1 to 
the plasma membrane to initiate autophagy of bacteria (Travassos et al. 2010). 
ATG16L1-deficient Paneth cells exhibit striking abnormalities in the granule 
exocytosis pathway (Cadwell et al. 2008). 
IRGM also interacts importantly within this axis (Chauhan et al. 2015). 
Polymorphisms of IRGM are associated with Crohn’s disease (Massey and Parkes 
2007) and in particular, fistulising disease (Latiano et al. 2009). This explains how 
polymorphisms altering expression or function of any of the three factors 




An acute clinical presentation with anorectal abscess is associated with the 
immediate or delayed finding of a perianal fistula in 26–41% of cases (Grace et al. 
1982; Henrichsen and Christiansen 1986).  
Culture of pus from anorectal abscesses shows that the infection is polymicrobial. In 
a retrospective study of 144 patients in a single hospital in the US, the commonest 
culture result from anorectal abscesses was mixed a growth of aerobic and anaerobic 
microorganisms (72%) with an average of three isolates per case (Brook and Frazier 
1997).  Most of the organisms isolated from the perirectal abscesses were of enteric 
(Bacteriodes fragilis and Escherichia coli) and skin (Staphylococcus aureus and 
 
42 
some Streptococcus spp.) flora origin. However, the complete list of identified 
species is extensive and varies between patients. Other retrospective studies have 
confirmed this general picture (de San Ildefonso Pereira et al. 2002; Ulug et al. 2010; 
Liu et al. 2011). In a retrospective study of 235 patients in a district general hospital 
in the UK, Coliforms or Bacteroides were found in 45%, mixed growth in 20%, skin 
flora including Staphylococcus aureus in 12%, and no growth in 7% (Leung et al. 
2009). 
Grace et al. (1982) studied 165 patients presenting with an anorectal abscess. A 
perianal fistula featured in 68 patients. Fistulae were absent in all patients whose 
abscess pus grew either Staphylococcus aureus or other skin-derived 
microorganisms. Likewise, Henrichsen and Christiansen (1986) found prospectively 
in 50 consecutive patients that when culture from the abscess revealed only skin 
flora, fistulae were absent. Lunniss and Phillips (1994) similarly reported this 
prospectively in 22 patients. They also concluded that culture of gut organisms was a 
good predictor of an underlying fistula. However, two later studies with similar 
sample sizes found no significant relationship between the type of bacteria and the 
subsequent development of a perianal fistula (de San Ildefonso Pereira et al. 2002; 
Leung et al. 2009). The relationship between routine microbiological culture results 
and fistula development must at best be considered uncertain. 
Fistula Tract 
Although bacterial infection is the primary feature of an anorectal abscess and 
generally accepted as the index pathogenic event, the role of microorganisms in the 
development and perpetuation of a perianal fistula is unclear. 
In a prospective study of 25 patients, Seow-Choen et al. (1992) found that the 
microbiology of non-acute perianal fistula tracts was similar to anorectal abscesses. 
However, there was a paucity of cultured organisms, even when most were incubated 
in enriched culture. This difference could have resulted from the fact that fistula tract 
cultures were performed on tissue whereas anorectal abscess cultures were 
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performed on pus. However, the authors concluded that the chronic inflammation in 
perianal fistulae does not seem to be maintained by either excessive numbers of 
organisms or organisms of an unusual type. Further work from the same group 
correlated culture results with fistula tract histology in eight patients (Lunniss et al. 
1993). Culture growth was again scanty. Histology revealed a pattern of active 
chronic inflammatory changes characterized by large numbers of plasma cells, 
scattered multinucleate foreign-body giant cells and prominent vascular proliferation, 
but no organisms were seen. 
Recently, gram staining, fluorescent in situ hybridization and scanning electron 
microscopy were used in 18 patients with idiopathic fistulae and 14 patients with 
Crohn’s perianal fistulae (Tozer et al. 2015). The six rRNA (ribosomal ribonucleic 
acid) probes targeted all bacteria, Bifidobacterium, the Clostridium coccoides–
Eubacterium rectale cluster, the Bacteroides–Prevotella cluster, Faecalibacterium 
prausnitzii, and Escherichia coli. Bacteria were only barely found in the fistula tract 
of one patient from the idiopathic group.  
While surgeons may find this counter-intuitive (on the basis that pus can be 
expressed from many fistula tracts), the above studies suggest that bacteria are not a 
feature of perianal fistulae and do not contribute to their persistence. However, it is 
possible that a putative organism has simply not yet been identified by the methods 
used to date. It is well known that many microorganisms are not detectable through 
traditional cultures. Recently developed gene amplification and sequencing 
techniques have led to the discovery of new pathogens as agents of disease. 
Researchers have not yet applied this to perianal fistulae, and so this remains a 
potential new area to be studied. 
Even if bacteria might not contribute directly to perianal fistula persistence, there is 
evidence that they may exert and indirect effect. Van Onkelen et al. (2013) examined 
tissue samples from the peri-sphincteric portion of the fistula tract in 10 patients 
using conventional microbiological culture, 16S small-RNA sequencing and 
immunohistochemistry to identify the presence of peptidoglycan, a polymer that 
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forms the cell wall of Gram positive bacteria. They found a paucity of bacteria, 
consistent with the studies previously mentioned. However, macrophages, 
neutrophils and dendritic cells containing peptidoglycan were abundant in the fistula 
tracts of 9 of the patients. And a host inflammatory response to peptidoglycan, 
demonstrated by expression of peptidoglycan recognition proteins was found in 6 
patients. The authors suggested that peptidoglycan stimulates the secretion of IL-1b 
and other inflammatory mediators in perianal fistulae. 
Effects of Antibiotics and Faecal Diversion 
The effect of antibiotics on perianal fistula has only been studied in relation to 
Crohn’s disease fistulation. No study has yet shown sustained fistula healing with 
antibiotics alone. However, there appears to be a noticeable short-term response, 
suggesting that bacteria have a role in fistula pathophysiology, at least in Crohn’s 
disease.  
Three small cohort studies totalling 55 patients investigated the effect of 
metronidazole. Clinical improvement can occur in 6–8 weeks (Bernstein et al. 1980) 
and 50% of patients can achieve fistula closure (Jakobovits and Schuster 1984). 
However, when the metronidazole is stopped, 80% of patients at four months 
experience recurrence (Brandt et al. 1982). If the metronidazole is continued, side-
effects are significant: a metallic taste in the mouth, dyspepsia, and risk of peripheral 
neuropathy.  
Ciprofloxacin is also used routinely in perianal Crohn’s disease. One pilot 
randomized controlled trial compared ciprofloxacin, metronidazole and placebo 
(Thia et al. 2009). In this study, 4 of 10 patients on ciprofloxacin, 1 of 7 patients on 
metronidazole, and 1 of 8 patients on placebo achieved a response at 10 weeks 
(defined as closure of at least half of fistulae that were draining at baseline). 
Faecal diversion, by either defunctioning ileostomy or colostomy, is an option for 
patients with Crohn’s disease whose perianal fistulae are refractory to all other 
treatments, save proctectomy. It is rarely employed in idiopathic disease. Its use 
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assumes that the absence of the faecal stream past the internal opening of the fistula, 
and reduction in luminal bacterial load have a therapeutic effect. 
In a retrospective analysis spanning 27 years, 31 patients with perianal Crohn’s 
disease underwent faecal diversion (Yamamoto et al. 2000). Although 25 (81%) 
showed an initial response, complete remission (defined as alleviation of the perianal 
disease with resolution of sepsis and active fistulas and objective improvement in the 
patient’s condition) only occurred in 8 patients (26%). 
A recent meta-analysis to evaluate the effectiveness, long-term outcomes and factors 
associated with success of temporary faecal diversion for perianal Crohn’s disease 
included 16 cohort studies and 556 patients (Singh et al. 2015). Almost two thirds 
(64%) of patients had early clinical response after faecal diversion. Restoration of 
bowel continuity was attempted in 35% of patients, but was successful in only 17%. 
In summary, the evidence, albeit weak, suggests that modifying the microbiological 
environment of perianal fistulae or the gastrointestinal lumen above them, either by 
antibiotic therapy or faecal diversion, has at best only a short-term effect. This is 
consistent with the assertion (section above) that bacteria do not play a direct role in 
fistula tract persistence, but may still have an indirect influence in fistula tract 
pathophysiology. 
1.12 Immunopathology 
Few studies have specifically focussed on the immunopathology of perianal fistula 
and most of these have been in relation to patients with Crohn’s disease. 
Morphology 
Bataille et al. (2004) compared the morphology of enterocutaneous and perianal 
fistulae from 84 patients with Crohn’s disease to 13 patients without inflammatory 
bowel disease. They showed that all fistulae, regardless of aetiology or site, appeared 
to have common features of a central fissure that penetrated the lamina propria and 
muscularis mucosae deep into the underlying tissue with a lining of granulation 
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tissue containing histiocytes and capillaries, and a lumen filled with nuclear debris, 
neutrophils and lymphocytes, thus indicating non-specific acute or chronic 
inflammation. Based on electron microscopy data from a small subset, the they 
concluded that the pathogenesis of fistulae involved myofibroblast-like cells, so-
called transition cells, that respond to tissue injury and become organised by 
development of gap junctions and the formation of a basement membrane between 
the transition cells and the granulation tissue. 
Bataille et al. also found differences between the groups. Crohn’s fistulae presented 
with a central infiltration by CD45R0 (cluster of differentiation 45 receptor 0) 
positive T cells, followed by a small band of CD68 positive macrophages and dense 
accumulation of CD20 positive B cells. In contrast, in the idiopathic group, there was 
dense infiltrate of CD68 positive macrophages with only few CD20 positive B cells 
and CD45R0 positive T cells. However, in this study, the majority of Crohn’s 
fistulae were enterocutaneous whereas the majority of the idiopathic fistulae were 
perianal, and subgroup analysis for perianal fistulae was not presented. Therefore, an 
alternative interpretation is that these were differences seen between enterocutaneous 
and perianal fistulae. 
Colonic Lamina Propria Fibroblasts (CLPF) 
Fibroblasts synthesize and degrade the extracellular matrix and play an important 
role in wound healing. Following tissue injury, migration of fibroblasts during the 
early stages of wound healing appears to be fundamental to wound contraction 
(Badid et al. 2000). Leeb et al. (2003) showed that fibroblasts from colonic mucosa 
of patients with inflammatory bowel disease displayed reduced migration compared 
to normal colonic mucosa. A follow-up study from the same group demonstrated that 
inflamed Crohn’s colonic mucosa had reduced expression of extra domain A and B 
isoforms of fibronectin, an extracellular glycoprotein important in inducing 
migration of CLPF (Brenmoehl et al. 2007). Expression of extra domain A and B 
isoforms in Crohn’s fistulae was virtually absent. A further study showed that 
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expression of galectin-3 in Crohn’s fistulae, a carbohydrate-binding protein that 
activates CLPF, was also reduced in Crohn’s fistulae (Lippert et al. 2008).  
These data, if correct, imply that in Crohn’s fistulae pathogenesis, CLPF functions 
are critically impaired, necessitating the activation of alternative pathological healing 
pathways, such as migration of intestinal epithelial cells. However, it must be noted 
that these findings pertain to enterocutaneous fistulae. Studies of CLPF function 
specifically in Crohn’s perianal fistulae are lacking, as are those on idiopathic 
fistulae. 
Epithelial to Mesenchymal Transition (EMT) 
EMT is a normal feature of tissue remodelling and wound healing. It is also 
associated with an increased migratory and invasive potential of epithelial cells in 
different tissues (Kalluri and Neilson 2003). A study of both Crohn’s disease and 
non-Crohn’s fistulae, which included intestinal fistulae, showed that around two-
thirds of Crohn’s fistulae were lined not by epithelium, but by a thin basement 
membrane layer of myofibroblast-like transitional cells (Bataille et al. 2004). 
Unfortunately, the study was not clear on the findings in the non-Crohn’s fistulae. In 
a follow-up study of 23 fistulae that included 18 Crohn’s and two non-Crohn’s 
perianal fistulae, Bataille et al. (2008) found that the distribution of markers in the 
transitional cell lining of the fistula tracts was typical of EMT. The findings in the 
Crohn’s fistulae were very similar to the two non-Crohn’s fistulae.  
Further evidence for the role of EMT was provided by Scharl et al. (2011). They 
demonstrated that the nuclei of the transitional cells lining the fistula tracts showed 
an increased expression of SNAIL1 transcription factors. SNAIL1 normally 
promotes the repression of the adhesion molecule E-cadherin to regulate EMT in 
embryonic development. They also found that TGF-β and integrin-avb6 were also 
highly expressed (2013). Interestingly, integrin-avb6 in colon cancer regulates cell 
migration and secretion and activation of proteases capable of degrading matrix 
barriers (Agrez et al. 1999), and the TGF-b family of growth factors can initiate and 
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maintain EMT by activating major signalling pathways and transcriptional regulators 
(Zavadil and Böttinger 2005). One such downstream effect is the secretion of IL-13 
from CLPF, which was demonstrated in patients with perianal Crohn’s disease 
compared with patients with non-perianal Crohn’s disease and healthy volunteers 
(Scharl et al. 2013). This pathway has not yet been studied in idiopathic perianal 
fistulae. 
TNF-a is also present in the transitional cell lining of perianal fistula tracts from both 
Crohn’s and non-Crohn’s disease patients (Scharl et al. 2011). It is also expressed in 
peri-fistula immune cells. TNF-a induces the expression of factors associated with 
EMT and invasion in intestinal epithelial cells and Crohn’s perianal fistula CLPF 
(Frei, Pesch, et al. 2013). This is blocked when anti-TNF-a antibody is administered 
in vitro. Furthermore, anti-TNF-a therapy is now a routine treatment for perianal 
Crohn’s disease following a trial that showed that it could achieve fistula closure in 
55% of patients (Present et al. 1999). 
Muramyl-dipeptide (MDP) is a bacterial wall component. MDP is a ligand for 
NOD2, an important gene conferring susceptibility to Crohn’s disease (see above). 
Together with TNF-a, it induces expression of factors associated with EMT and 
invasion in intestinal epithelial cells and Crohn’s perianal fistula CLPF (Frei, Pesch, 
et al. 2013). MDP has not yet been studied in idiopathic perianal fistula. 
Matrix Metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are a family of neutral proteases with the ability 
to degrade all components of extracellular matrix. MMPs are now recognised as key 
regulators of cell function through their ability to cleave a vast range of cytokines, 
chemokines, receptors, proteases, and adhesion molecules to alter their function 
(O’Sullivan et al. 2015). Pender et al. (1997) first demonstrated the role of MMPs in 
T cell injury in the gut. Baugh et al. (1999) then showed that MMP expression is 
significantly higher in the affected and non-affected mucosa of Crohn’s disease 
patients compared with healthy controls. With several subsequent studies providing 
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evidence, MMPs are now strongly implicated in the pathogenesis of inflammatory 
bowel disease (Pender and MacDonald 2004).  
MMP expression has also been studied in fistulae. Kirkegaard et al. (2004) obtained 
fistula specimens from patients with Crohn’s disease (n = 11), other diseases (n = 9) 
and normal colon (n = 5). Fistulae were mainly perianal, with a minority being 
enterocutaneous in both disease groups. Using single and double-labelled 
immunohistochemistry and in situ hybridisation, they found marked MMP-3 and 
MMP-9 upregulation in both Crohn’s and non-Crohn’s fistulae. Later in a small 
study that included Crohn’s and non-Crohn’s perianal fistulae specimens (n = 5), 
Frei et al. (2013) found MMP-9 and MMP-13 to be specifically expressed in cells 
lining the fistula tracts. 
Putting it All Together 
Recently Scharl and Rogler (2014) summarised the immunological evidence for the 
pathogenesis of fistulae (of all types) in Crohn’s disease. In their proposed 
mechanism (Figure 7), an epithelial defect caused by inflammation or injury allows 
pathogen-associated patterns to gain entry and induce various pathways mediated by 
TNF-a, TGF-b, IL-13, MMPs and integrin-avb6. These drive EMT, which allows 
cell invasion and migration, resulting in a penetrating fistula tract lined by 
transitional cells. Unfortunately, this theory is mainly based on the study of fistulae 
in patients with Crohn’s disease. It is therefore difficult to say if this theory is 




Figure 7 Pathogenesis of Crohn’s disease-associated fistulae as proposed by Scharl and Rogler (2014). An 
epithelial barrier defect favours the invasion of pathogen-associated patterns (PAMPs) into the gut mucosa 
(1). On the one hand, for wound healing purposes, intestinal epithelial cells (IEC) undergo epithelial-to-
mesenchymal transition (EMT) (2). On the other hand, the presence of PAMPs induce an inflammatory 
reaction resulting in increased secretion of tumour necrosis factor alpha (TNF-a) (3). TNF-a is able to 
induce secretion of transforming growth factor beta (TGF-b) as well as to induce EMT and expression of 
molecules associated with cell invasiveness, such as integrin-avb6 (aka b6-integrin). TGF-b-induced IL-13 
and elevated activation of matrix remodelling matrix metalloproteinases (MMPs) critically contribute to 
invasive cell growth (4). Finally, EMT, MMP over-activation and elevated expression of invasive molecules 





The majority of perianal fistula research to date has been conducted within the same 
paradigm built upon the assumption that idiopathic and Crohn’s perianal fistulae 
differ in their pathogenesis and pathophysiology. As previously discussed, the 
original theories of pathogenesis in these two disease groups were developed in 
parallel but separately and arose at different conclusions. Subsequent research has 
perpetuated this paradigm by continuing to study idiopathic and Crohn’s perianal 
fistulae in isolation from each other (Table 3).  
Only a handful of studies have attempted to compare the characteristics of perianal 
fistulae from each group. All these studies assumed there is a difference as the 
idiopathic group each time was used as the quasi-control group. These studies have 
indeed highlighted some differences between the groups.  However, the above 
careful review of the literature through a neutral construct has revealed that there just 
as many similarities as there are differences between idiopathic and Crohn’s perianal 
fistula disease. As such, this fundamental hypothesis has not yet been adequately 
tested.  
The core hypothesis of this study is that idiopathic and Crohn’s perianal fistulae 
differ in their pathogenesis and pathophysiology.  
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Table 3 The focus of previous studies of perianal fistulae. 
Idiopathic only Crohn’s disease only Idiopathic v. Crohn’s disease 
Parks (1961) 
Marks and Ritchie (1977) 
Grace et al. (1982) 
Seow-Cheon et al. (1992) 
Sangwan et al. (1984) 
Graf et al. (1995) 
de San Ildefonso Pereira et al. 
(2002) 
van Onkelen et al. (2013, 2016) 
Hughes (1978) 
Bernstein et al. (1980) 
Present et al. (1980, 1999) 
Marks et al. (1981) 
Brandt et al. (1982) 
Allan et al. (1982) 
Jacobovits and Schuster (1984) 
Irvine (1995) 
Bell at al. (2003) 
West et al. (2005) 
Roffolo et al. (2008) 
Maggie et al. (2013) 
Bataille et al. (2004, 2008) 
Kirkegaard et al. (2004) 
Tozer et al. (2011) 
 
1.14 Aim and Objectives 
The aim of this thesis was to compare idiopathic and Crohn’s perianal fistula disease. 
The objectives were to phenotypically compare: 
1. Clinical data, 
2. Cytokine profiles, 
3. Phosphoprotein profiles, and 
4. Dynamic contrast-enhanced (DCE) MRI data. 
The specific rationales for each of these approaches are discussed within their 




2.1 Study Design 
We conducted these observational studies within the basic construct of a prospective 
cohort study. This design appropriately balanced the potential for systematic high-
quality data collection across a range of outcomes (and covariates of outcome) 
against risk. We refrained from introducing any deviation from routine standard of 
care to minimise the latter.  
Nevertheless, we accepted that our design still carried limitations. One was the 
limitation of patient follow-up. This was constrained by the student’s tenure, which 
meant that the longest possible follow-up length was six months. We judged this to 
be adequate because clinical failures, such as recurrence of the fistula after surgery, 
usually occur within the first three to six months (Marks and Ritchie 1977). 
A possible alternative was a case-control study. Patients with Crohn’s perianal 
fistulae would have been selected consecutively as the cases and matched to 
idiopathic controls. This would have required fewer patients to be recruited but 
would have taken too long to achieve an adequate overall total. 
2.2 Controls 
The study of perianal fistulae is frustrated by the absence of an established control to 
compare it to. For instance, when studying colitis, we can compare affected colons 
with the colons of healthy individuals. However, perianal fistulae are non-existent in 
health. Therefore, like previous studies (Table 3 above), we chose to compare 
idiopathic with Crohn’s perianal fistulae, with the former acting as a quasi-control 
group.  
If we assume Park’s cryptogenic theory to be correct for both idiopathic and Crohn’s 
perianal fistulae, then the true control might be the healthy anal gland and its duct. 
Obtaining such tissue from healthy volunteers would cause unacceptable morbidity. 
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Such tissue could be available from abdominoperineal resection specimens. 
However, this option was not feasible for this study due to the generally low 
incidence of this operation and the fact that most are undertaken after neoadjuvant 
chemoradiotherapy, which has profound effects on the mucosa and submucosa. 
We also chose to biopsy the rectum in our participants (see Section 2.10). To provide 
a control for this, we also sampled the rectum in adults undergoing lower 
gastrointestinal endoscopy for non-inflammatory conditions. Further details on these 
participants are given in Chapter 4. 
2.3 Inclusion and Exclusion Criteria 
This study included all adults with an idiopathic or Crohn’s perianal fistula requiring 
surgical intervention. Studies that can be easily recruited to are able to maintain their 
momentum and achieve their target recruitment. Therefore, the inclusion criteria 
were intentionally broad to facilitate steady recruitment of a sample that was 
sufficiently generalizable. Adults without the capacity to give their informed consent 
were excluded. We did not include children because of the additional ethical barriers, 
the lower incidence and the possibility of a different pathogenesis.  
We excluded rectal, intestinal and subcutaneous fistulae because their pathogenesis is 
different. Rectal fistulae usually occur as a complication of previous surgery: 
improper probing of the external fistula tract can create a false tract and perforate the 
rectum. Intestinal fistulae can arise from intestinal pouches after a restorative 
proctocolectomy due to either anastomotic dehiscence or as a consequence of 
penetrating inflammatory bowel disease. Subcutaneous perianal fistulae may arise 
when an anal fissure heals over (Parks et al. 1976). 
To avoid undue heterogeneity, we excluded perianal fistulae secondary to diseases 
other than Crohn’s disease, such as tuberculosis and trauma.  
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2.4 Study Site 
The sole study site was Bart’s Health NHS Trust. It is the largest NHS Trust in the 
UK and serves a population of 2.5 million in the east of London and beyond (Barts 
Health NHS Trust 2015). It comprises five hospitals, three of which provide 
colorectal surgery services. 
The Royal London Hospital is the main centre within the Trust, and was the focus for 
the study. It is a secondary care centre and accepts referrals concerning patients with 
perianal fistulae from the surrounding community. A significant number of patients 
also initially present to the hospital’s urgent care centre and emergency department 
before being referred to the colorectal team, as either an inpatient admission or an 
outpatient appointment. The hospital is also a tertiary referral centre for patients with 
perianal fistula disease. Hospitals in north, central and east London, Essex and Kent, 
as well as the other four hospitals within the Trust, regularly refer patients who have 
not achieved clinical satisfaction with their treatment so far, which can range from 
none to multiple surgical attempts to eradicate the disease. The department also 
works closely with the co-located gastroenterology department, which itself is a 
tertiary referral centre for inflammatory bowel disease. As such, many patients with 
Crohn’s disease come as internal tertiary referrals.  
Whipps Cross University Hospital is also part of Barts Health and a secondary 
referral centre for perianal fistula disease. We included it as a recruitment centre, but 
we did not include Newham General Hospital, the third colorectal centre within the 
Trust, because resources were not available. 
2.5 Sample Size 
A formal sample size calculation was not relevant because this study was 
observational and there were no prior relevant data. We estimated that a reasonable 
degree of saturation would be provided by a minimum of 60 participants. 
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2.6 Study Scheme Diagram 
The overall study scheme is depicted in Figure 8. An explanation is given in the 
following paragraphs. 
 
Figure 8 Study scheme diagram. DCE, dynamic contrast enhanced; MRI, magnetic resonance imaging; 
PDAI, perineal disease activity index. 
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2.7 Participant Identification 
We identified potential participants at several points in their NHS care pathway, and 
then tracked them by recording their identifiers and upcoming hospital episodes in 
the research database. This then allowed the student to plan in advance whom to 
approach where and when, and minimised the number of potential participants 
missed. 
Referral Vetting 
The department agreed to channel all new referrals of patients with perianal disease 
to Professor Charles Knowles This common source allowed potential recruits to be 
tracked and approached by the student when they next visited the hospital.  
Outpatient Clinic 
All surgeons seeing patients with perianal fistula disease in the outpatient clinics 
were also asked to identify patients who met the inclusion criteria and notify the 
student or refer the patient on to Professor Knowles’ clinic. To maintain the profile 
of the study and thus encourage continued participant identification, the student 
maintained rapport through regular face-to-face contact with the surgeons. The 
student also saw patients in clinic on a regular basis and identified patients through 
this.  
Surgical Waiting Lists 
The student scanned the theatre schedules for potential participants each week, and 
regularly contacted the admissions team to ensure that ad hoc sessions outside the 




We also identified potential participants at a weekly meeting where surgeons, 
gastroenterologists and radiologists discussed patients with inflammatory bowel 
disease.  
Inpatients 
Surgeons who accepted acute admissions were asked to identify patients who met the 
inclusion criteria and notify the student. In many cases, their care was also 
transferred to Professor Knowles.  
Whipps Cross University Hospital 
Two consultant surgeons at Whipps Cross identified patients from their outpatient 
clinics and surgical waiting list. They explained the research and arranged for their 
operation on a dedicated list. 
2.8 Recruitment 
Eligible patients were approached in person by the student or, in some cases the 
research nurse, who explained the research, gave an information sheet, checked 
against the exclusion criteria and obtained written consent (Appendix 1). 
2.9 Baseline Evaluation 
Following recruitment, the student interviewed the participants to gather structured 
clinical information. In most cases, the student also examined the patient, except 
when a complete examination had recently been performed and documented by a 
senior surgeon. The student recorded the data on a bespoke paper case report form 
(CRF, Appendix 3), which included age, gender, ethnic origin, previous fistula 
disease and recurrence, presence of inflammatory bowel disease, previous medical 
and surgical treatment and response, current fistula disease duration and presence of 
seton, presence of stoma and smoking status. He also completed baseline Perineal 
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Disease Activity Index (PDAI, Irvine 1995) and EQ-5D-5L (Herdman et al. 2011) 
questionnaires with the participants. 
If after recruitment, participants required an MRI scan on a basis of clinical need (i.e. 
those who not had an MRI in the last year and had recurrent disease, suspected 
complex anatomy or an absent external fistula opening), it was arranged with the 
addition of a supplementary DCE protocol. Gathering DCE-MRI data from all 
participants would have been ideal. However this was not possible due to funding 
constraints and the observational nature of the design. Where only conventional MRI 
data were available, quantitative analysis was omitted. 
2.10 Surgery and Biopsies 
Participants underwent surgery as part of their clinical care. The student attended the 
operation and recorded the intraoperative findings on a bespoke CRF (Appendix 3). 
This included the number of fistulae and presence of branching, Parks’ classification, 
level of internal opening within the anal canal, position of the secondary tracts in 
relation to the levator ani, presence of horseshoe extensions, presence of associated 
collections (cavities > 3 mm diameter), rectal wall involvement, presence of 
hidradenitis suppurativa, and the surgical treatment given. If two or more separate 
fistulae were present, details of the most severe fistulae were recorded. 
During the procedure, biopsy samples were taken from 4 different sites: 
a. The fistula tract wall as far proximal as possible; 
b. The granulation tissue within the tract (if present); 
c. Mucosa from the internal opening (if present); and 
d. Mucosa from the distal rectum away from the internal opening. 
When the procedure was a lay-open, fistulectomy, LIFT or seton insertion (when an 
incision in the perineum at the external opening was initially necessary), it allowed 
adequate access to sample the fistula tract. To reduce the amount of cell damage and 
resultant artificial release of intracellular proteins, the surgeon used scissors and 
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scalpel and limited the use of diathermy until sampling was complete. When 
placement of a seton did not require an incision, they passed an endoscopic biopsy 
forceps into the external opening, advanced it to the proximal tract and used it to 
obtain the specimens. For the other biopsies, the surgeon sampled the granulation 
tissue with a blunt curette through the external opening, the internal opening with 
forceps and scissors through the anal canal, and the rectum with endoscopic cold 
biopsy forceps. 
The student immediately placed the samples in labelled containers with normal saline 
at 4°C, and then completed a specimen form (Appendix 3) and the specimen 
logbook. When all samples for an operating session had been obtained, the student 
transported them to the laboratory for immediate processing. The maximum time 
between taking the biopsies and delivery to the laboratory was 4 hours.  
2.11 Tissue Preparation and Storage 
In the laboratory, the student examined each specimen in a sterile petri dish under a 
microscope at room temperature, before trimming off faecal debris, blood clots, 
extraneous and damaged tissues using forceps and scissors. He then divided each 
specimen into equal samples approximately 2–3 mm3 in size. One sample was kept 
aside for immediate tissue culture. The remaining samples were transferred to 
cryotubes, labelled with participant ID and biopsy site, snap-frozen on dry ice for 
five minutes and then stored in a freezer at -80°C. Specific laboratory methods are 
discussed in the relevant chapters below. 
2.12 Clinical Follow-up 
We assessed participants in the outpatients’ clinic at six weeks and six months after 
their surgery. When this was not possible, the student reviewed the case notes and 
telephoned the participant. We recorded signs and symptoms suspicious for Crohn’s 
disease, investigations for Crohn’s disease (colonoscopy, barium meal and follow-
through, abdominal MRI, faecal calprotectin, intestinal biopsies), presence of 
confounding aetiology (HIV, TB), medical treatment received since recruitment, 
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overall response to treatment, management plan, microbiology results from surgery, 
PDAI and EQ-5D on a bespoke CRF (Appendix 3). 
2.13 Definitions and Classifications 
After considering the various grading definitions (see Section 1.4) together with our 
personal experience, we defined complex disease as a trans-sphincteric fistula with 
secondary tract or abscess or worse; or a recurrent or non-healing fistula after surgery 
with curative intent; or a fistula that only had a transient response or no response to 
seton insertion. We adopted the St Mark’s Hospital group’s definition of a low 
perianal fistula, which is an inter-sphincteric or trans-sphincteric fistula involving no 
more than 1 cm of external anal sphincter (Atkin et al. 2011). We classified patients 
as Crohn’s disease if they had received a formal diagnosis of Crohn’s disease from a 
specialist either before or during the study period.  
We classified the treatment intent as ‘symptom control’ when the procedure 
performed was none, curettage or seton insertion, and ‘cure’ when the procedure 
performed was lay open, fistulectomy or LIFT. For those whose treatment intent was 
symptom control, a satisfactory outcome was when symptoms were controlled or had 
resolved. For those whose treatment intent was cure, a satisfactory outcome was 
when symptoms had resolved. 
2.14 Study Database 
The student programmed a bespoke coded database using Access 2010 (Microsoft, 
Redmond WA). There were several features to minimise data entry errors. They were 
automatic assignment of a study identification number for each participant; 
automatic lookup to ensure data was recorded against the correctly registered 
participant; warnings for duplicate CRFs being entered; using codes with the 
corresponding label showing in a drop-down menu to allow quick visual checks; data 
validation and formatting rules; the on-screen layout corresponding to the paper CRF 
layout; and flagging of incomplete CRFs. The database also contained queries to 
derive calculated variables, which were length of follow-up in weeks, Van Assche 
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score, PDAI score, EQ-5D-5L health value, study group (idiopathic or Crohn’s 
disease), and treatment outcome subgroup. The database was validated before use by 
checking each table and query with dummy data. 
To facilitate effective case management, the database included a participant tracker, 
which listed upcoming events such as surgery, MRI and clinic visits, in 
chronological order along with the next action such as recruit, or follow up; a data 
tracker, which showed the complete and incomplete CRFs and when follow-up was 
due for each participant; and a recruitment tracker, which tabulated recruitment by 
group. Using these functions, the student periodically audited to identify missed 
appointments and missed follow-up. This allowed these anomalies to be corrected or 
mitigated in a timely manner. 
We determined data accuracy by selecting a random 10% sample of each CRF type 
and re-entering the data from the paper CRFs. This double-entered data was 
crosschecked against the originally entered data and mismatches were counted. One 
thousand four hundred and thirty-one data items across the six different CRFs were 
crosschecked. This revealed only nine (0.6%) mismatches. 
2.15 Statistical Analysis 
Once data collection was complete, the student extracted pseudo-anonymised data 
from the study database and imported it into SPSS Statistics version 22 (IBM, 
Armonk, NY). A standard process using SPSS syntax was used to ensure the data 
were handled appropriately with a full audit trail (Appendix 4). This process included 
reviewing and rectifying import errors; programming the data dictionary to set 
variable formats, variable labels, value labels, variable levels and user-missing 
values; programming filters to allow various analyses; inspecting the data for missing 
values, obvious mistakes and implausible values (uncertainties were resolved by 
consulting the original paper CRFs); and reviewing the histogram charts and 
Shapiro-Wilk tests of normality. Mean, standard deviation and parametric tests (e.g. 
independent samples t-test) were used for normal data, and median, interquartile 
 
63 
range and non-parametric tests (e.g. Kruskal-Wallis test) were used for non-normal 
data. We considered p ≤ 0.05 to be statistically significant, or p ≤ 0.01 where 




3. CLINICAL DATA 
3.1 Introduction 
As detailed in Chapter 1, perianal fistulae present with a broad range of clinical 
phenotypes: simple and complex, low and high, primary and recurrent, and 
idiopathic and secondary. Their morphology also varies, resulting in four main 
patho-anatomical types under the generally accepted Parks’ classification: inter-
sphincteric, trans-sphincteric, supra-sphincteric and extra-sphincteric (Parks et al. 
1976). The main symptoms are generally pain or discomfort and discharge, which 
can be present at varying levels of severity and fluctuate from week to week. In 
addition, the psychosocial impact upon the patient can range from none, to a 
prolonged period of unhappiness, sexual inhibition and poor work performance. 
Many colorectal surgeons believe that Crohn’s perianal fistulae tend to be more 
severe than idiopathic fistulae (Tozer et al. 2015). Crohn’s fistula morphology 
appears more commonly to be complex, with high fistulae, secondary tracts, 
horseshoe extensions and collections. They appear to exhibit a greater degree of 
inflammation and as such inflict a greater symptomatic burden upon the patient. 
Attempts to lay open and eradicate Crohn’s fistulae more commonly fail or end with 
recurrence. However, the literature lacks any direct comparison of the clinical 
phenotypes between these two groups. 
The clinical assessment of perianal fistulae is largely subjective, relying on the 
clinician to take a detailed history from the patient and perform a careful clinical 
examination. Methods of objectively measuring perianal fistula disease activity have 
only been developed in Crohn’s disease. These include that in Present et al. (1980), 
the Anal Disease Activity Index (Allan et al. 1992), the Perianal Disease Activity 
Index (PDAI, Irvine 1995), the Fistula Drainage Assessment (Present et al. 1999) 
and Pikarsky's Perianal Crohn's Disease Activity Index (Pikarsky et al. 2002). The 
Fistula Drainage Assessment measures the number of open draining fistulae 
(including enterocutaneous) on clinical examination, with criteria to describe either 
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improvement or remission, and was used as the primary endpoint in a seminal trial 
showing the efficacy of infliximab in treating Crohn’s fistulae (Present et al. 1999). 
The PDAI, which scores five domains on a Likert scale, has also been used in 
clinical trials (Present et al. 1999). Although it has not generally been adopted into 
routine clinical practice, it is considered the current gold standard for assessing 
perianal Crohn’s disease (Sostegni et al. 2003). 
There are currently no validated objective methods described for assessing the 
activity of idiopathic perianal fistulae. Of those described in perianal Crohn’s 
disease, the PDAI is most applicable, as it does not attempt to measure features that 
are generally only present in Crohn’s disease, e.g. concomitant intestinal disease, 
which is included in Pikarsky’s Perianal Crohn’s Disease Activity Index. 
Quality of life is also another important consideration. The commonest instrument 
used in trials concerning Crohn’s disease is the Inflammatory Bowel Disease 
Questionnaire (IBDQ, Guyatt et al. 1989). However the IBDQ has not been validated 
in patients with primarily fistulating Crohn’s disease. Similarly, quality of life data 
for patients with idiopathic perianal fistulae are scarce. Sailer et al. studied the 
Gastrointestinal Quality of Life Index (GIQLI) in patients with benign anorectal 
disorders, which included 22 patients with perianal fistula (Sailer et al. 1998). In 
subgroup analysis, the GIQLI did not discriminate between patients with perianal 
fistulae and the controls.  
In summary, the current literature contains little data on the clinical phenotypes that 
are present in both idiopathic and Crohn’s perianal fistula disease. This study aimed 
to describe and compare the clinical features of this disease in these groups. 
3.2 Methods 
The methodology for recruitment, data measurement, follow-up and analysis of the 
study cohort is described in Chapter 2. Two patient-reported outcome measures were 
chosen to augment the clinical assessment at baseline and follow-up: one to measure 
disease activity, and one to measure quality of life.  
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The PDAI was chosen as the measure of disease activity. It was judged to be the gold 
standard in Crohn’s perianal fistula and most easily applicable to the idiopathic 
group for the reasons discussed above. However, it is noted that the PDAI is only 
validated in Crohn’s perianal fistula. The instrument comprises five domains (Table 
4). Each domain of discharge, pain, restriction of sexual activity, type of perianal 
disease and degree of induration is estimated between patient and clinician on a 
Likert scale from zero to four. The final index score is the sum total of the scores in 
each domain, with a score greater than four suggesting active disease requiring 
medical or surgical treatment (Losco et al. 2009). 
General quality of life data was captured using the 5L version of the EQ-5D 
questionnaire (Herdman et al. 2011). It is a well-validated tool and one of the most 
widely used generic measures of health status. It comprises five questions that allow 
five levels of severity in their answers (Table 5). Concatenation of the numerical 
answers produces a five-digit health state. These health states are then mapped using 
published country-specific value sets (EuroQol 2015) to an index value on a scale 
anchored at one (full health) to zero (dead), which reflect the preferences of the 
general public. The questionnaire also has an additional item that asks the subject to 
grade their current overall health on a visual-analogue scale (VAS) ranging from 
zero to 100. 
Other measures were considered. The GIQLI, mentioned earlier, comprises 36 
multidimensional items covering symptoms, and physical, emotional and social 
dysfunction related to gastrointestinal diseases or their treatments. Each item scores 
between zero and four points. The overall score is the sum of all item scores where 
zero represents the worst and 144 represents the best possible results. The SF-36 is 
another widely-used generic health survey which gives an eight-scale profile of 
functional health and well-being scores as well as psychometrically-based physical 
and mental health summary measures and a preference-based health utility index 
(Ware 2002). Although these instruments may have provided greater granularity, 
many of the questions would have seemed irrelevant to the participants and the 
length of the questionnaire onerous. 
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Table 4 Perianal Crohn's Disease Activity Index (PDAI). 
Discharge: 
0 No discharge 
1 Minimal mucous discharge 
2 Moderate mucous or purulent discharge 
3 Substantial discharge 
4 Gross faecal soiling 
Type of perianal disease: 
0 No perianal disease / skin tags 
1 Anal fissure or mucosal tear 
2 < 3 Perianal fistulae 
3 ≥ 3 Perianal fistulae 
4 Anal sphincter ulceration or fistulae with 
significant undermining of skin 
Pain / restriction of activities: 
0 No activity restriction 
1 Mild discomfort, no restriction 
2 Mod. Discomfort, some limitation activities 
3 Marked discomfort marked limitation 
4 Severe pain, severe limitation 
Degree of induration: 
0 No induration 
1 Minimal induration 
2 Moderate induration 
3 Substantial induration 
4 Gross fluctuance / abscess 
Restriction of sexual activity: 
0 No restriction sexual activity 
1 Slight restriction sexual activity 
2 Mod. Limitation sexual activity 
3 Marked limitation sexual activity 
4 Unable to engage in sexual activity 




Table 5 EQ-5D-5L questionnaire. 
Mobility: 
1 I have no problems in walking about 
2 I have slight problems in walking about 
3 I have moderate problems in walking about 
4 I have severe problems in walking about 
5 I am unable to walk about 
Self-Care: 
1 I have no problems washing or dressing myself 
2 I have slight problems washing or dressing myself 
3 I have moderate problems washing or dressing myself 
4 I have severe problems washing or dressing myself 
5 I am unable to wash or dress myself 
Usual Activities: 
1 I have no problems doing my usual activities 
2 I have slight problems doing my usual activities 
3 I have moderate problems doing my usual activities 
4 I have severe problems doing my usual activities 
5 I am unable to do my usual activities 
Pain/discomfort: 
1 I have no pain or discomfort 
2 I have slight pain or discomfort 
3 I have moderate pain or discomfort 
4 I have severe pain or discomfort 
5 I have extreme pain or discomfort 
Anxiety/depression: 
1 I am not anxious or depressed 
2 I am slightly anxious or depressed 
3 I am moderately anxious or depressed 
4 I am severely anxious or depressed 
5 I am extremely anxious or depressed 
EQ VAS (question accompanied by linear graduated scale from 0 to 100) 
We would like to know how good or bad your health is today. This scale is numbered from 0 to 100. 
100 means the best health you can imagine. 0 means the worst health you can imagine. Mark an X 
on the scale to indicate how your health is TODAY. Now, please write the number you marked on 






Between March 2014 and April 2015, 130 consecutive patients were identified as 
potential participants. Figure 9 details the participant flow during the study. A total 
of 61 were included and followed-up, of whom 48 (79%) had idiopathic disease and 
13 (11%) had Crohn’s disease There was a preponderance of males (3:1) and the 
mean age was 40.0 years (SD = 13.3), in keeping with the general epidemiology of 
perianal fistula disease. The majority were of Asian ethnicity, reflecting the local 
population demographics. 
The median duration when the fistula had been present at recruitment was 36 months 
(IQR = 14–60) and the median number of previous operations was one (IQR = 0–4), 
demonstrating the chronicity and persistence of the disease (and perhaps referral 
practice). Ten (16%) had previously had surgery with curative intent. Further 
baseline characteristics are detailed in Table 6. Both idiopathic and Crohn’s disease 
groups had similar distributions of these characteristics, except for the number 
previously receiving antibiotics: this was higher in the idiopathic group (81% versus 
23%). 
None of the participants had a stoma. HIV infection was excluded by blood test in 28 
(46%) and clinically in 33 (54%). TB infection was excluded by TB culture in 49 




Figure 9 Participant flow diagram. 
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Table 6 Participant characteristics. SD, standard deviation; IQR, interquartile range. 
 Idiopathic Crohn's Disease All 
n 48 13 61 
Male 38 (79%) 8 (62%) 46 (75%) 

























Median fistula duration (IQR), months 35 (14–60) 48 (17–66) 36 (14–60) 
Previously received antibiotics 39 (81%) 3 (23%) 42 (69%) 
Median previous operations (IQR) 1 (0–4) 0 (0–4) 1 (0–4) 
Previously had surgery with curative 
intent 9 (19%) 1 (8%) 10 (16%) 
Current smoker 22 (46%) 4 (31%) 26 (43%) 
 
Of the 13 participants who had Crohn’s disease, six had previous abdominal fistulae, 
six had previous abdominal surgery, and two were diagnosed with Crohn’s disease 
during the study. At the time of recruitment, five participants were currently 
receiving and one had previously received anti-TNF-a antibody therapy (Table 7). 
All Crohn’s disease participants had imaging features that were consistent with 
Crohn’s disease; 12 had histological features consistent with Crohn’s disease and six 
of these featured granulomas (Figure 10). Imaging included diagnostic signs on 
colonoscopy, MRI abdomen or barium small bowel follow-through, or a combination 
thereof. 
In the 48 participants who had idiopathic disease, 32 participants underwent imaging, 
namely colonoscopy, MRI of the abdomen and/or barium small bowel follow-
through, to exclude underlying Crohn’s disease. This included one patient who had a 
single granuloma in a previous operative fistula specimen, but had subsequent 
 
72 
negative imaging and intestinal biopsy results. Of the other 16, none had symptoms 
to suggest Crohn’s disease. Reasons for not performing imaging in these participants 
were patient declined (n = 4) and not clinically indicated (12). Thus, no patient with 
abdominal symptoms suggestive of Crohn’s disease went un-investigated. 
Additionally, out of these 16 patients, 12 had their fistula specimens examined 
histologically, and none showed signs of Crohn’s disease. 
Table 7 Characteristics of Crohn's disease participants. 
n 13 
Crohn's disease diagnosed 
during study 2 (21%) 










Receiving anti-TNF-a at 
recruitment 5 (38%) 
Previous abdominal fistulae 6 (46%) 
Previous abdominal surgery 6 (46%) 
 
 
Figure 10 Diagnostic features of Crohn's disease participants. Imaging features includes diagnostic signs 




There were 44 participants with complex disease: 32 (67%) in the idiopathic group 
and 12 (92%) in the Crohn’s disease group (Figure 11).  
PDAI at baseline was measured in all but one participant. The mean scores for each 
PDAI domain were similar, except for induration, which was 0.61 and 2.29 in the 
idiopathic and Crohn’s disease participants respectively (Table 8 and Figure 12). The 
PDAI was significantly higher in the Crohn’s disease participants with a mean 
difference of 2.40 (95% CI = 0.52–4.28, p = 0.01). 
EQ-5D-5L was measured at baseline in all but one participant (98%). We checked 
the original data for two outliers with very low EQ index values and confirmed they 
were correct. One participant who was wheelchair-bound due to a neurological 
condition returned an EQ-5D-5L health state that corresponded to a negative index 
value (-0.034). A negative health value represents a state considered ‘worse than 
death’, a concept supported by prior literature (Kind et al. 2006). The other patient, 
whose index value at baseline was 0.091, also had poor mobility. 
Similar EQ-5D-5L levels were reported in the idiopathic and Crohn’s disease 
participants in each dimension except usual activities, where a higher proportion of 
Crohn’s disease participants reported higher levels (Table 9). The mean EQ VAS and 




Figure 11 Comparison of clinical features. Complex trans-sphincteric: trans-sphincteric fistulae with 
secondary tract or abscess; recurrent disease: a recurrent or non-healing fistula after curative surgery; 
inadequate response to a seton: transient or no symptomatic response from a seton. 
Table 8 PDAI at baseline. Mean (standard deviation) shown. N = 60. Each domain range is 0–4, PDAI 
range is 0–20. p estimated using independent samples t-test. 
 Idiopathic Crohn’s Disease All 
Discharge 1.37 (0.95) 1.86 (1.10) 1.48 (1.00) 
Pain/restriction 1.09 (1.09) 1.50 (1.29) 1.18 (1.14) 
Sexual function 0.59 (1.24) 0.43 (1.16) 0.55 (1.21) 
Type 2.02 (0.15) 2.00 (0.78) 2.02 (0.39) 
Induration 0.61 (0.74) 2.29 (1.27) 1.00 (1.13) 
PDAI 5.67 (2.76) 8.07 (3.99) 6.23 (3.22) 
 
PDAI mean difference = 2.40  





Figure 12 Mean PDAI at baseline. Range 0 to 20. Error bars show 95% confidence intervals. 
Table 9 EQ-5D-5L dimensions at baseline. Percentage of participants reporting levels 1 to 5 (level 1 = no 
problems). N = 60. 
  
Idiopathic Crohn's Disease All 
Mobility 
Level 1 67% 57% 65% 
Level 2 20% 21% 20% 
Level 3 4% 21% 8% 
Level 4 7% 0% 5% 
Level 5 2% 0% 2% 
Self-care 
Level 1 89% 93% 90% 
Level 2 4% 7% 5% 
Level 3 7% 0% 5% 
Level 4 0% 0% 0% 
Level 5 0% 0% 0% 
Usual activities 
Level 1 70% 43% 63% 
Level 2 15% 14% 15% 
Level 3 2% 36% 10% 
Level 4 7% 0% 5% 
Level 5 7% 7% 7% 
Pain/discomfort 
Level 1 33% 29% 32% 
Level 2 37% 36% 37% 
Level 3 26% 21% 25% 
Level 4 2% 14% 5% 
Level 5 2% 0% 2% 
Anxiety/depression 
Level 1 63% 50% 60% 
Level 2 26% 36% 28% 
Level 3 4% 7% 5% 
Level 4 4% 7% 5% 















Table 10 EQ VAS and index values at baseline. Mean (standard deviation) shown. N = 60. p estimated 
using independent samples t-test. 
 Idiopathic Crohn’s Disease All 
EQ VAS 71.2 (21.1) 63.4 (20.2) 69.4 (21.0) 
 p = 0.22  
EQ index 0.734 (0.259) 0.715 (0.214) 0.730 (0.247) 
 p = 0.80  
 
 
Figure 13 Mean EQ VAS and index at baseline. Error bars show 95% confidence intervals. 
Operative Findings 
Observations at operation revealed that 39% of patients had a seton in situ, reflecting 
that the fistulae were complex or refractory in a large proportion of this group (Table 
11). Multiple fistulae were more prevalent in Crohn’s disease participants as one 
would expect (23% versus 4%). The distribution of the different types of fistulae 
under the Parks’ classification was the same between the groups, with trans-
sphincteric being by far the commonest. Prevalence of a high primary tract and 
horseshoe extensions were also similar. However, supralevator extensions were 
statistically more common in Crohn’s disease group (Fisher exact two-sided test 
p = 0.02). The prevalence of collections was significantly higher in the Crohn’s 
group (92% versus 33%, p < 0.001). Rectal thickening was also significantly 
commoner in the Crohn’s disease group (54% versus 2%), however this is expected 






























Results of microbiological culture of intraoperative fistula specimens were available 
for 50 (82%) participants and yielded similar results for idiopathic and Crohn’s 
disease participants (Table 12). The commonest were no growth, Coliforms, 
Enterococcus and Streptococcus species. 
Table 11 Operative findings. N = 61. Fisher’s Exact test is two-sided.  
 Idiopathic Crohn’s Disease All 
Seton in situ 21 (44%) 3 (23%) 24 (39%) 

































 p = 0.54  
High primary tract 15 (31%) 6 (46%) 21 (34%) 

















 p = 0.02  
Horseshoe extension(s) 12 (25%) 5 (38%) 17 (38%) 
 p = 0.49  
Collection(s) 16 (33%) 12 (92%) 28 (46%) 
 p < 0.001  
Thickened rectum 1 (2%) 7 (54%) 8 (13%) 




Table 12 Bacterial isolates from culture of intraoperative fistula specimens. N = 50. 
 Idiopathic Crohn’s Disease All 
No growth 18 (46%) 5 (45%) 23 (46%) 
Coliforms 14 (36%) 4 (36%) 18 (36%) 
Enterococcus 2 (5%) 1 (9%) 3 (6%) 
Streptococcus 6 (15%) 1 (9%) 7 (14%) 
Proteus 1 (3%) 0 1 (2%) 
Morganella 0 1 (9%) 1 (2%) 
Bacillus 0 1 (9%) 1 (2%) 
Corneybacterium 0 1 (9%) 1 (2%) 
Klebsiella 2 (5%) 0 2 (4%) 
Staphylococcus 1 (3%) 0 1 (2%) 
Actinomyces 1 (3%) 0 1 (2%) 
 
Treatment Outcomes 
The majority of patients (62%) had an operation aimed at symptom control only 
(curettage or seton insertion; Table 13). A curative procedure was only performed in 
one Crohn’s disease participant, compared with 22 (45%) idiopathic disease 
participants. During the study, 30% received antibiotics. Almost half of the Crohn’s 
disease participants received anti-TNF-a therapy. One patient with severe perianal 
hidradenitis suppurativa but without Crohn’s disease also received anti-TNF-a 
therapy. 
All participants completed the first follow-up at a median of 7 weeks (IQR = 6–11); 
54 (89%) completed the second follow-up at a median of 29 weeks (25–37). By the 
end of the follow-up period only 12 (20%) had been discharged, 26 (43%) were 
being monitored or treated with drugs, while 23 (38%) were scheduled for further 
surgery. Proportionally less Crohn’s disease patients were scheduled for further 
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surgery, reflecting the general strategy in this group, which favours adjuvant anti-
TNF-a therapy. Of note, those scheduled for further surgery included those who had 
a seton inserted and required the next stage of their treatment, as well as those who 
had had an unsatisfactory outcome. 
When stratified by treatment intent, 28 (73%) of those whose treatment intent was 
symptom control had control or resolution of their symptoms (Table 14). Treatment 
response was similar for idiopathic and Crohn’s disease participants. For those 
whose treatment intent was cure, 13 (59%) had resolution of their symptoms. 
Comparisons between idiopathic and Crohn’s disease groups for this treatment intent 
were not possible as only one Crohn’s disease participant underwent a curative 
procedure. 
When treatment intent and response were considered together, 41 (68%) had a 
satisfactory outcome by the end of the follow-up period (Table 15). Similar rates of 
satisfactory outcomes were observed between the idiopathic and Crohn’s disease 
groups (see Section 2.13 for definitions). 
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Table 13 Clinical outcomes for participants after surgery. IQR, interquartile range; LIFT, ligation of 
inter-sphincteric fistula tract; 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor. 

























Medical treatment received  
(highest order):    
None 29 (62%) 2 (15%) 31 (52%) 
Antibiotics 16 (34%) 2 (15%) 18 (30%) 
5-ASA 0 1 (8%) 1 (2%) 
Steroids 1 (2%) 0 1 (2%) 
Immunosuppressants 0 2 (15%) 2 (3%) 
Anti-TNF-a 1 (2%) 6 (46%) 7 (12%) 
Management plan:    
Discharge 9 (19%) 3 (23%) 12 (20%) 
Monitor 18 (38%) 2 (15%) 20 (33%) 
Continue drugs 0 1 (8%) 1 (2%) 
Escalate drugs 1 (2%) 4 (31%) 5 (8%) 
Further surgery 20 (42%) 3 (23%) 23 (38%) 
 
Table 14 Treatment response by treatment intent. Symptom control operations were curettage and seton 
insertion. Curative operations were lay open, fistulectomy and LIFT (ligation of inter-sphincteric fistula 
tract). 
Treatment Intent and Response Idiopathic Crohn’s Disease All 
Symptom control 
None 1 (4%) 0 1 (3%) 
Inadequate 1 (4%) 1 (8%) 2 (5%) 
Transient 6 (23%) 1 (8%) 7 (18%) 
Controlled 17 (65%) 9 (75%) 26 (68%) 
Resolved 1 (4%) 1 (8%) 2 (5%) 
Total 26 12 38 
Cure 
None 0 0 0 
Inadequate 1 (5%) 0 1 (5%) 
Transient 4 (19%) 0 4 (18%) 
Controlled 3 (14%) 1 (100%) 4 (18%) 
Resolved 13 (62%) 0 13 (59%) 




Table 15 Treatment outcomes with treatment intent taken into consideration. When symptom control was 
intended a treatment response of controlled or resolved was classified as satisfactory. When a cure was 
intended, a treatment response of resolved only was classified as satisfactory. 
 Idiopathic Crohn’s Disease All 
Unsatisfactory 16 (34%) 3 (23%) 19 (32%) 
Satisfactory 31 (66%) 10 (77%) 41 (68%) 
 
Post-operative Perineal Disease Activity Index 
We measured the PDAI at the first and second follow-up points in 57 (93%) and 48 
(79%) participants respectively. Overall, the mean PDAI decreased from 6.23 (SD = 
3.22) at baseline, to 5.00 (3.91) at first follow-up and to 5.56 (4.21) at second follow-
up. Both groups had a similar post-operative decrease (Table 16 and Figure 14). In 
the idiopathic group, the ‘type’ domain showed the biggest change decreasing from 
2.02 (0.15) to 1.34 (0.94). This is because many participants in this group had an 
uncomplicated lay open and thus went from having a fistula opening to a fissure or 
no perianal disease. Conversely, in the Crohn’s disease group where insertion of a 
seton predominated, the ‘type’ domain showed little change. Rather in this group, 
there was a noticeable reduction in the discharge and induration domain scores. 
When divided by treatment outcome, the PDAI decreased in those who had a 
satisfactory outcome and increased in those who had an unsatisfactory outcome 
(Figure 14; Table 38 in Appendix 8). 
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Table 16 PDAI at baseline (t0), first follow-up 1 (t1) and second follow-up (t2). Mean (standard deviation) 
shown. Each domain range is 0–4, PDAI range is 0–20. 
 Idiopathic Crohn’s Disease All 
 t0 t1 t2 t0 t1 t2 t0 t1 t2 








































































































Figure 14 Mean PDAI from baseline to second follow-up by fistula type (left) and treatment outcome 






























We measured the EQ-5D-5L at the first and second follow-up points in 56 (92%) and 
48 (79%) participants respectively. The mean EQ VAS for both groups decreased 
between baseline and second follow-up. Both groups had a similar post-operative 
decrease (Table 17 and Figure 15). The mean EQ index for both groups also 
decreased between baseline and second follow-up.  
We also observed changes in the individual EQ-5D-5L dimensions. Compared with 
baseline, there were increased levels for mobility at both follow-up points (Table 18). 
Mobility returned to baseline levels by the second follow-up for Crohn’s disease but 
not idiopathic disease participants. Self-care levels worsened post-operatively, 
especially in the Crohn’s disease participants, where the proportion reporting no 
restrictions (level 1) fell from 93% at baseline to 73% at follow-up. Difficulties in 
performing usual daily activities remained the same post-operatively in both groups. 
Pain and discomfort in the idiopathic disease group improved post-operatively but 
returned to baseline at the second follow-up. Conversely, in the Crohn’s disease 
group, pain and discomfort increased post-operatively but then returned to baseline at 
the second follow-up. Anxiety and depression improved post-operatively in the 
idiopathic group, but increased in the Crohn’s disease group. 
When grouped by treatment outcome, the EQ VAS and EQ index improved in those 
who had a satisfactory outcome. In those who had an unsatisfactory outcome, these 
measures deteriorated (Figure 16; Table 39 and Table 40 in Appendix 8). 
 
84 
Table 17 EQ VAS and EQ index values at baseline (t0), follow-up 1 (t1) and follow-up 2 (t2). Mean 
(standard deviation) shown. 
 Idiopathic Crohn’s Disease All 














































































Table 18 EQ-5D-5L dimensions at baseline (t0), first follow-up (t1) and second follow-up (t2). Percentage 
of participants reporting levels 1 to 5 (level 1 = no problems). 
  Idiopathic Crohn’s Disease All 
  t0 t1 t2 t0 t1 t2 t0 t1 t2 
Mobility 
Level 1 67% 69% 65% 57% 43% 55% 65% 63% 63% 
Level 2 20% 5% 11% 21% 14% 18% 20% 7% 13% 
Level 3 4% 14% 16% 21% 36% 18% 8% 20% 17% 
Level 4 7% 10% 8% 0% 7% 9% 5% 9% 8% 
Level 5 2% 2% 0% 0% 0% 0% 2% 2% 0% 
Self-care 
Level 1 89% 81% 89% 93% 71% 73% 90% 79% 85% 
Level 2 4% 12% 3% 7% 21% 18% 5% 14% 6% 
Level 3 7% 7% 3% 0% 7% 9% 5% 7% 4% 
Level 4 0% 0% 5% 0% 0% 0% 0% 0% 4% 
Level 5 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Usual 
activities 
Level 1 70% 67% 73% 43% 50% 45% 63% 63% 67% 
Level 2 15% 5% 3% 14% 7% 9% 15% 5% 4% 
Level 3 2% 12% 14% 36% 29% 18% 10% 16% 15% 
Level 4 7% 12% 8% 0% 14% 18% 5% 13% 10% 
Level 5 7% 5% 3% 7% 0% 9% 7% 4% 4% 
Pain/ 
discomfort 
Level 1 33% 52% 30% 29% 14% 36% 32% 43% 31% 
Level 2 37% 17% 22% 36% 57% 9% 37% 27% 19% 
Level 3 26% 17% 19% 21% 29% 36% 25% 20% 23% 
Level 4 2% 14% 27% 14% 0% 18% 5% 11% 25% 
Level 5 2% 0% 3% 0% 0% 0% 2% 0% 2% 
Anxiety/ 
depression 
Level 1 63% 71% 70% 50% 43% 45% 60% 64% 65% 
Level 2 26% 7% 11% 36% 21% 0% 28% 11% 8% 
Level 3 4% 14% 5% 7% 21% 55% 5% 16% 17% 
Level 4 4% 7% 11% 7% 7% 0% 5% 7% 8% 





Figure 16 Mean EQ VAS and EQ index from baseline to second follow-up by treatment outcome. Error 
bars show 95% confidence intervals. 
3.4 Discussion 
We recruited a cohort of 61 consecutive participants with perianal fistula disease, 
carefully recording their clinical features at baseline and over a median follow-up 
period of 30 weeks. The age and sex distribution of the cohort was similar to 
previous studies (Marks and Ritchie 1977). All fistulae were chronic, with a median 
duration of disease prior to recruitment of 36 months. And at recruitment, 
participants were at varying stages of treatment, from those who had never had an 
operation, to those with a seton in situ, to those who had had up to four operations, 
including 10 (16%) who had previous surgery with curative intent. Simple and 
complex fistulae were also represented. 
Overall, the cohort had a wide distribution of phenotypes including those with simple 
and complex, low and high, and primary and recurrent perianal fistula disease in both 
the idiopathic and Crohn’s disease groups. 
In contrast to many previous studies that focused on idiopathic or Crohn’s disease 
fistulae separately (Table 3), we systematically recruited an adequate number of 
participants from both groups. The total of 61 recruited patients, including 13 with 
Crohn’s disease, makes this the largest study to date to phenotype the disease 
across both groups in detail. A further strength of this study was that we thoroughly 


































participants were diagnosed with Crohn’s disease during the study period. Equally, 
we systematically excluded Crohn’s disease in all participants in the idiopathic 
group. Participants in the Crohn’s disease group were well characterized with all 
having imaging findings consistent with Crohn’s disease, and all but one having 
histological features of Crohn’s disease. The group showed a range of clinical 
phenotypes including those with and without abdominal complications and those 
who were and were not naive to anti-TNF-a treatment. 
The PDAI was validated in a Crohn’s perianal fistula population (Irvine 1995; Losco 
et al. 2009) but it has not yet been tested in an idiopathic group. The present study 
found that measurement of the PDAI in this group was feasible. At baseline, the 
PDAI was significantly higher in the Crohn’s disease group, with a mean difference 
of 2.40 (95% CI = 0.52–4.28, p = 0.01). This may suggest that Crohn’s perianal 
fistulae in general exhibit a higher degree of disease activity, which would fit with 
the commonly held clinical impression that Crohn’s perianal fistulae are more severe 
than idiopathic. 
In the post-operative follow-up, the PDAI decreased by a small amount. The mean 
difference between the idiopathic and Crohn’s disease groups was maintained 
demonstrating stability of the index. When stratified by treatment outcome, the PDAI 
increased in those who had an unsatisfactory outcome, demonstrating the index’s 
sensitivity to clinical changes. Furthermore, this deterioration was only evident at the 
second follow-up. This is consistent with clinical experience and probably reflects 
time to surgical healing. 
The EQ-5D-5L is a generic measure of overall health and is commonly used in 
health economic evaluations. Data have been reported in many different diseases but 
not in perianal fistula disease. We found similar EQ index values in the idiopathic 
and Crohn’s disease groups. Patients with Crohn’s disease have a significant burden 
of disease. Whether their disease is active or quiescent, they have to cope with 
regular hospital appointments and investigations, blood tests, daily medication, 
dietary restrictions, and systemic symptoms. This commonly leads to a degree of 
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impairment of their lifestyle, aspirations and mood. The current results suggest (for 
the first time) that idiopathic fistula disease brings a burden of disease similar to 
Crohn’s disease. Perianal fistulae cause chronic and unpredictable symptoms that 
precipitate multiple hospital visits and interventions. The symptoms are also socially 
embarrassing and impact upon the patient’s confidence or ability to participate fully 
in day-to-day life and work. This was not previously appreciated.  
The EQ VAS population norm in the UK for ages 35–44 years is 86.6 (Szende et al. 
2014, pp.19–30). In our cohort, the EQ VAS at baseline was 71.2 (21.1) and 63.4 
(20.2) for the idiopathic and Crohn’s disease groups respectively. The EQ index 
population norm in England for ages 35–44 years is 0.891 (Szende et al. 2014, 
pp.19–30). In our cohort, the EQ index value at baseline was 0.734 (SD = 0.259) and 
0.715 (SD = 0.214) for the idiopathic and Crohn’s disease groups respectively. Other 
diseases which have a similar EQ index value include depression (0.732), ischaemic 
heart disease (0.738) and gastric ulcer (0.727) (Sullivan and Ghushchyan 2006). 
A comparison of the bacterial isolates from culture of intraoperative fistula 
specimens has not been previously published. The present study found no growth in 
46% of cases. The commonest isolates were both gut and skin-derived organisms: 
coliforms, enterococcus and streptococcus. Their distributions were similar between 
the groups.   
Our findings between the idiopathic and Crohn’s disease groups are summarised in 
Table 19. The baseline PDAI, a measure of disease activity (in perianal Crohn’s 
disease), was significantly higher in the Crohn’s disease group, mainly due to 
increased induration scores. At operation, there were more multiple fistulae, and 
significantly more supralevator extensions, collections and rectal thickening. To our 
knowledge, this is the first direct comparison that supports the current opinion that 
severe disease is more common in Crohn’s perianal fistulae. However, severe disease 
was not exclusive to the Crohn’s disease group. Both groups had fistulae on the full 
spectrum from simple to complex. We also observed many similarities between the 
groups. The baseline EQ VAS and EQ index scores, distribution of types by Park’s 
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classification, prevalence of high fistulae and horseshoe extensions, post-operative 
PDAI, EQ VAS and EQ index trends were all similar. Therefore despite the evidence 
above that Crohn’s perianal fistulae are often more severe than idiopathic fistulae, 
they are not phenotypically different. 
Table 19 Summary of clinical data comparisons between idiopathic and Crohn’s perianal fistulae. PDAI, 
perianal disease activity index; VAS, visual analogue score. 
 Similarities  Differences 
Baseline PDAI  Significantly higher PDAI in 
Crohn’s disease 
Baseline EQ-5D-5L Similar EQ VAS and EQ index  
Morphology Similar distribution of types by 
Parks’ classification 
Similar prevalence of high fistulae 
and horseshoe extensions 
More multiple fistulae in Crohn’s 
disease 
Significantly more supralevator 
extensions, collections and rectal 
thickening in Crohn’s disease 
Microbiological culture Similar isolates  
Post-operative PDAI Similar decrease in  
post-operative PDAI 
 
Post-operative EQ-5D-5L Similar decrease in post-operative 
EQ VAS and EQ index  
 
 
Regarding the operations and outcomes, the majority of participants (38/61, 62%) 
received an operation aimed at symptom control only (curettage or seton insertion). 
This is consistent with current practice for complex fistulae where symptom control 
is paramount before operations with curative intent such as lay open are attempted. It 
also reflected the referral pattern to Professor Knowles’ practice where many 
patients’ fistulae were previously worsened by unsuccessful curative procedures. 
When the operation was with intent to control symptoms only, this was successful in 
the majority of participants (28/38, 73%). When the operation was with curative 
intent, this was successful in the majority (13/22, 59%). Thus overall, 41/61 (68%) 
had a satisfactory outcome, and this was similar between the idiopathic and Crohn’s 
disease groups. Due to the heterogeneous distribution of the operative interventions 
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in this cohort, it is difficult to compare this outcome with other studies. However, the 
student recognises this to be in line with common clinical practice: it is frequent for a 
fistula operation to miss its therapeutic ambition and thus necessitate further 
intervention. 
Limitations 
We included patients from all stages of management, from those who were 
treatment-naïve, to those who had had multiple surgical procedures aimed at 
effecting a cure. This was to allow the study to recruit effectively within the time 
allowed. However this did increase the heterogeneity. 
We only recruited patients who were planned for surgery for one reason or another. 
Therefore those with perianal fistula disease that was too mild to meet the threshold 
for surgery were excluded. This selection bias therefore limits the applicability of 
these data to this segment of the population. Furthermore, the threshold for surgery 
could have been different between the groups due to differing clinical strategies. If 
so, this selection bias may have introduced a difference between the groups. 
The main study site was a tertiary referral centre. A more representative sample 
might have been achieved through multicentre recruitment. However, despite this, 
the recruited cohort of had participants with a wide distribution of disease 
phenotypes and an expected range of treatment outcomes. The sample size, although 
comparable to the majority of previous studies on the subject, was relatively small. 
This limited the capability of the statistical analysis. 
Analysis of the outcomes following operative intervention was limited by the 
observational design. There was a varied mix of different interventions with either 
intention to control symptoms or cure, and only one patient in the Crohn’s disease 
group underwent surgery with curative intent. The resultant heterogeneity made the 
clinical outcomes difficult to compare against contemporary data. Furthermore, the 
absence of observer blinding could have introduced a source of bias. However, 
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assessing the effect of operative intervention was not a primary objective of this 
study. 
We only performed standard laboratory microscopy and cultures of intraoperative 
specimens. Although the results provide useful information, we acknowledge that 
there are more sophisticated methods of interrogating the microbiota in fistula tracts 
(see Tozer et al. 2015). However, a detailed investigation of perianal fistula 
microbiota was not a primary objective of this study. 
3.5 Conclusions 
This is the largest study to date to phenotype perianal fistula disease in detail in both 
idiopathic and Crohn’s disease patients. Severe disease appears to be commoner in 
Crohn’s perianal fistulae compared with idiopathic perianal fistulae. However, there 
were also many phenotypic similarities between the groups, and thus overall, the 
groups did not appear to be phenotypically distinct. 
These data are also probably the most complete dataset to date using patient reported 
outcome measures, namely PDAI and EQ-5D, in these two groups. The PDAI 
appears to be a feasible, useful, stable and sensitive tool in measuring the disease 
activity in idiopathic as well as Crohn’s perianal fistulae. Patients with idiopathic and 
Crohn’s perianal fistulae have a similarly impaired quality of life, as measured by the 
EQ VAS and EQ index. Furthermore, the level of disease burden is akin to other 
significant chronic health conditions. Further validation studies are required and 
would lead to improved methodology in future perianal fistula disease research. 
A comparison of the bacterial isolates from cultures of intraoperative specimens 
showed a wide range of organisms, which was similar in both groups. 
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4. CYTOKINE PROFILES 
4.1 Introduction 
Cytokines are a large group of proteins, peptides and glycoproteins that act as 
intercellular signalling molecules to regulate immunity and inflammation. They are 
produced by a broad range of immune and non-immune cells, and can act in an 
autocrine, paracrine and endocrine manner. They exert their actions by binding to 
cell-surface receptors, which in turn potentiate their action by the activation of 
various intracellular signalling pathways. These pathways may affect other cell-
surface receptors and gene expression thereby stimulating or inhibiting cell 
behaviour and functions such as cell maturation, growth, adhesion and chemotaxis. 
There is much overlap and redundancy in the cytokine network. 
Cytokine expression is a normal part of human physiology as the process of 
immunity and inflammation is necessary in both health and disease. In contrast to 
nearly all other tissues, the mucosa of the small and large intestine has continuous, 
low-grade (physiologic) inflammation, most likely because the intestine is exposed to 
a great antigenic load from luminal bacteria and a large variety of Toll-like receptor 
ligands (MacDonald et al. 2011).  
Cytokine expression changes in response to an inflammatory or infectious stimulus. 
An appropriate response will handle and neutralise the threat in a proportionate 
manner before achieving resolution and restoring a normal state of health. However, 
cytokine expression can also be inappropriate or dysregulated, leading to diseases 
such as Crohn’s disease. The precise aetiology of Crohn’s disease is still unknown, 
but current theory suggests that it is the result of the interplay between three major 
factors – genetic susceptibility, intestinal microbiota and environmental factors – 
leading to a state of immune dysregulation (Kaser et al. 2010). Cytokines play a 
major part in this state of immune dysregulation, and many differences between 
Crohn’s disease affected mucosa and healthy mucosa have been demonstrated. It is 
now generally accepted that there are significant differences in the expression of 
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many pro-inflammatory cytokines, such as IL-1, TNF-α, IL-6, IL-8, IL-12, IL-17 and 
IL-21, and anti-inflammatory cytokines, namely IL-10 and TGF-b (Műzes et al. 
2012). These features of the cytokine network can be regarded as a molecular 
fingerprint that can be used as a way to identify the inflammatory phenotype of the 
affected tissue. 
Little is known about the role of cytokines in perianal fistula disease. Kiehne et al. 
(2007) studied the perianal fistulae of 47 patients, excluding Crohn’s disease. They 
obtained tissue from the fistula tract and, using immunohistochemistry, compared it 
to tissue from uninvolved perianal skin in the same patients and rectal mucosa in 
healthy control patients. IL-1b showed the most pronounced expression in the distal 
part of the fistula (8-fold increase compared with uninvolved perianal skin), while 
IL-8 was prominently expressed in the proximal part (63-fold increase). Expression 
of IL-6, IL-10 and TNF-a was low in the fistula. The perianal skin and rectal mucosa 
both showed very low levels of expression of all the analysed cytokines. 
Ruffolo et al. (2007) studied cytokine concentrations in the blood of 12 patients with 
active perianal Crohn’s disease and a low Crohn’s disease activity index, 7 patients 
with indeterminate colitis after restorative panproctocolectomy with perianal 
complications, 7 patients with active intestinal Crohn’s disease without perianal 
manifestations, and 19 healthy controls sex- and age-matched to the perianal Crohn’s 
disease and the indeterminate colitis groups. Serum TNF-α and IL-6 concentrations 
were significantly higher in patients with perianal fistulas. Serum IL-1b and IL-12 
concentrations were similar between the groups. 
Following on from this, Ruffolo et al. (2008) studied the cytokine network in rectal 
mucosal biopsies, sampled endoscopically and mechanically homogenised, and 
serum samples. They included seventeen patients with perianal Crohn’s disease, 7 
patients with Crohn’s disease without perianal involvement, and 7 healthy controls. 
Patients with idiopathic perianal fistula were not included. Mucosal and serum IL-6 
concentrations were higher in the perianal Crohn’s disease group, and the authors 
suggested that IL-6 contributes to the maintenance of perianal fistulae. Mucosal IL-
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1b was also higher in perianal Crohn’s disease and correlated with mucosal levels of 
TGF-b, TNF-a, and IL-6 and serum levels of TNF-a and IL-6. Mucosal TNF-a was 
the same among the three groups. The authors noted this was in contrast to previous 
studies, which showed an increase in mucosal TNF-a in Crohn’s disease (Reimund 
et al. 1996), and could have been partially due to the patient sample. Mucosal IL-12 
and TGF-b concentrations were the same among the three groups. Overall, IL-1b, 
IL-6 and TNF-a seemed to play an important role in perianal Crohn’s disease. Van 
Onkelen et al. (2016) studied cytokine expression in 27 idiopathic perianal fistula 
tracts using immunohistochemistry. They also reported abundant expression of IL-
1b. Expression of IL-8, IL-12p40 and TNF-a was also commonly observed. 
In a cohort that included participants with idiopathic (n = 18) and Crohn’s disease (n 
= 20) perianal fistulae, and healthy controls (n = 10), Tozer (2011) used multiplex 
methods to measure the concentrations of seven cytokines and chemokines in tissue 
culture supernatants: IL-2, IL-4, IL-6, IP-10 (interferon-gamma-inducible protein-
10), TNF-a, IFN-g and IL-17A. Biopsies from the fistula tract and rectum were 
studied. He found no significant differences in the concentrations of IL-2, IL-4, IL-6, 
IP-10, TNF-a and IFN-g between the groups at either biopsy site. There was a 
difference between the healthy controls and Crohn’s disease groups at the rectal 
biopsy site for IL-17A. The median concentration in the healthy controls was 3.01 
pg/ml (IQR = 0.00–3.86) compared with 2.63 pg/ml (2.37–3.86) in the Crohn’s 
disease group (p = 0.04, Mann-Whitney U test with Bonferonni correction). 
However, this result is of questionable significance because the investigators 
measured cytokines using the CBA Human Th1/Th2/Th17 Cytokine Kit (BD 
Biosciences, Europe), whose standard curve only reaches down to 20 pg/ml. 
Furthermore, the minimum detectable concentration for the IL-17A assay was 18.9 
pg/ml. The reported concentrations of IL-17A were well below this level and as such 
were unlikely to be reliable and the subsequent hypothesis testing was therefore 
invalid. Accepting this important methodological consideration, Tozer did not find a 
difference in the cytokine concentrations between the three groups. In summary, 
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from these four studies, it appears that IL-1b, IL-6, IL-8, and TNF-a, may have an 
important role in perianal fistulae immunopathology.  
As previously discussed in Section 0, it is believed that idiopathic and Crohn’s 
disease fistulae differ in their pathogenesis and pathophysiology. Only one study by 
Tozer has tested this hypothesis with respect to a handful of cytokines, and no clear 
differences in the cytokine network were found. Building on this work, the current 
study aimed to more comprehensively describe the cytokine network in perianal 
fistula disease and compare the phenotypes between the idiopathic and Crohn’s 
disease groups. 
4.2 Methods 
Participants and Biopsies 
The methodology for recruitment of the study cohort and obtaining biopsy specimens 
(fistula tract, granulation tissue, internal opening and rectal mucosa) from 
participants is described in Chapter 2. In addition, we recruited further participants to 
serve as healthy controls for rectal biopsy tissue. The student screened consecutive 
patients from endoscopy lists for eligibility. We included adults undergoing lower 
gastrointestinal endoscopy for non-inflammatory conditions and excluded those who 
had a prior history, or upon endoscopy were suspected to have ileal, colonic or rectal 
inflammation, as well as those with a history of chemotherapy, radiotherapy, TB or 
HIV. The student approached potential participants asked for their consent to 
participate, which was recorded on a signed consent form, before obtaining a clinical 
history and recording the findings of the endoscopy. The endoscopist took three 
rectal biopsies using endoscopic cold biopsy forceps. The methods to collect, process 





All laboratory experiments were conducted in reference to a written protocol, to 
ensure the methods remained consistent (Appendix 4). 
Working under a tissue culture hood at room temperature, the student arranged the 
samples reserved for tissue culture in a 24-well culture plate, covered each sample 
with 300 µl serum free HL-1 medium (Lonza, Cambridge, UK) containing 
10 units/ml penicillin and streptokinase, 32 µg/ml gentamicin and 1 in 100 
L-glutamine (Sigma-Aldrich, Gillingham, UK) using a filtered pipette (Figure 17), 
and then placed the covered culture plate in a controlled incubator at 37°C and 5% 
carbon dioxide for 24 hours. He then drew off the supernatants with a pipette and put 
them into mini Eppendorf tubes, labelled with participant ID and biopsy site, snap 
froze them on dry ice for 5 minutes and transferred them to -80°C freezer for storage. 
In a small number of cases where the tissue sample interfered with pipetting, the cell 
debris was removed by centrifugation at 12,000 rpm for 5 minutes. 
 
Figure 17 Tissue samples covered with culture medium in a 24-well culture plate. 
Multi-analyte Panel 
When all participant specimens had been processed and stored, the student 
performed quantification of the cytokine concentrations within the 24-hour tissue 
culture supernatant in batches using the 30-plex Milliplex MAP Human 
Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica, 
Massachusetts; Figure 18). This kit is based on the Luminex xMAP technology (see 
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Figure 19 for an explanation). We chose the Milliplex kit because there was excellent 
validation data that showed negligible cross-reactivity between the antibodies, high 
assay sensitivities, low intra- and inter-assay coefficients of variation (CV), and 
excellent spike recoveries (a measure of interference between the sample matrix and 
the assay). 
The main advantage of using a multiplex system was that a large number of 
measurements could be made with the limited resources available. The main 
disadvantage of this approach was that super-sensitive assays could not be included 
in the multiplex because the standard curve needs to cover the same concentrations 
for all analytes and assay cross-reactivity can occur. We judged that multiplexing 
was best suited to the research objectives and chose a standard kit with 30 analytes to 
maximise the breadth of the cytokine profile being measured: EGF (epidermal 
growth factor), eotaxin, G-CSF (granulocyte-colony stimulating factor), GM-CSF 
(granulocyte-macrophage-CSF), IFN-α2, IFN-γ, IL-10, IL-12p40†, IL-12p70, IL-13, 
IL-15, IL-17, IL-1RA (interlukin-1 receptor agonist), IL-1α, IL-1β, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1 (monocyte chemoattractant protein-1), MIP-1α 
(macrophage inflammatory protein-1 alpha), MIP-1β, TNF-α, TNF-β, RANTES 
(regulated on activation normal T cell expressed and secreted), and VEGF (vascular 
endothelial growth factor). 
                                               
 
† IL-12 is encoded by two separate genes. Protein synthesis results in an active heterodimer (p70), and 




Figure 18 Thirty-plex Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel kit (EMD 
Millipore, Billerica, Massachusetts). 
 
Figure 19 Principles of xMAP technology. Microspheres are colour-coded with two internal fluorescent 
dyes to create up to 100 distinct sets, each of which is coated by a specific capture antibody. Each bead 
captures its target protein in the test sample. Incubation with a biotinylated detection antibody, and a 
reporter molecule, streptavidin-phycoerythrin (PE) conjugate, completes the reaction. Within the 
automated analyser, the microspheres are passed through a laser, which excites the microsphere dyes. A 
second laser excites phycoerythrin, the fluorescent dye on the reporter molecule. Then, high-speed digital-
signal processors identify each individual microsphere using its unique fluorescence code and then 
measure the fluorescence intensity of the reporter molecules. A standard curve is used to convert the 
fluorescence intensity is into an absolute concentration value. 
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The student thawed the tissue culture supernatant samples at room temperature and 
centrifuged them at 7,000 rpm for 5 minutes to remove any cell debris. After 
allowing the Milliplex kit to warm to room temperature, according to the 
instructions, he meticulously reconstituted the wash buffer, the two quality controls 
and the standards, using a one in five serial dilution to achieve decreasing 
concentrations (10,000, 2,000, 400, 80, 16 and 3.2 pg/ml). The background standard 
(0 pg/ml) comprised assay buffer only. He then sonicated, combined and vortexed 
the antibody-immobilized magnetic beads.  
The student washed the 96-well plate according to the instructions and then laid it 
out with an automatic multi-pipette according to the plate plan (Table 20). Each well 
received 25 µl of either standard or control or sample, plus 25 µl of either the culture 
medium used previously (for standards and controls) or assay buffer (for samples), 
plus 25 µl of antibody-immobilized magnetic beads. Standards and controls were laid 
out in duplicate; samples were done in singlet. We considered running the samples in 
duplicate, however this was not possible due to limited funding. Furthermore, the 
intra-assay CV ranged between 1.5% and 3.4% with the exception of Eotaxin (7.2%, 
Appendix 6). We therefore judged that the level of variability from singlet testing 
was acceptable given the research objectives.  
The student covered the completed plate with sealing tape and foil and incubated it 
overnight (16–18 hours) on a plate shaker at 500 rpm at 4°C. Then after allowing the 
plate to warm to room temperature for 30 minutes on the plate shaker at 500 rpm, he 
performed two manual wash cycles according to the instructions using wash buffer. 
During the decanting step of this process, a handheld plate magnet retained the 
magnetic beads within the wells. After this, the student added 25 µl of detection 
antibodies to each well in the plate, incubated it for 1 hour on a plate shaker at 
500 rpm, then added 25 µl of streptavidin-phycoerythrin to each well before 
incubating for a further 30 minutes on a plate shaker at 500 rpm. After two more 
wash cycles, he resuspended the well contents in 100 µl of drive fluid and mixed 
them for 10 minutes on a plate shaker at 500 rpm. All these steps were performed at 
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room temperature. Sealing tape minimised evaporation during incubation and a foil 
cover prevented light degradation of the signal from the beads. 
Table 20 Plate plan for Milliplex 96-well plate. QC, quality control. 
 1 2 3 4 5 6 7 8 9 10 11 12 




Control Sample Sample Sample Sample Sample Sample Sample Sample Sample 




Control Sample Sample Sample Sample Sample Sample Sample Sample Sample 
C 3.2 Standard 
2,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
D 3.2 Standard 
2,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
E 16 Standard 
10,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
F 16 Standard 
10,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
G 80 Standard 
QC-1 
Control Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
H 80 Standard 
QC-1 
Control Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
 
MAGPIX Measurement 
The student prepared the MAGPIX multiplexing instrument (Luminex Corporation, 
Austin, TX) using the maintenance protocols on the xPONENT software. The probe 
was cleaned, checked for damage before calibrating its height. The system was 
cleaned by soaking it in 1M sodium hydroxide over the previous night. The 
instrument was then calibrated using the MAGPIX Calibration Kit (Luminex 
Corporation, Austin, Texas) and its performance was verified to within acceptable 
margins of error using the MAGPIX Performance Verification Kit (Luminex 
Corporation, Austin, Texas, Appendix 7). 
The student programmed the xPONENT software to standardise plate processing and 
analysis. This specified the logistic 5P method to fit the standard curve to all the 
standards, a minimum required bead count of 50 per well, the analyte names and 
their bead regions, the known concentrations of the analytes in the standards and 
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controls, and participant identification numbers and biopsy sites for the sample wells. 
A second person double-checked all parameter entries.  
After the above preparation, the MAGPIX system performed the programmed 
automated analysis. Halfway through the plate-reading, the system cleaned itself to 
reduce the build-up of protein and magnetic beads within the tubing and thus reduce 
the risk of encountering technical problems. The student reviewed the standard 
curves within the xPONENT software (Figure 20), and with each of the 30 analytes 
in turn, used the percentage recovery of the standards to determine the fit of each 
point to the standard curve. Points with a recovery less than 70% or greater than 
130% were invalidated. Once all points lay within the acceptable percentage 
recovery range, the control results were reviewed to verify the standard curve fit.  
For quality assurance, the student invalidated any analyte result that failed to reach a 
minimum bead count of 50. Protein or beads can adhere to the narrow channel within 
the instrument’s probe and clog it causing low bead counts. Although a result is still 
obtainable, the reliability is lower. Therefore the MAGPIX system re-analysed the 
affected samples on the same plate to obtain the missing data. 
Where the estimated concentration fell well outside the lower or upper limits of the 
standard curve, the xPONENT software returned a non-numerical value (e.g. 
< 3.2 pg/ml). To allow us to use these results with the rest of the continuous data, the 
student imputed either the minimum or the maximum result recorded for the affected 
analyte. For example, many results for EGF were “< 3.2 pg/ml”. Imputation changed 
these values to 1.95 pg/ml, the lowest recorded EGF value. Results from all the 




Figure 20 Adjusting the fit of the standard curve for EGF. The second Standard1 was invalidated because 
its result was outside the acceptable margin of error: the percentage recovery was > 130%. This process 
was repeated for each analyte. 
4.3 Results 
Specimens 
Out of the 61 participants, one did not undergo biopsy due to unavailability of the 
student at the time. We approached nine healthy controls, however two declined and 
one was subsequently excluded due to ileal inflammation found during colonoscopy. 
Thus we recruited six healthy controls. Their characteristics are shown in Table 21. 
Five were female, and the mean age was 53.5 years (SD = 20.6). 
Not all specimens were taken or analysed in each participant. Technical error caused 
the loss of four participants’ specimens. Other problems were technical difficulty in 
taking the specimen, paucity of the tissue samples, and an absence of the tissue to be 
sampled (granulation tissue and internal opening sites only). A breakdown of the 
specimens analysed is shown in Table 22. Overall, a total of 202 specimens were 
available for cytokine quantification, specifically six control, 159 idiopathic and 37 
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Crohn’s disease samples. With thirty cytokines measured per specimen, we made 
6,060 measurements overall. 
Table 21 Characteristics of healthy controls. 
 Demographics Indication Endoscopic result 
1 Female, 59 years Survey for extra-mammary Paget’s disease 
Ileocolonoscopy revealed left 
sided diverticulosis only 
2 Female, 71 years Loose stools and bloating Ileocolonoscopy revealed one small polyp only 
3 Female, 30 years Constipation Normal flexible sigmoidoscopy 
4 Male, 65 years Anorectal bleeding Normal flexible sigmoidoscopy 
5 Female, 21 years Constipation Normal ileocolonoscopy 
6 Female, 75 years Iron deficiency anaemia Normal colonoscopy 
 
Table 22 Specimens processed for cytokine quantification. NA, not applicable. 
 Healthy Control Idiopathic Crohn’s Disease All 
Fistula Tract NA 45 9 54 
Granulation Tissue NA 29 9 38 
Internal Opening NA 42 10 52 
Rectal Mucosa 6 43 9 58 
Total 6 159 37 202 
 
Experiment Quality Control 
All the specimens from the participants were processed using three Milliplex kits 
from the same batch, but due to manufacturing constraints, all the specimens from 
the healthy controls were processed using a different batch. We judged this to be 
acceptable as the inter-assay CVs were at most, 18% (Appendix 6).  
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We ran five plates, each with four quality controls for each of the 30 analytes. Thus 
there were 600 quality controls in total. The percentage recovery is the deviation of 
the measured analyte concentration from the expected concentration with 100% 
representing perfect agreement. As mentioned in the methods, a percentage recovery 
in the range 70–130% was acceptable. Eleven fell below this range and 22 fell above 
it. Thus 567 (95%) of the quality controls fell within the acceptable range. Over the 
150 analytes (30 analytes by 5 plates), 17 had one out of four controls fail, eight had 
two out of four controls fail, and none had more than two controls fail. 
Low bead counts affected 3.3% of results (N.B. in this context, result refers to a 
single concentration value, e.g. the EGF concentration for a fistula tract specimen 
from a single participant). After the student re-analysed the affected samples, only 
0.03% of results remained invalidated.  
The data comprised 3.78% of results returned as < 3.2 pg/ml, 0.06% as 
> 2,000 pg/ml, and 1.14% as > 10,000 pg/ml. Thus overall, 4.99% of results were 
non-numerical and required adjustment using the imputation rules described above. 
The cytokines that had > 5% of results imputed with the minimum value were 
eotaxin (14%), IL-3 (42%), and MIP-1a (6%). G-CSF had 35% of results imputed 
with the maximum value. 
The data comprised 5.04% of results returned below the minimum detectable 
concentration for the assay. However, overall median concentrations only fell below 
the minimum detectable level for IL-3 (fistula tract-Crohn’s disease, granulation 
tissue-idiopathic, rectal mucosa-all). 
Cytokine Concentrations 
All the four specimens (fistula tract, granulation tissue, internal opening and rectal 
mucosa) yielded significant levels of IL-1RA, IL-6, MCP-1, RANTES and VEGF, 
with very high levels of G-CSF and IL-8 (Table 23). Other cytokines were also 
moderately abundant in the granulation tissue, internal opening and rectal mucosa 
specimens: GM-CSF, IFN-a2, IP-10, MIP-1a and MIP-1b. The results also showed 
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that granulation tissue, compared to the other specimen sites, yielded higher 
concentration of G-CSF, IL-10, IL-1RA, and IL-1b. 
We observed significant differences in just 2 instances. The IL-12p70 concentration 
at the internal opening specimen site was higher in the Crohn’s disease group (Figure 
21). The median concentration was 28.3 pg/ml (IQR = 7.4–50.1) compared with 
7.4 pg/ml (4.6–12.7) in the idiopathic group. The median difference was 19.7 pg/ml 
(Hodges-Lehman, 99% CI = 0.2–40.4; Mann-Whitney U, p = 0.008). 
The IL-1RA/IL-1b ratio was significantly lower in the Crohn’s disease group at the 
internal opening specimen site (Figure 22; Table 45 in Appendix 8). The median 
ratio was 3.3 (1.8–7.6) compared with 19.0 (4.3–51.2) in the idiopathic group. The 
median difference was 15.0 (99% CI = 0.4–50.5, p = 0.008). 
There were no significant differences in any of the other cytokine concentrations 
between the idiopathic and Crohn’s disease groups at the four specimen sites (Figure 
23; Table 41, Table 42, Table 43 and Table 44 in Appendix 8). There were also no 
significant differences in the cytokine concentrations between the rectal mucosa of 
healthy controls and Crohn’s disease groups (Figure 24; Table 46 in Appendix 8).  
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Table 23 Median cytokine concentrations (pg/ml). HC, healthy controls; CD, Crohn’s disease.  
* statistically significant difference p < 0.01. 
⁑ result below the minimum detectable concentration for the assay. 
 
Fistula Tract Granulation Tissue Internal Opening Rectal Mucosa 
 
Idiopathic CD Idiopathic CD Idiopathic CD HC Idiopathic CD 
EGF 14.7 17.4 34.8 28.7 20.5 28.2 20.7 22.7 20.8 
Eotaxin 13.2 10.7 14.6 11 18 21.1 20.9 17.2 14.2 
G-CSF 950.6 4693.6 22402.3 22402.3 7214.2 22402.3 2638.8 3139.5 1605.1 
GM-CSF 14 30 69.3 128.5 34.5 203.6 32.1 31.2 30.2 
IFN-α2 19.7 16.8 28.2 22.1 37.4 41.1 40.5 49.7 39 
IFN-γ 4 5.7 12.3 28.9 7.4 12.6 11.6 8.4 9 
IL-10 24.7 29.2 321.5 155.2 55.6 67.7 17.5 13.5 7.2 
IL-12p40 12.4 8.8 24 21.7 19.2 29.1 33.3 37.2 28.7 
IL-12p70 3.7 2.5 5.7 8.1 7.4* 28.3* 16.2 18.1 15.9 
IL-13 3.9 5.2 6 6 8 7.5 5.9 6.9 4 
IL-15 3.7 4.3 8.8 7.9 5 7.8 5.9 6.8 7.6 
IL-17A 4.1 4.3 13.3 18.4 4.1 7.4 4.1 5.5 4 
IL-1RA 31.8 244.5 741 541.7 516.1 128.3 79.6 72 84.9 
IL-1α 10.5 24 140.5 51 24.3 17.4 10.8 11.4 13.7 
IL-1β 4.4 4.3 302.2 263.3 20.2 58.3 22.7 20.6 15.5 
IL-2 1.9 2.3 2.8 2.5 3.7 5.7 6.6 8.4 5.8 
IL-3 1.15 0.32⁑ 0.04⁑ 0.88 1.20 1.09 0.32⁑ 0.04⁑ 0.04⁑ 
IL-4 9.9 9.1 12.1 11.1 17.3 22.7 22.2 18.9 14.9 
IL-5 1.1 2 2.5 2.3 2.1 3.2 2.8 2.7 1.9 
IL-6 324.6 576.5 646.4 1010.2 6362.3 6181.2 580.6 638.3 427 
IL-7 11 9.5 13.4 10.3 18.5 21 21.1 19.9 17.8 
IL-8 8063.7 7996.7 8281.7 7863.6 10811.1 11902.6 6442.8 6002.3 4415.4 
IP-10 16 22.8 30.3 116 26.6 33.4 23.9 30.5 29 
MCP-1 540.7 709.8 744.1 678.6 1296.8 3390.3 1642.1 1089.2 741.4 
MIP-1α 16.3 15.6 61.6 43.8 66.6 93.9 58.2 43 31.4 
MIP-1β 9.9 14.9 34.6 32.5 23.4 36.8 22.5 26.9 17.9 
RANTES 324.4 529.6 801.4 814.5 169.3 233.8 49 94.9 84.9 
TNF-α 8.4 9.7 28.3 16.5 30.9 25 20.2 18.6 12.6 
TNF-β 1.8 2.5 3.2 2.8 3.2 5.2 3.8 3.8 3.4 
VEGF 82.2 107.1 124.4 104.5 173.5 284.3 230.7 225.8 159.4 
 





Figure 21 Boxplot for IL-12p70 concentrations. Median difference at the internal opening, 19.7 pg/ml 
(Hodges-Lehman, 99% CI = 0.2–40.4; Mann-Whitney U, p = 0.008). Circle marker, outlier within 1.5 x 























Figure 22 Boxplot for IL-1RA/IL-1b ratios. Median difference at the internal opening, 15.0 (Hodges-
Lehman, 99% CI = 0.4–50.5; Mann-Whitney U, p = 0.008). Circle marker, outlier within 1.5 x interquartile 



























Figure 23 Relative median difference in cytokine concentrations between idiopathic and Crohn's disease 




Figure 24 Comparison with healthy controls. Rectal mucosa relative median difference in cytokine 
concentrations between healthy controls and Crohn's disease groups. Error bars show 99% confidence 
intervals estimated using Hodges-Lehman method. See Appendix 8 for absolute values. 
4.4 Discussion 
This study aimed to describe the cytokine profile in perianal fistula disease and 
compare profiles between the idiopathic and Crohn’s disease groups in order to test 
the hypothesis that perianal fistulae of these types differ in their pathophysiology, 
specifically immunopathology.  
To reiterate the findings from Chapter 3, the cohort had a wide distribution of clinical 
and anatomical phenotypes including those with simple and complex, low and high, 
and primary and recurrent perianal fistula disease in both the idiopathic and Crohn’s 
disease groups. Therefore these laboratory data can be considered to fairly 
encompass the breadth of the disease under study. They are also probably the most 
substantial to date in terms of breadth of cytokines measured for a cohort of 
participants with both idiopathic and Crohn’s perianal fistula disease. We used a 
well-validated multiplex method to efficiently make thousands of accurate 
quantitative measurements. Several quality control features, such as data re-entry, 
experimental controls and calibration procedures, ensured the results were accurate 
and reliable. Analysis used medians and interquartile ranges to allow for skewed data 
in several of the analytes, 99% confidence intervals to allow for multiple hypothesis 




We systematically measured the concentrations of 30 cytokines (EGF, Eotaxin, G-
CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-12P40, IL-12P70, IL-13, IL-15, IL-17, IL-
1RA, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, 
MIP-1β, TNF-α, TNF-β, RANTES, and VEGF) in the supernatant of a standard 
tissue culture of specimens. With 202 specimens analysed, this resulted in a total of 
6,060 measurements. The median concentrations of each cytokine were compared 
between the disease groups for each of the four biopsy sites.  
We observed significant differences between the groups in only two instances: IL-
12p70 and the IL-1RA/IL-1b ratio, both at the internal opening specimen site. The 
relevance of these findings is discussed. 
IL-12 is a proinflammatory cytokine produced by dendritic cells and macrophages. It 
comprises two subunits: IL-12p35 and IL-12p40. On its own, the p40 subunit acts as 
a natural antagonist.‡ The IL-12 receptor is found mainly on T cells and natural killer 
cells. In its combined form as IL-12p70, the cytokine induces the production of IFN-
g, promotes T helper 1 cell differentiation and forms a link between innate resistance 
and acquired immunity (Trinchieri 2003). IL-12 plays an important role in Crohn’s 
disease pathogenesis. The expression of IL-12 is upregulated in Crohn’s disease 
mucosa (Monteleone et al. 1997). The present study found significantly higher 
concentrations of IL-12p70 at the internal opening in the Crohn’s disease group. This 
may suggest a similarly important role for IL-12 in Crohn’s perianal fistula and may 
represent a difference in its pathophysiology compared with idiopathic perianal 
fistula disease. However, these data do need to be interpreted with caution, as the 
99% CI came very close to zero. Further studies in the role of IL-12 in perianal 
fistula are therefore required. 
                                               
 
‡ When measuring IL-12p40, it needs to be taken into account that the p40 subunit is shared with IL-
23, another member of the IL-12 family (Oppmann et al. 2000). 
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The IL-1a and IL-1b mediate immune and inflammatory responses. They are 
primarily produced by tissue macrophages, monocytes, fibroblasts, and dendritic 
cells and enable transmigration of immune cells to the site of inflammation. Dionne 
et al. (1998) reported concentrations of IL-1 cytokines in colonic mucosa explant 
supernatants after 18 hours culture in healthy controls, Crohn’s disease patients’ 
inflamed mucosa, and Crohn’s disease patients’ uninflamed mucosa groups. IL-1b 
concentration was low in healthy controls and in uninflamed Crohn’s disease, and 
increased in inflamed Crohn’s disease. The present study also found low 
concentrations in the all groups at the fistula tract, internal opening and rectal 
mucosa sites, with no significant differences between the groups. This might suggest 
that Crohn’s perianal fistula (and idiopathic for that matter) differ from inflamed 
Crohn’s disease mucosa in their IL-1 mediated inflammatory response. For the 
receptor antagonist, IL-1RA, Dionne et al. (1998) did not find any significant 
difference in its culture supernatant concentration between the groups. This is also 
borne out by the present study’s data.  
However, when studying the IL-1RA/IL-1b ratio, Dionne et al. (1998) found the 
ratio was lower in the inflamed Crohn’s disease group, compared to the healthy 
controls and uninflamed Crohn’s disease groups. We made similar findings at the 
internal opening specimen site in that the ratio was significantly lower in the Crohn’s 
disease group compared to the idiopathic group.  
The current data also revealed that the concentrations of G-CSF, IL-10, IL-1RA, and 
IL-1b found at the granulation tissue sites were higher relative to the other three 
sites. This is likely to be a reflection of the acute on chronic inflammatory 
microenvironment of the fistula tract granulation tissue, which contains histiocytes 
and capillaries, neutrophils and lymphocytes (Bataille et al. 2004). 
There were no significant differences between the groups for any of the other 
measurements. When the cytokine concentrations from the rectal mucosa of Crohn’s 
disease participants were compared with the healthy controls, again no significant 
differences were found. The above comparisons are summarised in Table 24. 
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As discussed in Section 1, Crohn’s disease is characterised by chronic inflammation. 
At the molecular level, in general, pro-inflammatory cytokines and chemokines are 
upregulated and anti-inflammatory cytokines and chemokines are suppressed. Within 
the currently accepted theory, idiopathic perianal fistulae do not have an underlying 
dysregulated inflammation. Therefore, we would expect this contrast to be evident in 
the cytokine and chemokine profiles. However, our data is striking in its lack of 
demonstrable differences between the two groups and therefore challenges the 
current thinking that they these groups are immunologically separate.  
Table 24 Summary of cytokine profile data comparisons between idiopathic and Crohn’s perianal fistulae. 
 Similarities  Differences  
Cytokine concentrations Similar concentrations of 27 
cytokines at all four biopsy sites 
(EGF, eotaxin, G-CSF, GM-CSF, 
IFN-α2, IFN-γ, IL-10, IL-12p40, 
IL-13, IL-15, IL-17, IL-1α, IL-2, 
IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, 
IP-10, MCP-1, MIP-1α, MIP-1β, 
TNF-α, TNF-β, RANTES and 
VEGF) 
Significantly higher IL-12p70 
concentration at internal opening in 
Crohn’s disease 
Significantly lower IL-1RA/IL-1b 
ratio concentration at internal 
opening in Crohn’s disease 
 
Comparison with Prior Data 
Two previous studies described in the introduction provided comparable data. In 
comparison with Tozer’s measurements, we found similar concentrations of the 
corresponding cytokines at the corresponding biopsy sites within the same study 
groups (Table 25). 
A comparison with Ruffolo et al. (2008) is shown in Table 26. However this is 
interpreted cautiously as their laboratory methods differed to ours. Instead of 
analysing the supernatant from 24-hour tissue culture, they homogenized the fresh 
frozen biopsies before directly measuring the cytokine concentrations using enzyme-
linked immunosorbent assays. Compared with Ruffolo et al., we found lower 
absolute concentrations of rectal IL-12 in both healthy controls and Crohn’s disease 
participants. However, like Ruffolo et al., there was no statistically significant 
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difference between the Crohn’s disease and healthy controls groups. For IL-1b, 
Ruffolo et al. found that concentrations were low in healthy rectal mucosa and 
significantly higher in Crohn’s disease. Contrastingly, we found no significant 
difference. For IL-6, we measured much higher absolute concentrations in the rectal 
mucosa compared with Ruffolo et al. And for TNF-a, we found rectal mucosal 
concentrations lower than in Ruffolo et al. So overall, the results from this study 
differ from Ruffolo et al. but it is difficult to comment why as it could just be a 
reflection of the different laboratory methods used, especially considering that the 
present study’s results are congruent with Tozer, as described above. 
Table 25 Comparison of cytokine median concentrations, pg/ml (IQR) with Tozer (2011). 
 Fistula Tract Rectal Mucosa 
 Idiopathic Crohn’s Disease Healthy Controls 
 
This study Tozer 2011 This study Tozer 2011 This study Tozer 2011 
IL-2 1.9 1.9 2.3 2.0 6.6 2.3 (1.2–2.7) (1.8–2.5) (1.0–3.5) (1.8–2.3) (5.7–7.1) (2.0–2.6) 
IL-4 9.9 1.9 9.1 1.9 22.2 1.9 (5.1–12.8) (1.9–2.1) (5.8–18.0) (1.8–2.0) (17.2–27.4) (1.5–2.1) 
IL-6 325 1201 577 334 581 350 (83–1977) (250–4692) (29–2302) (106–1345) (497–1689) (283–1213) 
IP-10 16.0 2.8 22.8 1.9 23.9 2.0 (6.7–28.4) (1.4–6.2) (17.2–80.2) (1.6–4.1) (21.4–27.7) (1.5–2.8) 
TNF-α 8.4 2.9 9.8 1.6 20.2 2.2 (3.2–21.0) (2.1–6.6) (4.1–29.8) (1.2–2.7) (13.9–35.6) (1.7–2.9) 
IFN-γ 4.0 4.0 5.7 1.4 11.6 1.5 (1.6–7.3) (1.7–7.5) (1.1–10.9) (1.2–1.7) (8.2–12.0) (1.4–2.5) 
IL-17A 4.1 3.4 4.3 2.6 4.1 3.0 (2.0–6.3) (3.1–4.6) (1.1–12.7) (2.4–3.9) (3.3–4.5) (0.0–3.9) 
 




Table 26 Comparison of cytokine median concentrations, pg/ml (IQR) with Ruffolo (2008). Note that 




Healthy Controls Crohn's Disease 
 
This Study Ruffolo 2008 This Study Ruffolo 2008 
IL-12 16.2 40 15.9 40 (14.1–25.7) (16–82) (13–20.8) (13–140) 
IL-1β 22.7 0.4 15.5 46.3 (11.9–74.7) (5–64.4) (9.7–35.7) (3.4–641) 
IL-6 580.6 2 427 2.2 (496.9–1689.3) (2–10.9) (161.7–1314.6) (2–58.8) 
TNF-α 20.2 32.2 12.6 33.3 (13.9–35.6) (28.4–264) (11–16.5) (26.7–1000) 
 
                     0.1  1  10  100  1000  10000 
 
Comparison with Current Theory 
Across all specimens and groups, we found significant levels of G-CSF, IL-6, IL-8, 
MCP-1, RANTES and VEGF.  
G-CSF is produced by macrophages, endothelium and other immune cells. It is an 
important pro-inflammatory mediator, mediating the proliferation and maturation of 
neutrophils in the bone marrow, and survival, adhesion and phagocytosis of mature 
neutrophils in the blood. Expression of the G-CSF receptor has been demonstrated on 
a wide variety of haemopoetic cells, including monocytes and lymphocytes. G-CSF 
in perianal fistula disease has not been previously reported. Considering the chronic 
inflammatory nature of all perianal fistulae, which have been shown to contain T 
cells, macrophages, B cells and monocytes (Bataille et al. 2004), our findings 
regarding G-CSF are consistent. 
In our data, IL-6 concentrations were high. Atreya et al. (2000) demonstrated that 
IL-6 is a principle cytokine produced by macrophages in the lamina propria of the 
gut wall. Production of IL-6 and expression of the IL-6 receptor is increased in 
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inflammatory bowel disease. Stimulation of the IL-6 receptor in T cells causes 
activation of the STAT-3 pathway, preventing apoptosis. Thus IL-6 promotes a pro-
inflammatory phenotype. Serum IL-6 is higher in Crohn’s disease patients with 
perianal fistulae compared with Crohn’s disease patients without perianal fistulae 
and healthy controls (Ruffolo et al. 2007). Anti-IL-6 therapy for Crohn’s disease can 
cause remission and also perianal fistula closure (Ito et al. 2004). We found tissue 
from the internal opening yielded the highest IL-6 concentrations with no statistically 
significant differences in between the groups. The importance of this is unclear. It 
could suggest that the inflammatory phenotype is similar in perianal fistulae of both 
types. Further clarity could come from comparing against normal anal mucosa. 
However obtaining such tissue could be ethically challenging. 
IL-8 is another pro-inflammatory cytokine. It is released by many cell types in 
response to inflammatory stimuli and attracts neutrophils, basophils and T cells, but 
not monocytes into tissues. It also is involved in neutrophil activation (Hornbeck et 
al. 2015). Il-8 concentrations are increased in colitic mucosa, compared with healthy 
controls (Rodríguez-Perálvarez et al. 2012). Interestingly, IL-8 expression is 
increased in idiopathic perianal fistula tracts, especially proximally, compared with 
rectal mucosa and perianal skin (Kiehne et al. 2007). We also found substantial 
concentrations of IL-8 in all specimens, with the highest found at the internal 
opening. This is consistent with the above, and further supports the case for IL-8 as 
an important mediator of inflammation in both idiopathic and Crohn’s perianal 
fistulae. 
MCP-1 is a chemotactic factor that attracts monocytes and basophils but not 
neutrophils or eosinophils. Compared with normal colonic mucosa from health 
controls, the epithelium, inflammatory cells, and stromal cells from endoscopic 
biopsies from Crohn’s disease affected colon show significantly higher expression of 
MCP-1 (Banks et al. 2003). We found substantial concentrations of MCP-1, 
especially at the internal opening, although there were no significant differences 
between the groups. MCP-1 has not been reported before in perianal fistula disease. 
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RANTES is a chemotactic factor for monocytes, memory T helper cells and 
eosinophils. It has not been implicated in Crohn’s disease pathogenesis (Moriyama et 
al. 2005). We demonstrated RANTES was present at all the specimen sites in all the 
groups. Concentrations were higher at the fistula tract, granulation tissue and internal 
opening sites compared with the rectal mucosa. This may just be a reflection of a 
higher degree of inflammation in these specimens. It could, however also be a clue to 
the pathophysiology of perianal fistulae. 
VEGF is a growth factor active in angiogenesis, vasculogenesis and endothelial cell 
growth. IL-4 reduces VEGF production in peripheral blood mononuclear cells from 
patients with inflammatory bowel disease to normal levels. The known defective 
immunosuppressive effect of IL-4 in inflammatory bowel disease may contribute to 
the pathogenic cascade leading to inflammation mediated by VEGF (Griga et al. 
2000). We found significant concentrations of VEGF at all specimen sites. VEGF in 
perianal fistulae has not been studied before. 
Limitations 
Our cohort included a broad range of clinical phenotypes, representing the full 
spectrum of perianal fistula disease. However, this introduced heterogeneity. As the 
sample size, although comparable to the vast majority of previous studies on perianal 
fistula, was relatively small, differences may not have been apparent within the 
heterogeneity. 
Collection of tissue specimens followed a protocol, and in most cases were 
performed by the same two surgeons (JBH, CHK) to standardise the method as much 
as possible. However, patient and operative factors influenced the size, depth and 
position of the specimens taken relative to the internal opening, and these differences 
in theory may have impacted on the results obtained. 
This study analysed fresh biopsy specimens cultured ex vivo. Therefore the validity 
of the results is based upon the assumption that these tissues function within culture 
in a way that is similar or at least relevant to their natural in vivo environment. 
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We only examined certain cytokines. Their selection was influenced by what was 
possible to be co-measured using a commercial multiplex assay. A key cytokine not 
measured was TGF-b, which together with IL-13 might play a synergistic role in the 
pathogenesis of Crohn’s disease fistulae (Scharl et al. 2013). By examining a broad 
panel of cytokines, a deeper interrogation of the role of each cytokine and how they 
interact in perianal fistula disease was not feasible. Only a cautious comparison and 
triangulation of these data with current knowledge was therefore possible. 
Almost half of the Crohn’s disease group had received anti-TNF-a prior to or at 
recruitment. This could have attenuated the cytokine concentrations in the Crohn’s 
disease group and masked any differences with the idiopathic group. However the 
same could also be said for those in the idiopathic group who had prior treatment, 
such as a lay open or seton. A future ideal study should study treatment-naïve 
patients from the time of their index presentation. 
There is no accepted healthy control for perianal fistulae and was therefore not 
included in this study (see Section 2.2 for discussion). This limited the interpretation 
of the data. 
4.5 Conclusions 
The concentrations of 30 cytokines at 4 specimen sites in 60 participants with 
idiopathic and Crohn’s perianal fistulae were examined. We found no clear 
differences in the overall cytokine profiles between the groups. Furthermore, when 
comparing the rectal mucosa of healthy controls to the participants with Crohn’s 
perianal fistulae, no differences were observed. 
Only two significant differences in individual cytokines were found. At the internal 
opening specimen site, IL-12p70 was higher, and IL-1RA/IL-1b ratio was lower in 
the Crohn’s disease group. These findings are consistent with current knowledge on 
the general pathophysiology of Crohn’s disease. However, given that multiple 
hypothesis tests were performed, these results should be treated with caution and 
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further focussed research is needed. Immunocytochemistry, using normal anal 
mucosa as the control, for example, would offer further interrogation.  
These data agree with and add considerably to what Tozer (2011) found using similar 
techniques. Significant levels of G-CSF, IL-6, IL-8, MCP-1, RANTES and VEGF 
were found across all specimens and groups. These findings are broadly consistent 
with current theories on inflammation, and may point towards further research 
opportunities in perianal fistulae. 
Previous studies suggested that IL-1b, IL-6, IL-8, and TNF-a, may have an 
important role in perianal fistulae immunopathology (Kiehne et al. 2007; Ruffolo et 
al. 2007; Ruffolo et al. 2008; Tozer 2011). These data also suggest IL-1b, IL-6 and 
IL-8 may be important. However, results regarding TNF-a were unremarkable. 
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5. PHOSPHOPROTEIN PROFILES 
5.1 Introduction 
Receptor tyrosine kinases (RTKs) and intracellular signalling pathways control and 
regulate cell behaviour (Gilbert 2000). Activation of RTKs usually involves the 
binding of a ligand to the extracellular component of the receptor. This causes 
dimerization of the receptor, which allows autophosphorylation of the intracellular 
component. Often the signal will not exert its effect directly, but will be transduced 
along intracellular signalling pathways. Thus the next phase involves the recruitment 
and activation of a host of downstream signalling molecules. As RTKs have multiple 
phosphotyrosines that can involve numerous docking proteins, they can thus recruit 
and influence many different signalling molecules. Therefore an activated RTK and 
the downstream signalling molecules can be thought of nodes within a complex 
signalling network that transmit information from outside to inside the cell. The end 
effect, which may be up- or downregulation of gene transcription, cell function or 
apoptosis, is influenced at each level by receptor downregulation, the activation 
states of the other signalling pathways within the cell, and positive and negative 
feedback mechanisms. The outcome is regulation of critical cellular processes, such 
as proliferation and differentiation, cell survival and metabolism, cell migration and 
cell cycle control. 
Humans have 58 known RTKs, which fall into twenty subfamilies (Lemmon and 
Schlessinger 2010). Abnormalities in RTK structure and function have been linked to 
several diseases such as cancers, diabetes, bone disorders, arteriosclerosis and 
inflammation. The role of RTKs and signalling molecules in gut homeostasis and 
inflammation have been studied individually for the EphRs (ephrin receptors), Axl 
(AXL receptor tyrosine kinase), Tie 1 (tyrosine kinase with immunoglobulin like and 
epidermal growth factor like domains 1), VEGFRs (vascular endothelial growth 
factor receptors), TrkA/NTRK1 (neurotrophic receptor tyrosine kinase 1), 
Ron/MST1R (macrophage stimulating 1 receptor), InsR (insulin receptor), Jak/Stat 
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(Janus kinase/signal transducers and activators of transcription), MAPK (mitogen-
activated protein kinases), and Akt/PKB/Rac (protein kinase B) subfamilies amongst 
others (Frey and Polk 2014; Rothlin et al. 2014; Linares et al. 2014; Linares and 
Gisbert 2011; Steinkamp et al. 2012; Gorlatova et al. 2011; Zhao et al. 2011; Coskun 
et al. 2013; Setia et al. 2014). 
Vossenkämper et al. (2014) studied the molecular signature of healthy and inflamed 
colon. They measured the phosphorylation status of 39 RTKs and signalling 
molecules in freshly isolated colonic mucosa of healthy subjects and patients with 
inflammatory bowel disease using a phosphorylation-specific protein array. Healthy 
colon showed very few phosphorylation events. In contrast, colonic mucosa from 
patients in the Crohn’s disease and ulcerative colitis groups showed higher relative 
intensities in the majority of the analysed phosphoproteins. When otelixizumab, a 
monoclonal immunoglobulin against human CD3, was added to the explants from 
the disease groups, the phosphorylation of the majority of the kinases was strongly 
reduced.  
As previously discussed in Section 0, it is believed that idiopathic and Crohn’s 
disease fistulae differ in their pathogenesis and pathophysiology. The 
phosphorylation status of the RTKs and signalling molecules gives an insight into 
disease processes in the tissue, and have not been analysed in perianal fistulae. We 
therefore aimed to describe the phosphorylation profile in this cohort and compare 
between the idiopathic and Crohn’s disease groups. 
5.2 Methods 
Participants and Biopsies 
The methodology for recruitment of the study cohort and obtaining biopsy specimens 
(fistula tract, granulation tissue, internal opening and rectal mucosa) from 
participants is described in Chapter 2. Recruitment of participants to serve as healthy 




The student thawed the fresh-frozen tissue samples at room temperature. Working on 
ice, he added 100 µl of radioimmunoprecipitation assay buffer containing one 
microlitre of Phosphatase Inhibitor Cocktail 2 and one microlitre of Protease 
Inhibitor in dimethyl sulfoxide (Sigma-Aldrich, Gillingham, UK) to each sample 
(Figure 25), and lysed the cells with a manual ultrasonic cell disruptor. Restricting 
sonication to short bursts prevented excessive warming of the samples. After 10 
minutes of incubation, with mixing every one minute, centrifugation at 16,250 g for 
5 minutes at 4°C separated off the cell debris. The cell lysate supernatant was drawn 
off with a pipette into labelled Eppendorf tubes and either used immediately or stored 
at -80°C.  
 
Figure 25 Manual ultrasonication of tissue sample. 
Bradford Assay 
The student prepared the standards using a one-in-two serial dilution of 40 µl of 2 
mg/ml Bovine Gamma Globulin (Bio-Rad Laboratories Inc., Hercules, California) in 
40 µl of distilled water to achieve concentrations of 1.0, 0.5, 0.25, 0.125, 0.063, 
0.031, 0.016 mg/ml and then placed 10 µl of each standard and diluted lysate (1 in 
100 concentration in distilled water) in duplicate into a 96-well plate. Fifty 
microlitres of 1X QuickStart Bradford Dye Reagent (Bio-Rad Laboratories Inc., 
Hercules, California) added to each well produced a colour change. A visual check 
determined if any lysates fell outside the standard range. For these lysates, alternative 
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dilutions were also prepared (e.g. 1 in 50 or 1 in 200) and added to the 96-well plate 
with dye reagent. An ELx800 plate reader and Gen5 2.00.18 software (Biotek 
Instruments Ltd., Winooski VT) measured the optical density of each well at 595 nm. 
Using Excel 2010 (Microsoft, Redmond, WA), the results from the standards 
generated a quadratic polynomial equation, which estimated the protein 
concentration of each cell lysate (Figure 26).  
 
Figure 26 Bradford assay standard curve example, showing quadratic polynomial curve used to estimate 
the protein concentrations. 
Antibody Array 
The PathScan RTK Signaling Antibody Array, Chemiluminescent Readout (Cell 
Signaling Technology, Danvers, Massachusetts) was used to quantify the 
phosphorylation status of receptor tyrosine kinases in the cell lysates (Figure 27). It 
is a slide-based antibody array founded upon the sandwich immunoassay principle 
(Cell Signaling Technology 2015). It measures the relative levels of 28 RTKs and 11 
signalling nodes, when phosphorylated at tyrosine or other residues. Each 
nitrocellulose-coated glass slide holds target-specific capture antibody microdots 
arranged in duplicate in eight arrays, which after processing yields chemiluminescent 




Figure 27 PathScan RTK Signaling Antibody Array kit, Chemiluminescent Readout (Cell Signaling 
Technology, Danvers, Massachusetts). 
 
Figure 28 Sandwich immunoassay principle. In this established technique, the capture antibody is bound 
to the slide. The target protein in the sample binds to the capture antibody. Detection antibody then binds 
to the target protein so that it is 'sandwiched’ between the two antibodies. The amount of detection 
antibody on the slide is directly proportional to the concentration of the analyte. In the PathScan RTK 
Signaling Antibody Array, the detection antibody is biotinylated, allowing it to avidly bind the reporter 
molecule, streptavidin-conjugated horseradish peroxidase (HRP). LumiGLO reagent activates it to 
produce a chemiluminescent signal whose intensity varies in proportion to the concentration. The signal is 
captured on radiographic film. 
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Working at room temperature, the student assembled the slide into an eight-well 
cassette, added 150 µl of Array Blocking Buffer to each well and incubated it on a 
rocker at 12 rpm for 15 minutes. Using the results from the Bradford assay, an 
individually calculated volume of Array Diluent Buffer added to each cell lysate 
achieved a consistent protein concentration of 0.75 mg/ml. Each well received 150 µl 
of each diluted cell lysate. The cassette was then covered with sealing tape and 
incubated at 4°C overnight (16–20 hours).  
The student then washed the cassette was according to the instructions, added 150 µl 
of Biotinylated Detection Antibody Cocktail to each well, covered the cassette and 
incubated it on a rocker for 1 hour. Following further washing, he added 150 µl of 
Streptavidin-conjugated Horseradish Peroxidase to each well, covered the cassette 
and incubated it on a rocker for 30 minutes. After further washing the cassette was 
then dismantled and covered evenly with LumiGLO-peroxide reagent. An even 
coverage ensured no air bubbles and reduced the risk of image artefact. Exposure to 
Amersham Hyperfilm ECL (GE Healthcare Life Sciences, Buckinghamshire, UK) in 
a dark room at varying exposures between 20 and 50 seconds captured the image of 
the slide. An automatic film developer (Amersham Pharmacia Biotech, Amersham, 
UK) processed the film, which was then labelled and checked for quality. 
Image Digitisation 
The student developed a bespoke method of digitising the image. Previously in the 
laboratory, a flatbed scanner (HP LaserJet 100 Colour MFP M175nw, Hewlett 
Packard, Palo Alto, California) was used to scan the developed film into a digital 
image (Vossenkämper et al. 2014). However, this method yielded images with poor 
contrast because of the following reason. Flatbed scanners have their CCD camera on 
the same side as the light source, which means they capture reflected light. This is 
suitable when scanning opaque media as reflectivity is high. However, 
chemiluminescent film is transparent and has low reflectivity. The highest contrast 
can only be achieved by having the light source behind the transparency. Flatbed 
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scanners can be used to reliably digitise radiographs, but only when used with a slide 
kit for scanning transparencies (Chen and Hollender 1995). 
To address this limitation, the student set up a light box and digital camera held 
within a rig (Figure 29a). The closest possible distance from the film to the camera 
(Nikon D70 digital camera with a Nikon 18–70 mm 1:3.5–4.5G DX lens, Nikon 
Corporation, Tokyo, Japan) was used and kept constant at 51.5 cm. The light box is 
illuminated by fluorescent light tubes, which due to their physical properties flicker 
at 100 to 120 Hz. This results in fluctuations in light intensity and colour 
temperature. Using a slow shutter speed of 1/10 second with an ISO of 200 captured 
enough cycles to achieve a smooth, consistent picture. Different apertures from f22 
to f16 allowed adjustment of the exposure. The digital image was stored in raw 
format to allow greatest fidelity. The full settings are listed in Appendix 4. 
The student captured each film at different exposures and reviewed their pixel 
histograms on the camera display. These histograms plot the frequency of pixels 
within the image against their brightness value ranging from zero (black) to 255 
(white). If the histogram is clipped at the left, then the image may be underexposed 
and consequently differentiation between pixels of a low brightness are lost, e.g. an 
underexposed image may not show a difference between black and dark grey as all 
those pixels have been stored with a brightness value of zero. If the histogram is 
clipped at the right, then the image may be overexposed and consequently 
differentiation between pixels of a high brightness is lost. For the images of the 
antibody array, the information of interest mainly existed in the pixels with a low 
brightness value (i.e. blacks and greys). Therefore the optimum exposure chosen was 
one where the histogram was never clipped on the left and just touching the right-
hand edge of the graph (Figure 29). 
After checking the images in Zoner Photo Studio 17 (Zoner Inc., Kennesaw GA), to 
ensure that overexposed areas did not encroach onto the slide, the student converted 




Figure 29 (A) Light box setup with digital camera clamped into rig above. (B) Histogram showing an 
absence of pixels towards the right of the graph indicating underexposure. (C) Histogram showing 
truncation of the graph on the right indicating overexposure. (D) Histogram showing the graph just 
touching the right-hand limit and no truncation of the graph on the left (optimum exposure). 
Comparison of Image Digitization Methods 
To validate the new method of image digitization, the student processed the same 
film from the first experiment (eight arrays) using both the flatbed scanner and the 
digital camera (Figure 30). A visual inspection revealed that the digital camera 
produced images with a better contrast between the background and the spots. An 
analysis of the pixel histograms in ImageJ (Schneider et al. 2012) confirmed that the 
digital camera produced a digital image with greater dynamic range: the range of 
pixel brightness was 188 compared to 160. The intensities of the 720 spots were then 
quantified using ImageQuant TL 2005 (GE Healthcare Life Sciences, Pittsburg PA) 
using the method described below. The mean background absolute pixel intensity 
was lower in the digital camera image: 12,108 (SD = 993) versus 69,141 (6,823). A 
lower background signal means less noise obscuring the signal from the spots. The 
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histograms of the absolute pixel intensities showed that there was a clearer bimodal 
distribution of pixel intensities measured from the digital camera image. A bimodal 
distribution is expected as most spots are light, giving the high peak towards the left, 
and the positive controls, which feature less frequently, are dark giving the smaller 
peak towards the right. 
 
Figure 30 (A) One array digitized using flatbed scanner. (B) The same array digitized using digital camera, 
showing better contrast between the background and the spots. (C) Pixel histograms from the digitized 
images of eight arrays (one experiment), showing a wider dynamic range acquired by the digital camera. 
(D) Histograms from the results of the analysed images of those eight arrays, showing a clearer bimodal 
distribution of pixel intensities measured from the digital camera image. 
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Spot Intensity Quantification 
The student analysed the digital images in ImageQuant TL 2005 (GE Healthcare Life 
Sciences, Pittsburg PA), using a standard spot grid pre-programmed with the 
manufacturer’s target map and key (Figure 31, Figure 32 and Table 27). The edge of 
the slide where it appeared lightest specified the background pixel intensity. The 
mean pixel intensity of the positive controls defined 100% against which the analyte 
pixel intensity values were normalised. The data were imported into the study 
database. AS then double-entered the corresponding participant identification 
numbers and biopsy sites to ensure accuracy. 
 
Figure 31 Spot intensity quantification using ImageQuant software. 
 




Table 27 Key to target map listing the 28 receptor tyrosine kinases and 11 signalling nodes. 
Label Protein (phosphorylation site) Name 
Receptor tyrosine kinases 
1 EGFR/ErbB1 Epidermal growth factor receptor 
2 HER2/ErbB2 Human epidermal growth factor receptor 2 
3 HER3/ErbB3 Human epidermal growth factor receptor 3 
4 FGFR1 Fibroblast growth factor receptor 1 
5 FGFR3 Fibroblast growth factor receptor 3 
6 FGFR4 Fibroblast growth factor receptor 4 
7 InsR Insulin receptor 
8 IGF-IR Insulin-like growth factor receptor 1 
9 TrkA/NTRK1 Tyrosine kinase receptor A 
10 TrkB/NTRK2 Tyrosine kinase receptor B 
11 Met/HGFR Hepatocyte growth factor receptor 
12 Ron/MST1R Macrophage stimulating 1 receptor 
13 Ret Ret proto-oncogene receptor tyrosine kinase 
14 ALK Anaplastic lymphoma kinase 
15 PDGFR Platelet-derived growth factor receptor 
16 c-Kit/SCFR Stem cell growth factor receptor 
17 FLT3/Flk2 Foetal liver kinase 2 
18 M-CSFR/CSF-1R Macrophage colony-stimulating factor 1 receptor 
19 EphA1 Ephrin type-A receptor 1 
20 EphA2 Ephrin type-A receptor 2 
21 EphA3 Ephrin type-A receptor 3 
22 EphB1 Ephrin type-B receptor 1 
23 EphB3 Ephrin type-B receptor 3 
24 EphB4 Ephrin type-B receptor 4 
25 Tyro3/Dtk Tyro3 tyrosine-protein kinase 
26 Axl AXL receptor tyrosine kinase 
27 Tie2/TEK Tunica interna endothelial cell kinase 
28 VEGFR2/KDR Vascular endothelial growth factor receptor 2 
Signalling Nodes 
29 Akt/PKB/Rac (Thr308) Proto-oncogene c-Akt / protein kinase B 
30 Akt/PKB/Rac (Ser473) Proto-oncogene c-Akt / protein kinase B 
31 p44/42 MAPK Mitogen-activated protein kinase isoform p44 
32 S6 Ribosomal Protein S6 Ribosomal Protein 
33 c-Abl Abelson murine leukaemia viral oncogene homolog 1 
34 IRS-1 Insulin receptor substrate 1 
35 Zap-70 70 kDa zeta-associated protein 
36 Src Rous sarcoma 
37 Lck Lymphocyte cell-specific protein-tyrosine kinase 
38 Stat1 Signal transducer and activator of transcription 1 




Choice of Spot Result Value 
The target-specific capture antibody microdots are arranged in duplicate (Figure 32), 
and the mean of each pair is usually used as the result value. However, visual 
inspection of the films revealed that the positive control spots, even at very short 
exposure times, gave an intense signal that encroached asymmetrically on adjacent 
analyte spots (Figure 33). 
To assess the effect of this signal overlap, the student calculated the difference in the 
normalised pixel intensity, the pixel intensity range, between each spot pair for 8,892 
spot pairs. For the spots that did not suffer encroachment from adjacent positive 
control spots, the mean pixel intensity range was small, 3.19 (SD = 3.56). This 
demonstrated that variability between spot pairs when there was no encroachment 
was low, and that the performance of the array was consistent enough to justify a 
result based on a single spot instead of the mean of the pair. For the spots that did 
suffer from encroachment, the mean pixel intensity range was larger, 11.73 (SD = 
10.17). This showed that the signal from the affected spots was significantly 
amplified. To control for this, the minimum pixel intensity from each spot pair was 
used as the result value. 
 
Figure 33 One array from the PathScan RTK Signaling Antibody Array, showing asymmetrical 






Out of the 61 participants, one did not undergo biopsy due to unavailability of the 
student at the time. Additionally, as described in Section 4.3, six healthy controls 
underwent biopsy of their rectal mucosa only. 
Not all specimens were taken or analysed in each participant. Reasons were: 
technical difficulty in taking the specimen, inadequate specimen, and an absence of 
the tissue to be sampled (granulation tissue and internal opening sites only). A 
breakdown of the specimens analysed is shown in Table 28. Overall, a total of 224 
specimens were available for phosphoprotein quantification, specifically six control, 
171 idiopathic, and 47 Crohn’s disease samples. With 39 phosphoproteins measured 
per specimen, we made 17,472 measurements overall. 
Experiment Quality Controls 
Each array contained positive and negative control spots. The median pixel 
intensities for the negative control spots for each specimen site were below 20% 
(Figure 34 and Table 47 in Appendix 8). The positive control spots served as a 
reference for 100%, thus their median pixel intensities were 100%. Two negative 
control samples were run: one array containing lysis buffer and one containing 
distilled water. The majority of the spots produced no signal. EGFR/ErbB1, 
HER2/ErbB2, HER3/ErbB3, FGR1, FGR4 and Stat3 produced a pixel intensity 




Table 28 Specimens processed for phosphoprotein quantification. NA, not applicable. 
 Healthy Control Idiopathic Crohn’s Disease All 
Fistula Tract NA 46 12 58 
Granulation Tissue NA 33 11 44 
Internal Opening NA 45 12 57 
Rectal Mucosa 6 47 12 65 
Total 6 171 47 224 
 
 
Figure 34 Control results. Boxplots of results from negative and positive control spots from each array and 
bar chart showing pixel intensities from the negative control samples: one array containing lysis buffer 































































































































































































































































































































All the four specimens (fistula tract, granulation tissue, internal opening and rectal 
mucosa) yielded consistently positive results across both disease groups for 
EGFR/ErbB1, HER2/ErbB2 HER3/ErbB3, FGFR1, FGFR3, FGFR4, Stat1, and 
Stat3. In the rectal mucosa, positive levels for InsR, IGF-1R, c-Kit/SCFR, Tie2/TEK, 
Akt/PKB/Rac at phosphorylation site Thr308, S6 Ribosomal Protein, IRS-1 and Src 
were also seen in both disease groups and the healthy controls (Table 29). 
There were no significant differences in the phosphoprotein levels between the 
idiopathic and Crohn’s disease groups at the four specimen sites (Figure 35; Table 
48, Table 49, Table 50 and Table 51 in Appendix 8). Example microarray images are 
shown in Figure 36. When comparing the healthy controls and the Crohn’s disease 
groups at the rectal mucosa specimen site, the levels of six phosphoproteins were 
significantly higher in the healthy controls: EphA1, EphA2, EphB1, EphB4, 
Tyro3/Dtk and VEGFR2/KDR (Figure 37; Table 52 in Appendix 8). Example 
microarray images are shown in Figure 38. 
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Table 29 Median pixel intensities (%) of phosphoproteins. Id, idiopathic; CD, Crohn's disease; HC, healthy 
controls. 
* statistically significant difference compared with Crohn’s disease, p <0.01.  




Opening Rectal Mucosa 
 Id CD Id CD Id CD HC Id CD 
EGFR/ErbB1 26.7 41.1 26.0 37.3 35.0 43.8 30.5 48.2 45.4 
HER2/ErbB2 18.1 26.6 17.1 24.2 23.4 22.4 59.2 37.3 36.3 
HER3/ErbB3 37.4 49.4 37.5 41.0 50.7 47.2 81.0 63.2 75.0 
FGFR1 24.1 29.7 23.1 22.5 28.6 36.3 56.8 40.9 43.7 
FGFR3 21.8 22.6 33.8 26.6 43.5 36.3 71.0 60.1 68.4 
FGFR4 27.4 30.1 23.0 28.6 33.2 33.2 51.6 42.7 46.4 
InsR 10.4 16.3 9.3 19.4 17.8 20.2 67.7 35.9 42.6 
IGF-1R 7.3 10.5 7.0 13.1 13.6 16.1 58.0 29.0 42.1 
TrkA/NTRK1 8.2 6.7 5.6 10.4 12.6 12.2 62.6 22.6 28.9 
TrkB/NTRK2 10.0 6.5 6.9 7.2 12.7 9.1 41.2 17.0 17.9 
Met/HGFR 1.4 1.3 0.8 2.2 0.8 0.0 16.7 7.7 8.2 
Ron/MST1R 4.3 2.3 2.9 8.2 5.7 3.7 34.2 15.2 21.7 
Ret 1.6 0.1 1.0 2.9 1.5 0.4 9.7 0.5 1.9 
ALK 1.0 0.1 0.1 0.2 0.1 0.0 3.3 0.5 0.1 
PDGFR 5.3 2.4 1.7 6.2 4.5 1.2 17.5 5.5 6.8 
c-Kit/SCFR 10.7 15.1 8.9 14.8 14.0 9.3 55.5 30.6 33.8 
FLT3/Flk2 3.8 4.0 3.3 6.3 4.8 2.2 12.8 6.9 4.8 
M-CSFR/CSF-1R 6.4 5.8 5.0 7.8 11.3 6.7 39.1 20.6 15.9 
EphA1 1.5 1.2 2.0 5.1 3.3 0.3 42.2 13.7 10.3 
EphA2 3.3 4.1 4.0 4.0 5.0 0.8 27.1 10.0 7.6 
EphA3 3.8 3.1 3.5 6.0 11.1 3.0 32.7 10.3 9.6 
EphB1 2.8 1.2 4.2 3.6 3.2 1.1 46.9 7.9 5.9 
EphB3 0.2 0.0 0.2 0.6 0.1 0.0 22.7 0.1 0.0 
EphB4 2.3 2.5 1.5 0.0 6.9 0.1 68.3 23.2 17.1 
Tyro3/Dtk 0.0 0.1 0.7 0.0 0.9 0.0 35.8 9.4 3.7 
Axl 0.3 1.4 0.9 0.0 1.3 0.0 36.1 10.9 6.1 
Tie2/TEK 9.2 13.1 13.5 10.6 22.8 17.1 70.6 41.6 38.4 
VEGFR2/KDR 0.7 0.9 3.6 2.1 8.2 0.9 81.1 14.1 15.5 
Akt/PKB/Rac @Thr308 9.2 12.8 8.4 5.8 37.4 11.9 31.1 41.4 34.1 
Akt/PKB/Rac @Ser473 0.6 1.2 0.7 0.0 4.2 0.0 32.5 11.5 7.2 
p44/42 MAPK (ERK1/2) 4.6 3.6 0.4 0.0 12.2 3.9 24.3 23.9 10.7 
S6 Ribosomal Protein 1.3 0.2 2.6 0.2 14.5 1.0 62.6 24.9 23.1 
c-Abl 0.2 0.0 0.9 0.1 5.6 0.0 30.8 9.5 5.3 
IRS-1 13.1 13.3 20.9 16.4 26.1 7.3 73.7 40.9 25.0 
Zap-70 9.1 9.1 13.0 7.0 11.5 0.1 28.1 18.7 6.8 
Src 17.4 13.9 18.2 10.1 35.1 7.5 29.4 35.7 23.3 
Lck 4.7 4.2 9.3 4.5 10.9 0.8 27.2 14.4 5.6 
Stat1 16.6 37.0 27.8 40.6 49.3 33.9 50.9 40.8 35.8 
Stat3 48.7 57.7 62.7 64.7 74.0 59.8 40.3 62.4 53.6 
          





Figure 35 Relative median difference in phosphoprotein pixel intensities between idiopathic and Crohn's 




Figure 36 Example microarray images. Fistula tract samples from (A) idiopathic and (B) Crohn’s disease 
participants. Granulation tissue samples from (C) idiopathic and (D) Crohn’s disease participants. 
Internal opening samples from (E) idiopathic and (F) Crohn’s disease participants. 
 
Figure 37 Comparison with healthy controls rectal mucosa. Relative median difference in phosphoprotein 
pixel intensities between healthy controls and Crohn's disease groups. Error bars show 99% confidence 
intervals estimated using Hodges-Lehman method. See Appendix 8 for absolute values.  




Figure 38 Example microarray images. (A) Negative control array containing lysis buffer only, showing an 
absent signal from all spots, except the positive control spots. (B) Healthy control rectal mucosa showing 
positive signal from numerous spots including EphA1 (19), EphB1 (22), EphB4 (24), Tyro3/Dtk (25) and 
VEGFR (28). (C) Idiopathic rectal mucosa showing significantly lower signal from the same highlighted 
spots. (D) Crohn’s disease rectal mucosa, again showing significantly lower signal from the same 
highlighted spots. 
5.4 Discussion 
We aimed to describe the phosphorylation profile in this cohort and compare 
between the idiopathic and Crohn’s disease groups in order to test the hypothesis that 
perianal fistulae of these types differ in their pathophysiology. The relative 
concentrations, measured as pixel intensities, of 28 receptor tyrosine kinases and 11 
signalling nodes, when phosphorylated at tyrosine or other residues, in fresh tissue 
homogenates taken from the study cohort were systematically measured.  
To reiterate the findings from Chapter 3, the cohort had a wide distribution of 
phenotypes including those with simple and complex, low and high, and primary and 
recurrent perianal fistula disease in both the idiopathic and Crohn’s disease groups. 
Therefore these laboratory data encompass the breadth of the disease under study. 
We used a well-validated multiplex method efficiently make thousands of accurate 
quantitative measurements. Our laboratory had prior experience in these techniques 
and showed them capable of demonstrating differences in mucosa from 
inflammatory bowel disease patients compared with healthy volunteers 
(Vossenkämper et al. 2014). We employed several quality control features, such as 
data re-entry and experimental controls to ensure the results were accurate and 
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reliable. Analysis used medians and interquartile ranges to allow for skewed data, 
99% confidence intervals to allow for multiple hypothesis testing, and non-
parametric methods to avoid problems with small subgroup numbers. 
With 61 participants, 4 biopsy sites (fistula tract, granulation tissue, internal opening 
and rectal mucosa) and 39 analytes (EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, 
FGFR1, FGFR3, FGFR4, InsR, IGF-IR, TrkA/NTRK1, TrkB/NTRK2, Met/HGFR, 
Ron/MST1R, Ret, ALK, PDGFR, c-Kit/SCFR, FLT3/Flk2, M-CSFR/CSF-1R, 
EphA1, EphA2, EphA3, EphB1, EphB3, EphB4, Tyro3/Dtk, Axl, Tie2/TEK, 
VEGFR2/KDR, Akt/PKB/Rac (at Thr308), Akt/PKB/Rac (at Ser473), p44/42 
MAPK, S6 Ribosomal Protein, c-Abl, IRS-1, Zap-70, Src, Lck, Stat1 and Stat3), a 
total of 17,472 measurements were made. Despite this extensive approach, there 
were no significant differences in the median pixel intensities of each phosphoprotein 
between the disease groups for each of the four biopsy sites (Table 30). 
When comparing the phosphoprotein levels from the rectal mucosa of Crohn’s 
disease participants with the healthy controls, we found significantly higher levels in 
the healthy controls for six phosphoproteins: EphA1, EphA2, EphB1, EphB4, 
Tyro3/Dtk and VEGFR2/KDR. The first four are RTKs from the Ephrin subfamily. 
They are membrane-bound cell surface receptors and are mainly activated through 
direct cell-cell interaction with membrane-bound ephrin ligands. Ephrin receptor and 
ephrin signalling is important in controlling cellular proliferation in the crypts and 
differentiation of enterocytes on the villi. Loss of ephrin receptor and ephrin 
signalling appears to contribute to wound healing defects, as in inflammatory bowel 
disease, and tumorigenesis (Perez White and Getsios 2014). Thus, the present study 
suggests that suppression of ephrin receptor expression in the rectal mucosa may be a 
pathological feature in patients with both idiopathic and Crohn’s perianal fistulae. 
The consequence of this conclusion is potentially important for two reasons: (1) it 
suggests that idiopathic and Crohn’s perianal fistulae may be similar in their 
immunopathology with regards to ephrin signalling, and (2) it suggests that 
abnormalities in those with idiopathic perianal fistulae are not confined to the peri-
fistula tissue, a notion that has not previously been reported. 
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Tyro3 is a RTK that, along with Axl and Mertk (c-Mer proto-oncogene tyrosine 
kinase), and their ligands Gas6 (Growth arrest-specific protein 6) and Protein S, 
makes up the TAM (Tyro3, Axl, Mertk) signalling pathway. This pathway is 
involved in the negative regulation of inflammation, removal of apoptotic cells and 
potential induction of the tissue repair response. In inflammatory bowel disease, 
TAM signalling is suppressed, which, in the presence of intestinal mucosal injury, 
leads to an accumulation of apoptotic neutrophils and a failure of intestinal 
macrophages to acquire an alternative activation state (Rothlin et al. 2014). The 
present study with respect to the rectal mucosa in the Crohn’s disease group is 
consistent with this. However, it also suggests that suppression of Tyro3 may also 
occur in the rectal mucosa of those with idiopathic perianal fistulae, further 
supporting the notions described at the end of the previous paragraph. 
VEGFR2 is the principle RTK that transmits VEGF signals in the vascular 
endothelium. The principle effect of VEGFR2 activation is angiogenesis, which is a 
feature of both health and disease. Algaba et al. (2013) measured the concentrations 
of angiogenic and lymphangiogenic factors, including VEGFR2, in colonic mucosa 
culture supernatants in patients with endoscopically active and quiescent Crohn’s 
disease, compared with healthy controls. They concluded the concentration of these 
factors correlated with disease activity. However, closer inspection of the data shows 
that VEGFR2 was higher in the active compared with quiescent Crohn’s disease 
groups, but not significantly different to the healthy control group. The lowest 
concentration of VGEFR2 was found in the quiescent Crohn’s disease group. It could 
therefore be the case that VEGFR2 is suppressed in those with quiescent Crohn’s 
disease. We found that VEGFR2 levels in the fresh colonic mucosa homogenates 
were lower in patients both with idiopathic and Crohn’s perianal fistulae, compared 
with healthy controls. This could suggest that expression of this RTK is suppressed 
in these diseases. This may also correlate with results presented in the previous 
chapter, where significant concentrations of VEGF were seen in each group at all 
specimen sites. There were no significant differences between the groups, but in the 
rectal mucosa there was a trend to higher expression in the healthy controls. 
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Table 30 Summary of phosphoprotein profile data comparisons between idiopathic and Crohn’s perianal 
fistulae. 
 Similarities  Differences  
Phosphoprotein 
concentrations 
Similar levels of 39 
phosphoproteins at the four 
specimen sites 
(EGFR/ErbB1, HER2/ErbB2, 
HER3/ErbB3, FGFR1, FGFR3, 
FGFR4, InsR, IGF-IR, 
TrkA/NTRK1, TrkB/NTRK2, 
Met/HGFR, Ron/MST1R, Ret, 
ALK, PDGFR, c-Kit/SCFR, 
FLT3/Flk2, M-CSFR/CSF-1R, 
EphA1, EphA2, EphA3, EphB1, 
EphB3, EphB4, Tyro3/Dtk, Axl, 
Tie2/TEK, VEGFR2/KDR, 
Akt/PKB/Rac (at Thr308), 
Akt/PKB/Rac (at Ser473), p44/42 
MAPK, S6 Ribosomal Protein, c-




Comparison with Current Theory 
All the four specimens (fistula tract, granulation tissue, internal opening and rectal 
mucosa) yielded consistently positive results across both disease groups for 
phosphorylated EGFR/ErbB1, HER2/ErbB2 and HER3/ErbB3. The first three are 
receptor tyrosine kinases (RTKs) from the ErbB family and are involved in epithelial 
cell growth and survival. Activation leads to phosphorylation and subsequent 
intracellular signalling. Intracellular signal transduction utilises several pathways, 
including Akt and MAPK (Gerbin 2010). ErbB activation in colonic epithelial cells 
appears to be protective during inflammation. For example, activation of 
EGFR/ErbB1 by EGF stimulates proliferation, reduction in cytokine-induced 
apoptosis, and migration/wound healing, both in vitro and in vivo (Frey and Polk 
2014). Mice that are deficient in EGFR or the ligand TGF-a develop more severe 
experimental colitis (Dubé et al. 2012; Egger et al. 1997). Our results for 
phosphorylated ErbB receptors are therefore consistent with this current knowledge. 
Looking at the rectal mucosa, although there were no statistically significant 
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differences between the groups, there was a consistent trend of higher levels of 
phosphorylated ErbB in the healthy controls compared with both disease groups. 
Suppression of ErbB would be expected in Crohn’s disease mucosa, but suppression 
also in the idiopathic group is an interesting possibility, as it would also support the 
ideas that idiopathic and Crohn’s perianal fistulae have a similar immunopathology 
and that immunopathological changes are not confined to the peri-fistula tissue in 
idiopathic disease. We raise this idea cautiously as the results presented in the 
previous chapter do not seem to fit: there were no trends in the EGF concentrations 
across the groups. 
The four sample sites also yielded consistently positive results across both disease 
groups for phosphorylated FGFR1, FGFR3, FGFR4, Stat1, and Stat3. The FGFR 
family of RTKs is also involved in cellular proliferation, migration, survival, 
angiogenesis and wound healing. When ligands bind to the extracellular component, 
phosphorylation of the cytoplasmic kinase domain induces Akt, MAPK, and Jak/Stat 
intracellular signalling pathways. Numerous FGFR gene mutations have been found 
in many different cancers, however its role in gut homeostasis and inflammation has 
not been reported. One could speculate that its role in gut health and disease is 
similar to ErbB, given its similar functions in cell behaviour, which would then lead 
to similar conclusions regarding the present study’s results. 
Limitations 
The cohort included a broad range of clinical phenotypes, representing the full 
spectrum of perianal fistula disease. However, this meant that the data were naturally 
heterogeneous. As our sample size, although comparable to the vast majority of 
previous studies on perianal fistula, was relatively small, differences may not have 
been apparent within the heterogeneity. 
Collection of tissue specimens followed a protocol and in most cases performed by 
the same two surgeons (JH, CHK) to standardise the methods as much as possible. 
However, patient and operative factors influenced the size, depth and position of the 
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specimens taken, relative to the internal opening, and these differences in theory may 
have impacted on the results obtained. 
By examining a broad panel of phosphoproteins, a deeper interrogation of the role of 
each one and how they interact in perianal fistula disease was not feasible. Only a 
cautious comparison and triangulation of these data with current knowledge was 
therefore possible. 
A healthy control for specimens taken from the fistula tract, granulation tissue and 
internal opening was not included in this study for reasons discussed in Section 2.2. 
5.5 Conclusions 
After examining the relative concentrations of 28 receptor tyrosine kinases and 11 
signalling nodes, when phosphorylated at tyrosine or other residues, in fresh tissue 
homogenates taken at four specimen sites in 60 participants with idiopathic and 
Crohn’s perianal fistula disease, there was no clear difference in the overall 
phosphoprotein profile between idiopathic and Crohn’s perianal fistulae.  
When we compared the rectal mucosa of healthy controls against the participants 
with Crohn’s perianal fistulae, differences were seen in six phosphoproteins: EphA1, 
EphA2, EphB1, EphB4, Tyro3/Dtk and VEGFR2/KDR. Considering what is already 
known about the role of these receptors in gut health and disease, this pattern raises 
the possibility that idiopathic and Crohn’s perianal fistulae have similar 




6. DYNAMIC CONTRAST-ENHANCED MRI 
6.1 Introduction 
MRI for perianal fistulae was first described by Lunniss et al. (1992) and has since 
emerged as the technique of choice for preoperative evaluation of perianal fistulae to 
improve patient outcome (Criado et al. 2012). It is superior to computed tomography 
in terms of demonstrating the soft tissue structures of interest, namely the internal 
and external anal sphincters and their relationship to the fistula disease; and it is 
superior to anal endo-ultrasonography, which can fail to demonstrate fistula tracts 
that are outside the close imaging field. 
The use of MRI to evaluate perianal fistulae is now standard practice and is indicated 
in recurrent disease, suspected complex disease, non-idiopathic aetiology, and when 
clinical examination fails to demonstrate an external opening. Fat-suppressed T2-
weighted sequences such as short tau inversion recovery (STIR) or frequency-
selective fat-saturated T2-weighted fast spin-echo (FSE) usually provide the 
necessary information to accurately understand the course of the primary tract, the 
presence and anatomy of any secondary tracts and abscesses, and the anatomy of the 
anal canal and its relationship with the tracts. This information is useful as it can help 
the clinician evaluate how much of the anal sphincters are spared, and therefore the 
likely risks of incontinence from laying open of the fistula. The information can also 
aid the operative strategy as it allows the surgeon to target clinically occult disease 
and thus reduce recurrence. In a study of 71 patients with recurrent perianal fistula, 
Buchanan et al. found that surgery guided by MRI reduced further recurrence by 
75% (Buchanan et al. 2002). 
Interpretation of conventional MRI is usually subjective and qualitative. In an 
attempt to quantify the severity of disease, two image grading systems were 
developed. In Crohn’s disease, the severity of disease can be graded using the Van 
Assche score (Van Assche et al. 2003), which consists of both anatomic variables 
and variables indicative of active inflammation and ranges from 0 to 22, with higher 
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scores indicating more severe disease. For all perianal fistulae, the St James’s 
University Hospital Classification can be applied. This anatomical grading system 
arranges fistulae into five grades of increasing severity: grade 1, simple linear inter-
sphincteric fistula; grade 2, inter-sphincteric with abscess or secondary tract; grade 3, 
trans-sphincteric; grade 4, trans-sphincteric with abscess or secondary tract in 
ischiorectal or ischioanal fossa; grade 5, supralevator and translevator. These grades 
demonstrate significant correlation with outcome (Spencer et al. 1998). 
However, both these grading systems are still subjective, as they require a certain 
degree of judgement by the radiologist reviewing the images. Objective quantitative 
information from MRI can be obtained using dynamic contrast-enhanced (DCE) 
protocols. In DCE-MRI, images are acquired serially during the delivery of an 
intravenous contrast material to obtain volumes in four dimensions: three spatial and 
one temporal. The dynamic tissue enhancement of a region of interest can be seen 
and measured over time to produce a time-intensity curve (TIC). Local tissue 
characteristics such as inflammation or tumour affect the inflow of blood into the 
tissue of interest and subsequent distribution in the extravascular space. Thus these 
tissue characteristics are reflected in differences in the TIC.  
DCE-MRI is now established as a clinical tool in a number of diseases including 
breast cancer, where quantitative data before and after treatment are used to assess 
response (Wang et al. 2014). Three methods of analysis of DCE-MRI data have been 
reported: TIC shape analysis, parametric analysis and pharmacokinetic modelling 
(Lavini et al. 2013). TIC shape analysis categorizes the shape of the curve against 
known types. Parametric analysis involves the generation of parameters describing 
the TIC, such as maximum enhancement, wash in rate, wash out rate and area under 
the TIC. Pharmacokinetic modelling permits the extraction of physiologically 
relevant quantities that reflect intrinsic properties of the tissue, such as micro-
vascularity permeability, tissue perfusion and cellular density. 
The use of DCE-MRI in perianal fistula is not established. Horsthuis et al. (2009) 
was the first to report on the use of DCE-MRI in perianal fistulae. Only Crohn’s 
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disease patients were included in their cohort of 33. They concluded from TIC shape 
and parametric analysis that DCE-MRI could be used to determine disease activity in 
perianal Crohn’s disease, and might be helpful in selecting a subpopulation of 
patients who should be monitored more closely for development of more extensive 
disease. The same institution then applied DCE-MRI with pharmacokinetic 
modelling in a pilot study of 16 consecutive patients with perianal Crohn’s disease. 
A second DCE-MRI examination was also performed in six patients six weeks after 
starting treatment with anti-TNF-α. They concluded that maximum enhancement and 
wash in rate correlate with disease activity in perianal Crohn’s disease, and Ktrans (the 
forward transfer coefficient of gadolinium between plasma and the extracellular 
extravascular space) may be an indicator of the effect of therapy on patients starting 
anti-TNF-α. The use of DCE-MRI has not been reported in idiopathic perianal fistula 
disease.  
The aims of this study were to: demonstrate the feasibility of DCE-MRI in both 
idiopathic and Crohn’s perianal fistulae; provide, for the first time, reference DCE-
MRI data in idiopathic disease; and compare the DCE-MRI characteristics between 
idiopathic and Crohn’s disease groups in order to test the hypothesis that perianal 
fistulae of these types differ. 
6.2 Methods 
Participants 
We selected a subgroup of participants from the whole cohort in this study. 
Eligibility was based on the requirement for pelvic MRI scan as part of their routine 
clinical evaluation. This limitation was due to the excess costs involved in 
performing de novo MRIs for the purposes of this research. Indications for MRI 
included recurrent disease or persistence of symptoms after surgery with curative 
intent (e.g. lay open), deterioration of symptoms after surgery with symptomatic 
control intent (e.g. seton), absence of an external opening and/or presence of 
supralevator sepsis on examination.  
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Prior to the recruitment of the main cohort, we recruited consecutive patients from 
the MRI waiting list into a pilot cohort, the purpose of which was to determine 
feasibility. The same inclusion and exclusion criteria as the main cohort were 
applied. Following DCE-MRI acquisition, the pilot subjects only underwent clinical 
follow-up by their direct care team. We recorded outcomes from these follow-up 
episodes, but did not perform PDAI and EQ-5D-5L measurements. 
MRI Acquisition 
Firstly, conventional MRI series were acquired. A survey sequence delineated the 
anatomy. A STIR sagittal sequence then followed. STIR is a Short TI Inversion 
Recovery technique that suppresses the signal from fat and thus improves the 
contrast and appearance of the fistula (white) against the surrounding ischioanal fat 
(black). We then acquired STIR sequences parallel (coronal oblique) and 
perpendicular (axial oblique) to the axis of the anal canal. This was followed by an e-
THRIVE sequence in the axial oblique plane. e-THRIVE is a T1-weighted High 
Resolution Isotropic Volume Examination designed for DCE studies using SPAIR 
(SPectral Attenuated Inversion Recovery) fat suppression: a hybrid technique that 
offers an even homogenous fat suppression.  
The dynamic MRI series was then acquired. An automated injection pump delivered 
a bolus of 10 ml gadolinium contrast agent followed by 30 ml normal saline at a rate 
of 4 ml/s into an antecubital intravenous cannula. Image acquisition started 
simultaneously. PJ identified the most prominent part of the fistula, and therefore the 
presumed site of maximum inflammation, on the previous e-THRIVE series. Centred 
on this area, an e-THRIVE technique acquired a six-section axial oblique volume 10 
consecutive times with a temporal resolution of 4.2 seconds. A post-contrast e-
THRIVE sequence was then also acquired. 
A senior MRI technician (PJ) and experienced consultant gastrointestinal radiologist 
(AP) adapted this protocol from a standard commercial protocol for DCE-MRI of the 
prostate (Philips, Amsterdam, Netherlands). They chose a high temporal resolution 
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because previous studies have shown that most perianal fistulae show early 
enhancement, which is likely due to their high vascularization (Horsthuis et al. 2009; 
Ziech et al. 2013).  
We took care to ensure these DCE-MRI studies were performed in a consistent 
manner: the same 3T MRI scanner (Philips, Amsterdam, Netherlands) at St 
Bartholomew’s Hospital was used for all participants, with the same six-channel 
torso phased-array body coil applied around the pelvic area in the supine position; 
the same senior MRI technician conducted the scans using the same protocol stored 
on the scanner’s software; the same contrast agent, injection pump, syringe, tubing 
and intravenous cannula diameter were used to achieve the same image enhancement 
conditions. 
Qualitative Analysis 
A departmental gastrointestinal radiologist reported the conventional series as part of 
routine NHS care. The student, who had been trained to interpret these images, 
reviewed the report and the images, and gathered data on a bespoke CRF (Appendix 
3), which included the number of fistulae and presence of branching, Parks’ 
classification, level of internal opening within the anal canal, position of the 
secondary tracts in relation to the levator ani, presence of horseshoe extensions, 
presence of associated collections (cavities > 3 mm diameter), rectal wall 
involvement, T2 hyperintensity, and the Van Assche Score. 
Van Assche Score 
We graded the severity of perianal fistula from the conventional MRI series using the 
Van Assche score (also known as the MRI-based score). It comprises six dimensions 
covering criteria of local extension of fistulas: complexity, supralevator extension, 
relation to the sphincters; and criteria of active inflammation: T2 hyperintensity, 
presence of cavities/abscesses, and rectal wall involvement. Van Assche et al. (2003) 
devised and developed the score using the MRI data from 18 patients with Crohn’s 
disease. The scoring system demonstrated good inter-observer concordance, with k 
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values ranging from 0.79 to 1.00, and overall significant correlation with p < 0.001. 
The score was also sensitive to change: patients who had a clinical response 
infliximab treatment showed a reduction in the MRI-based score at 6 and 46 weeks 
after commencement. Subsequent studies also showed a reduction in the Van Assche 
score with a decrease in the clinical severity of the disease (Karmiris et al. 2011; 
Kulkarni et al. 2014). One study did not show this concordance, although it was 
limited by the small number of patients (N = 16) included in the analysis (Horsthuis 
et al. 2011).  
The current study did not include T2-weighted images. In the Van Assche score, the 
most important measure of local inflammation is T2 hyperintensity. However, 
gadolinium-enhanced T1-weighted images are better indicators of fistula activity 
(Semelka et al. 1997). On gadolinium-enhanced T1-weighted images, a marked 
increase in signal intensity of inflammatory tissue can be seen because of increased 
tissue perfusion (Weinmann et al. 1984). Therefore, as a proxy in this study, we 
estimated fistula hyperintensity from the post-contrast e-THRIVE series. 
Quantitative Analysis 
The student analysed the dynamic series using the Extended MR Workspace (version 
2.6.3.5, Philips, Amsterdam, Netherlands). Within the six sections dynamic volume, 
the section with the most extensive and most hyperintense lesion was used for 
analysis. The student, aided by AP, manually drew a single oval-shaped region of 
interest around the fistula on the last dynamic image of the chosen section, 
corresponding to 42 seconds after injection (Figure 39). For each region of interest, 
the software calculated the maximum enhancement, maximum relative enhancement, 
wash in rate, wash out rate, area under the curve and plotted a time-intensity curve 
(TIC). The student classified the shape of the TIC by comparing it against a standard 




Figure 39 DCE-MRI. (A) Region of interest drawn around the fistula where it is most prominent. (B) 
Perfusion heat map overlaid. 
 
Figure 40 Standard chart used to classify time-intensity curves (Lavini et al. 2007). Type 1 (gray), no 
enhancement; Type 2 (green), slow enhancement, maximum of the curve is reached after half scan; Type 3 
(blue), quick enhancement, followed by a signal plateau; Type 4 (magenta), fast enhancement and quick 
washout; Type 5 (yellow), quick enhancement, followed by a slow constant enhancement; Type 6 (red), 
artery; Type 7 (white/light gray), all others. 
6.3 Results 
Participant Characteristics 
Eight participants from the main cohort and 16 from the pilot (March to September 
2013) underwent DCE-MRI. Thus a total of 24 participants were included in this 
study, including 15 participants with idiopathic and nine with Crohn’s perianal 
fistulae. There was a male preponderance (2:1) and the mean age was 36.2 years (SD 
= 14.5) in keeping with the general epidemiology of perianal fistula disease. The 
majority were of Asian ethnicity, reflecting the local population demographics. 
The median time since fistula development at recruitment was eight months (IQR = 
4–26) and the median number of previous operations was one (0–2). Four (17%) had 
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previously had surgery with curative intent. Further baseline characteristics are 
detailed in Table 31. 
In the Crohn’s disease group, participants had a moderately lower median age and 
the majority had received anti-TNF-a therapy. The mean PDAI (measured only in 
the main cohort) was 12.0 (SD = 2.6). Follow up was for a median of 30 months 
(IQR = 21–50). 
Conventional MRI Characteristics 
Most of the fistulae were single (n = 22, 92%) and trans-sphincteric (19, 79%). Five 
(21%) were high, 14 (58%) had secondary tracts, eight (33%) had horseshoe 
extensions, 10 (42%) had associated collections and four (17%) had a thickened 
rectum (Table 32). The mean Van Assche score was 11.4 (SD = 5.2). Fistulae 
morphology ranged through all described types. The majority of the participants had 
complex fistula morphologies with a Van Assche score indicating significant disease 
activity. The distribution of the characteristics between the groups was similar, apart 
from thickened rectum, which was only seen in the Crohn’s disease group. 
Dynamic Contrast-Enhanced MRI Parametric Analysis 
DCE-MRI measurements were consistently obtained from all participants. The mean 
maximum enhancement, maximum relative enhancement, wash in rate, wash out rate 
and area under the TIC measurements are presented in Table 33. 
There were no differences in any of the DCE-MRI measurements between the 
idiopathic and Crohn’s disease groups. There were also no significant differences 
when sub-grouped by fistula disease duration (<12 versus ≥ 12 months; Table 53 and 
Table 54 in Appendix 8). When sub-grouped by Parks’ classification (inter-
sphincteric versus trans- or supra-sphincteric), the mean maximum enhancement 
(p = 0.04) and mean maximum relative enhancement (p = 0.03) were both 
significantly higher in trans- or supra-sphincteric fistulae (Figure 41; Table 55 in 
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Appendix 8). The mean area under TIC was also higher but this trend did not reach 
statistical significance (p = 0.06). 
Table 31 Participant characteristics in DCE-MRI study. SD, standard deviation; IQR, interquartile range. 
 Idiopathic Crohn's Disease All 
n 15 9 24 
Male 10 (67%) 6 (67%) 16 (67%) 
Mean age (SD), years 40.5 (14.9) 29.0 (11.2) 36.2 (14.5) 
Ethnic origin:    
White 2 (13%) 5 (56%) 7 (29%) 
Asian 7 (47%) 4 (44%) 11 (46%) 
Black 2 (13%) 0 2 (8%) 
Other 4 (27%) 0 4 (17%) 
Median fistula duration (IQR), months 10 (4–18) 8 (4–40) 8 (4–26) 
Previously received antibiotics 6 (40%) 0 6 (25%) 
Previously received anti-TNF-a 0 8 (89%) 8 (33%) 
Median previous operations (IQR) 0 (0–2) 1 (0–1) 1 (0–2) 
Previously had surgery with curative intent 1 (7%) 3 (33%) 4 (17%) 




Table 32 Conventional MRI characteristics. SD, standard deviation. 
 
Idiopathic Crohn's Disease All 
Number of fistulae: 
   Single unbranched 7 (47%) 3 (33%) 10 (42%) 
Single branched 8 (53%) 4 (44%) 12 (50%) 
Multiple 0 2 (22%) 2 (8%) 
Parks’ classification: 
   Inter-sphincteric 3 (20%) 1 (11%) 4 (17%) 
Trans-sphincteric 12 (80%) 7 (78%) 19 (79%) 
Supra-sphincteric 0 1 (11%) 1 (4%) 
High fistula on MRI at baseline 3 (20%) 2 (22%) 5 (21%) 
Secondary tract(s): 
   None 6 (40%) 4 (44%) 10 (42%) 
Infralevator 8 (53%) 4 (44%) 12 (50%) 
Supralevator 1 (7%) 1 (11%) 2 (8%) 
Horseshoe extension(s) 6 (40%) 2 (22%) 8 (33%) 
Collection(s) 5 (33%) 5 (56%) 10 (42%) 
Thickened rectum 0 4 (44%) 4 (17%) 
Fistula hyperintensity: 
   Absent 2 (13%) 0 2 (8%) 
Mild 8 (53%) 5 (56%) 13 (54%) 
Pronounced 5 (33%) 4 (44%) 9 (38%) 




Table 33 DCE-MRI characteristics. Hypotheses tested using T test (significance level 0.05). SD, standard 
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Figure 41 DCE-MRI measurements sub-grouped by Parks’ classification. Max enhancement mean 
difference 449 (95% CI = 36–863; p = 0.04), max relative enhancement mean difference 0.522 (0.056–0.988; 
p = 0.03), area under TIC mean difference 9872 (-343–20087; p = 0.06). TIC, time intensity curve. 
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Time Intensity Curve Shape Analysis 
TIC types 2, 3, 4 and 5 were observed. Examples are shown in Figure 42. The 
commonest was type 3 (Table 34), and overall, 21 (87%) had a TIC with a quick 
enhancement phase (type 3–5). There was no difference in the distribution of TIC 
types between the idiopathic and Crohn’s disease groups (p = 0.37 Fisher’s Exact 
Test). 
There were no significant differences in the distribution of Parks’ classification 
(inter- versus trans- or supra-sphincteric), fistula disease duration (<12 versus ≥ 12 
months) and treatment outcome when sub-grouped into quick enhancement TIC, 
types 3–5, versus slow enhancement TIC, type 2 (Table 56 in Appendix 8). 
 
Figure 42 Examples of the time-intensity curve types. 
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Table 34 Time intensity curve (TIC) types. No significant differences found between the groups (p = 0.37 
Fisher’s Exact Test). 
TIC type Idiopathic Crohn's Disease All 
2 1 (7%) 2 (22%) 3 (13%) 
3 7 (47%) 5 (56%) 12 (50%) 
4 1 (7%) 1 (11%) 2 (8%) 
5 6 (40%) 1 (11%) 7 (29%) 
 
6.4 Discussion 
We aimed to demonstrate the feasibility of DCE-MRI in both idiopathic and Crohn’s 
perianal fistulae; to provide for the first time reference DCE-MRI data in idiopathic 
disease; and to compare the DCE-MRI characteristics between idiopathic and 
Crohn’s disease groups in order to test the hypothesis that perianal fistulae of these 
types differ perhaps reflecting differences in pathophysiology. 
Twenty-four participants were included consisting 16 participants from the pilot 
study and 8 participants from the main study. The gender and age distributions were 
in keeping with the general epidemiology. The cohort had a wide distribution of 
clinical phenotypes: number of fistulae, Parks’ classification, high and low fistulae, 
secondary tracts, horseshoe extensions, collections and rectal thickening, thus being a 
fair representation of the population. These characteristics were also evenly 
distributed between the idiopathic and Crohn’s disease groups, except for previous 
anti-TNF-a therapy: almost all participants in the Crohn’s disease group had 
received or were currently receiving anti-TNF-a therapy, compared with none in the 
idiopathic group. 
Obtaining DCE-MRI measurements was feasible. The methods did not fail in any 
participant. These techniques were previously reported in exclusively Crohn’s 
perianal fistulae cohorts (Horsthuis et al. 2009; Villa et al. 2012; Ziech et al. 2013). 
Although idiopathic fistulae are generally less thick and prominent on MRI, which 
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makes drawing a region of interest around them more difficult, we demonstrated that 
DCE-MRI measurements are also feasible in idiopathic disease. 
There were no differences in any of the DCE-MRI measurements between the 
idiopathic and Crohn’s disease groups. As these measurements are an indirect 
measure of tissue vascularity and permeability, they are thus an indicator of local 
tissue inflammation. These data suggest there is no obvious difference in the degree 
of inflammation associated with idiopathic and Crohn’s perianal fistulae. It is 
however possible that a larger sample size is needed to find small differences. 
Further sub-group analysis suggested that DCE-MRI measurements also do not 
correlate with fistula disease duration or treatment outcome. However significant 
differences were found when sub-grouped by Parks’ classification. We found higher 
mean maximum enhancement and maximum relative enhancement in those with 
trans- or supra-sphincteric fistulae. This may suggest those with more 
pathoanatomically advanced disease have a greater degree of peri-fistula 
inflammation. 
The majority of the perianal fistulae had a TIC with a quick enhancement phase 
(types 3–5). TIC shape reflects tissue viability and permeability to the contrast agent 
from the capillary to the extravascular space, from which the agent is later 
reabsorbed by the blood pool, resulting eventually in a signal decrease (Lavini et al. 
2013). Areas of high perfusion and permeability, such as acutely inflamed tissue, 
typically show a quick enhancement; areas of low perfusion and permeability, such 
as fibrotic tissue tend to enhance in a much slower fashion, and the signal does not 
decrease until after the end of the DCE-MRI scan (TIC type 2).   
TIC shape analysis, which is established and standardised in breast imaging, is still 
evolving in other diseases such as perianal fistulae. Horsthuis et al. (2009) used a 
modified method to analyse the TIC shapes. Instead of obtaining a single averaged 
TIC from a region of interest, the authors measured the frequency of the different 
TIC types on a pixel-by-pixel basis within the region of interest. They found that 
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significantly higher numbers of quickly enhancing pixels were seen in patients who 
then developed new perianal abscesses and needed medication changes during 
follow-up. Ziech et al. (2013) also used the same method but only reported that total 
pixel counts of individual TIC types had moderate to strong correlation with the Van 
Assche score. 
We found no differences in the distribution of the TIC types between the idiopathic 
and Crohn’s disease groups. This may be further evidence for a similar inflammatory 
phenotype between the two groups, although as the significance of TIC types in 
perianal fistula disease in general is still unknown, further study is required before 
this conclusion can be made. The above comparisons are summarised in Table 35. 
Table 35 Summary of DCE-MRI data comparisons between idiopathic and Crohn’s disease perianal 
fistulae. DCE-MRI, dynamic contrast-enhanced-magnetic resonance imaging; TIC, time-intensity curve. 
 Similarities  Differences  
DCE-MRI Similar mean maximum 
enhancement, maximum relative 
enhancement, wash in rate, wash 





Participants were selected based on their clinical indication for MRI. We therefore 
excluded many patients such as those with simple primary fistulae, and those who 
had been recently imaged before recruitment. The cohort was also heterogeneous 
(primary and recurrent disease, treatment-naïve and previously operated). Future 
studies would need to consider performing DCE-MRI in all participants at the same 
point in the natural history of their perianal fistula disease, and reducing the 
heterogeneity of the cohort.  
Because almost all participants in the Crohn’s disease group were subjected to anti-
TNF-a, the results in this group could have been attenuated: anti-TNF-a may have 
reduced peri-fistula inflammation and thus disease severity, resulting in any 
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difference between the groups being nullified. This arose due to the study’s 
pragmatic design: inclusion was not restricted to those who were treatment-naïve. 
PDAI was used as a clinical measure of disease severity. However it was only 
measured in the main cohort. It is likely that the PDAI distribution in the pilot cohort 
is similar to the main cohort, given that the fistula characteristics and indications for 
performing the MRI were the same. Nevertheless, this limited analysis of this 
variable. 
Distribution of the PDAI was confined to the middle of the index’s scale. Due to the 
indications for MRI and the inclusion criteria, there were no participants with PDAI 
of ≤ 4, the cut-off above which active disease requiring medical or surgical treatment 
is suggested. There were also no participants with PDAI towards the top of the scale. 
It might be the case that a wider range of disease severity is needed before 
differences in these DCE-MRI data are seen. 
Parametric analysis of DCE-MRI signal intensity is vulnerable to variability across 
participants in clinical studies as the parameters used in the T1-weighted MRI 
sequence significantly affect the relationship between the amount of contrast agent in 
the tissue and the signal intensity change (Evelhoch 1999). This inter-participant 
variability was minimised by keeping all parameters and methods the same for all 
participants: the MRI machine, the contrast injector, the contrast agent, the MRI 
sequence protocol, the MRI technician running the sequences, and the post-hoc 
analysis software remained consistent throughout the study. More accurate 
quantitative analysis using pharmacokinetic models have been described in the 
literature (Tofts et al. 1999). These techniques have the advantage of extracting 
physiologically relevant quantities that reflect the intrinsic properties of the tissue. 
However, its complex implementation was beyond the expertise available to the 
study. 
Due to limited resources, it was not possible conduct this study in a way that enabled 
analysis of the intra- and inter-observer variability. This would have provided a 
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degree of confidence in the reliability of the measurements, as although the majority 
of the DCE analysis is quantitative and objective, defining the region of interest 
requires a degree of subjective human judgement. 
6.5 Conclusions 
We examined the DCE-MRI characteristics of perianal fistulae in 24 participants 
with idiopathic and Crohn’s disease. The feasibility of this modality in idiopathic 
disease was demonstrated for the first time. Data for this cohort is now available and 
will serve as a useful reference for future studies.  
We found no differences in the DCE-MRI measurements and the TIC types between 
the idiopathic and Crohn’s disease groups. However, secondary sub-group analysis 
revealed the mean maximum enhancement and maximum relative enhancement were 
significantly higher in participants with a more advanced pathoanatomy (trans- or 
supra-sphincteric fistulae). Further study into this area needs to consider performing 
de novo MRI in all participants, a more homogenous cohort, and including inter-





This research aimed to test the broad hypothesis that idiopathic and Crohn’s perianal 
fistulae differ in their pathogenesis and pathophysiology. We prospectively recruited 
a cohort of 61 participants and phenotyped them in detail using clinical assessment, 
MRI, operative assessment, biopsy, and clinical follow-up. We interrogated the 
biopsy samples in the laboratory to characterize their profiles for 30 cytokines and 39 
phosphoproteins. Over 12,000 clinical and 23,500 laboratory measurements were 
made. 
Chapter 3: Clinical Data 
• This is the largest study to date to phenotype perianal fistula disease in detail in 
both idiopathic and Crohn’s disease patients. Severe disease appears to be 
commoner in Crohn’s perianal fistulae compared with idiopathic perianal fistulae. 
However, there were also many phenotypic similarities between the groups, and 
thus overall, the groups did not appear to be phenotypically distinct. 
• These data are also probably the most complete dataset to date using patient 
reported outcome measures, namely PDAI and EQ-5D, in these two groups. The 
PDAI appears to be a feasible, useful, stable and sensitive tool in measuring the 
disease activity in idiopathic as well as Crohn’s perianal fistulae. Patients with 
idiopathic and Crohn’s perianal fistulae have a similarly impaired quality of life, 
as measured by the EQ VAS and EQ index. Furthermore, the level of disease 
burden is akin to other significant chronic health conditions. Further validation 
studies are required and would lead to improved methodology in future perianal 
fistula disease research. 
• A comparison of the bacterial isolates from cultures of intraoperative specimens 
showed a wide range of organisms, which was similar in both groups. 
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Chapter 4: Cytokine Profiles 
• The concentrations of 30 cytokines at 4 specimen sites in 60 participants with 
idiopathic and Crohn’s perianal fistulae were examined. We found no clear 
differences in the overall cytokine profiles between the groups. Furthermore, 
when comparing the rectal mucosa of healthy controls to the participants with 
Crohn’s perianal fistulae, no differences were observed. 
• Only two significant differences in individual cytokines were found. At the internal 
opening specimen site, IL-12p70 was higher, and IL-1RA/IL-1b ratio was lower 
in the Crohn’s disease group. These findings are consistent with current 
knowledge on the general pathophysiology of Crohn’s disease. However, given 
that multiple hypothesis tests were performed, these results should be treated with 
caution and further focussed research is needed. Immunocytochemistry, using 
normal anal mucosa as the control, for example, would offer further interrogation.  
• These data agree with and add considerably to what Tozer (2011) found using 
similar techniques. Significant levels of G-CSF, IL-6, IL-8, MCP-1, RANTES and 
VEGF were found across all specimens and groups. These findings are broadly 
consistent with current theories on inflammation, and may point towards further 
research opportunities in perianal fistulae. 
• Previous studies suggested that IL-1b, IL-6, IL-8, and TNF-a, may have an 
important role in perianal fistulae immunopathology (Kiehne et al. 2007; Ruffolo 
et al. 2007; Ruffolo et al. 2008; Tozer 2011). These data also suggest IL-1b, IL-6 
and IL-8 may be important. However, results regarding TNF-a were 
unremarkable. 
Chapter 5: Phosphoprotein Profiles 
• After examining the relative concentrations of 28 receptor tyrosine kinases and 11 
signalling nodes, when phosphorylated at tyrosine or other residues, in fresh tissue 
homogenates taken at four specimen sites in 60 participants with idiopathic and 
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Crohn’s perianal fistula disease, there was no clear difference in the overall 
phosphoprotein profile between idiopathic and Crohn’s perianal fistulae.  
• When we compared the rectal mucosa of healthy controls against the participants 
with Crohn’s perianal fistulae, differences were seen in six phosphoproteins: 
EphA1, EphA2, EphB1, EphB4, Tyro3/Dtk and VEGFR2/KDR. Considering 
what is already known about the role of these receptors in gut health and disease, 
this pattern raises the possibility that idiopathic and Crohn’s perianal fistulae have 
similar immunopathology that is not confined to the peri-fistula tissue.  
Chapter 6: Dynamic Contrast-Enhanced MRI 
• We examined the DCE-MRI characteristics of perianal fistulae in 24 participants 
with idiopathic and Crohn’s disease. The feasibility of this modality in idiopathic 
disease was demonstrated for the first time. Data for this cohort is now available 
and will serve as a useful reference for future studies.  
• We found no differences in the DCE-MRI measurements and the TIC types 
between the idiopathic and Crohn’s disease groups. However, secondary sub-
group analysis revealed the mean maximum enhancement and maximum relative 
enhancement were significantly higher in participants with a more advanced 
pathoanatomy (trans- or supra-sphincteric fistulae). Further study into this area 
needs to consider performing de novo MRI in all participants, a more homogenous 
cohort, and including inter-observer variability assessment. 
Limitations 
The pragmatic study design brought certain limitations. We included patients from 
all stages of management, from those who were treatment-naïve, to those who had 
had multiple surgical procedures aimed at achieving a cure. This allowed effective 




We only recruited patients who were planned for surgery for one reason or another. 
Therefore those with perianal fistula disease that was too mild to meet the threshold 
for surgery were excluded. This selection bias limits the applicability of these data to 
a non-operated population. Furthermore, the threshold for surgery could have been 
different between the groups due to differing clinical strategies. If so, this selection 
bias may have introduced a difference between the groups. 
The main study site was a tertiary referral centre. A more representative sample 
might have been achieved through multicentre recruitment. However, despite this, 
the recruited cohort had participants with a wide distribution of disease phenotypes 
and an expected range of treatment outcomes.  
We did not perform a formal sample size calculation, as there were no prior relevant 
data. However this is the largest study to date to phenotype the disease across both 
groups in detail. 
Further limitations specific to each results section were discussed within their 
respective chapters. 
7.2 Overall Conclusions 
In summary, over 200 variables were measured in each participant within this cohort, 
and only a handful showed possible differences between idiopathic and Crohn’s 
disease groups (Table 36). Further research is required to look deeper into these 
particular differences. Certainly, these data do not give clear support to the study 
hypothesis that idiopathic and Crohn’s perianal fistulae differ in their pathogenesis 
and pathophysiology.  
As argued in Chapter 1, the majority of perianal fistula research to date has been 
conducted within the same paradigm built upon the assumption that idiopathic and 
Crohn’s perianal fistulae differ in their pathogenesis and pathophysiology. Only a 
handful of studies have attempted to compare the characteristics of perianal fistulae 
from each group. All these studies have assumed there is a difference as the 
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idiopathic group each time has been used as a quasi-control group against which the 
Crohn’s disease group is compared. These studies have indeed highlighted some 
differences between the groups.  
However, the careful review of the literature in Chapter 1 through a neutral construct 
revealed that there just as many similarities as there are differences between 
idiopathic and Crohn’s perianal fistula disease. The present study is commensurate 
with this. 
It may be that further research to test the hypothesis that idiopathic and Crohn’s 
perianal fistulae differ in their pathogenesis and pathophysiology is required before it 
is proven. An alternative explanation may be that the chronic fistula is a common 
pathway for both idiopathic and Crohn’s perianal fistulae, but the initial pathogenesis 
or mechanism of susceptibility is separate. Countering this is the argument that if the 
two diseases begin separately, then differences between each type should be seen 
throughout the full course of the disease. 
However, it may also be time to consider approaching perianal fistula research from 
the antithesis. From this stance, the underlying assumption would be that idiopathic 
and Crohn’s perianal fistulae are the same pathology on a spectrum across which the 
pathogenic and pathophysiological features are distributed in a skewed manner. This 
notion is analogous to clinical practice. Surgeons often observe that some patients 
with complex idiopathic perianal fistulae have a disease that behaves like perianal 
Crohn’s disease, except all subsequent investigations to diagnose Crohn’s disease 
prove negative. Within this new research paradigm, the idiopathic group would no 
longer be a valid quasi-control and instead, other control groups would have to be 
employed. This may be the key to unravelling our understanding of the disease’s 
aetiology. It would also be a construct within which trials of biological therapy, such 
as infliximab, could be justified for idiopathic disease. 
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Table 36 Summary of data comparisons between idiopathic and Crohn's disease perianal fistulae. DCE-
MRI, dynamic contrast-enhanced-magnetic resonance imaging; PDAI, perianal disease activity index; 
TIC, time-intensity curve; VAS, visual analogue score. 
 Similarities Differences 
Baseline PDAI  Significantly higher PDAI in 
Crohn’s disease 
Baseline EQ-5D-5L Similar EQ VAS and EQ index  
Morphology Similar distribution of types by 
Parks’ classification 
Similar prevalence of high fistulae 
and horseshoe extensions 
More multiple fistulae in Crohn’s 
disease 
Significantly more supralevator 
extensions, collections and rectal 
thickening in Crohn’s disease 
Microbiological culture Similar isolates  
Post-operative PDAI Similar decrease in  
post-operative PDAI 
 
Post-operative EQ-5D-5L Similar decrease in post-operative 
EQ VAS and EQ index 
 
Cytokine concentrations Similar concentrations of 27 
cytokines at all four biopsy sites 
(EGF, eotaxin, G-CSF, GM-CSF, IFN-α2, 
IFN-γ, IL-10, IL-12p40, IL-13, IL-15, IL-17, 
IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, 
TNF-β, RANTES and VEGF) 
Significantly higher IL-12p70 
concentration at internal opening in 
Crohn’s disease 
Significantly lower IL-1RA/IL-1b 
ratio concentration at internal 
opening in Crohn’s disease 
Phosphoprotein 
concentrations 
Similar levels of 39 
phosphoproteins at the four 
specimen sites 
(EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, 
FGFR1, FGFR3, FGFR4, InsR, IGF-IR, 
TrkA/NTRK1, TrkB/NTRK2, Met/HGFR, 
Ron/MST1R, Ret, ALK, PDGFR, c-
Kit/SCFR, FLT3/Flk2, M-CSFR/CSF-1R, 
EphA1, EphA2, EphA3, EphB1, EphB3, 
EphB4, Tyro3/Dtk, Axl, Tie2/TEK, 
VEGFR2/KDR, Akt/PKB/Rac (at Thr308), 
Akt/PKB/Rac (at Ser473), p44/42 MAPK, 
S6 Ribosomal Protein, c-Abl, IRS-1, Zap-
70, Src, Lck, Stat1 and Stat3) 
 
DCE-MRI Similar mean maximum 
enhancement, maximum relative 
enhancement, wash in rate, wash 






7.3 Future Research 
This study has identified some worthwhile targets for future basic science research: 
the role of IL-12p70, and the IL-1RA/IL-1b ratio at the internal opening; the role of 
EphA1, EphA2, EphB1, EphB4, Tyro3/Dtk and VEGFR2/KDR in the rectal mucosa. 
And further clinical research into the validity of PDAI in non-Crohn’s perianal 
fistula disease and the utility of DCE-MRI in all types of perianal fistulae is also 
warranted.§ 
However, greater advances may ultimately come from studies working from the 
paradigm that idiopathic and Crohn’s perianal fistulae are the same disease entity. 
Thus, they would be aimed at finding pathophysiological mechanisms in idiopathic 
perianal fistula disease that are already known to be of importance in Crohn’s 
perianal fistulae. This would lead to greater insights into the disease across both 
these groups. The long-term goal of such research would be to support the hypothesis 
that idiopathic and Crohn’s perianal fistulae share the same pathogenesis and 
pathophysiology. This would then be translatable into clinical trials of infliximab and 
other biological agents in idiopathic perianal fistulae. With curative outcome in 
idiopathic perianal fistulae having essentially not improved significantly since 
Hippocrates, such trials would hold the promise of a step change in its management. 
                                               
 
§ The Bowel Disease Research Foundation’s on-going ENIGMA project, developed alongside the 
Association of Coloproctology of Great Britain and Ireland and the British Society of 
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Participant Information Sheet 
Research Study Title: Perianal Fistula Research 
Researcher Name: Professor Charles Knowles 
 
We would like to invite you to take part in a research study. Please take time to read the 
following information carefully. Talk to others about the study if you wish. We will give 
you at least a day to make your decision, but please take as much time as you like. 
PART 1: About the research 
What is the purpose of this study? 
This research is looking into perianal fistulas, which are abnormal connections 
between the back passage and the nearby skin. We still do not know why many fistulas 
form and why they do not heal on their own. This research aims to understand more 
about the biology of fistulas and why some are more difficult to cure than others. This 
could lead to better treatments for some patients in the future.  
 We also do not have accurate ways of measuring the symptoms caused by perianal 
fistulas. Therefore this research will also aim to develop a questionnaire tool to 
measure these symptoms. In the future, this questionnaire will help us to assess how 
well certain treatments work. 
Why have I been invited? 
You have been asked to participate because you have attended this hospital for 
diagnosis and/or treatment of a perianal fistula. 
Do I have to take part? 
Participation is entirely voluntary. It is up to you to decide to join the study. We will 
describe the study and go through this information sheet. If you agree to take part, we 
will then ask you to sign a consent form. You are free to withdraw at any time, without 
giving a reason. This would not affect the standard of care you receive. 
What will happen if I take part? 
You will be asked to complete a 10-minute symptom questionnaire up to four times in 
total, before, during and after your care. This can be done by post or online or during 
one of your hospital visits. You may also be invited to a 60-minute interview, if 
convenient, to explore your symptoms in more depth. We may ask to audio tape this 
interview if you are happy with this. 
 If you need a MRI scan, it will routinely involve an injection of contrast agent into 
your veins via a plastic cannula. For the purposes of this research, we will use a special 
setting on the machine to take pictures that allows us to measure the blood flow in the 
fistula.  
 If you need surgery, whilst you are asleep under general anaesthetic, we will take 
four tiny biopsy samples from your fistula and the lining of your back passage. This 
would take us about 5 minutes to do. 
 During your follow-up we will examine you to record how successful your treatment 
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your views on this research. Your participation in the research will end when you are 
discharged from outpatient follow-up, which will be approximately within 6 to 12 months. 
How will participating affect me? 
We will give you a minimum of 24 hours to decide whether you wish to participate in the 
study or not. 
 There will be little that affects you other than giving your time as detailed above. 
Your tests and treatment will not be different and will proceed as planned with your 
clinical team. There will also be no delays to your treatment as a result of participating in 
this research. 
 For those having an MRI scan, the special setting we will use is already done 
routinely for some types of brain scans in the NHS. There are no known side effects to 
MRI scanning. If you need surgery, the tiny biopsy samples will be done whilst you are 
asleep under the same general anaesthetic. There is a small risk of pain, bleeding and 
infection afterwards.  
Will my taking part in this study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be 
handled in the strictest confidence. Electronic data and paper files containing details 
that could identify you, such as your name, date of birth and hospital number, and any 
audio tapings, will be destroyed 1 year after the study has ended. Data collected for the 
research will be stripped of your personal details so you cannot be identified. This 
anonymous data will be used for analysis and to report our findings. It will then be 
encrypted and kept secure for 10 years, and we may use it for other related research. 
Only members of the research team will have access to the data. The data will not be 
used or transferred to commercial organisations. 
Will my biopsy samples be stored? 
Your biopsy samples will be stored until the project ends in October 2016. They will be 
stored in a secure freezer at our research facilities and will be linked to the anonymous 
data, but not to your personal details. If we have made some discoveries that suggest 
further testing on these samples would be useful, we will apply for ethical approval for 
this further research to be done. If we don’t apply by the end of the project, the samples 
will be destroyed safely. 
PART 2: Information if you participate 
What will happen if I don’t want to carry on with the study? 
You are free to drop out at any time. This would not affect your care. If you wish any 
unused specimens to be discarded please let us know.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. The main research fellow, 
Mr James Haddow, can be contacted on 020 7882 8755 or jameshaddow@nhs.net. If 
you remain unhappy and wish to complain the normal NHS complaints mechanisms will 
be available to you through the hospital’s Patient Advice and Liaison Service (PALS) 
on 020 3594 2040 or pals@bartshealth.nhs.uk. 
 We do not expect you to suffer any harm or injury as a result of this research. In the 
event that something does go wrong and you are harmed during the research and this 
is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against the sponsor Queen Mary University of London, but you may have 
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What will happen to the results of this study? 
We aim to publish our work in scientific journals and present at meetings and 
conferences. Patient identifiable information will not be divulged. 
How can I be kept informed? 
As the information from this research will not be directly relevant to your treatment we 
will not be routinely feeding back this information to you. However it is possible for you 
to know more about the research and what has happened to any specimens collected: 
• You are welcome to visit our research office and talk to us about our research  
• We have a web page http://blizard.qmul.ac.uk/centres/digestive-diseases.html for 
information on our other research 
• Mr Haddow maintains a log of the specimens and what has happened to them 
and this can been seen on request 
• You can sign up to an emailing list by going to http://eepurl.com/Gxghn 
Who is organising and funding this research? 
We are a collaboration involving surgeons, gastroenterologists, immunologists, 
radiologists and nurses. There are both hospital and university staff from Bart's Health, 
North West London Hospitals, and Queen Mary University of London. The Sponsor, 
who is overall responsible for this research, is Queen Mary University of London. 
 We are funded by the NHS (through the National Institute for Health Research) and 
Department of Health (through the Healthcare Technology Co-operative, Enteric). If 
further funding is secured, this will be from charitable or commercial sources. At all 
times, our autonomy will be preserved, meaning that none of the funders will be able to 
influence the conduct, analysis or results of this research. 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and approved by Queen’s Square Research Ethics 
Committee. 
Further information and contact details 
The research team is based at the National Centre for Bowel Research and Surgical 
Innovation, Blizard Institute, 1st Floor Abernethy Building, 2 Newark St, Whitechapel, 
London E1 2AT.  
 The chief investigator is Professor Charles Knowles. The hospital’s research fellow 
is Mr James Haddow and can be contacted on 020 7882 8755 or 
jameshaddow@nhs.net 
 The office that oversees all research at Queen Mary University of London is the 
Joint Research Management Office, Queen Mary Innovation Centre, Lower Ground 
Floor 5 Walden St, London E1 2EF. The Director is Gerry Leonard and can be 
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Consent Form for Participation in Research 
Research Study Title: Perianal Fistula Research 
Name of Researcher: Professor Charles Knowles 
Participant Details (or please affix sticker) 
Surname  Hospital No  
First name    
Statement of Participant Please initial each box 
I confirm that I have read and understood the information sheet (version 2.3). I 
have had the opportunity to consider the information ask questions and have 
had these answered satisfactorily.  
I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.  
I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals from 
Queen Mary University of London, or from regulatory authorities, where it is 
relevant to my taking part in this research. I give permission for these individuals 
to have access to my records. 
 
I understand that the Sponsor research administrators at Queen Mary University 
of London may also access my data for monitoring and audit purposes.  
If I am invited to a 60-minute interview, I understand that this may be audio 
taped and transcribed. I am aware that I can decline this at the time.  
If I undergo surgery I give permission for biopsy samples to be taken, stored 
and used for research purposes and potential future studies that will be ethically 
approved.  
I agree to take part in this research. 
 
 
   
Name of participant Signature Date 
   
Name of person taking consent Signature Date 
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Fistula CRF-Registration 






1. Introduce self and research 
2. Check eligbility 
Include any adult (18+) with a perianal fistula 
Exclude rectal or intestinal fistulae; fistulae secondary to diseases other than Crohn’s; 
positivity for blood-borne viruses (e.g. HIV, Hep B/C); lack capacity 
3. Give patient information sheet 
4. Obtain written consent 
A1. Date patient approached 
dd/mm/yyyy 
A2. Registration Outcome 
Ineligible Declined Recruited    





A5. Substudy Enrolment 
PROM ¨ All eligible 
DCE-MRI ¨ Include those having MRI; exclude those who’ve had anti-TNF within last year 
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Patient tracking 
OPD Pending ¨ dd/mm/yyyy 
MRI Pending ¨ dd/mm/yyyy 
Colonoscopy Pending ¨ dd/mm/yyyy 
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Fistula CRF-Baseline 
To be completed before treatment 
Hospital Number 
 





Male Female     
¨1 ¨10     
B4. Ethnic Origin 
White ¨10 Asian Indian ¨18 
Mixed White and Black African ¨11 Asian Pakistani ¨19 
Mixed White and Black 
Caribbean ¨12 Asian Bangladeshi ¨20 
Mixed White and Asian ¨13 Asian Other ¨21 
Mixed Other ¨14 Chinese ¨22 
Black African ¨15 Arab ¨23 
Black Caribbean ¨16   
Black Other ¨17 Other ¨24 
  Not answered ¨0 
B5. Previous Fistula 
None Single Multifocal    
¨1 ¨10 ¨11    
B6. Previous Fistula Recurrence 
No Yes     
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B7. IBD history 
No IBD UC Indeterminate Crohn’s   
¨1 ¨2 ¨10 ¨11   
B8. Previous medical treatment (highest order) 
None Antibiotics Steroids 
Immuno-
suppressants Anti-TNF 5-ASA 
¨1 ¨10 ¨11 ¨12 ¨13 ¨14 
B9. Anti-TNF timing 
>1 year ago Within last year Currently   Not applicable 
¨1 ¨10 ¨11   ¨0 
B10. Previous number of operations 
 
B11. Previous surgical treatment (highest order) 
None Curettage Seton Lay open LIFT Fistulectomy 
¨1 ¨10 ¨11 ¨12 ¨13 ¨14 
B12. Treatment response (current situation) 
None Inadequate Transient Controlled Resolved Not applicable 
¨1 ¨2 ¨3 ¨4 ¨10 ¨0 
B13. Total fistula disease duration 
months 
B14. Current Stoma 
No Yes     
¨1 ¨10     
B15. Current Seton 
No Yes     
¨1 ¨10     
B16. Smoking status 
Never Ex-smoker 
Current 
Smoker    
¨1 ¨10 ¨11    
Notes 





Page 6 of 16 is BLANK 
Fistula CRFs – RLH | Version 1.8 | 27/01/2015 Page 5 of 16 
Fistula CRF-PDAI 
To be completed before treatment, 6 weeks post treatment; 6 months post treatment 
Hospital Number 
 
C1. Date CRF done 
dd/mm/yyyy 
C2. Time point 
Baseline 6-weeks 6-months 
¨1 ¨10 ¨11 
C3. Discharge 
No discharge ¨1 
Minimal mucous discharge ¨2 
Moderate mucous or purulent 
discharge ¨3 
Substantial discharge ¨4 
Gross fecal soiling ¨5 
C4. Pain/restriction of activities 
No activity restriction ¨1 
Mild discomfort, no restriction ¨2 
Moderate discomfort, some 
limitation activities ¨3 
Marked discomfort, marked 
limitation ¨4 
Severe pain, severe limitation ¨5 
C5. Restriction of sexual activities 
No restriction sexual activity ¨1 
Slight restriction sexual activity ¨2 
Moderate limitation sexual 
activity ¨3 
Marked limitation sexual activity ¨4 
Unable to engage in sexual 
activity ¨5 
C6. Type of perianal disease 
No perianal disease / skin tags ¨1 
Anal fissure or mucosal tear ¨2 
<3 perianal fistulae ¨3 
≥3 perianal fistulae ¨4 
Anal spincter ulceration or 
fistulae with significant 
undermining of skin 
¨5 
C7. Degree of induration 
No induration ¨1 
Minimal induration ¨2 
Moderate induration ¨3 
Substantial induration ¨4 
Gross fluctuance/abscess ¨5 
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Fistula CRF-EQ5D 
To be completed before treatment, 6 weeks post treatment; 6 months post treatment 
Hospital Number (office use) 
 
D1. Date CRF done (office use) 
dd/mm/yyyy 
D2. Time point (office use) 
Baseline 6-weeks 6-months 
¨1 ¨10 ¨11 
 
Under each heading, please tick the ONE 
box that best describes your health 
TODAY: 
D3. Mobility 
I have no problems in walking 
about ¨1 
I have slight problems in walking 
about ¨2 
I have moderate problems in 
walking about ¨3 
I have severe problems in 
walking about ¨4 
I am unable to walk about ¨5 
D4. Self-care 
I have no problems with self-care ¨1 
I have slight problems washing or 
dressing ¨2 
I have moderate problems 
washing or dressing myself ¨3 
I have severe problems washing 
or dressing ¨4 
I am unable to wash or dress 
myself ¨5 
D5. Usual Activities (e.g. work, study, 
housework, family or leisure activities) 
I have no problems with 
performing my usual activities ¨1 
I have slight problems with 
performing my usual activities ¨2 
I have moderate problems with 
performing my usual activities ¨3 
I have severe problems with 
performing my usual activities ¨4 
I am unable to do my usual 
activities ¨5 
D6. Pain / Discomfort 
I have no pain or discomfort ¨1 
I have slight pain or discomfort ¨2 
I have moderate pain or 
discomfort ¨3 
I have severe pain or discomfort ¨4 
I have extreme pain or discomfort ̈ 5 
D7. Anxiety / Depression 
I am not anxious or depressed ¨1 
I am slightly anxious or 
depressed ¨2 
I am moderately anxious or 
depressed ¨3 
I am severely anxious or 
depressed ¨4 
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We would like to know how good or bad 
your health is TODAY. 
• This scale is numbered from 0 to 
100. 
• 100 means the best health you can 
imagine. 0 means the worst health 
you can imagine. 
• Mark an X on the scale to indicate 
how your health is TODAY. 
• Now, please write the number you 
marked on the scale in the box 
below. 
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Fistula CRF-MRI 
To be completed for each MRI 
Hospital Number 
 
E1. Date MRI done 
dd/mm/yyyy 
E2. Timepoint 
Baseline 6-weeks 6-months    
¨1 ¨10 ¨11    




branched Multiple   None 
¨1 ¨2 ¨10   ¨0 







Not applicable ¨0 
E5. Fistula level of most severe fistula 
Low High    Not applicable 
¨10 ¨11    ¨0 
E6. Secondary tracts of most severe fistula 
None Infralevator Supralevator   Not applicable 
¨1 ¨10 ¨11   ¨0 
E7. Horseshoe extension of most severe fistula 
No Yes    Not applicable 
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E8. Associated collections (cavities >3mm diameter) 
No Yes    Not applicable 
¨1 ¨10    ¨0 
E9. Rectal wall involvement 
Normal Thickened    Not applicable 
¨1 ¨10    ¨0 
E10. Hyperintensity on T2-weighted images 
Absent Mild Pronounced   Not applicable 
¨1 ¨10 ¨11   ¨0 
E11. MRI Based Score 
To be derived from above data 
E18. Perfusion data 
1. Select the slice which shows the fistula with its maximum enhancement 
2. Draw a region of interest around the whole fistula 
3. Set the reference point to the lowest enhancement value 
4. Store the images 
Conventional MRI, perfusion map, quantitative data table, perfusion curve 
5. Append the data table and graph to this CRF 
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Fistula CRF-Surgery 
To be completed at surgery 
Hospital Number 
 
F1. Date of Surgery 
dd/mm/yyyy 




branched Multiple   None 
¨1 ¨2 ¨10   ¨0 







Not applicable ¨0 
F4. Fistula level of most severe fistula 
Low High    Not applicable 
¨10 ¨11    ¨0 
F5. Secondary tracts of most severe fistula 
None Infralevator Supralevator   Not applicable 
¨1 ¨10 ¨11   ¨0 
F6. Horseshoe extension of most severe fistula 
No Yes    Not applicable 
¨1 ¨10    ¨0 
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F7. Associated collections (cavities >3mm diameter) 
No Yes    Not applicable 
¨1 ¨10    ¨0 
F8. Rectal wall involvement 
Normal Thickened    Not applicable 
¨1 ¨10    ¨0 
F9. Surgical treatment given (highest order) 
None Curettage Seton Lay open LIFT Fistulectomy 
¨1 ¨10 ¨11 ¨12 ¨13 ¨14 
F10. Tract epithelialized 
No Yes    Unknown 
¨1 ¨10    ¨0 
F11. Hydradenitis supprativa 
No Yes    Unknown 
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Fistula Biopsy Specimen Form 
To be completed at surgery 
Participant ID (not hospital no) 
 
Procedure 
Equipment required: curette, biopsy forceps, 4 specimen containers each containing 10ml Normal 
Saline (no formalin or additive). 
1. The surgeon takes each specimen when appropriate and places in a universal 
container with 10ml of Normal Saline 
2. Store on ice 
3. At the end of the session, the specimens are transported immediately to the lab for 
processing 
Take the following specimens and place in plain containers 
 Not taken Taken Label 
Microbiology biopsy or swab  
for MC&S and AAFB ¨1 ¨10 For micro lab processing 
Histopathology fistula biopsy ¨1 ¨10 For histopath lab processing 
F: Fistula tract ¨1 ¨10 [Participant ID]-F 
G: Granulation tissue from 
within the fistula tract ¨1 ¨10 [Participant ID]-G 
M: Mucosa adjacent to internal 
opening ¨1 ¨10 [Participant ID]-M 
R: Rectal mucosa ¨1 ¨10 [Participant ID]-R 
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Fistula CRF-Follow-up 
To be completed 6 weeks post treatment; 6 months post treatment 
Hospital Number 
 
G1. Date CRF done 
dd/mm/yyyy 
G2. Timepoint 
6-weeks 6-months     
¨10 ¨11     
G3. Any symptoms suspicious of Crohn’s to date 
No Yes     
¨1 ¨10     
G4. Any abdominal fistula suspicious of Crohn’s to date 
No Yes     
¨1 ¨10     
G5. Any abdominal surgery for Crohn’s to date 
No Yes     
¨1 ¨10     
G6. Any colonoscopies to date 
No IBD UC Declined Indeterminate Crohn’s Never had 
¨1 ¨2 ¨3 ¨10 ¨11 ¨0 
G7. Any barium follow through / enemas to date 
No IBD UC Declined Indeterminate Crohn’s Never had 
¨1 ¨2 ¨3 ¨10 ¨11 ¨0 
G8. Any MRI Abdomen (not pelvis) to date 
No IBD UC Declined Indeterminate Crohn’s Never had 
  ¨2 ¨3 ¨10 ¨11 ¨0 
G9. Highest faecal calprotectin to date 
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G10. Any histology to date 
No IBD UC Indeterminate Crohn’s  Never had 
¨1 ¨2 ¨10 ¨11  ¨0 
G11. Any granulomas on histology to date 
No Yes    Not applicable 
¨1 ¨10    ¨0 
G12. Any HIV aetiology to date 
Excluded 
No clinical 
suspicion Causing fistula   Not considered 
¨1 ¨2 ¨10   ¨0 
G13. Any TB aetiology to date 
Excluded 
No clinical 
suspicion Causing fistula   Not considered 
¨1 ¨2 ¨10   ¨0 
G14. Medical treatment received since recruitment (highest order) 
None Antibiotics Steroids 
Immuno-
suppressants Anti-TNF 5-ASA 
¨1 ¨10 ¨11 ¨12 ¨13 ¨14 
G15. Date medical treatment started since recruitment 
dd/mm/yyyy If not applicable, leave blank 
G16. Response (current situation) 
None Inadequate Transient Controlled Resolved Not applicable 
¨1 ¨2 ¨3 ¨4 ¨10 ¨0 








¨1 ¨2 ¨3 ¨10 ¨11  
G18. Fistula microbiology results (specify up to 2 microorganisms) 
No growth Coliforms Enterococcus Bacteroides Mycobacterium Mixed growth 
¨1 ¨10 ¨11 ¨12 ¨13 ¨15 
Other please specify   Not done 
     ¨0 
G20. Histopathology lab number from surgery specimens 
 If none, leave blank 
END OF CRF 
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APPENDIX 4 SPSS SYNTAX 
Data Preparation 
* OPEN DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2015-10 Clinical'. 
 
* FORMAT DATA. 
FORMATS ParticipantID(F4.0). 
VARIABLE LABELS ParticipantID "Participant ID". 
VARIABLE LEVEL ParticipantID(Nominal). 
FORMATS B02_Age(F4.1). 
VARIABLE LABELS B02_Age "Age (years)". 
VARIABLE LEVEL B02_Age(Scale). 
FORMATS B03_Gender(F4.0). 
VARIABLE LABELS B03_Gender "Gender". 
VALUE LABELS B03_Gender 1 "Male" 10 "Female" . 
VARIABLE LEVEL B03_Gender(Nominal). 
FORMATS B04_EthnicOrigin(F4.0). 
VARIABLE LABELS B04_EthnicOrigin "Ethinic origin". 
VALUE LABELS B04_EthnicOrigin 0 "Not answered" 10 "White" 11 "Mixed 
White and Black African"  
12 "Mixed White and Black Caribbean" 13 "Mixed White and Asian" 14 
"Mixed Other" 15 "Black African"  
16 "Black Caribbean" 17 "Black Other" 18 "Asian Indian" 19 "Asian 
Pakistani" 20 "Asian Bangladeshi"  
21 "Asian Other" 22 "Chinese" 23 "Arab" 24 "Other" . 
VARIABLE LEVEL B04_EthnicOrigin(Nominal). 
MISSING VALUES B04_EthnicOrigin(0). 
FORMATS B05_PrevFistula(F4.0). 
VARIABLE LABELS B05_PrevFistula "Previous fistula". 
VALUE LABELS B05_PrevFistula 1 "None" 10 "Single" 11 "Multifocal" . 
VARIABLE LEVEL B05_PrevFistula(Ordinal). 
FORMATS B06_PrevFistulaRecurrence(F4.0). 
VARIABLE LABELS B06_PrevFistulaRecurrence "Previous fistula 
recurrence". 
VALUE LABELS B06_PrevFistulaRecurrence 1 "No" 10 "Yes" . 
VARIABLE LEVEL B06_PrevFistulaRecurrence(Ordinal). 
FORMATS B07_PrevIBD(F4.0). 
VARIABLE LABELS B07_PrevIBD "IBD History". 
VALUE LABELS B07_PrevIBD 1 "None" 2 "UC" 10 "Indeterminate Colitis" 
11 "Crohn's" . 
VARIABLE LEVEL B07_PrevIBD(Ordinal). 
FORMATS B08_PrevRxMed(F4.0). 
VARIABLE LABELS B08_PrevRxMed "Previous medical treatment (highest 
order)". 
VALUE LABELS B08_PrevRxMed 1 "None" 10 "Antibiotics" 11 "Steriods" 
12 "Immunosuppressants" 13 "Anti-TNF" 14 "5-ASA" . 
VARIABLE LEVEL B08_PrevRxMed(Ordinal). 
FORMATS B09_PrevRxAntiTNF(F4.0). 
VARIABLE LABELS B09_PrevRxAntiTNF "Anti-TNF timing". 
VALUE LABELS B09_PrevRxAntiTNF 0 "NA" 1 ">1 year ago" 10 "Within 
last year" 11 "Currently" . 




VARIABLE LABELS B10_PrevRxSurgNo "Previous operations". 
VARIABLE LEVEL B10_PrevRxSurgNo(Scale). 
FORMATS B11_PrevRxSurg(F4.0). 
VARIABLE LABELS B11_PrevRxSurg "Previous surgical treatment (highest 
order)". 
VALUE LABELS B11_PrevRxSurg 1 "None" 10 "Curettage" 11 "Seton" 12 
"Lay open" 13 "LIFT" 14 "Fistulectomy" . 
VARIABLE LEVEL B11_PrevRxSurg(Ordinal). 
FORMATS B12_PrevRxResponse(F4.0). 
VARIABLE LABELS B12_PrevRxResponse "Previous treatment response". 
VALUE LABELS B12_PrevRxResponse 0 "NA" 1 "None" 2 "Inadequate" 3 
"Transient" 4 "Controlled" 10 "Resolved" . 
VARIABLE LEVEL B12_PrevRxResponse(Ordinal). 
FORMATS B13_FistulaDuration(F4.0). 
VARIABLE LABELS B13_FistulaDuration "Fistula disease duration 
(months)". 
VARIABLE LEVEL B13_FistulaDuration(Scale). 
FORMATS B14_CurrentStoma(F4.0). 
VARIABLE LABELS B14_CurrentStoma "Stoma". 
VALUE LABELS B14_CurrentStoma 1 "No" 10 "Yes" . 
VARIABLE LEVEL B14_CurrentStoma(Ordinal). 
FORMATS B15_CurrentSeton(F4.0). 
VARIABLE LABELS B15_CurrentSeton "Seton in situ at recruitment". 
VALUE LABELS B15_CurrentSeton 1 "No" 10 "Yes" . 
VARIABLE LEVEL B15_CurrentSeton(Ordinal). 
FORMATS B16_Smoking(F4.0). 
VARIABLE LABELS B16_Smoking "Smoking status". 
VALUE LABELS B16_Smoking 1 "Never" 10 "Ex-smoker" 11 "Current 
smoker" . 
VARIABLE LEVEL B16_Smoking(Ordinal). 
FORMATS MaxOfG03_CDClinical(F4.0). 
VARIABLE LABELS MaxOfG03_CDClinical "Crohn's symptoms". 
VALUE LABELS MaxOfG03_CDClinical 1 "No" 10 "Yes" . 
VARIABLE LEVEL MaxOfG03_CDClinical(Ordinal). 
FORMATS MaxOfG04_CDAbdoFistula(F4.0). 
VARIABLE LABELS MaxOfG04_CDAbdoFistula "Abdominal Crohn's fistulae". 
VALUE LABELS MaxOfG04_CDAbdoFistula 1 "No" 10 "Yes" . 
VARIABLE LEVEL MaxOfG04_CDAbdoFistula(Ordinal). 
FORMATS MaxOfG05_CDAbdoSurgery(F4.0). 
VARIABLE LABELS MaxOfG05_CDAbdoSurgery "Abdominal surgery for 
Crohn's". 
VALUE LABELS MaxOfG05_CDAbdoSurgery 1 "No" 10 "Yes" . 
VARIABLE LEVEL MaxOfG05_CDAbdoSurgery(Ordinal). 
FORMATS MaxOfG06_CDColonoscopy(F4.0). 
VARIABLE LABELS MaxOfG06_CDColonoscopy "Previous colonoscopies". 
VALUE LABELS MaxOfG06_CDColonoscopy 0 "None" 1 "No IBD" 2 "UC" 3 
"Declined" 10 "Indeterminate Colitis" 11 "Crohn's" . 
VARIABLE LEVEL MaxOfG06_CDColonoscopy(Ordinal). 
FORMATS MaxOfG07_CDBariumFT(F4.0). 
VARIABLE LABELS MaxOfG07_CDBariumFT "Previous barium studies". 
VALUE LABELS MaxOfG07_CDBariumFT 0 "None" 1 "No IBD" 2 "UC" 3 
"Declined" 10 "Indeterminate Colitis" 11 "Crohn's" . 
VARIABLE LEVEL MaxOfG07_CDBariumFT(Ordinal). 
FORMATS MaxOfG08_CDMRIAbdo(F4.0). 
VARIABLE LABELS MaxOfG08_CDMRIAbdo "Previous abdominal MRIs". 
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VALUE LABELS MaxOfG08_CDMRIAbdo 0 "None" 1 "No IBD" 2 "UC" 3 
"Declined" 10 "Indeterminate Colitis" 11 "Crohn's" . 
VARIABLE LEVEL MaxOfG08_CDMRIAbdo(Ordinal). 
FORMATS MaxOfG09_CDCalprotectin(F4.1). 
VARIABLE LABELS MaxOfG09_CDCalprotectin "Highest faecal 
calprotectin". 
VARIABLE LEVEL MaxOfG09_CDCalprotectin(Scale). 
FORMATS MaxOfG10_CDHistoDiagnosis(F4.0). 
VARIABLE LABELS MaxOfG10_CDHistoDiagnosis "Previous histology". 
VALUE LABELS MaxOfG10_CDHistoDiagnosis 0 "None" 1 "No IBD" 2 "UC" 10 
"Indeterminate Colitis" 11 "Crohn's" . 
VARIABLE LEVEL MaxOfG10_CDHistoDiagnosis(Ordinal). 
FORMATS MaxOfG11_CDHistoGranulomas(F4.0). 
VARIABLE LABELS MaxOfG11_CDHistoGranulomas "Granulomas on 
histology". 
VALUE LABELS MaxOfG11_CDHistoGranulomas 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL MaxOfG11_CDHistoGranulomas(Ordinal). 
FORMATS MaxOfG12_HIVAetiology(F4.0). 
VARIABLE LABELS MaxOfG12_HIVAetiology "HIV status". 
VALUE LABELS MaxOfG12_HIVAetiology 0 "Unknown" 1 "Excluded" 2 "No 
clinical suspicion" 10 "Positive" . 
VARIABLE LEVEL MaxOfG12_HIVAetiology(Ordinal). 
MISSING VALUES MaxOfG12_HIVAetiology(0). 
FORMATS MaxOfG13_TBAetiology(F4.0). 
VARIABLE LABELS MaxOfG13_TBAetiology "TB status". 
VALUE LABELS MaxOfG13_TBAetiology 0 "Unknown" 1 "Excluded" 2 "No 
clinical suspicion" 10 "Positive" . 
VARIABLE LEVEL MaxOfG13_TBAetiology(Ordinal). 
MISSING VALUES MaxOfG13_TBAetiology(0). 
FORMATS WeeksSurgery(F4.1). 
VARIABLE LABELS WeeksSurgery "Recruitment to surgery (weeks)". 
VARIABLE LEVEL WeeksSurgery(Scale). 
FORMATS F02_FistulaNo(F4.0). 
VARIABLE LABELS F02_FistulaNo "Number of fistula at surgery". 
VALUE LABELS F02_FistulaNo 0 "None" 1 "Single unbranched" 2 "Single 
branched" 10 "Multiple" . 
VARIABLE LEVEL F02_FistulaNo(Ordinal). 
FORMATS F03_FistulaParks(F4.0). 
VARIABLE LABELS F03_FistulaParks "Park's Classification at surgery". 
VALUE LABELS F03_FistulaParks 0 "NA" 10 "Subcutaneous" 11 "Inter-
sphincteric" 12 "Trans-sphincteric" 13 "Supra-sphincteric" 14 
"Extra-sphincteric" . 
VARIABLE LEVEL F03_FistulaParks(Ordinal). 
FORMATS F04_FistulaLevel(F4.0). 
VARIABLE LABELS F04_FistulaLevel "Level of fistula at surgery". 
VALUE LABELS F04_FistulaLevel 0 "NA" 10 "Low" 11 "High" . 
VARIABLE LEVEL F04_FistulaLevel(Ordinal). 
FORMATS F05_FistulaSecondaryTracts(F4.0). 
VARIABLE LABELS F05_FistulaSecondaryTracts "Secondary tracts at 
surgery". 
VALUE LABELS F05_FistulaSecondaryTracts 0 "NA" 1 "None" 10 
"Infralevator" 11 "Supralevator" . 
VARIABLE LEVEL F05_FistulaSecondaryTracts(Ordinal). 
FORMATS F06_FistulaHorseshoe(F4.0). 
VARIABLE LABELS F06_FistulaHorseshoe "Horseshoe extension at 
surgery". 
VALUE LABELS F06_FistulaHorseshoe 0 "NA" 1 "No" 10 "Yes" . 
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VARIABLE LEVEL F06_FistulaHorseshoe(Ordinal). 
FORMATS F07_FistulaCollections(F4.0). 
VARIABLE LABELS F07_FistulaCollections "Collections at surgery". 
VALUE LABELS F07_FistulaCollections 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL F07_FistulaCollections(Ordinal). 
FORMATS F08_FistulaRectalInvolvement(F4.0). 
VARIABLE LABELS F08_FistulaRectalInvolvement "Rectal involvement at 
surgery". 
VALUE LABELS F08_FistulaRectalInvolvement 0 "NA" 1 "Normal" 10 
"Thickened" . 
VARIABLE LEVEL F08_FistulaRectalInvolvement(Ordinal). 
FORMATS F09_RxSurg(F4.0). 
VARIABLE LABELS F09_RxSurg "Surgery performed". 
VALUE LABELS F09_RxSurg 1 "None" 10 "Curettage" 11 "Seton" 12 "Lay 
open" 13 "LIFT" 14 "Fistulectomy" . 
VARIABLE LEVEL F09_RxSurg(Ordinal). 
FORMATS F10_FistulaEpithelialized(F4.0). 
VARIABLE LABELS F10_FistulaEpithelialized "Epithelialization at 
surgery". 
VALUE LABELS F10_FistulaEpithelialized 0 "Unknown" 1 "No" 10 "Yes" . 
VARIABLE LEVEL F10_FistulaEpithelialized(Ordinal). 
MISSING VALUES F10_FistulaEpithelialized(0). 
FORMATS MaxOfG14_RxMed(F4.0). 
VARIABLE LABELS MaxOfG14_RxMed "Medical treatment since recruitment 
(highest order)". 
VALUE LABELS MaxOfG14_RxMed 1 "None" 10 "Antibiotics" 11 "Steriods" 
12 "Immunosuppressants" 13 "Anti-TNF" 14 "5-ASA" . 
VARIABLE LEVEL MaxOfG14_RxMed(Ordinal). 
FORMATS LastOfG16_RxResponse(F4.0). 
VARIABLE LABELS LastOfG16_RxResponse "Treatment response at follow-
up". 
VALUE LABELS LastOfG16_RxResponse 0 "NA" 1 "None" 2 "Inadequate" 3 
"Transient" 4 "Controlled" 10 "Resolved" . 
VARIABLE LEVEL LastOfG16_RxResponse(Ordinal). 
FORMATS MaxOfG17_RxPlan(F4.0). 
VARIABLE LABELS MaxOfG17_RxPlan "Management plan at follow-up". 
VALUE LABELS MaxOfG17_RxPlan 1 "Discharge" 2 "Monitor" 3 "Continue 
drugs" 10 "Escalate drugs" 11 "Further surgery" . 
VARIABLE LEVEL MaxOfG17_RxPlan(Ordinal). 
FORMATS G18_FistulaMicro(F4.0). 
VARIABLE LABELS G18_FistulaMicro "Fistula microbiology". 
VALUE LABELS G18_FistulaMicro 0 "Unknown" 1 "No growth" 10 
"Coliforms" 11 "Enterococcus" 12 "Bacteroides" 13 "Mycobacterium"  
14 "Streptococcus" 15 "Mixed growth" 16 "Proteus" 17 
"Bifidobacterium" 18 "Morganella" 19 "Bacillus" 20 "Corneybacterium"  
21 "Klebsiella" 22 "Staphylococcus" 23 "Actinomyces" . 
VARIABLE LEVEL G18_FistulaMicro(Ordinal). 
MISSING VALUES G18_FistulaMicro(0). 
FORMATS G19_FistulaMicro2(F4.0). 
VARIABLE LABELS G19_FistulaMicro2 "Fistula microbiology 2". 
VALUE LABELS G19_FistulaMicro2 0 "Unknown" 1 "No growth" 10 
"Coliforms" 11 "Enterococcus" 12 "Bacteroides" 13 "Mycobacterium"  
14 "Streptococcus" 15 "Mixed growth" 16 "Proteus" 17 
"Bifidobacterium" 18 "Morganella" 19 "Bacillus" 20 "Corneybacterium"  
21 "Klebsiella" 22 "Staphylococcus" 23 "Actinomyces" . 
VARIABLE LEVEL G19_FistulaMicro2(Ordinal). 




VARIABLE LABELS G21_WeeksFollowUp "Length of follow-up (weeks)". 
VARIABLE LEVEL G21_WeeksFollowUp(Scale). 
FORMATS G22_WeeksMedsStart(F4.0). 
VARIABLE LABELS G22_WeeksMedsStart "Recruitment to medical treatment 
start (weeks)". 
VARIABLE LEVEL G22_WeeksMedsStart(Scale). 
FORMATS BasePDAIC03_PDAIDischarge(F4.0). 
VARIABLE LABELS BasePDAIC03_PDAIDischarge "PDAI Discharge at 
baseline". 
VALUE LABELS BasePDAIC03_PDAIDischarge 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Gross faeces" . 
VARIABLE LEVEL BasePDAIC03_PDAIDischarge(Ordinal). 
FORMATS BasePDAIC04_PDAIPain(F4.0). 
VARIABLE LABELS BasePDAIC04_PDAIPain "PDAI Pain at baseline". 
VALUE LABELS BasePDAIC04_PDAIPain 1 "None" 2 "Mild" 3 "Moderate" 4 
"Marked" 5 "Severe" . 
VARIABLE LEVEL BasePDAIC04_PDAIPain(Ordinal). 
FORMATS BasePDAIC05_PDAISexual(F4.0). 
VARIABLE LABELS BasePDAIC05_PDAISexual "PDAI Sexual Restriction at 
baseline". 
VALUE LABELS BasePDAIC05_PDAISexual 1 "None" 2 "Slight" 3 "Moderate" 
4 "Marked" 5 "Total" . 
VARIABLE LEVEL BasePDAIC05_PDAISexual(Ordinal). 
FORMATS BasePDAIC06_PDAIDiseaseType(F4.0). 
VARIABLE LABELS BasePDAIC06_PDAIDiseaseType "PDAI Disease Type at 
baseline". 
VALUE LABELS BasePDAIC06_PDAIDiseaseType 1 "No perianal disease" 2 
"Anal fissure or mucosal tear" 3 "<3 perianal fistulae" 4 ">= 
perianal fistulae" 5 "Sphincter ulceration" . 
VARIABLE LEVEL BasePDAIC06_PDAIDiseaseType(Ordinal). 
FORMATS BasePDAIC07_PDAIInduration(F4.0). 
VARIABLE LABELS BasePDAIC07_PDAIInduration "PDAI Induration at 
baseline". 
VALUE LABELS BasePDAIC07_PDAIInduration 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Abscess" . 
VARIABLE LEVEL BasePDAIC07_PDAIInduration(Ordinal). 
FORMATS BasePDAIC08_PDAI(F4.0). 
VARIABLE LABELS BasePDAIC08_PDAI "PDAI Score at baseline". 
VARIABLE LEVEL BasePDAIC08_PDAI(Scale). 
FORMATS FUp1PDAIC03_PDAIDischarge(F4.0). 
VARIABLE LABELS FUp1PDAIC03_PDAIDischarge "PDAI Discharge at follow-
up 1". 
VALUE LABELS FUp1PDAIC03_PDAIDischarge 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Gross faeces" . 
VARIABLE LEVEL FUp1PDAIC03_PDAIDischarge(Ordinal). 
FORMATS FUp1PDAIC04_PDAIPain(F4.0). 
VARIABLE LABELS FUp1PDAIC04_PDAIPain "PDAI Pain at follow-up 1". 
VALUE LABELS FUp1PDAIC04_PDAIPain 1 "None" 2 "Mild" 3 "Moderate" 4 
"Marked" 5 "Severe" . 
VARIABLE LEVEL FUp1PDAIC04_PDAIPain(Ordinal). 
FORMATS FUp1PDAIC05_PDAISexual(F4.0). 
VARIABLE LABELS FUp1PDAIC05_PDAISexual "PDAI Sexual Restriction at 
follow-up 1". 
VALUE LABELS FUp1PDAIC05_PDAISexual 1 "None" 2 "Slight" 3 "Moderate" 
4 "Marked" 5 "Total" . 




VARIABLE LABELS FUp1PDAIC06_PDAIDiseaseType "PDAI Disease Type at 
follow-up 1". 
VALUE LABELS FUp1PDAIC06_PDAIDiseaseType 1 "No perianal disease" 2 
"Anal fissure or mucosal tear" 3 "<3 perianal fistulae" 4 ">= 
perianal fistulae" 5 "Sphincter ulceration" . 
VARIABLE LEVEL FUp1PDAIC06_PDAIDiseaseType(Ordinal). 
FORMATS FUp1PDAIC07_PDAIInduration(F4.0). 
VARIABLE LABELS FUp1PDAIC07_PDAIInduration "PDAI Induration at 
follow-up 1". 
VALUE LABELS FUp1PDAIC07_PDAIInduration 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Abscess" . 
VARIABLE LEVEL FUp1PDAIC07_PDAIInduration(Ordinal). 
FORMATS FUp1PDAIC08_PDAI(F4.0). 
VARIABLE LABELS FUp1PDAIC08_PDAI "PDAI Score at follow-up 1". 
VARIABLE LEVEL FUp1PDAIC08_PDAI(Scale). 
FORMATS FUp2PDAIC03_PDAIDischarge(F4.0). 
VARIABLE LABELS FUp2PDAIC03_PDAIDischarge "PDAI Discharge at follow-
up 2". 
VALUE LABELS FUp2PDAIC03_PDAIDischarge 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Gross faeces" . 
VARIABLE LEVEL FUp2PDAIC03_PDAIDischarge(Ordinal). 
FORMATS FUp2PDAIC04_PDAIPain(F4.0). 
VARIABLE LABELS FUp2PDAIC04_PDAIPain "PDAI Pain at follow-up 2". 
VALUE LABELS FUp2PDAIC04_PDAIPain 1 "None" 2 "Mild" 3 "Moderate" 4 
"Marked" 5 "Severe" . 
VARIABLE LEVEL FUp2PDAIC04_PDAIPain(Ordinal). 
FORMATS FUp2PDAIC05_PDAISexual(F4.0). 
VARIABLE LABELS FUp2PDAIC05_PDAISexual "PDAI Sexual Restriction at 
follow-up 2". 
VALUE LABELS FUp2PDAIC05_PDAISexual 1 "None" 2 "Slight" 3 "Moderate" 
4 "Marked" 5 "Total" . 
VARIABLE LEVEL FUp2PDAIC05_PDAISexual(Ordinal). 
FORMATS FUp2PDAIC06_PDAIDiseaseType(F4.0). 
VARIABLE LABELS FUp2PDAIC06_PDAIDiseaseType "PDAI Disease Type at 
follow-up 2". 
VALUE LABELS FUp2PDAIC06_PDAIDiseaseType 1 "No perianal disease" 2 
"Anal fissure or mucosal tear" 3 "<3 perianal fistulae" 4 ">= 
perianal fistulae" 5 "Sphincter ulceration" . 
VARIABLE LEVEL FUp2PDAIC06_PDAIDiseaseType(Ordinal). 
FORMATS FUp2PDAIC07_PDAIInduration(F4.0). 
VARIABLE LABELS FUp2PDAIC07_PDAIInduration "PDAI Induration at 
follow-up 2". 
VALUE LABELS FUp2PDAIC07_PDAIInduration 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Abscess" . 
VARIABLE LEVEL FUp2PDAIC07_PDAIInduration(Ordinal). 
FORMATS FUp2PDAIC08_PDAI(F4.0). 
VARIABLE LABELS FUp2PDAIC08_PDAI "PDAI Score at follow-up 2". 
VARIABLE LEVEL FUp2PDAIC08_PDAI(Scale). 
FORMATS FUpLastPDAIC03_PDAIDischarge(F4.0). 
VARIABLE LABELS FUpLastPDAIC03_PDAIDischarge "PDAI Discharge at 
follow-up". 
VALUE LABELS FUpLastPDAIC03_PDAIDischarge 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Gross faeces" . 
VARIABLE LEVEL FUpLastPDAIC03_PDAIDischarge(Ordinal). 
FORMATS FUpLastPDAIC04_PDAIPain(F4.0). 
VARIABLE LABELS FUpLastPDAIC04_PDAIPain "PDAI Pain at follow-up". 
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VALUE LABELS FUpLastPDAIC04_PDAIPain 1 "None" 2 "Mild" 3 "Moderate" 
4 "Marked" 5 "Severe" . 
VARIABLE LEVEL FUpLastPDAIC04_PDAIPain(Ordinal). 
FORMATS FUpLastPDAIC05_PDAISexual(F4.0). 
VARIABLE LABELS FUpLastPDAIC05_PDAISexual "PDAI Sexual Restriction 
at follow-up". 
VALUE LABELS FUpLastPDAIC05_PDAISexual 1 "None" 2 "Slight" 3 
"Moderate" 4 "Marked" 5 "Total" . 
VARIABLE LEVEL FUpLastPDAIC05_PDAISexual(Ordinal). 
FORMATS FUpLastPDAIC06_PDAIDiseaseType(F4.0). 
VARIABLE LABELS FUpLastPDAIC06_PDAIDiseaseType "PDAI Disease Type at 
follow-up". 
VALUE LABELS FUpLastPDAIC06_PDAIDiseaseType 1 "No perianal disease" 
2 "Anal fissure or mucosal tear" 3 "<3 perianal fistulae" 4 ">= 
perianal fistulae" 5 "Sphincter ulceration" . 
VARIABLE LEVEL FUpLastPDAIC06_PDAIDiseaseType(Ordinal). 
FORMATS FUpLastPDAIC07_PDAIInduration(F4.0). 
VARIABLE LABELS FUpLastPDAIC07_PDAIInduration "PDAI Induration at 
follow-up". 
VALUE LABELS FUpLastPDAIC07_PDAIInduration 1 "None" 2 "Minimal" 3 
"Moderate" 4 "Substantial" 5 "Abscess" . 
VARIABLE LEVEL FUpLastPDAIC07_PDAIInduration(Ordinal). 
FORMATS FUpLastPDAIC08_PDAI(F4.0). 
VARIABLE LABELS FUpLastPDAIC08_PDAI "PDAI Score at follow-up". 
VARIABLE LEVEL FUpLastPDAIC08_PDAI(Scale). 
FORMATS PDAI_Change(F4.0). 
VARIABLE LABELS PDAI_Change "PDAI Score change from baseline at 
follow-up". 
VARIABLE LEVEL PDAI_Change(Scale). 
FORMATS BaseEQ5DValueSetsEQ5D_Health_UK(F4.3). 
VARIABLE LABELS BaseEQ5DValueSetsEQ5D_Health_UK "EQ-5D health value 
at baseline". 
VARIABLE LEVEL BaseEQ5DValueSetsEQ5D_Health_UK(Scale). 
FORMATS FUp1EQ5DValueSetsEQ5D_Health_UK(F4.3). 
VARIABLE LABELS FUp1EQ5DValueSetsEQ5D_Health_UK "EQ-5D health value 
at follow-up 1". 
VARIABLE LEVEL FUp1EQ5DValueSetsEQ5D_Health_UK(Scale). 
FORMATS FUp2EQ5DValueSetsEQ5D_Health_UK(F4.3). 
VARIABLE LABELS FUp2EQ5DValueSetsEQ5D_Health_UK "EQ-5D health value 
at follow-up 2". 
VARIABLE LEVEL FUp2EQ5DValueSetsEQ5D_Health_UK(Scale). 
FORMATS LastEQ5DValueSetsEQ5D_Health_UK(F4.3). 
VARIABLE LABELS LastEQ5DValueSetsEQ5D_Health_UK "EQ-5D health value 
at follow-up". 
VARIABLE LEVEL LastEQ5DValueSetsEQ5D_Health_UK(Scale). 
FORMATS EQ5D_Change(F4.3). 
VARIABLE LABELS EQ5D_Change "EQ-5D health value change from baseline 
at follow-up". 
VARIABLE LEVEL EQ5D_Change(Scale). 
FORMATS BaseEQ5DD08_EQVAS(F4.0). 
VARIABLE LABELS BaseEQ5DD08_EQVAS "EQ-5D VAS at baseline". 
VARIABLE LEVEL BaseEQ5DD08_EQVAS(Scale). 
FORMATS FUp1EQ5DD08_EQVAS(F4.0). 
VARIABLE LABELS FUp1EQ5DD08_EQVAS "EQ-5D VAS at follow-up 1". 
VARIABLE LEVEL FUp1EQ5DD08_EQVAS(Scale). 
FORMATS FUp2EQ5DD08_EQVAS(F4.0). 
VARIABLE LABELS FUp2EQ5DD08_EQVAS "EQ-5D VAS at follow-up 2". 
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VARIABLE LEVEL FUp2EQ5DD08_EQVAS(Scale). 
FORMATS FUpLastEQ5DD08_EQVAS(F4.0). 
VARIABLE LABELS FUpLastEQ5DD08_EQVAS "EQ-5D VAS at follow-up". 
VARIABLE LEVEL FUpLastEQ5DD08_EQVAS(Scale). 
FORMATS EQVAS_Change(F4.0). 
VARIABLE LABELS EQVAS_Change "EQ-5D VAS change from baseline at 
follow-up". 
VARIABLE LEVEL EQVAS_Change(Scale). 
FORMATS WeeksMRIBase(F4.1). 
VARIABLE LABELS WeeksMRIBase "Recruitment to baseline MRI (weeks)". 
VARIABLE LEVEL WeeksMRIBase(Scale). 
FORMATS BaseMRIE03_FistulaNo(F4.0). 
VARIABLE LABELS BaseMRIE03_FistulaNo "Number of fistula on MRI at 
baseline". 
VALUE LABELS BaseMRIE03_FistulaNo 0 "None" 1 "Single unbranched" 2 
"Single branched" 10 "Multiple" . 
VARIABLE LEVEL BaseMRIE03_FistulaNo(Ordinal). 
FORMATS BaseMRIE04_FistulaParks(F4.0). 
VARIABLE LABELS BaseMRIE04_FistulaParks "Park's Classification on 
MRI at baseline". 
VALUE LABELS BaseMRIE04_FistulaParks 0 "NA" 10 "Subcutaneous" 11 
"Inter-sphincteric" 12 "Trans-sphincteric" 13 "Supra-sphincteric" 14 
"Extra-sphincteric" . 
VARIABLE LEVEL BaseMRIE04_FistulaParks(Ordinal). 
FORMATS BaseMRIE05_FistulaLevel(F4.0). 
VARIABLE LABELS BaseMRIE05_FistulaLevel "Level of fistula on MRI at 
baseline". 
VALUE LABELS BaseMRIE05_FistulaLevel 0 "NA" 10 "Low" 11 "High" . 
VARIABLE LEVEL BaseMRIE05_FistulaLevel(Ordinal). 
FORMATS BaseMRIE06_SecondaryTracts(F4.0). 
VARIABLE LABELS BaseMRIE06_SecondaryTracts "Secondary tracts on MRI 
at baseline". 
VALUE LABELS BaseMRIE06_SecondaryTracts 0 "NA" 1 "None" 10 
"Infralevator" 11 "Supralevator" . 
VARIABLE LEVEL BaseMRIE06_SecondaryTracts(Ordinal). 
FORMATS BaseMRIE07_FistulaHorseshoe(F4.0). 
VARIABLE LABELS BaseMRIE07_FistulaHorseshoe "Horseshoe extension on 
MRI at baseline". 
VALUE LABELS BaseMRIE07_FistulaHorseshoe 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL BaseMRIE07_FistulaHorseshoe(Ordinal). 
FORMATS BaseMRIE08_Collections(F4.0). 
VARIABLE LABELS BaseMRIE08_Collections "Collections on MRI at 
baseline". 
VALUE LABELS BaseMRIE08_Collections 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL BaseMRIE08_Collections(Ordinal). 
FORMATS BaseMRIE09_RectalInvolvement(F4.0). 
VARIABLE LABELS BaseMRIE09_RectalInvolvement "Rectal involvement on 
MRI at baseline". 
VALUE LABELS BaseMRIE09_RectalInvolvement 0 "NA" 1 "Normal" 10 
"Thickened" . 
VARIABLE LEVEL BaseMRIE09_RectalInvolvement(Ordinal). 
FORMATS BaseMRIE10_FistulaHyperintensityT2(F4.0). 
VARIABLE LABELS BaseMRIE10_FistulaHyperintensityT2 "Hyperintensity 
on MRI at baseline". 
VALUE LABELS BaseMRIE10_FistulaHyperintensityT2 0 "NA" 1 "Absent" 10 
"Mild" 11 "Pronounced" . 




VARIABLE LABELS E11_MRIScoreFistulaNo "MRI score fistula number". 
VARIABLE LEVEL E11_MRIScoreFistulaNo(Scale). 
FORMATS E12_MRIScoreLocation(F4.0). 
VARIABLE LABELS E12_MRIScoreLocation "MRI score location". 
VARIABLE LEVEL E12_MRIScoreLocation(Scale). 
FORMATS E13_MRIScoreExtension(F4.0). 
VARIABLE LABELS E13_MRIScoreExtension "MRI score extension". 
VARIABLE LEVEL E13_MRIScoreExtension(Scale). 
FORMATS E14_MRIScoreCollections(F4.0). 
VARIABLE LABELS E14_MRIScoreCollections "MRI score collections". 
VARIABLE LEVEL E14_MRIScoreCollections(Scale). 
FORMATS E15_MRIScoreRectum(F4.0). 
VARIABLE LABELS E15_MRIScoreRectum "MRI score rectum". 
VARIABLE LEVEL E15_MRIScoreRectum(Scale). 
FORMATS E16_MRIScoreHyperintensity(F4.0). 
VARIABLE LABELS E16_MRIScoreHyperintensity "MRI score 
hyperintensity". 
VARIABLE LEVEL E16_MRIScoreHyperintensity(Scale). 
FORMATS BaseMRIE17_MRIScoreTotal(F4.0). 
VARIABLE LABELS BaseMRIE17_MRIScoreTotal "MRI score at baseline". 
VARIABLE LEVEL BaseMRIE17_MRIScoreTotal(Scale). 
FORMATS E18_SliceNo(F4.0). 
VARIABLE LABELS E18_SliceNo "Slice number". 
VARIABLE LEVEL E18_SliceNo(Scale). 
FORMATS E19_MaxEnhance(F6.0). 
VARIABLE LABELS E19_MaxEnhance "Max enhancement". 
VARIABLE LEVEL E19_MaxEnhance(Scale). 
FORMATS E20_MaxRelEnhance(F4.3). 
VARIABLE LABELS E20_MaxRelEnhance "Max relative enhancement". 
VARIABLE LEVEL E20_MaxRelEnhance(Scale). 
FORMATS E21_T0(F4.1). 
VARIABLE LABELS E21_T0 "T0". 
VARIABLE LEVEL E21_T0(Scale). 
FORMATS E22_TPeak(F4.1). 
VARIABLE LABELS E22_TPeak "Time to peak". 
VARIABLE LEVEL E22_TPeak(Scale). 
FORMATS E23_WashIn(F4.1). 
VARIABLE LABELS E23_WashIn "Wash in rate". 
VARIABLE LEVEL E23_WashIn(Scale). 
FORMATS E24_WashOut(F4.1). 
VARIABLE LABELS E24_WashOut "Wash out rate". 
VARIABLE LEVEL E24_WashOut(Scale). 
FORMATS E25_Brevity(F4.1). 
VARIABLE LABELS E25_Brevity "Brevity". 
VARIABLE LEVEL E25_Brevity(Scale). 
FORMATS E26_AUC(F6.0). 
VARIABLE LABELS E26_AUC "Area under the perfusion curve". 
VARIABLE LEVEL E26_AUC(Scale). 
FORMATS E27_RegionArea(F4.1). 
VARIABLE LABELS E27_RegionArea "Region area". 
VARIABLE LEVEL E27_RegionArea(Scale). 
FORMATS E28_NoPixels(F4.0). 
VARIABLE LABELS E28_NoPixels "Number of pixels". 
VARIABLE LEVEL E28_NoPixels(Scale). 
FORMATS E29_D1(F6.0). 
VARIABLE LABELS E29_D1 "D1". 
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VARIABLE LEVEL E29_D1(Scale). 
FORMATS E30_D2(F6.0). 
VARIABLE LABELS E30_D2 "D2". 
VARIABLE LEVEL E30_D2(Scale). 
FORMATS E31_D3(F6.0). 
VARIABLE LABELS E31_D3 "D3". 
VARIABLE LEVEL E31_D3(Scale). 
FORMATS E32_D4(F6.0). 
VARIABLE LABELS E32_D4 "D4". 
VARIABLE LEVEL E32_D4(Scale). 
FORMATS E33_D5(F6.0). 
VARIABLE LABELS E33_D5 "D5". 
VARIABLE LEVEL E33_D5(Scale). 
FORMATS E34_D6(F6.0). 
VARIABLE LABELS E34_D6 "D6". 
VARIABLE LEVEL E34_D6(Scale). 
FORMATS E35_D7(F6.0). 
VARIABLE LABELS E35_D7 "D7". 
VARIABLE LEVEL E35_D7(Scale). 
FORMATS E36_D8(F6.0). 
VARIABLE LABELS E36_D8 "D8". 
VARIABLE LEVEL E36_D8(Scale). 
FORMATS E37_D9(F6.0). 
VARIABLE LABELS E37_D9 "D9". 
VARIABLE LEVEL E37_D9(Scale). 
FORMATS E38_D10(F6.0). 
VARIABLE LABELS E38_D10 "D10". 
VARIABLE LEVEL E38_D10(Scale). 
FORMATS E39_DReference(F4.0). 
VARIABLE LABELS E39_DReference "DReference". 
VARIABLE LEVEL E39_DReference(Scale). 
FORMATS E40_TICType(F4.0). 
VARIABLE LABELS E40_TICType "Time-intensity curve type". 
VARIABLE LEVEL E40_TICType(Nominal). 
FORMATS WeeksSurgerytoMRILast(F4.1). 
VARIABLE LABELS WeeksSurgerytoMRILast "Surgery to follow-up MRI 
(weeks)". 
VARIABLE LEVEL WeeksSurgerytoMRILast(Scale). 
FORMATS FUpLastMRIE03_FistulaNo(F4.0). 
VARIABLE LABELS FUpLastMRIE03_FistulaNo "Number of fistula on MRI at 
follow-up". 
VALUE LABELS FUpLastMRIE03_FistulaNo 0 "None" 1 "Single unbranched" 
2 "Single branched" 10 "Multiple" . 
VARIABLE LEVEL FUpLastMRIE03_FistulaNo(Ordinal). 
FORMATS FUpLastMRIE04_FistulaParks(F4.0). 
VARIABLE LABELS FUpLastMRIE04_FistulaParks "Park's Classification on 
MRI at follow-up". 
VALUE LABELS FUpLastMRIE04_FistulaParks 0 "NA" 10 "Subcutaneous" 11 
"Inter-sphincteric" 12 "Trans-sphincteric" 13 "Supra-sphincteric" 14 
"Extra-sphincteric" . 
VARIABLE LEVEL FUpLastMRIE04_FistulaParks(Ordinal). 
FORMATS FUpLastMRIE05_FistulaLevel(F4.0). 
VARIABLE LABELS FUpLastMRIE05_FistulaLevel "Level of fistula on MRI 
at follow-up". 
VALUE LABELS FUpLastMRIE05_FistulaLevel 0 "NA" 10 "Low" 11 "High" . 




VARIABLE LABELS FUpLastMRIE06_SecondaryTracts "Secondary tracts on 
MRI at follow-up". 
VALUE LABELS FUpLastMRIE06_SecondaryTracts 0 "NA" 1 "None" 10 
"Infralevator" 11 "Supralevator" . 
VARIABLE LEVEL FUpLastMRIE06_SecondaryTracts(Ordinal). 
FORMATS FUpLastMRIE07_FistulaHorseshoe(F4.0). 
VARIABLE LABELS FUpLastMRIE07_FistulaHorseshoe "Horseshoe extension 
on MRI at follow-up". 
VALUE LABELS FUpLastMRIE07_FistulaHorseshoe 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL FUpLastMRIE07_FistulaHorseshoe(Ordinal). 
FORMATS FUpLastMRIE08_Collections(F4.0). 
VARIABLE LABELS FUpLastMRIE08_Collections "Collections on MRI at 
follow-up". 
VALUE LABELS FUpLastMRIE08_Collections 0 "NA" 1 "No" 10 "Yes" . 
VARIABLE LEVEL FUpLastMRIE08_Collections(Ordinal). 
FORMATS FUpLastMRIE09_RectalInvolvement(F4.0). 
VARIABLE LABELS FUpLastMRIE09_RectalInvolvement "Rectal involvement 
on MRI at follow-up". 
VALUE LABELS FUpLastMRIE09_RectalInvolvement 0 "NA" 1 "Normal" 10 
"Thickened" . 
VARIABLE LEVEL FUpLastMRIE09_RectalInvolvement(Ordinal). 
FORMATS FUpLastMRIE10_FistulaHyperintensityT2(F4.0). 
VARIABLE LABELS FUpLastMRIE10_FistulaHyperintensityT2 
"Hyperintensity on MRI at follow-up". 
VALUE LABELS FUpLastMRIE10_FistulaHyperintensityT2 0 "NA" 1 "Absent" 
10 "Mild" 11 "Pronounced" . 
VARIABLE LEVEL FUpLastMRIE10_FistulaHyperintensityT2(Ordinal). 
FORMATS FUpLastMRIE17_MRIScoreTotal(F4.0). 
VARIABLE LABELS FUpLastMRIE17_MRIScoreTotal "MRI score at follow-
up". 
VARIABLE LEVEL FUpLastMRIE17_MRIScoreTotal(Scale). 
FORMATS MRIScore_Change(F4.0). 
VARIABLE LABELS MRIScore_Change "MRI score change from baseline at 
follow-up". 
VARIABLE LEVEL MRIScore_Change(Scale). 
FORMATS ResultsPseudoSubgroupsParticipantID(F4.0). 
VARIABLE LABELS ResultsPseudoSubgroupsParticipantID "Participant 
ID". 
VARIABLE LEVEL ResultsPseudoSubgroupsParticipantID(Nominal). 
FORMATS Study_Outcomes(F4.0). 
VARIABLE LABELS Study_Outcomes "Outcomes Study". 
VALUE LABELS Study_Outcomes 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_Outcomes(Nominal). 
FORMATS Study_Immuno(F4.0). 
VARIABLE LABELS Study_Immuno "Immunopathology study". 
VALUE LABELS Study_Immuno 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_Immuno(Nominal). 
FORMATS Study_DCEMRI_Main(F4.0). 
VARIABLE LABELS Study_DCEMRI_Main "DCE-MRI study (main)". 
VALUE LABELS Study_DCEMRI_Main 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_DCEMRI_Main(Nominal). 
FORMATS Study_DCEMRI_Pilot(F4.0). 
VARIABLE LABELS Study_DCEMRI_Pilot "DCE-MRI study (pilot)". 
VALUE LABELS Study_DCEMRI_Pilot 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_DCEMRI_Pilot(Nominal). 
FORMATS Study_DCEMRI_All(F4.0). 
VARIABLE LABELS Study_DCEMRI_All "DCE-MRI study". 
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VALUE LABELS Study_DCEMRI_All 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_DCEMRI_All(Nominal). 
FORMATS S01_TypeBy3(F4.0). 
VARIABLE LABELS S01_TypeBy3 "Fistula type". 
VALUE LABELS S01_TypeBy3 0 "No fistula" 1 "Hidradenitis suppurativa 
only" 2 "Idiopathic" 3 "Intermediate" 10 "Crohn's" . 
VARIABLE LEVEL S01_TypeBy3(Ordinal). 
FORMATS S02_TypeBy2(F4.0). 
VARIABLE LABELS S02_TypeBy2 "Fistula type (binary)". 
VALUE LABELS S02_TypeBy2 0 "No fistula" 1 "Hidradenitis suppurativa 
only" 2 "Idiopathic" 10 "Crohn's" . 
VARIABLE LEVEL S02_TypeBy2(Ordinal). 
FORMATS S03_PrevRxSurgGE2(F4.0). 
VARIABLE LABELS S03_PrevRxSurgGE2 "Previous operations >=2". 
VALUE LABELS S03_PrevRxSurgGE2 1 "No" 10 "Yes" . 
VARIABLE LEVEL S03_PrevRxSurgGE2(Ordinal). 
FORMATS S04_PrevRxSurgGE3(F4.0). 
VARIABLE LABELS S04_PrevRxSurgGE3 "Previous operations >=3". 
VALUE LABELS S04_PrevRxSurgGE3 1 "No" 10 "Yes" . 
VARIABLE LEVEL S04_PrevRxSurgGE3(Ordinal). 
FORMATS S05_PrevRxSurgGE4(F4.0). 
VARIABLE LABELS S05_PrevRxSurgGE4 "Previous operations >=4". 
VALUE LABELS S05_PrevRxSurgGE4 1 "No" 10 "Yes" . 
VARIABLE LEVEL S05_PrevRxSurgGE4(Ordinal). 
FORMATS S06_PrevRxCure(F4.0). 
VARIABLE LABELS S06_PrevRxCure "Previous curative treatment". 
VALUE LABELS S06_PrevRxCure 1 "No" 10 "Yes" . 
VARIABLE LEVEL S06_PrevRxCure(Ordinal). 
FORMATS S07_PrevRxAntiTNF(F4.0). 
VARIABLE LABELS S07_PrevRxAntiTNF "Previous anti-TNF". 
VALUE LABELS S07_PrevRxAntiTNF 1 "No" 10 "Yes" . 
VARIABLE LEVEL S07_PrevRxAntiTNF(Ordinal). 
FORMATS S08_PrevRxAntiTNFRecent(F4.0). 
VARIABLE LABELS S08_PrevRxAntiTNFRecent "Previous anti-TNF within 
last year". 
VALUE LABELS S08_PrevRxAntiTNFRecent 1 "No" 10 "Yes" . 
VARIABLE LEVEL S08_PrevRxAntiTNFRecent(Ordinal). 
FORMATS S09_CurrentSeton(F4.0). 
VARIABLE LABELS S09_CurrentSeton "Seton in situ at recruitment". 
VALUE LABELS S09_CurrentSeton 1 "No" 10 "Yes" . 
VARIABLE LEVEL S09_CurrentSeton(Ordinal). 
FORMATS S10_CrohnsDiagnosed(F4.0). 
VARIABLE LABELS S10_CrohnsDiagnosed "Crohn's diagnosed since 
recruitment". 
VALUE LABELS S10_CrohnsDiagnosed 1 "No" 10 "Yes" . 
VARIABLE LEVEL S10_CrohnsDiagnosed(Ordinal). 
FORMATS S11_HS(F4.0). 
VARIABLE LABELS S11_HS "Hidradenitis suppurativa". 
VALUE LABELS S11_HS 1 "No" 10 "Yes" . 
VARIABLE LEVEL S11_HS(Ordinal). 
FORMATS S12_RxSatisfactory(F4.0). 
VARIABLE LABELS S12_RxSatisfactory "Treatment outcome". 
VALUE LABELS S12_RxSatisfactory 1 "Unsatisfactory" 10 "Satisfactory" 
. 




VARIABLE LABELS S13_RxSatisfactory_FUp1 "Treatment outcome at 
follow-up 1". 
VALUE LABELS S13_RxSatisfactory_FUp1 1 "Unsatisfactory" 10 
"Satisfactory" . 
VARIABLE LEVEL S13_RxSatisfactory_FUp1(Ordinal). 
FORMATS S14_RxSatisfactory_FUp2(F4.0). 
VARIABLE LABELS S14_RxSatisfactory_FUp2 "Treatment outcome at 
follow-up 2". 
VALUE LABELS S14_RxSatisfactory_FUp2 1 "Unsatisfactory" 10 
"Satisfactory" . 
VARIABLE LEVEL S14_RxSatisfactory_FUp2(Ordinal). 
MISSING VALUES MaxOfG06_CDColonoscopy(0). 
MISSING VALUES MaxOfG07_CDBariumFT(0). 
MISSING VALUES MaxOfG08_CDMRIAbdo(0). 
 
*Correct values. 
IF ParticipantID = 65  LastEQ5DValueSetsEQ5D_Health_UK = -0.034. 
IF ParticipantID = 65  EQ5D_Change = -0.034 + 0.002. 
EXECUTE. 
 
*Compute new dichotomous variables. 
COMPUTE S15_RxIntent =  (F09_RxSurg > 11)*9+1. 
COMPUTE Study_OutcomesFistula = S01_TypeBy3 >1 AND Study_Outcomes. 
COMPUTE CrohnsOnImaging = MaxOfG06_CDColonoscopy = 11 OR 
MaxOfG07_CDBariumFT = 11 OR MaxOfG08_CDMRIAbdo = 11. 
COMPUTE RecurrentDisease = B11_PrevRxSurg > 11 OR ( F09_RxSurg >11 
AND LastOfG16_RxResponse < 10). 
COMPUTE SetonUnresponsive =  (B11_PrevRxSurg = 11 AND 
B12_PrevRxResponse < 4) OR ( F09_RxSurg = 11 AND 
LastOfG16_RxResponse < 4). 
COMPUTE ComplexAnatomy =  F03_FistulaParks > 12 OR (F03_FistulaParks 
= 12 AND (F05_FistulaSecondaryTracts > 9 OR F07_FistulaCollections > 
9)). 
COMPUTE CrohnsExcludedOnImaging = MIN( MaxOfG06_CDColonoscopy, 
MaxOfG07_CDBariumFT, MaxOfG08_CDMRIAbdo). 
EXECUTE. 
IF MISSING(CrohnsExcludedOnImaging) CrohnsExcludedOnImaging = 0. 
E F09_RxSurg F09_RxSurgXECUTE. 
 
*Recode S12_RxSatisfactory to S16_RxSatisfactory. 
COMPUTE S16_RxSatisfactory = ((S15_RxIntent = 1 AND 
LastOfG16_RxResponse > 3) OR (S15_RxIntent = 10 AND 
LastOfG16_RxResponse > 9))*9+1. 
EXECUTE. 
FORMATS S16_RxSatisfactory(F4.0). 
VARIABLE LABELS S16_RxSatisfactory "Treatment outcome". 
VALUE LABELS S16_RxSatisfactory 1 "Unsatisfactory" 10 "Satisfactory" 
. 
VARIABLE LEVEL S16_RxSatisfactory(Ordinal). 
 
*Reassign Fistula Type. 
*Caution. This saves original data in new variables then overwrites 
existing data. 
 * COMPUTE OLD_S01_TypeBy3 = S01_TypeBy3. 
 * EXECUTE. 
 * COMPUTE OLD_S02_TypeBy2 = S02_TypeBy2. 




IF  S01_TypeBy3 >1 S01_TypeBy3 =  (RecurrentDisease OR 
SetonUnresponsive OR ComplexAnatomy) + 2. 
EXECUTE. 
IF CrohnsOnImaging S01_TypeBy3 = 10. 
EXECUTE. 
IF MISSING(S01_TypeBy3) S01_TypeBy3 = OLD_S01_TypeBy3. 
EXECUTE. 
COMPUTE S02_TypeBy2 = S01_TypeBy3. 
EXECUTE. 
IF S02_TypeBy2 = 3 S02_TypeBy2 = 2. 
EXECUTE. 
COMPUTE Study_DCEMRI_All_Acute = Study_DCEMRI_All AND  
B13_FistulaDuration <=12. 
EXECUTE. 
RECODE E40_TICType (3,4,5 = 4)(else=copy) INTO E41_TICType2.  
EXECUTE. 
COMPUTE ChronicFistula =  B13_FistulaDuration >= 12. 
EXECUTE. 
 
*Calculate St James' grade. 
IF  BaseMRIE04_FistulaParks = 11 BaseMRIE42_StJames = (1 + ( 
BaseMRIE06_SecondaryTracts > 1 OR  BaseMRIE08_Collections > 1)). 
IF  BaseMRIE04_FistulaParks = 12 BaseMRIE42_StJames = (3 +  ( 
BaseMRIE06_SecondaryTracts > 1 OR  BaseMRIE08_Collections > 1)). 
IF  BaseMRIE04_FistulaParks > 12 BaseMRIE42_StJames = (5). 
EXECUTE. 
 




VARIABLE LABELS Study_OutcomesFistula "Outcomes study (Fistula)". 
VALUE LABELS Study_OutcomesFistula 0 "No" 1 "Yes" . 
VARIABLE LEVEL Study_OutcomesFistula(Nominal). 
FORMATS CrohnsOnImaging(F4.0).  
VARIABLE LABELS CrohnsOnImaging "Imaging evidence of Crohn's".  
VALUE LABELS CrohnsOnImaging 0 "No" 1 "Yes" .  
VARIABLE LEVEL CrohnsOnImaging(Nominal). 
FORMATS RecurrentDisease(F4.0). 
VARIABLE LABELS RecurrentDisease "Recurrent disease". 
VALUE LABELS RecurrentDisease 0 "No" 1 "Yes" . 
VARIABLE LEVEL RecurrentDisease(Nominal). 
FORMATS SetonUnresponsive(F4.0). 
VARIABLE LABELS SetonUnresponsive "Inadequate response to seton". 
VALUE LABELS SetonUnresponsive 0 "No" 1 "Yes" . 
VARIABLE LEVEL SetonUnresponsive(Nominal). 
FORMATS ComplexAnatomy(F4.0). 
VARIABLE LABELS ComplexAnatomy "Complex transphincteric fistula or 
worse". 
VALUE LABELS ComplexAnatomy 0 "No" 1 "Yes" . 
VARIABLE LEVEL ComplexAnatomy(Nominal). 
FORMATS CrohnsExcludedOnImaging(F4.0).  
VARIABLE LABELS CrohnsExcludedOnImaging "Imaging exclusion of 
Crohn's".  
VALUE LABELS CrohnsExcludedOnImaging 0 "None" 1 "No IBD" 2 "UC" 3 
"Declined" 10 "Indeterminate Colitis" 11 "Crohn's" . 
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VARIABLE LEVEL CrohnsExcludedOnImaging(Nominal).  
FORMATS S15_RxIntent(F4.0). 
VARIABLE LABELS S15_RxIntent "Treatment intent".  
VALUE LABELS S15_RxIntent 1 "Symptom control" 10 "Cure" .  
VARIABLE LEVEL S15_RxIntent(Ordinal). 
FORMATS E41_TICType2(F4.0). 
VARIABLE LABELS E41_TICType2 "Time-intensity curve type". 
VARIABLE LEVEL E41_TICType2(Nominal). 
FORMATS ChronicFistula(F4.0). 
VARIABLE LABELS ChronicFistula "Chronic Fistula". 
VALUE LABELS ChronicFistula 0 "No" 1 "Yes" . 
VARIABLE LEVEL ChronicFistula(Ordinal). 
FORMATS BaseMRIE42_StJames(F4.0). 
VARIABLE LABELS BaseMRIE42_StJames "St James' Grade at Baseline 
MRI". 
VARIABLE LEVEL BaseMRIE42_StJames(Ordinal). 
FORMATS StJamesHigh(F4.0). 
VARIABLE LABELS StJamesHigh "St James' Grade 3-5". 
VALUE LABELS StJamesHigh 0 "No" 1 "Yes" . 
VARIABLE LEVEL StJamesHigh(Ordinal). 
FORMATS F11_FistulaIntersphincteric(F4.0). 
VARIABLE LABELS F11_FistulaIntersphincteric "Intersphincteric at 
Surgery". 
VALUE LABELS F11_FistulaIntersphincteric 0 "No" 1 "Yes" . 
VARIABLE LEVEL F11_FistulaIntersphincteric(Ordinal). 
 





*1 Find unlikely values with frequency tables and histograms and 
define as missing variables. 
FREQUENCIES VARIABLES=ParticipantID to S14_RxSatisfactory_FUp2. 
FREQUENCIES VARIABLES=B02_Age B13_FistulaDuration 
MaxOfG09_CDCalprotectin WeeksSurgery  
    G21_WeeksFollowUp G22_WeeksMedsStart BasePDAIC08_PDAI 
FUp1PDAIC08_PDAI FUp2PDAIC08_PDAI  
    FUpLastPDAIC08_PDAI PDAI_Change BaseEQ5DValueSetsEQ5D_Health_UK 
FUp1EQ5DValueSetsEQ5D_Health_UK  
    FUp2EQ5DValueSetsEQ5D_Health_UK LastEQ5DValueSetsEQ5D_Health_UK 
EQ5D_Change BaseEQ5DD08_EQVAS  
    FUp1EQ5DD08_EQVAS FUp2EQ5DD08_EQVAS FUpLastEQ5DD08_EQVAS 
EQVAS_Change WeeksMRIBase  
    E11_MRIScoreFistulaNo E12_MRIScoreLocation E13_MRIScoreExtension 
E14_MRIScoreCollections  
    E15_MRIScoreRectum E16_MRIScoreHyperintensity 
BaseMRIE17_MRIScoreTotal E18_SliceNo E19_MaxEnhance  
    E20_MaxRelEnhance E21_T0 E22_TPeak E23_WashIn E24_WashOut 
E25_Brevity E26_AUC E27_RegionArea  
    E28_NoPixels E29_D1 E30_D2 E31_D3 E32_D4 E33_D5 E34_D6 E35_D7 
E36_D8 E37_D9 E38_D10 E39_DReference  
    FUpLastMRIE17_MRIScoreTotal MRIScore_Change 
WeeksSurgerytoMRILast 
  /FORMAT=NOTABLE 
  /HISTOGRAM 




*2 Check total number of cases and total number of variables. 
*3 Check meaning of variables and values - use FREQUENCIES to check 
the variable and value labels, coding (higher values represent more 
positive answers), user missing values, and that frequencies make 
sense. 
*4 Check missing values per variable with DESCRIPTIVES and delete or 
exclude variables with high amounts of missing data. 
DESCRIPTIVES VARIABLES=ParticipantID to S14_RxSatisfactory_FUp2 
/STATISTICS=MEAN STDDEV MIN MAX. 
 
*5 Check normality of data. 
EXAMINE VARIABLES=B02_Age B10_PrevRxSurgNo B13_FistulaDuration 
MaxOfG09_CDCalprotectin WeeksSurgery G21_WeeksFollowUp 
G22_WeeksMedsStart  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  
  /NOTOTAL. 
EXAMINE VARIABLES=BasePDAIC03_PDAIDischarge BasePDAIC04_PDAIPain 
BasePDAIC05_PDAISexual BasePDAIC06_PDAIDiseaseType 










FUpLastPDAIC07_PDAIInduration FUpLastPDAIC08_PDAI PDAI_Change  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  
  /NOTOTAL. 
EXAMINE VARIABLES=BaseEQ5DValueSetsEQ5D_Health_UK 
FUp1EQ5DValueSetsEQ5D_Health_UK FUp2EQ5DValueSetsEQ5D_Health_UK 
LastEQ5DValueSetsEQ5D_Health_UK EQ5D_Change BaseEQ5DD08_EQVAS 
FUp1EQ5DD08_EQVAS FUp2EQ5DD08_EQVAS FUpLastEQ5DD08_EQVAS 
EQVAS_Change  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  
  /NOTOTAL. 
EXAMINE VARIABLES=WeeksMRIBase E11_MRIScoreFistulaNo 
E12_MRIScoreLocation E13_MRIScoreExtension E14_MRIScoreCollections 
E15_MRIScoreRectum E16_MRIScoreHyperintensity 
BaseMRIE17_MRIScoreTotal  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  
  /NOTOTAL. 
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EXAMINE VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E22_TPeak 
E23_WashIn E24_WashOut E25_Brevity E26_AUC  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  
  /NOTOTAL. 
EXAMINE VARIABLES=WeeksSurgerytoMRILast FUpLastMRIE17_MRIScoreTotal 
MRIScore_Change  
  /PLOT HISTOGRAM NPPLOT  
  /STATISTICS NONE  
  /CINTERVAL 95  
  /MISSING LISTWISE  




* OPEN DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2015-10 Clinical'. 
 
* FILTER CASES. 
FILTER by Study_OutcomesFistula.  
SHOW filter. 
 
* ANALYSE DATA. 
* Patient characteristics. 
CTABLES 
  /VLABELS VARIABLES=B03_Gender B02_Age B04_EthnicOrigin 
B13_FistulaDuration B08_PrevRxMed S03_PrevRxSurgGE2  
    S06_PrevRxCure S09_CurrentSeton B16_Smoking S02_TypeBy2  
    DISPLAY=LABEL 
  /TABLE B03_Gender [C][COUNT F40.0, COLPCT.TOTALN PCT40.0] + 
B02_Age [S][MEAN, STDDEV] + B04_EthnicOrigin [COUNT F40.0, 
COLPCT.TOTALN PCT40.0] + 
    B13_FistulaDuration [S][MEDIAN, PTILE 25, PTILE 75] + 
B08_PrevRxMed [C][COUNT F40.0, COLPCT.TOTALN  
    PCT40.0] + B10_PrevRxSurgNo [MEDIAN, PTILE 25, PTILE 75] + 
S06_PrevRxCure [C][COUNT  
    F40.0, COLPCT.TOTALN PCT40.0] + S09_CurrentSeton [C][COUNT 
F40.0, COLPCT.TOTALN PCT40.0] +  
    B16_Smoking [C][COUNT F40.0, COLPCT.TOTALN PCT40.0] BY 
S02_TypeBy2 [C] 
  /SLABELS POSITION=ROW 
  /CATEGORIES VARIABLES=B03_Gender [1, 10, OTHERNM] EMPTY=INCLUDE 
TOTAL=YES POSITION=BEFORE 
  /CATEGORIES VARIABLES=B04_EthnicOrigin [10, HSUBTOTAL='White', 18, 
19, 20, 21, HSUBTOTAL='Asian', 16, 17, 15, HSUBTOTAL='Black', 11, 
12, 13, 14, 22, 23, 24, HSUBTOTAL='Other', OTHERNM, MISSING] 
EMPTY=INCLUDE POSITION=AFTER 
  /CATEGORIES VARIABLES=B08_PrevRxMed [1, 10, 11, 12, 13, 14, 
OTHERNM] EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S06_PrevRxCure [1, 10, OTHERNM] 
EMPTY=INCLUDE 




  /CATEGORIES VARIABLES=B16_Smoking [1, 10, 11, OTHERNM] 
EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* Chron's characteristics. 
CTABLES 
  /VLABELS VARIABLES=B07_PrevIBD S10_CrohnsDiagnosed B08_PrevRxMed 
B09_PrevRxAntiTNF  
    MaxOfG04_CDAbdoFistula MaxOfG05_CDAbdoSurgery S02_TypeBy2  
    DISPLAY=LABEL 
  /TABLE B07_PrevIBD [C] + S10_CrohnsDiagnosed [C] + B08_PrevRxMed 
[C] + B09_PrevRxAntiTNF [C] +  
    MaxOfG04_CDAbdoFistula [C] + MaxOfG05_CDAbdoSurgery [C] BY 
S02_TypeBy2 [C][COUNT F40.0,  
    COLPCT.TOTALN PCT40.0] 
  /SLABELS POSITION=ROW 
  /CATEGORIES VARIABLES=B07_PrevIBD ORDER=A KEY=VALUE EMPTY=INCLUDE 
TOTAL=YES POSITION=BEFORE 
  /CATEGORIES VARIABLES=S10_CrohnsDiagnosed B08_PrevRxMed 
B09_PrevRxAntiTNF MaxOfG04_CDAbdoFistula  
    MaxOfG05_CDAbdoSurgery ORDER=A KEY=VALUE  
    EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S02_TypeBy2 [10] EMPTY=EXCLUDE. 
 
* Crhon's diagnosis.  
CTABLES  
  /VLABELS VARIABLES=CrohnsOnImaging MaxOfG10_CDHistoDiagnosis 
MaxOfG11_CDHistoGranulomas S02_TypeBy2 DISPLAY=LABEL  
  /TABLE CrohnsOnImaging [C] > MaxOfG10_CDHistoDiagnosis [C] > 
MaxOfG11_CDHistoGranulomas [C] BY S02_TypeBy2 [C][COUNT F40.0]  
  /SLABELS POSITION=ROW  
  /CATEGORIES VARIABLES=CrohnsOnImaging MaxOfG10_CDHistoDiagnosis 
MaxOfG11_CDHistoGranulomas ORDER=A KEY=VALUE MISSING=INCLUDE 
EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 MISSING=INCLUDE EMPTY=INCLUDE. 
 
* Complex disease. 
CTABLES 
  /VLABELS VARIABLES=RecurrentDisease SetonUnresponsive 
ComplexAnatomy S02_TypeBy2 DISPLAY=LABEL 
  /TABLE RecurrentDisease > SetonUnresponsive > ComplexAnatomy BY 
S02_TypeBy2 [C][COUNT F40.0] 
  /SLABELS POSITION=ROW 
  /CATEGORIES VARIABLES=RecurrentDisease SetonUnresponsive 
ComplexAnatomy ORDER=A KEY=VALUE  
    EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S02_TypeBy2 EMPTY=INCLUDE. 
 
* Crohn's exclusion.  
CTABLES  
  /VLABELS VARIABLES=MaxOfG03_CDClinical CrohnsExcludedOnImaging 
MaxOfG10_CDHistoDiagnosis S02_TypeBy2 DISPLAY=LABEL  
  /TABLE MaxOfG03_CDClinical [C] > CrohnsExcludedOnImaging [C] > 
MaxOfG10_CDHistoDiagnosis [C] BY S02_TypeBy2 [C][COUNT F40.0]  
  /SLABELS VISIBLE=NO  
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  /CATEGORIES VARIABLES=MaxOfG03_CDClinical CrohnsExcludedOnImaging 
MaxOfG10_CDHistoDiagnosis S02_TypeBy2 ORDER=A KEY=VALUE 
EMPTY=EXCLUDE MISSING=EXCLUDE. 
 
* Surgical findings.  
CTABLES  
  /VLABELS VARIABLES=B15_CurrentSeton F02_FistulaNo F03_FistulaParks 
F04_FistulaLevel F05_FistulaSecondaryTracts F06_FistulaHorseshoe  
F07_FistulaCollections F08_FistulaRectalInvolvement F09_RxSurg 
S02_TypeBy2  
    DISPLAY=LABEL  
  /TABLE B15_CurrentSeton [C][COUNT F40.0, COLPCT.COUNT PCT40.0] + 
F02_FistulaNo [C][COUNT F40.0, COLPCT.COUNT PCT40.0] +  
F03_FistulaParks [C][COUNT F40.0, COLPCT.COUNT PCT40.0] + 
F04_FistulaLevel [C][COUNT F40.0, COLPCT.COUNT PCT40.0] +  
F05_FistulaSecondaryTracts [C][COUNT F40.0, COLPCT.COUNT PCT40.0] + 
F06_FistulaHorseshoe [C][COUNT F40.0, COLPCT.COUNT PCT40.0] +  
F07_FistulaCollections [C][COUNT F40.0, COLPCT.COUNT PCT40.0] + 
F08_FistulaRectalInvolvement [C][COUNT F40.0, COLPCT.COUNT PCT40.0] 
+  
F09_RxSurg [C][COUNT F40.0, COLPCT.COUNT PCT40.0] BY S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=B15_CurrentSeton F02_FistulaNo 
F03_FistulaParks F04_FistulaLevel F05_FistulaSecondaryTracts 
F06_FistulaHorseshoe  
F07_FistulaCollections F08_FistulaRectalInvolvement F09_RxSurg 
ORDER=A KEY=VALUE EMPTY=INCLUDE TOTAL=YES POSITION=AFTER  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Weeks to surgery. 
CTABLES 
  /VLABELS VARIABLES=WeeksSurgery S02_TypeBy2 DISPLAY=LABEL 
  /TABLE WeeksSurgery [MEDIAN, PTILE 25, PTILE 75] BY S02_TypeBy2 
[C] 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All'  
    POSITION=AFTER. 
 
* Define Multiple Response Sets.  
MRSETS  
  /MCGROUP NAME=$FistulaMicroSet LABEL='Fistula microbiology' 
VARIABLES=G18_FistulaMicro G19_FistulaMicro2  
  /DISPLAY NAME=[$FistulaMicroSet]. 
FREQUENCIES VARIABLES=G18_FistulaMicro 
  /ORDER=ANALYSIS. 
 
* Micro.  
CTABLES  
  /VLABELS VARIABLES=$FistulaMicroSet S02_TypeBy2 DISPLAY=LABEL  
  /TABLE $FistulaMicroSet [C] BY S02_TypeBy2 [C][COUNT F40.0, 
COLPCT.COUNT PCT40.0]  
  /CATEGORIES VARIABLES=$FistulaMicroSet ORDER=A KEY=VALUE 
EMPTY=EXCLUDE MISSING=EXCLUDE TOTAL=YES  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 




  /VLABELS VARIABLES=G21_WeeksFollowUp S02_TypeBy2 DISPLAY=LABEL  
  /TABLE G21_WeeksFollowUp [MEDIAN, PTILE 25, PTILE 75] BY 
S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Outcome by treatment intent.  
CTABLES  
  /VLABELS VARIABLES=S15_RxIntent LastOfG16_RxResponse S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE S15_RxIntent [C] > LastOfG16_RxResponse [C] BY S02_TypeBy2 
[C][COUNT F40.0, COLPCT.COUNT PCT40.0]  
  /CATEGORIES VARIABLES=S15_RxIntent ORDER=A KEY=VALUE EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=LastOfG16_RxResponse ORDER=A KEY=VALUE 
EMPTY=EXCLUDE TOTAL=YES 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Outcome.  
CTABLES  
  /VLABELS VARIABLES=S16_RxSatisfactory S02_TypeBy2 DISPLAY=LABEL  
  /TABLE S16_RxSatisfactory [COUNT F40.0, COLPCT.COUNT PCT40.0] BY 
S02_TypeBy2  
  /CATEGORIES VARIABLES=S16_RxSatisfactory ORDER=A KEY=VALUE 
EMPTY=EXCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER 
  /SIGTEST TYPE=CHISQUARE ALPHA=0.05 INCLUDEMRSETS=YES 
CATEGORIES=ALLVISIBLE. 
 
* Fisher Exact Tests for Operative Findings. 
CROSSTABS 
  /TABLES=F02_FistulaNo F03_FistulaParks F04_FistulaLevel 
F05_FistulaSecondaryTracts  
    F06_FistulaHorseshoe F07_FistulaCollections 
F08_FistulaRectalInvolvement BY S02_TypeBy2 
  /FORMAT=AVALUE TABLES 
  /STATISTICS=CHISQ  
  /CELLS=COUNT 
  /COUNT ROUND CELL 
  /METHOD=EXACT TIMER(5). 
 
 
Perineal Disease Activity Index    
* OPEN DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2016-01 Symptoms'. 
 
* FILTER CASES. 
FILTER by Study_OutcomesFistula. 
SHOW filter. 
 
* ANALYSE DATA. 




  /VLABELS VARIABLES=C03_PDAIDischarge C04_PDAIPain C05_PDAISexual 
C06_PDAIDiseaseType C07_PDAIInduration C08_PDAI C02_Timepoint  
    DISPLAY=LABEL  
  /TABLE C03_PDAIDischarge [COUNT F40.0, MISSING] + C04_PDAIPain 
[COUNT F40.0, MISSING] + C05_PDAISexual [COUNT F40.0, MISSING] 
 + C06_PDAIDiseaseType [COUNT F40.0, MISSING] + C07_PDAIInduration 
[COUNT F40.0, MISSING] + C08_PDAI [COUNT F40.0, MISSING] BY 
C02_Timepoint  
  /CATEGORIES VARIABLES=C02_Timepoint ORDER=A KEY=VALUE 
EMPTY=INCLUDE. 
 
* Check distributions. 
FREQUENCIES VARIABLES=C03_PDAIDischarge C04_PDAIPain C05_PDAISexual 
C06_PDAIDiseaseType C07_PDAIInduration C08_PDAI  
  /FORMAT=NOTABLE  
  /HISTOGRAM  
  /ORDER=ANALYSIS. 
 
* PDAI at baseline, by Type.  
CTABLES  
  /VLABELS VARIABLES=C03_PDAIDischarge C04_PDAIPain C05_PDAISexual 
C06_PDAIDiseaseType C07_PDAIInduration C08_PDAI C02_Timepoint 
S02_TypeBy2  
    DISPLAY=LABEL  
  /TABLE C03_PDAIDischarge [S][MEAN, STDDEV] + C04_PDAIPain 
[S][MEAN, STDDEV] + C05_PDAISexual [S][MEAN, STDDEV] 
 + C06_PDAIDiseaseType [S][MEAN, STDDEV] + C07_PDAIInduration 
[S][MEAN, STDDEV] + C08_PDAI [S][MEAN, STDDEV] BY C02_Timepoint [C] 
> S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=C02_Timepoint [1] EMPTY=INCLUDE  






T-TEST GROUPS=S02_TypeBy2(2 10)  
  /MISSING=ANALYSIS  
  /VARIABLES=C08_PDAI  
  /CRITERIA=CI(.95). 
 
* Barchart PDAI at baseline by type..  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=S02_TypeBy2 
MEANCI(C08_PDAI, 95)[name="MEAN_C08_PDAI" LOW="MEAN_C08_PDAI_LOW" 
HIGH="MEAN_C08_PDAI_HIGH"] MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: MEAN_C08_PDAI=col(source(s), name("MEAN_C08_PDAI"))  
  DATA: LOW=col(source(s), name("MEAN_C08_PDAI_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_C08_PDAI_HIGH"))  
  GUIDE: axis(dim(2), label("Mean PDAI"))  
  SCALE: cat(dim(1), include("2", "10"))  
  SCALE: linear(dim(2), include(0))  
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  ELEMENT: interval(position(S02_TypeBy2*MEAN_C08_PDAI), 
shape.interior(shape.square))  





FILTER by Study_OutcomesFistula. 
SHOW filter. 
 
* Longitudinal analysis. 
 
* PDAI by Type and Timepoint.  
CTABLES  
  /VLABELS VARIABLES=C03_PDAIDischarge C04_PDAIPain C05_PDAISexual 
C06_PDAIDiseaseType C07_PDAIInduration C08_PDAI S02_TypeBy2 
C02_Timepoint  
    DISPLAY=LABEL  
  /TABLE C03_PDAIDischarge [MEAN, STDDEV] + C04_PDAIPain [MEAN, 
STDDEV] + C05_PDAISexual [MEAN, STDDEV] + C06_PDAIDiseaseType [MEAN, 
STDDEV] + C07_PDAIInduration [MEAN, STDDEV] + C08_PDAI [MEAN, 
STDDEV] BY S02_TypeBy2 > C02_Timepoint  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER  
  /CATEGORIES VARIABLES=C02_Timepoint ORDER=A KEY=VALUE 
EMPTY=INCLUDE. 
 
* PDAI by Type and timepoint.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=C02_Timepoint 
MEANCI(C08_PDAI, 95)[name="MEAN_C08_PDAI" LOW="MEAN_C08_PDAI_LOW" 
HIGH="MEAN_C08_PDAI_HIGH"] S02_TypeBy2 MISSING=LISTWISE 
REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: C02_Timepoint=col(source(s), name("C02_Timepoint"), 
unit.category())  
  DATA: MEAN_C08_PDAI=col(source(s), name("MEAN_C08_PDAI"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_C08_PDAI_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_C08_PDAI_HIGH"))  
  GUIDE: axis(dim(2), label("Mean PDAI"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("2", 
"10"))  
  ELEMENT: line(position(C02_Timepoint*MEAN_C08_PDAI), 
color.interior(S02_TypeBy2), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(C02_Timepoint*(LOW+HIGH))), 
shape.interior(shape.ibeam), color.interior(S02_TypeBy2))  
END GPL. 
 




  /VLABELS VARIABLES=C03_PDAIDischarge C04_PDAIPain C05_PDAISexual 
C06_PDAIDiseaseType C07_PDAIInduration C08_PDAI S02_TypeBy2 
C02_Timepoint S16_RxSatisfactory 
    DISPLAY=LABEL  
  /TABLE S16_RxSatisfactory > C03_PDAIDischarge [MEAN, STDDEV] + 
S16_RxSatisfactory > C04_PDAIPain [MEAN, STDDEV] + 
S16_RxSatisfactory > C05_PDAISexual [MEAN, STDDEV] +  
S16_RxSatisfactory > C06_PDAIDiseaseType [MEAN, STDDEV] + 
S16_RxSatisfactory > C07_PDAIInduration [MEAN, STDDEV] + 
S16_RxSatisfactory > C08_PDAI [MEAN, STDDEV]  
BY S02_TypeBy2 > C02_Timepoint  
  /CATEGORIES VARIABLES=S16_RxSatisfactory ORDER=A KEY=VALUE 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER  
  /CATEGORIES VARIABLES=C02_Timepoint ORDER=A KEY=VALUE 
EMPTY=INCLUDE. 
 
* PDAI by treatment outcome and timepoint.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=C02_Timepoint 
MEANCI(C08_PDAI, 95)[name="MEAN_C08_PDAI" LOW="MEAN_C08_PDAI_LOW" 
HIGH="MEAN_C08_PDAI_HIGH"] S16_RxSatisfactory MISSING=LISTWISE 
REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: C02_Timepoint=col(source(s), name("C02_Timepoint"), 
unit.category())  
  DATA: MEAN_C08_PDAI=col(source(s), name("MEAN_C08_PDAI"))  
  DATA: S16_RxSatisfactory=col(source(s), 
name("S16_RxSatisfactory"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_C08_PDAI_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_C08_PDAI_HIGH"))  
  GUIDE: axis(dim(2), label("Mean PDAI"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  GUIDE: text.footnote(label("Error Bars: 95% CI"))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("1", 
"10"))  
  ELEMENT: line(position(C02_Timepoint*MEAN_C08_PDAI), 
color.interior(S16_RxSatisfactory), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(C02_Timepoint*(LOW+HIGH))), 





* OPEN DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2016-01 Symptoms'. 
 
* FILTER CASES. 





* ANALYSE DATA. 
* Baseline analysis. 
* Show n.  
CTABLES  
  /VLABELS VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D08_EQVAS EQ5D_Health_UK D02_Timepoint  
    DISPLAY=LABEL  
  /TABLE D03_EQMobility [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] 
+ D04_EQSelfCare [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] +  
D05_EQActivities [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] + 
D06_EQPain [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] +  
D07_EQAnxiety [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] + 
D08_EQVAS [COUNT F40.0, MISSING] + EQ5D_Health_UK [COUNT F40.0, 
MISSING] BY D02_Timepoint  
  /CATEGORIES VARIABLES=D03_EQMobility D04_EQSelfCare 
D05_EQActivities D06_EQPain D07_EQAnxiety ORDER=A KEY=VALUE 
EMPTY=INCLUDE TOTAL=YES POSITION=AFTER  
  /CATEGORIES VARIABLES=D02_Timepoint [1] EMPTY=EXCLUDE. 
 
* Show distributions. 
FREQUENCIES VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D08_EQVAS EQ5D_Health_UK 
  /FORMAT=NOTABLE  
  /HISTOGRAM  
  /ORDER=ANALYSIS. 
 
* EQ-5D at baseline, by Type.  
CTABLES  
  /VLABELS VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D02_Timepoint S02_TypeBy2  
    DISPLAY=LABEL  
  /TABLE D03_EQMobility [C] + D04_EQSelfCare [C] + D05_EQActivities 
[C] + D06_EQPain [C] + D07_EQAnxiety [C] BY D02_Timepoint [C] > 
S02_TypeBy2 [C][COLPCT.COUNT PCT40.0]  
  /CATEGORIES VARIABLES=D03_EQMobility D04_EQSelfCare 
D05_EQActivities D06_EQPain D07_EQAnxiety ORDER=A KEY=VALUE 
EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=D02_Timepoint [1] EMPTY=EXCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* EAQ VAS and index at baseline.  
CTABLES  
  /VLABELS VARIABLES=D08_EQVAS EQ5D_Health_UK D02_Timepoint 
S02_TypeBy2 DISPLAY=LABEL  
  /TABLE D08_EQVAS [S][MEAN, STDDEV] + EQ5D_Health_UK [S][MEAN, 
STDDEV] BY D02_Timepoint [C] > S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=D02_Timepoint [1] EMPTY=INCLUDE  






* T-Test EQ VAS and index. 
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T-TEST GROUPS=S02_TypeBy2(2 10)  
  /MISSING=ANALYSIS  
  /VARIABLES=D08_EQVAS EQ5D_Health_UK 
  /CRITERIA=CI(.95). 
 
* Barchart EQ VAS at baseline.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=S02_TypeBy2 
MEANCI(D08_EQVAS, 95)[name="MEAN_D08_EQVAS" LOW="MEAN_D08_EQVAS_LOW" 
HIGH="MEAN_D08_EQVAS_HIGH"] MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: MEAN_D08_EQVAS=col(source(s), name("MEAN_D08_EQVAS"))  
  DATA: LOW=col(source(s), name("MEAN_D08_EQVAS_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_D08_EQVAS_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ VAS"))  
  SCALE: cat(dim(1), include("2", "10"))  
  SCALE: linear(dim(2), include(0))  
  ELEMENT: interval(position(S02_TypeBy2*MEAN_D08_EQVAS), 
shape.interior(shape.square))  





* Barchart EQ index at baseline.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=S02_TypeBy2 
MEANCI(EQ5D_Health_UK, 95)[name="MEAN_EQ5D_Health_UK" 
LOW="MEAN_EQ5D_Health_UK_LOW" HIGH="MEAN_EQ5D_Health_UK_HIGH"] 
MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: MEAN_EQ5D_Health_UK=col(source(s), 
name("MEAN_EQ5D_Health_UK"))  
  DATA: LOW=col(source(s), name("MEAN_EQ5D_Health_UK_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_EQ5D_Health_UK_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ index"))  
  GUIDE: text.footnote(label("Error Bars: 95% CI"))  
  SCALE: cat(dim(1), include("2", "10"))  
  SCALE: linear(dim(2), include(0))  
  ELEMENT: interval(position(S02_TypeBy2*MEAN_EQ5D_Health_UK), 
shape.interior(shape.square))  










* Longitudinal analysis. 
* Show n.  
CTABLES  
  /VLABELS VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D08_EQVAS EQ5D_Health_UK D02_Timepoint  
    DISPLAY=LABEL  
  /TABLE D03_EQMobility [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] 
+ D04_EQSelfCare [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] +  
D05_EQActivities [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] + 
D06_EQPain [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] +  
D07_EQAnxiety [COUNT F40.0, TOTALS[COUNT F40.0, MISSING]] + 
D08_EQVAS [COUNT F40.0, MISSING] + EQ5D_Health_UK [COUNT F40.0, 
MISSING] BY D02_Timepoint  
  /CATEGORIES VARIABLES=D03_EQMobility D04_EQSelfCare 
D05_EQActivities D06_EQPain D07_EQAnxiety ORDER=A KEY=VALUE 
EMPTY=INCLUDE TOTAL=YES POSITION=AFTER  
  /CATEGORIES VARIABLES=D02_Timepoint EMPTY=EXCLUDE. 
 
* EQ-5D, by Type.  
CTABLES  
  /VLABELS VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D02_Timepoint S02_TypeBy2  
    DISPLAY=LABEL  
  /TABLE D03_EQMobility [C] + D04_EQSelfCare [C] + D05_EQActivities 
[C] + D06_EQPain [C] + D07_EQAnxiety [C] BY S02_TypeBy2 [C] > 
D02_Timepoint [C][COLPCT.COUNT PCT40.0]  
  /CATEGORIES VARIABLES=D03_EQMobility D04_EQSelfCare 
D05_EQActivities D06_EQPain D07_EQAnxiety ORDER=A KEY=VALUE 
EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=D02_Timepoint EMPTY=EXCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* EQ-5D, by Type and Outcome.  
CTABLES  
  /VLABELS VARIABLES=D03_EQMobility D04_EQSelfCare D05_EQActivities 
D06_EQPain D07_EQAnxiety D02_Timepoint S02_TypeBy2 
S16_RxSatisfactory 
    DISPLAY=LABEL  
  /TABLE S16_RxSatisfactory [C] > D03_EQMobility [C] + 
S16_RxSatisfactory [C] > D04_EQSelfCare [C] + S16_RxSatisfactory [C] 
> D05_EQActivities [C] +  
S16_RxSatisfactory [C] > D06_EQPain [C] + S16_RxSatisfactory [C] > 
D07_EQAnxiety [C] BY S02_TypeBy2 [C] > D02_Timepoint 
[C][COLPCT.COUNT PCT40.0]  
  /CATEGORIES VARIABLES=D03_EQMobility D04_EQSelfCare 
D05_EQActivities D06_EQPain D07_EQAnxiety ORDER=A KEY=VALUE 
EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=D02_Timepoint EMPTY=EXCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* EQ-VAS and EQ-Index by Type.  
CTABLES  
  /VLABELS VARIABLES=D08_EQVAS EQ5D_Health_UK D02_Timepoint 
S02_TypeBy2 DISPLAY=LABEL  
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  /TABLE D08_EQVAS [S][MEAN, STDDEV] + EQ5D_Health_UK [S][MEAN, 
STDDEV] BY S02_TypeBy2 [C] > D02_Timepoint [C]  
  /CATEGORIES VARIABLES=D02_Timepoint EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* Line chart EQ VAS by type.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=D02_Timepoint 
MEANCI(EQ5D_Health_UK, 95)[name="MEAN_EQ5D_Health_UK" 
LOW="MEAN_EQ5D_Health_UK_LOW" HIGH="MEAN_EQ5D_Health_UK_HIGH"] 
S02_TypeBy2 MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: D02_Timepoint=col(source(s), name("D02_Timepoint"), 
unit.category())  
  DATA: MEAN_EQ5D_Health_UK=col(source(s), 
name("MEAN_EQ5D_Health_UK"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_EQ5D_Health_UK_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_EQ5D_Health_UK_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ index"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("2", 
"10"))  
  ELEMENT: line(position(D02_Timepoint*MEAN_EQ5D_Health_UK), 
color.interior(S02_TypeBy2), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(D02_Timepoint*(LOW+HIGH))), 
shape.interior(shape.ibeam), color.interior(S02_TypeBy2))  
END GPL. 
 
* Line chart EQ index by type.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=D02_Timepoint 
MEANCI(D08_EQVAS, 95)[name="MEAN_D08_EQVAS" LOW="MEAN_D08_EQVAS_LOW" 
HIGH="MEAN_D08_EQVAS_HIGH"] S02_TypeBy2 MISSING=LISTWISE 
REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: D02_Timepoint=col(source(s), name("D02_Timepoint"), 
unit.category())  
  DATA: MEAN_D08_EQVAS=col(source(s), name("MEAN_D08_EQVAS"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("0", "1"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_D08_EQVAS_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_D08_EQVAS_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ VAS"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
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  SCALE: cat(aesthetic(aesthetic.color.interior), include("2", 
"10"))  
  ELEMENT: line(position(D02_Timepoint*MEAN_D08_EQVAS), 
color.interior(S02_TypeBy2), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(D02_Timepoint*(LOW+HIGH))), 
shape.interior(shape.ibeam), color.interior(S02_TypeBy2))  
END GPL. 
 
* EQ-VAS and EQ-Index by Type and treatment outcome.  
CTABLES  
  /VLABELS VARIABLES=D08_EQVAS EQ5D_Health_UK D02_Timepoint 
S02_TypeBy2 S16_RxSatisfactory DISPLAY=LABEL  
  /TABLE S16_RxSatisfactory > D08_EQVAS [S][MEAN, STDDEV] + 
S16_RxSatisfactory > EQ5D_Health_UK [S][MEAN, STDDEV] BY S02_TypeBy2 
[C] > D02_Timepoint [C]  
  /CATEGORIES VARIABLES=D02_Timepoint EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S16_RxSatisfactory ORDER=A KEY=VALUE 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* Line chart EQ VAS by treatment outcome.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=D02_Timepoint 
MEANCI(D08_EQVAS, 95)[name="MEAN_D08_EQVAS" LOW="MEAN_D08_EQVAS_LOW" 
HIGH="MEAN_D08_EQVAS_HIGH"] S16_RxSatisfactory MISSING=LISTWISE 
REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: D02_Timepoint=col(source(s), name("D02_Timepoint"), 
unit.category())  
  DATA: MEAN_D08_EQVAS=col(source(s), name("MEAN_D08_EQVAS"))  
  DATA: S16_RxSatisfactory=col(source(s), 
name("S16_RxSatisfactory"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_D08_EQVAS_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_D08_EQVAS_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ VAS"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("1", 
"10"))  
  ELEMENT: line(position(D02_Timepoint*MEAN_D08_EQVAS), 
color.interior(S16_RxSatisfactory), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(D02_Timepoint*(LOW+HIGH))), 
shape.interior(shape.ibeam), color.interior(S16_RxSatisfactory))  
END GPL. 
 
* Line chart EQ index by treatment outcome.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=D02_Timepoint 
MEANCI(EQ5D_Health_UK, 95)[name="MEAN_EQ5D_Health_UK" 
LOW="MEAN_EQ5D_Health_UK_LOW" HIGH="MEAN_EQ5D_Health_UK_HIGH"] 
S16_RxSatisfactory MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
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BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: D02_Timepoint=col(source(s), name("D02_Timepoint"), 
unit.category())  
  DATA: MEAN_EQ5D_Health_UK=col(source(s), 
name("MEAN_EQ5D_Health_UK"))  
  DATA: S16_RxSatisfactory=col(source(s), 
name("S16_RxSatisfactory"), unit.category())  
  DATA: LOW=col(source(s), name("MEAN_EQ5D_Health_UK_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_EQ5D_Health_UK_HIGH"))  
  GUIDE: axis(dim(2), label("Mean EQ index"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  SCALE: cat(dim(1), include("1", "10", "11"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("1", 
"10"))  
  ELEMENT: line(position(D02_Timepoint*MEAN_EQ5D_Health_UK), 
color.interior(S16_RxSatisfactory), missing.wings())  
  ELEMENT: 
interval(position(region.spread.range(D02_Timepoint*(LOW+HIGH))), 




Cytokine and Phosphoprotein Phenotyping 
* OPEN AND PREPARE DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2015-10 Lab'. 
 
* FILTER CASES. 




* Show n.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF Biopsy S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [S][VALIDN F40.0] > Biopsy [C] BY S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=Biopsy ORDER=A KEY=VALUE EMPTY=INCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER 
  /CATEGORIES VARIABLES=S02_TypeBy2 [0, 2, 10] EMPTY=INCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* NON-PARAMETRIC TESTS. 
FILTER by FilterFistula. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
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H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN, PTILE 25, 
PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
* Granulation. 
FILTER by FilterGranulation. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN F40.2, PTILE 
25, PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S02_TypeBy2  
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  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
* Mucosa. 
FILTER by FilterMucosa. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN, PTILE 25, 
PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  





FILTER by FilterRectum. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN F40.3, PTILE 
25, PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
* ControlsVCrohns. 
FILTER by FilterControlsVCrohns. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
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H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN F40.3, PTILE 
25, PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
* ControlsVFistulae. 
FILTER by FilterControls. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF H02_Eotaxin S15_TypeBy1 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN, PTILE 25, PTILE 75] + H02_Eotaxin [MEDIAN, 
PTILE 25, PTILE 75] + H03_GCSF [MEDIAN, PTILE 25, PTILE 75] +  
H04_GMCSF [MEDIAN, PTILE 25, PTILE 75] + H05_IFNa2 [MEDIAN, PTILE 
25, PTILE 75] + H06_IFNg [MEDIAN, PTILE 25, PTILE 75] +  
H07_IL10 [MEDIAN, PTILE 25, PTILE 75] + H08_IL12p40 [MEDIAN, PTILE 
25, PTILE 75] + H09_IL12p70 [MEDIAN, PTILE 25, PTILE 75] +  
H10_IL13 [MEDIAN, PTILE 25, PTILE 75] + H11_IL15 [MEDIAN, PTILE 25, 
PTILE 75] + H12_IL17A [MEDIAN, PTILE 25, PTILE 75] +  
H13_IL1RA [MEDIAN, PTILE 25, PTILE 75] + H14_IL1a [MEDIAN, PTILE 25, 
PTILE 75] + H15_IL1b [MEDIAN, PTILE 25, PTILE 75] +  
H16_IL2 [MEDIAN, PTILE 25, PTILE 75] + H17_IL3 [MEDIAN F40.3, PTILE 
25, PTILE 75] + H18_IL4 [MEDIAN, PTILE 25, PTILE 75] +  
H19_IL5 [MEDIAN, PTILE 25, PTILE 75] + H20_IL6 [MEDIAN, PTILE 25, 
PTILE 75] + H21_IL7 [MEDIAN, PTILE 25, PTILE 75] +  
H22_IL8 [MEDIAN, PTILE 25, PTILE 75] + H23_IP10 [MEDIAN, PTILE 25, 
PTILE 75] + H24_MCP1 [MEDIAN, PTILE 25, PTILE 75] +  
H25_MIP1a [MEDIAN, PTILE 25, PTILE 75] + H26_MIP1b [MEDIAN, PTILE 
25, PTILE 75] + H27_RANTES [MEDIAN, PTILE 25, PTILE 75] +  
H28_TNFa [MEDIAN, PTILE 25, PTILE 75] + H29_TNFb [MEDIAN, PTILE 25, 
PTILE 75] + H30_VEGF [MEDIAN, PTILE 25, PTILE 75] 
 BY S15_TypeBy1  
  /CATEGORIES VARIABLES=S15_TypeBy1 ORDER=A KEY=VALUE EMPTY=EXCLUDE 




* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H01_EGF H02_Eotaxin H03_GCSF H04_GMCSF 
H05_IFNa2 H06_IFNg H07_IL10 H08_IL12p40 H09_IL12p70  
H10_IL13 H11_IL15 H12_IL17A H13_IL1RA H14_IL1a H15_IL1b H16_IL2 
H17_IL3 H18_IL4 H19_IL5 H20_IL6 H21_IL7 H22_IL8  
H23_IP10 H24_MCP1 H25_MIP1a H26_MIP1b H27_RANTES H28_TNFa H29_TNFb 
H30_VEGF) GROUP (S15_TypeBy1) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by Study_ImmunoExHS. 
SHOW filter. 
 
* Medians across all specimens.  
CTABLES  
  /VLABELS VARIABLES=H01_EGF Biopsy S02_TypeBy2 DISPLAY=LABEL  
  /TABLE H01_EGF [MEDIAN] + H02_Eotaxin [MEDIAN] + H03_GCSF [MEDIAN] 
+  
H04_GMCSF [MEDIAN] + H05_IFNa2 [MEDIAN] + H06_IFNg [MEDIAN] +  
H07_IL10 [MEDIAN] + H08_IL12p40 [MEDIAN] + H09_IL12p70 [MEDIAN] +  
H10_IL13 [MEDIAN] + H11_IL15 [MEDIAN] + H12_IL17A [MEDIAN] +  
H13_IL1RA [MEDIAN] + H14_IL1a [MEDIAN] + H15_IL1b [MEDIAN] +  
H16_IL2 [MEDIAN] + H17_IL3 [MEDIAN F40.3] + H18_IL4 [MEDIAN] +  
H19_IL5 [MEDIAN] + H20_IL6 [MEDIAN] + H21_IL7 [MEDIAN] +  
H22_IL8 [MEDIAN] + H23_IP10 [MEDIAN] + H24_MCP1 [MEDIAN] +  
H25_MIP1a [MEDIAN] + H26_MIP1b [MEDIAN] + H27_RANTES [MEDIAN] +  
H28_TNFa [MEDIAN] + H29_TNFb [MEDIAN] + H30_VEGF [MEDIAN] BY Biopsy 
> S02_TypeBy2  
  /CATEGORIES VARIABLES=Biopsy [1,2,3,4] EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 [0, 2, 10] EMPTY=INCLUDE. 
 
* Table to compare cytokine concentration medians with Tozer et al. 
CTABLES  
  /VLABELS VARIABLES=H16_IL2 H18_IL4 H20_IL6 H23_IP10 H28_TNFa 
H06_IFNg H12_IL17A S01_TypeBy3 Biopsy  
    DISPLAY=LABEL  
  /TABLE H16_IL2 [MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] + 
H18_IL4 [MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] + H20_IL6 
[MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] +  
  H23_IP10 [MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] + H28_TNFa 
[MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] + H06_IFNg [MEDIAN 
F40.2, PTILE 25 F40.2, PTILE 75 F40.2] +  
  H12_IL17A [MEDIAN F40.2, PTILE 25 F40.2, PTILE 75 F40.2] BY 
S01_TypeBy3 > Biopsy  
  /SLABELS POSITION=ROW  
  /CATEGORIES VARIABLES=S01_TypeBy3 [0, HSUBTOTAL='Normal', 2, 3, 
HSUBTOTAL='Idiopathic', 10] EMPTY=INCLUDE POSITION=AFTER  
  /CATEGORIES VARIABLES=Biopsy [1, 4] EMPTY=INCLUDE. 
 
* IL-1RA/ IL-1 Ratio 
FILTER by Study_ImmunoExHS. 
SHOW filter. 
 




  /VLABELS VARIABLES=H31_IL1RA_IL1_Ratio Biopsy S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE H31_IL1RA_IL1_Ratio [MEDIAN, PTILE 25, PTILE 75] > Biopsy 
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=Biopsy [1, 2, 3, 4] EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 [2, 10] EMPTY=INCLUDE TOTAL=YES 
LABEL='All' POSITION=AFTER. 
 
FILTER by FilterFistula. 
SHOW Filter. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H31_IL1RA_IL1_Ratio) GROUP (S02_TypeBy2) 
MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterGranulation. 
SHOW Filter. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H31_IL1RA_IL1_Ratio) GROUP (S02_TypeBy2) 
MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterMucosa. 
SHOW Filter. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H31_IL1RA_IL1_Ratio) GROUP (S02_TypeBy2) 
MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterRectum. 
SHOW Filter. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H31_IL1RA_IL1_Ratio) GROUP (S02_TypeBy2) 
MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
* ControlsVCrohns. 
FILTER by FilterControlsVCrohns. 
SHOW Filter. 
 
* Medians and IQRs. 
CTABLES  




  /TABLE H31_IL1RA_IL1_Ratio [MEDIAN, PTILE 25, PTILE 75] > Biopsy 
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=Biopsy [1, 2, 3, 4] EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 [0, 10] EMPTY=EXCLUDE. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (H31_IL1RA_IL1_Ratio) GROUP (S02_TypeBy2) 
MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by Study_ImmunoExHS. 
SHOW filter. 
 
* IL-1RA/IL-1β Ratio.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=Biopsy 
H31_IL1RA_IL1_Ratio S02_TypeBy2 MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: Biopsy=col(source(s), name("Biopsy"),  
notIn("5", "6"), unit.category())  
  DATA: H31_IL1RA_IL1_Ratio=col(source(s), 
name("H31_IL1RA_IL1_Ratio"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("1"), unit.category())  
  DATA: id=col(source(s), name("$CASENUM"), unit.category())  
  COORD: rect(dim(1,2), cluster(3,0))  
  GUIDE: axis(dim(2), label("IL-1RA/IL-1β Ratio"))  
  GUIDE: legend(aesthetic(aesthetic.color), label(""))  
  SCALE: cat(dim(3), include("1", "2", "3", "4"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color), sort.values("2", "10", 
"0"))  
  SCALE: cat(dim(1), sort.values("2", "10", "0"))  
  ELEMENT: 
schema(position(bin.quantile.letter(S02_TypeBy2*H31_IL1RA_IL1_Ratio*
Biopsy)), color(S02_TypeBy2), label(id))  
END GPL. 
 
FREQUENCIES VARIABLES=H31_IL1RA_IL1_Ratio  




  /GRAPHDATASET NAME="graphdataset" VARIABLES=Biopsy H09_IL12p70 
S02_TypeBy2 MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: Biopsy=col(source(s), name("Biopsy"),  
notIn("5", "6"), unit.category())  
  DATA: H09_IL12p70=col(source(s), name("H09_IL12p70"))  
  DATA: S02_TypeBy2=col(source(s), name("S02_TypeBy2"),  
notIn("1"), unit.category())  
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  DATA: id=col(source(s), name("$CASENUM"), unit.category())  
  COORD: rect(dim(1,2), cluster(3,0))  
  GUIDE: axis(dim(2), label("IL-12p70"))  
  GUIDE: legend(aesthetic(aesthetic.color), label(""))  
  SCALE: cat(dim(3), include("1", "2", "3", "4"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color), sort.values("2", "10", 
"0"))  
  SCALE: cat(dim(1), sort.values("2", "10", "0"))  
  ELEMENT: 
schema(position(bin.quantile.letter(S02_TypeBy2*H09_IL12p70*Biopsy))
, color(S02_TypeBy2), label(id))  
END GPL. 
 
FREQUENCIES VARIABLES=H09_IL12p70  
  /ORDER=ANALYSIS. 
 
* PHOSPHOPROTEINS. 
* Show n.  
CTABLES  
  /VLABELS VARIABLES= I01_EGFR_ErbB1 S02_TypeBy2 DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1 [S][VALIDN F40.0] > Biopsy [C] BY 
S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=Biopsy ORDER=A KEY=VALUE EMPTY=INCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER 
  /CATEGORIES VARIABLES=S02_TypeBy2 [0, 2, 10] EMPTY=INCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* NON-PARAMETRIC TESTS. 
FILTER by FilterFistula. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 H02_Eotaxin S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1[MEDIAN, PTILE 25, PTILE 75] + 
I02_HER2_ErbB2[MEDIAN, PTILE 25, PTILE 75] +  
I03_HER3_ErbB3[MEDIAN, PTILE 25, PTILE 75] + I04_FGFR1[MEDIAN, PTILE 
25, PTILE 75] + I05_FGFR3[MEDIAN, PTILE 25, PTILE 75] + 
I06_FGFR4[MEDIAN, PTILE 25, PTILE 75] + I07_InsR[MEDIAN, PTILE 25, 
PTILE 75] + I08_IGF_IR[MEDIAN, PTILE 25, PTILE 75] +  
I09_TrkA_NTRK1[MEDIAN, PTILE 25, PTILE 75] + I10_TrkB_NTRK2[MEDIAN, 
PTILE 25, PTILE 75] + I11_Met_HGFR[MEDIAN, PTILE 25, PTILE 75] + 
I12_Ron_MST1R[MEDIAN, PTILE 25, PTILE 75] + I13_Ret[MEDIAN, PTILE 
25, PTILE 75] +  
I14_ALK[MEDIAN, PTILE 25, PTILE 75] + I15_PDGFR[MEDIAN, PTILE 25, 
PTILE 75] + I16_c_Kit_SCFR[MEDIAN, PTILE 25, PTILE 75] + 
I17_FLT3_Flk2[MEDIAN, PTILE 25, PTILE 75] + 
I18_M_CSFR_CSF_1R[MEDIAN, PTILE 25, PTILE 75] +  
I19_EphA1[MEDIAN, PTILE 25, PTILE 75] + I20_EphA2[MEDIAN, PTILE 25, 
PTILE 75] + I21_EphA3[MEDIAN, PTILE 25, PTILE 75] + 
I22_EphB1[MEDIAN, PTILE 25, PTILE 75] + I23_EphB3[MEDIAN, PTILE 25, 
PTILE 75] + I24_EphB4[MEDIAN, PTILE 25, PTILE 75] +  
I25_Tyro3_Dtk[MEDIAN F40.3, PTILE 25 F40.3, PTILE 75 F40.3] + 
I26_Axl[MEDIAN, PTILE 25, PTILE 75] + I27_Tie2_TEK[MEDIAN, PTILE 25, 
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PTILE 75] + I28_VEGFR2_KDR[MEDIAN, PTILE 25, PTILE 75] + 
I29_Akt_PKB_Rac@Thr308[MEDIAN, PTILE 25, PTILE 75] +  
I30_Akt_PKB_Rac@Ser473[MEDIAN, PTILE 25, PTILE 75] + 
I31_p44_42_MAPK[MEDIAN, PTILE 25, PTILE 75] + 
I32_S6_Ribosomal_Protein[MEDIAN, PTILE 25, PTILE 75] + 
I33_c_Abl[MEDIAN, PTILE 25, PTILE 75] +  
I34_IRS_1[MEDIAN, PTILE 25, PTILE 75] + I35_Zap_70[MEDIAN, PTILE 25, 
PTILE 75] + I36_Src[MEDIAN, PTILE 25, PTILE 75] + I37_Lck[MEDIAN, 
PTILE 25, PTILE 75] + I38_Stat1[MEDIAN, PTILE 25, PTILE 75] + 
I39_Stat3 [MEDIAN, PTILE 25, PTILE 75]  
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (I01_EGFR_ErbB1 I02_HER2_ErbB2  
I03_HER3_ErbB3 I04_FGFR1 I05_FGFR3 I06_FGFR4 I07_InsR I08_IGF_IR  
I09_TrkA_NTRK1 I10_TrkB_NTRK2 I11_Met_HGFR I12_Ron_MST1R I13_Ret  
I14_ALK I15_PDGFR I16_c_Kit_SCFR I17_FLT3_Flk2 I18_M_CSFR_CSF_1R  
I19_EphA1 I20_EphA2 I21_EphA3 I22_EphB1 I23_EphB3 I24_EphB4  
I25_Tyro3_Dtk I26_Axl I27_Tie2_TEK I28_VEGFR2_KDR 
I29_Akt_PKB_Rac@Thr308  
I30_Akt_PKB_Rac@Ser473 I31_p44_42_MAPK I32_S6_Ribosomal_Protein 
I33_c_Abl  
I34_IRS_1 I35_Zap_70 I36_Src I37_Lck I38_Stat1 I39_Stat3) GROUP 
(S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterGranulation. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 H02_Eotaxin S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1[MEDIAN, PTILE 25, PTILE 75] + 
I02_HER2_ErbB2[MEDIAN, PTILE 25, PTILE 75] +  
I03_HER3_ErbB3[MEDIAN, PTILE 25, PTILE 75] + I04_FGFR1[MEDIAN, PTILE 
25, PTILE 75] + I05_FGFR3[MEDIAN, PTILE 25, PTILE 75] + 
I06_FGFR4[MEDIAN, PTILE 25, PTILE 75] + I07_InsR[MEDIAN, PTILE 25, 
PTILE 75] + I08_IGF_IR[MEDIAN, PTILE 25, PTILE 75] +  
I09_TrkA_NTRK1[MEDIAN, PTILE 25, PTILE 75] + I10_TrkB_NTRK2[MEDIAN, 
PTILE 25, PTILE 75] + I11_Met_HGFR[MEDIAN, PTILE 25, PTILE 75] + 
I12_Ron_MST1R[MEDIAN, PTILE 25, PTILE 75] + I13_Ret[MEDIAN, PTILE 
25, PTILE 75] +  
I14_ALK[MEDIAN, PTILE 25, PTILE 75] + I15_PDGFR[MEDIAN, PTILE 25, 
PTILE 75] + I16_c_Kit_SCFR[MEDIAN, PTILE 25, PTILE 75] + 
I17_FLT3_Flk2[MEDIAN, PTILE 25, PTILE 75] + 
I18_M_CSFR_CSF_1R[MEDIAN, PTILE 25, PTILE 75] +  
I19_EphA1[MEDIAN, PTILE 25, PTILE 75] + I20_EphA2[MEDIAN, PTILE 25, 
PTILE 75] + I21_EphA3[MEDIAN, PTILE 25, PTILE 75] + 
I22_EphB1[MEDIAN, PTILE 25, PTILE 75] + I23_EphB3[MEDIAN, PTILE 25, 
PTILE 75] + I24_EphB4[MEDIAN, PTILE 25, PTILE 75] +  
I25_Tyro3_Dtk[MEDIAN, PTILE 25, PTILE 75] + I26_Axl[MEDIAN, PTILE 
25, PTILE 75] + I27_Tie2_TEK[MEDIAN, PTILE 25, PTILE 75] + 
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I28_VEGFR2_KDR[MEDIAN, PTILE 25, PTILE 75] + 
I29_Akt_PKB_Rac@Thr308[MEDIAN, PTILE 25, PTILE 75] +  
I30_Akt_PKB_Rac@Ser473[MEDIAN, PTILE 25, PTILE 75] + 
I31_p44_42_MAPK[MEDIAN, PTILE 25, PTILE 75] + 
I32_S6_Ribosomal_Protein[MEDIAN, PTILE 25, PTILE 75] + 
I33_c_Abl[MEDIAN, PTILE 25, PTILE 75] +  
I34_IRS_1[MEDIAN, PTILE 25, PTILE 75] + I35_Zap_70[MEDIAN, PTILE 25, 
PTILE 75] + I36_Src[MEDIAN, PTILE 25, PTILE 75] + I37_Lck[MEDIAN, 
PTILE 25, PTILE 75] + I38_Stat1[MEDIAN, PTILE 25, PTILE 75] + 
I39_Stat3 [MEDIAN, PTILE 25, PTILE 75]  
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (I01_EGFR_ErbB1 I02_HER2_ErbB2  
I03_HER3_ErbB3 I04_FGFR1 I05_FGFR3 I06_FGFR4 I07_InsR I08_IGF_IR  
I09_TrkA_NTRK1 I10_TrkB_NTRK2 I11_Met_HGFR I12_Ron_MST1R I13_Ret  
I14_ALK I15_PDGFR I16_c_Kit_SCFR I17_FLT3_Flk2 I18_M_CSFR_CSF_1R  
I19_EphA1 I20_EphA2 I21_EphA3 I22_EphB1 I23_EphB3 I24_EphB4  
I25_Tyro3_Dtk I26_Axl I27_Tie2_TEK I28_VEGFR2_KDR 
I29_Akt_PKB_Rac@Thr308  
I30_Akt_PKB_Rac@Ser473 I31_p44_42_MAPK I32_S6_Ribosomal_Protein 
I33_c_Abl  
I34_IRS_1 I35_Zap_70 I36_Src I37_Lck I38_Stat1 I39_Stat3) GROUP 
(S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterMucosa. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 H02_Eotaxin S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1[MEDIAN, PTILE 25, PTILE 75] + 
I02_HER2_ErbB2[MEDIAN, PTILE 25, PTILE 75] +  
I03_HER3_ErbB3[MEDIAN, PTILE 25, PTILE 75] + I04_FGFR1[MEDIAN, PTILE 
25, PTILE 75] + I05_FGFR3[MEDIAN, PTILE 25, PTILE 75] + 
I06_FGFR4[MEDIAN, PTILE 25, PTILE 75] + I07_InsR[MEDIAN, PTILE 25, 
PTILE 75] + I08_IGF_IR[MEDIAN, PTILE 25, PTILE 75] +  
I09_TrkA_NTRK1[MEDIAN, PTILE 25, PTILE 75] + I10_TrkB_NTRK2[MEDIAN, 
PTILE 25, PTILE 75] + I11_Met_HGFR[MEDIAN, PTILE 25, PTILE 75] + 
I12_Ron_MST1R[MEDIAN, PTILE 25, PTILE 75] + I13_Ret[MEDIAN, PTILE 
25, PTILE 75] +  
I14_ALK[MEDIAN, PTILE 25, PTILE 75] + I15_PDGFR[MEDIAN, PTILE 25, 
PTILE 75] + I16_c_Kit_SCFR[MEDIAN, PTILE 25, PTILE 75] + 
I17_FLT3_Flk2[MEDIAN, PTILE 25, PTILE 75] + 
I18_M_CSFR_CSF_1R[MEDIAN, PTILE 25, PTILE 75] +  
I19_EphA1[MEDIAN, PTILE 25, PTILE 75] + I20_EphA2[MEDIAN, PTILE 25, 
PTILE 75] + I21_EphA3[MEDIAN, PTILE 25, PTILE 75] + 
I22_EphB1[MEDIAN, PTILE 25, PTILE 75] + I23_EphB3[MEDIAN F40.3, 
PTILE 25, PTILE 75] + I24_EphB4[MEDIAN, PTILE 25, PTILE 75] +  
I25_Tyro3_Dtk[MEDIAN, PTILE 25, PTILE 75] + I26_Axl[MEDIAN, PTILE 
25, PTILE 75] + I27_Tie2_TEK[MEDIAN, PTILE 25, PTILE 75] + 
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I28_VEGFR2_KDR[MEDIAN, PTILE 25, PTILE 75] + 
I29_Akt_PKB_Rac@Thr308[MEDIAN, PTILE 25, PTILE 75] +  
I30_Akt_PKB_Rac@Ser473[MEDIAN, PTILE 25, PTILE 75] + 
I31_p44_42_MAPK[MEDIAN, PTILE 25, PTILE 75] + 
I32_S6_Ribosomal_Protein[MEDIAN, PTILE 25, PTILE 75] + 
I33_c_Abl[MEDIAN, PTILE 25, PTILE 75] +  
I34_IRS_1[MEDIAN, PTILE 25, PTILE 75] + I35_Zap_70[MEDIAN, PTILE 25, 
PTILE 75] + I36_Src[MEDIAN, PTILE 25, PTILE 75] + I37_Lck[MEDIAN, 
PTILE 25, PTILE 75] + I38_Stat1[MEDIAN, PTILE 25, PTILE 75] + 
I39_Stat3 [MEDIAN, PTILE 25, PTILE 75]  
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (I01_EGFR_ErbB1 I02_HER2_ErbB2  
I03_HER3_ErbB3 I04_FGFR1 I05_FGFR3 I06_FGFR4 I07_InsR I08_IGF_IR  
I09_TrkA_NTRK1 I10_TrkB_NTRK2 I11_Met_HGFR I12_Ron_MST1R I13_Ret  
I14_ALK I15_PDGFR I16_c_Kit_SCFR I17_FLT3_Flk2 I18_M_CSFR_CSF_1R  
I19_EphA1 I20_EphA2 I21_EphA3 I22_EphB1 I23_EphB3 I24_EphB4  
I25_Tyro3_Dtk I26_Axl I27_Tie2_TEK I28_VEGFR2_KDR 
I29_Akt_PKB_Rac@Thr308  
I30_Akt_PKB_Rac@Ser473 I31_p44_42_MAPK I32_S6_Ribosomal_Protein 
I33_c_Abl  
I34_IRS_1 I35_Zap_70 I36_Src I37_Lck I38_Stat1 I39_Stat3) GROUP 
(S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterRectum. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 H02_Eotaxin S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1[MEDIAN, PTILE 25, PTILE 75] + 
I02_HER2_ErbB2[MEDIAN, PTILE 25, PTILE 75] +  
I03_HER3_ErbB3[MEDIAN, PTILE 25, PTILE 75] + I04_FGFR1[MEDIAN, PTILE 
25, PTILE 75] + I05_FGFR3[MEDIAN, PTILE 25, PTILE 75] + 
I06_FGFR4[MEDIAN, PTILE 25, PTILE 75] + I07_InsR[MEDIAN, PTILE 25, 
PTILE 75] + I08_IGF_IR[MEDIAN, PTILE 25, PTILE 75] +  
I09_TrkA_NTRK1[MEDIAN, PTILE 25, PTILE 75] + I10_TrkB_NTRK2[MEDIAN, 
PTILE 25, PTILE 75] + I11_Met_HGFR[MEDIAN, PTILE 25, PTILE 75] + 
I12_Ron_MST1R[MEDIAN, PTILE 25, PTILE 75] + I13_Ret[MEDIAN, PTILE 
25, PTILE 75] +  
I14_ALK[MEDIAN, PTILE 25, PTILE 75] + I15_PDGFR[MEDIAN, PTILE 25, 
PTILE 75] + I16_c_Kit_SCFR[MEDIAN, PTILE 25, PTILE 75] + 
I17_FLT3_Flk2[MEDIAN, PTILE 25, PTILE 75] + 
I18_M_CSFR_CSF_1R[MEDIAN, PTILE 25, PTILE 75] +  
I19_EphA1[MEDIAN, PTILE 25, PTILE 75] + I20_EphA2[MEDIAN, PTILE 25, 
PTILE 75] + I21_EphA3[MEDIAN, PTILE 25, PTILE 75] + 
I22_EphB1[MEDIAN, PTILE 25, PTILE 75] + I23_EphB3[MEDIAN, PTILE 25, 
PTILE 75] + I24_EphB4[MEDIAN, PTILE 25, PTILE 75] +  
I25_Tyro3_Dtk[MEDIAN, PTILE 25, PTILE 75] + I26_Axl[MEDIAN, PTILE 
25, PTILE 75] + I27_Tie2_TEK[MEDIAN, PTILE 25, PTILE 75] + 
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I28_VEGFR2_KDR[MEDIAN, PTILE 25, PTILE 75] + 
I29_Akt_PKB_Rac@Thr308[MEDIAN, PTILE 25, PTILE 75] +  
I30_Akt_PKB_Rac@Ser473[MEDIAN, PTILE 25, PTILE 75] + 
I31_p44_42_MAPK[MEDIAN, PTILE 25, PTILE 75] + 
I32_S6_Ribosomal_Protein[MEDIAN, PTILE 25, PTILE 75] + 
I33_c_Abl[MEDIAN, PTILE 25, PTILE 75] +  
I34_IRS_1[MEDIAN, PTILE 25, PTILE 75] + I35_Zap_70[MEDIAN, PTILE 25, 
PTILE 75] + I36_Src[MEDIAN, PTILE 25, PTILE 75] + I37_Lck[MEDIAN, 
PTILE 25, PTILE 75] + I38_Stat1[MEDIAN, PTILE 25, PTILE 75] + 
I39_Stat3 [MEDIAN, PTILE 25, PTILE 75]  
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (I01_EGFR_ErbB1 I02_HER2_ErbB2  
I03_HER3_ErbB3 I04_FGFR1 I05_FGFR3 I06_FGFR4 I07_InsR I08_IGF_IR  
I09_TrkA_NTRK1 I10_TrkB_NTRK2 I11_Met_HGFR I12_Ron_MST1R I13_Ret  
I14_ALK I15_PDGFR I16_c_Kit_SCFR I17_FLT3_Flk2 I18_M_CSFR_CSF_1R  
I19_EphA1 I20_EphA2 I21_EphA3 I22_EphB1 I23_EphB3 I24_EphB4  
I25_Tyro3_Dtk I26_Axl I27_Tie2_TEK I28_VEGFR2_KDR 
I29_Akt_PKB_Rac@Thr308  
I30_Akt_PKB_Rac@Ser473 I31_p44_42_MAPK I32_S6_Ribosomal_Protein 
I33_c_Abl  
I34_IRS_1 I35_Zap_70 I36_Src I37_Lck I38_Stat1 I39_Stat3) GROUP 
(S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by FilterControlsVCrohns. 
SHOW Filter. 
 
* Medians and IQRs.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 H02_Eotaxin S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1[MEDIAN, PTILE 25, PTILE 75] + 
I02_HER2_ErbB2[MEDIAN, PTILE 25, PTILE 75] +  
I03_HER3_ErbB3[MEDIAN, PTILE 25, PTILE 75] + I04_FGFR1[MEDIAN, PTILE 
25, PTILE 75] + I05_FGFR3[MEDIAN, PTILE 25, PTILE 75] + 
I06_FGFR4[MEDIAN, PTILE 25, PTILE 75] + I07_InsR[MEDIAN, PTILE 25, 
PTILE 75] + I08_IGF_IR[MEDIAN, PTILE 25, PTILE 75] +  
I09_TrkA_NTRK1[MEDIAN, PTILE 25, PTILE 75] + I10_TrkB_NTRK2[MEDIAN, 
PTILE 25, PTILE 75] + I11_Met_HGFR[MEDIAN, PTILE 25, PTILE 75] + 
I12_Ron_MST1R[MEDIAN, PTILE 25, PTILE 75] + I13_Ret[MEDIAN, PTILE 
25, PTILE 75] +  
I14_ALK[MEDIAN, PTILE 25, PTILE 75] + I15_PDGFR[MEDIAN, PTILE 25, 
PTILE 75] + I16_c_Kit_SCFR[MEDIAN, PTILE 25, PTILE 75] + 
I17_FLT3_Flk2[MEDIAN, PTILE 25, PTILE 75] + 
I18_M_CSFR_CSF_1R[MEDIAN, PTILE 25, PTILE 75] +  
I19_EphA1[MEDIAN, PTILE 25, PTILE 75] + I20_EphA2[MEDIAN, PTILE 25, 
PTILE 75] + I21_EphA3[MEDIAN, PTILE 25, PTILE 75] + 
I22_EphB1[MEDIAN, PTILE 25, PTILE 75] + I23_EphB3[MEDIAN, PTILE 25, 
PTILE 75] + I24_EphB4[MEDIAN, PTILE 25, PTILE 75] +  
I25_Tyro3_Dtk[MEDIAN, PTILE 25, PTILE 75] + I26_Axl[MEDIAN, PTILE 
25, PTILE 75] + I27_Tie2_TEK[MEDIAN, PTILE 25, PTILE 75] + 
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I28_VEGFR2_KDR[MEDIAN, PTILE 25, PTILE 75] + 
I29_Akt_PKB_Rac@Thr308[MEDIAN, PTILE 25, PTILE 75] +  
I30_Akt_PKB_Rac@Ser473[MEDIAN, PTILE 25, PTILE 75] + 
I31_p44_42_MAPK[MEDIAN, PTILE 25, PTILE 75] + 
I32_S6_Ribosomal_Protein[MEDIAN, PTILE 25, PTILE 75] + 
I33_c_Abl[MEDIAN, PTILE 25, PTILE 75] +  
I34_IRS_1[MEDIAN, PTILE 25, PTILE 75] + I35_Zap_70[MEDIAN, PTILE 25, 
PTILE 75] + I36_Src[MEDIAN, PTILE 25, PTILE 75] + I37_Lck[MEDIAN, 
PTILE 25, PTILE 75] + I38_Stat1[MEDIAN, PTILE 25, PTILE 75] + 
I39_Stat3 [MEDIAN, PTILE 25, PTILE 75]  
BY S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (I01_EGFR_ErbB1 I02_HER2_ErbB2  
I03_HER3_ErbB3 I04_FGFR1 I05_FGFR3 I06_FGFR4 I07_InsR I08_IGF_IR  
I09_TrkA_NTRK1 I10_TrkB_NTRK2 I11_Met_HGFR I12_Ron_MST1R I13_Ret  
I14_ALK I15_PDGFR I16_c_Kit_SCFR I17_FLT3_Flk2 I18_M_CSFR_CSF_1R  
I19_EphA1 I20_EphA2 I21_EphA3 I22_EphB1 I23_EphB3 I24_EphB4  
I25_Tyro3_Dtk I26_Axl I27_Tie2_TEK I28_VEGFR2_KDR 
I29_Akt_PKB_Rac@Thr308  
I30_Akt_PKB_Rac@Ser473 I31_p44_42_MAPK I32_S6_Ribosomal_Protein 
I33_c_Abl  
I34_IRS_1 I35_Zap_70 I36_Src I37_Lck I38_Stat1 I39_Stat3) GROUP 
(S02_TypeBy2) MANN_WHITNEY HODGES_LEHMANN  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE  
  /CRITERIA ALPHA=0.01  CILEVEL=99. 
 
FILTER by Study_ImmunoExHS. 
SHOW filter. 
 
* Medians across all specimens.  
CTABLES  
  /VLABELS VARIABLES=I01_EGFR_ErbB1 Biopsy S02_TypeBy2 DISPLAY=LABEL  
  /TABLE I01_EGFR_ErbB1 [MEDIAN] + I02_HER2_ErbB2 [MEDIAN] +  
I03_HER3_ErbB3 [MEDIAN] + I04_FGFR1 [MEDIAN] + I05_FGFR3 [MEDIAN] + 
I06_FGFR4 [MEDIAN] + I07_InsR [MEDIAN] + I08_IGF_IR [MEDIAN] +  
I09_TrkA_NTRK1 [MEDIAN] + I10_TrkB_NTRK2 [MEDIAN] + I11_Met_HGFR 
[MEDIAN] + I12_Ron_MST1R [MEDIAN] + I13_Ret [MEDIAN] +  
I14_ALK [MEDIAN] + I15_PDGFR [MEDIAN] + I16_c_Kit_SCFR [MEDIAN] + 
I17_FLT3_Flk2 [MEDIAN] + I18_M_CSFR_CSF_1R [MEDIAN] +  
I19_EphA1 [MEDIAN] + I20_EphA2 [MEDIAN] + I21_EphA3 [MEDIAN] + 
I22_EphB1 [MEDIAN] + I23_EphB3 [MEDIAN] + I24_EphB4 [MEDIAN] +  
I25_Tyro3_Dtk [MEDIAN] + I26_Axl [MEDIAN] + I27_Tie2_TEK [MEDIAN] + 
I28_VEGFR2_KDR [MEDIAN] + I29_Akt_PKB_Rac@Thr308 [MEDIAN] +  
I30_Akt_PKB_Rac@Ser473 [MEDIAN] + I31_p44_42_MAPK [MEDIAN] + 
I32_S6_Ribosomal_Protein [MEDIAN] + I33_c_Abl [MEDIAN] +  
I34_IRS_1 [MEDIAN] + I35_Zap_70 [MEDIAN] + I36_Src [MEDIAN] + 
I37_Lck [MEDIAN] + I38_Stat1 [MEDIAN] + I39_Stat3 [MEDIAN] 
BY Biopsy > S02_TypeBy2  
  /CATEGORIES VARIABLES=Biopsy [1,2,3,4] EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 [0, 2, 10] EMPTY=INCLUDE. 
 
* Controls. 




  /GRAPHDATASET NAME="graphdataset" VARIABLES=Biopsy I00_ControlNeg 
MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE. 
 BEGIN GPL 
   SOURCE: s=userSource(id("graphdataset")) 
   DATA: Biopsy=col(source(s), name("Biopsy"), 
 notIn("5", "6"), unit.category()) 
   DATA: I00_ControlNeg=col(source(s), name("I00_ControlNeg")) 
   DATA: id=col(source(s), name("$CASENUM"), unit.category()) 
   GUIDE: axis(dim(2), label("Pixel intensity %")) 
   GUIDE: text.title(label("Negative control spots")) 
   SCALE: cat(dim(1), include("1", "2", "3", "4")) 
   SCALE: linear(dim(2), include(0)) 
   ELEMENT: 
schema(position(bin.quantile.letter(Biopsy*I00_ControlNeg)), 
label(id)) 
 END GPL. 
 
* Positive controls.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=Biopsy I99_ControlPos 
MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE. 
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: Biopsy=col(source(s), name("Biopsy"),  
notIn("5", "6"), unit.category())  
  DATA: I99_ControlPos=col(source(s), name("I99_ControlPos"))  
  DATA: id=col(source(s), name("$CASENUM"), unit.category())  
  GUIDE: axis(dim(2), label("Pixel intensity %"))  
  GUIDE: text.title(label("Positive control spots"))  
  SCALE: cat(dim(1), include("1", "2", "3", "4"))  
  SCALE: linear(dim(2), include(0))  





* Negative Control Samples.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=MEDIAN(I01_EGFR_ErbB1) 
MEDIAN(I02_HER2_ErbB2)  
MEDIAN(I03_HER3_ErbB3) MEDIAN(I04_FGFR1) MEDIAN(I05_FGFR3) 
MEDIAN(I06_FGFR4) MEDIAN(I07_InsR) MEDIAN(I08_IGF_IR)  
MEDIAN(I09_TrkA_NTRK1) MEDIAN(I10_TrkB_NTRK2) MEDIAN(I11_Met_HGFR) 
MEDIAN(I12_Ron_MST1R) MEDIAN(I13_Ret)  
MEDIAN(I14_ALK) MEDIAN(I15_PDGFR) MEDIAN(I16_c_Kit_SCFR) 
MEDIAN(I17_FLT3_Flk2) MEDIAN(I18_M_CSFR_CSF_1R)  
MEDIAN(I19_EphA1) MEDIAN(I20_EphA2) MEDIAN(I21_EphA3) 
MEDIAN(I22_EphB1) MEDIAN(I23_EphB3) MEDIAN(I24_EphB4)  
MEDIAN(I25_Tyro3_Dtk) MEDIAN(I26_Axl) MEDIAN(I27_Tie2_TEK) 
MEDIAN(I28_VEGFR2_KDR) MEDIAN(I29_Akt_PKB_Rac@Thr308)  
MEDIAN(I30_Akt_PKB_Rac@Ser473) MEDIAN(I31_p44_42_MAPK) 
MEDIAN(I32_S6_Ribosomal_Protein) MEDIAN(I33_c_Abl)  




    Biopsy MISSING=LISTWISE REPORTMISSING=NO  
    TRANSFORM=VARSTOCASES(SUMMARY="#SUMMARY" INDEX="#INDEX")  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: SUMMARY=col(source(s), name("#SUMMARY"))  
  DATA: INDEX=col(source(s), name("#INDEX"), unit.category())  
  DATA: Biopsy=col(source(s), name("Biopsy"),  
notIn("1", "2", "3", "4"), unit.category())  
  COORD: rect(dim(1,2), cluster(3,0))  
  GUIDE: axis(dim(2), label("Median pixel intensity, %"))  
  GUIDE: legend(aesthetic(aesthetic.color.interior), label(""))  
  GUIDE: text.title(label("Negative control samples"))  
  SCALE: cat(dim(3), include("0", "1"))  
  SCALE: linear(dim(2), include(0))  
  SCALE: cat(aesthetic(aesthetic.color.interior), include("5", "6"))  
  SCALE: cat(dim(1), include("5", "6"))  
  ELEMENT: interval(position(Biopsy*SUMMARY*INDEX), 




Dynamic Contrast-Enhanced MRI 
* OPEN DATA. 
CD '/Users/james/Dropbox/Fistula Studies/Analysis/2015-10 Clinical'. 
 
* FILTER CASES. 
FILTER by Study_DCEMRI_All.  
SHOW filter. 
 
* ANALYSE DATA. 
* Table to show patient characteristics. 
CTABLES 
  /VLABELS VARIABLES=B03_Gender B02_Age B04_EthnicOrigin 
B13_FistulaDuration B08_PrevRxMed S03_PrevRxSurgGE2  
    S06_PrevRxCure S09_CurrentSeton B16_Smoking  BasePDAIC08_PDAI 
S02_TypeBy2  
    DISPLAY=LABEL 
  /TABLE B03_Gender [C][COUNT F40.0, COLPCT.TOTALN PCT40.0] + 
B02_Age [S][MEAN, STDDEV] + B04_EthnicOrigin [COUNT F40.0, 
COLPCT.TOTALN PCT40.0] + 
    B13_FistulaDuration [S][MEDIAN, PTILE 25, PTILE 75] + 
B08_PrevRxMed [C][COUNT F40.0, COLPCT.TOTALN  
    PCT40.0] + B10_PrevRxSurgNo [MEDIAN, PTILE 25, PTILE 75] + 
S06_PrevRxCure [C][COUNT  
    F40.0, COLPCT.TOTALN PCT40.0] + S09_CurrentSeton [C][COUNT 
F40.0, COLPCT.TOTALN PCT40.0] +  
    B16_Smoking [C][COUNT F40.0, COLPCT.TOTALN PCT40.0] + 
BasePDAIC08_PDAI [S][MEAN, STDDEV F40.1] BY S02_TypeBy2 [C] 
  /SLABELS POSITION=ROW 
  /CATEGORIES VARIABLES=B03_Gender [1, 10, OTHERNM] EMPTY=INCLUDE 
TOTAL=YES POSITION=BEFORE 
  /CATEGORIES VARIABLES=B04_EthnicOrigin [10, HSUBTOTAL='White', 18, 
19, 20, 21, HSUBTOTAL='Asian', 16, 17, 15, HSUBTOTAL='Black', 11, 
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12, 13, 14, 22, 23, 24, HSUBTOTAL='Other', OTHERNM, MISSING] 
EMPTY=INCLUDE POSITION=AFTER 
  /CATEGORIES VARIABLES=B08_PrevRxMed [1, 10, 11, 12, 13, 14, 
OTHERNM] EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S06_PrevRxCure [1, 10, OTHERNM] 
EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S09_CurrentSeton [1, 10, OTHERNM] 
EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=B16_Smoking [1, 10, 11, OTHERNM] 
EMPTY=INCLUDE 
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES POSITION=AFTER. 
 
* Follow-up.  
CTABLES  
  /VLABELS VARIABLES=G21_WeeksFollowUp S02_TypeBy2 DISPLAY=LABEL  
  /TABLE G21_WeeksFollowUp [MEDIAN, PTILE 25, PTILE 75] BY 
S02_TypeBy2  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=INCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Conventional MRI.  
CTABLES  




BaseMRIE10_FistulaHyperintensityT2 BaseMRIE42_StJames S02_TypeBy2  
    DISPLAY=LABEL  
  /TABLE BaseMRIE03_FistulaNo [C] + BaseMRIE04_FistulaParks [C] + 
BaseMRIE05_FistulaLevel [C] + BaseMRIE06_SecondaryTracts [C] + 
BaseMRIE07_FistulaHorseshoe [C] +  
BaseMRIE08_Collections [C] + BaseMRIE09_RectalInvolvement [C] + 
BaseMRIE10_FistulaHyperintensityT2 [C] + BaseMRIE42_StJames [C] BY 
S02_TypeBy2 [C][COUNT F40.0, COLPCT.COUNT PCT40.0]  




BaseMRIE10_FistulaHyperintensityT2 BaseMRIE42_StJames ORDER=A 
KEY=VALUE EMPTY=INCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* Conventional MRI.  
CTABLES  
  /VLABELS VARIABLES=BaseMRIE17_MRIScoreTotal S02_TypeBy2 
DISPLAY=LABEL  
  /TABLE BaseMRIE17_MRIScoreTotal [MEAN F40.1, STDDEV F40.1] BY 
S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
* DCE-MRI Parametric.  
CTABLES  
  /VLABELS VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn 
E24_WashOut E26_AUC S02_TypeBy2 DISPLAY=LABEL  
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  /TABLE E19_MaxEnhance [MEAN, STDDEV] + E20_MaxRelEnhance [MEAN, 
STDDEV] + E23_WashIn [MEAN, STDDEV] + E24_WashOut [MEAN, STDDEV] + 
E26_AUC [MEAN, STDDEV] BY S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
T-TEST GROUPS=S02_TypeBy2(2 10)  
  /MISSING=ANALYSIS  
  /VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn E24_WashOut 
E26_AUC  
  /CRITERIA=CI(.95). 
 
T-TEST GROUPS= ChronicFistula(0 1) 
  /MISSING=ANALYSIS  
  /VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn E24_WashOut 
E26_AUC  
  /CRITERIA=CI(.95). 
 
T-TEST GROUPS=S16_RxSatisfactory(10 1) 
  /MISSING=ANALYSIS  
  /VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn E24_WashOut 
E26_AUC  
  /CRITERIA=CI(.95). 
 
T-TEST GROUPS=StJamesHigh(0 1) 
  /MISSING=ANALYSIS  
  /VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn E24_WashOut 
E26_AUC  
  /CRITERIA=CI(.95). 
 
FILTER by Study_DCEMRI_All_Acute.  
SHOW filter. 
 
T-TEST GROUPS=S02_TypeBy2(2 10)  
  /MISSING=ANALYSIS  
  /VARIABLES=E19_MaxEnhance E20_MaxRelEnhance E23_WashIn E24_WashOut 
E26_AUC  
  /CRITERIA=CI(.95). 
 
FILTER by Study_DCEMRI_All.  
SHOW filter. 
 
* Mean ME by Parks.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=StJamesHigh 
MEANCI(E19_MaxEnhance, 95)[name="MEAN_E19_MaxEnhance" 
LOW="MEAN_E19_MaxEnhance_LOW" HIGH="MEAN_E19_MaxEnhance_HIGH"] 
MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: StJamesHigh=col(source(s), name("StJamesHigh"), 
unit.category())  
  DATA: MEAN_E19_MaxEnhance=col(source(s), 
name("MEAN_E19_MaxEnhance"))  
  DATA: LOW=col(source(s), name("MEAN_E19_MaxEnhance_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_E19_MaxEnhance_HIGH"))  
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  GUIDE: axis(dim(1), label("St James' Grade 3-5"))  
  GUIDE: axis(dim(2), label("Mean max enhancement"))  
  SCALE: cat(dim(1), include("0", "1"))  
  SCALE: linear(dim(2), include(0))  
  ELEMENT: point(position(StJamesHigh*MEAN_E19_MaxEnhance))  





* Mean MRE by Parks.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=StJamesHigh 
MEANCI(E20_MaxRelEnhance, 95)[name="MEAN_E20_MaxRelEnhance" 
LOW="MEAN_E20_MaxRelEnhance_LOW" HIGH="MEAN_E20_MaxRelEnhance_HIGH"] 
MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: StJamesHigh=col(source(s), name("StJamesHigh"), 
unit.category())  
  DATA: MEAN_E20_MaxRelEnhance=col(source(s), 
name("MEAN_E20_MaxRelEnhance"))  
  DATA: LOW=col(source(s), name("MEAN_E20_MaxRelEnhance_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_E20_MaxRelEnhance_HIGH"))  
  GUIDE: axis(dim(2), label("Mean max relative enhancement"))  
  SCALE: cat(dim(1), include("0", "1"))  
  SCALE: linear(dim(2), include(0))  
  ELEMENT: point(position(StJamesHigh*MEAN_E20_MaxRelEnhance))  





* Mean AUC by Parks.  
GGRAPH  
  /GRAPHDATASET NAME="graphdataset" VARIABLES=StJamesHigh 
MEANCI(E26_AUC, 95)[name="MEAN_E26_AUC" LOW="MEAN_E26_AUC_LOW" 
HIGH="MEAN_E26_AUC_HIGH"] MISSING=LISTWISE REPORTMISSING=NO  
  /GRAPHSPEC SOURCE=INLINE.  
BEGIN GPL  
  SOURCE: s=userSource(id("graphdataset"))  
  DATA: StJamesHigh=col(source(s), name("StJamesHigh"), 
unit.category())  
  DATA: MEAN_E26_AUC=col(source(s), name("MEAN_E26_AUC"))  
  DATA: LOW=col(source(s), name("MEAN_E26_AUC_LOW"))  
  DATA: HIGH=col(source(s), name("MEAN_E26_AUC_HIGH"))  
  GUIDE: axis(dim(2), label("Mean area under TIC"))  
  SCALE: cat(dim(1), include("0", "1"))  
  SCALE: linear(dim(2), include(0))  
  ELEMENT: point(position(StJamesHigh*MEAN_E26_AUC))  









  /VLABELS VARIABLES=E40_TICType S02_TypeBy2 DISPLAY=LABEL  
  /TABLE E40_TICType [C][COUNT F40.0, COLPCT.COUNT PCT40.0] BY 
S02_TypeBy2 [C]  
  /CATEGORIES VARIABLES=E40_TICType ORDER=A KEY=VALUE EMPTY=EXCLUDE  
  /CATEGORIES VARIABLES=S02_TypeBy2 ORDER=A KEY=VALUE EMPTY=EXCLUDE 
TOTAL=YES LABEL='All' POSITION=AFTER. 
 
CROSSTABS  
  /TABLES=E40_TICType BY S02_TypeBy2  
  /FORMAT=AVALUE TABLES  
  /STATISTICS=CHISQ  
  /CELLS=COUNT  
  /COUNT ROUND CELL  
  /METHOD=EXACT TIMER(5). 
 
CROSSTABS  
  /TABLES=ChronicFistula S16_RxSatisfactory StJamesHigh BY 
E41_TICType2  
  /FORMAT=AVALUE TABLES  
  /STATISTICS=CHISQ  
  /CELLS=COUNT  
  /COUNT ROUND CELL  




APPENDIX 5 LABORATORY PROTOCOL 
Collection of Specimens 
1. Collect biopsy specimens after patient is positioned, prepped and draped and before the surgery 
begins. 
2. Use a sterile curette to obtain the granulation tissue. 
3. Use scissors or endoscopic biopsy forceps to acquire the remaining specimens.  
4. Wash with sterile saline in-between samplings.  
5. The specimens required are: 
F: Fistula tract 
G: Granulation tissue from within the fistula tract 
M: Mucosa adjacent to internal opening 
R: Rectal mucosa 
6. Store each specimen in a separate plain sterile pot filled with 10 ml saline. Keep on ice if not going 
to lab immediately. 
7. Label with participant ID and specimen letter. 
8. Complete the specimen form. 
9. Transport in specimen bag to the lab. 
 
Preparation of Specimens 
10. If specimens cannot be processed immediately, then decant off saline and cover each with 10 ml 
PBS and store on ice overnight. 
11. Examine specimens in a sterile petri dish under the microscope and trim off extraneous tissue (e.g. 
fat, blood clot) using instruments sterilised in alcohol and aseptic technique. 
12. Where possible, divide specimens into equal 2-3 mm3 samples. 
 
Snap Freezing of Fresh Samples 
13. Work at room temperature in tissue culture lab.  
14. Place samples in cryotube. 
15. Snap freeze on dry ice for 5 min. 
16. Transfer to -80°C freezer. 
17. Complete the specimen log. 
 
Tissue Culture 
18. Work under the extractor hood at room temperature. 
19. Place samples into a 24-well culture plate and label. 
20. Cover each sample with 300 µl culture medium (500ml Lonza HL-1, 10 ml / 5000 units penicillin 
and streptokinase, 1.6 ml Gentamicin 10 mg/ml, 5 ml L-Glutamine) using a filtered pipette. 




Tissue Culture: Snap Freezing Samples 
22. Work under the extractor hood at room temperature. 
23. Remove samples from incubator. 
24. Pipette supernatant into mini Eppendorf tubes. (If necessary, first pipette supernatant and tissue 
component into a cryotube, centrifuge at 12,000 rpm for 5 min.) 
25. Place tissue components into cryotubes. 
26. Snap freeze the samples on dry ice for 5 min. 
27. Transfer to -80°C freezer. 
28. Complete the specimen log. 
 
Phosphoarray: Preparing Cell Lysates 
29. Work on ice in open laboratory. Keep reagents on ice. 
30. Collect 8 (or 16) samples, label and record. 
31. Prepare lysis buffer as follows (NB double volumes for 16 samples): 
Pipette 1000 µl of RIPA Buffer (Sigma R0278-50ML) into an Eppendorf tube. Add an extra 
100 µl for each sample that is large.  
Add 10 µl of Phosphatase Inhibitor Cocktail 2 (Sigma P5726-1ML). 
Add 10 µl of Protease Inhibitor in DMSO (Sigma P8340-1ML; thaw at hand temperature, or 
room temperature for 10 minutes and then vortex; refreeze entire vial at -20°C after use). 
Vortex. 
32. Add 100 µl of lysis buffer to each sample. 
33. Use ultrasonic cell disruptor to lyse cells: 
Administer 2-3 watts for a few seconds. Don’t touch the bottom of the tube, this will cause a 
hole. 
Allow to cool on ice. 
Repeat at least once. 
34. Pre-chill centrifuge to 4°C. 
35. Incubate on ice for 10 mins, vortexing every 1 minute. 
36. Centrifuge at 13,300 rpm for 5 min at 4°C. 
37. Pipette off each sample lysate supernatant into Eppendorf tubes, labelled 1-8. 
38. Use immediately or store in -80°C freezer. 
39. Discard cell pellet. 
 
Phosphoarray: Bradford Assay 
40. Work on ice in open laboratory. Keep reagents on ice. 
41. Prepare standard samples by serial dilution as follows: 
Label mini Eppendorf tubes A-H. 
Add 40 µl distilled water to each tube. 
Add 40 µl Bovine Gamma Globulin (2 mg/ml) (Bio-Rad #500-0209) into tube A. Vortex. 
Then take 40 µl from tube A and add to tube B. Vortex. 
Repeat serially to G. Leave H untouched. 
Tubes A-G now have concentrations of Bovine Gamma Globulin from 1 mg/ml to 0.016 mg/ml. 
42. Prepare 1 in 100 solutions of each sample lysate as follows: 
Label mini Eppendorf tubes 1-8. 
Add 99 µl distilled water to each tube. 
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Add 1 µl of each sample lysate to each tube.  
Vortex. 
43. Add 10 µl of each sample in duplicate to a 96-well plate as follows: 
 
 Standard Standard PA01 PA01 PA02 PA02     Dilutions Dilutions 
 1 2 3 4 5 6 7 8 9 10 11 12 
A A A Sample Sample Sample Sample       
B B B Sample Sample Sample Sample       
C C C Sample Sample Sample Sample       
D D D Sample Sample Sample Sample       
E E E Sample Sample Sample Sample       
F F F Sample Sample Sample Sample       
G G G Sample Sample Sample Sample       
H H H Sample Sample Sample Sample       
 
44. Pipette 50 µl of (1X) QuickStart Bradford Dye Reagent (Bio-Rad #500-0205) into each occupied 
well using a multipipetter. 
45. If any wells of lysate samples appear outside the standard range then prepare a stronger or weaker 
concentration (i.e. 1 in 50 or 1 in 200) and pipette into adjacent wells. 
46. Use ELx800 plate reader and Gen5 2.00.18 software (BioTek Instruments Ltd., Winooski VT) to 
record the optical densities at 595 nm. 
47. Samples in the 96-well plate can be discarded and plate cleaned with distilled water. 
48. Store lysates in -80°C freezer. 
49. Use Excel 2010 (Microsoft, Redmond WA) spreadsheet to calculate what volume lysate is needed 
to achieve 150 µg of protein for each sample as follows: 
Calculate the mean optical density for each duplicate sample. 
Calculate the slope and intercept for a linear best fit line through the standard sample plot 
(excluding points at the extremes where linearity is poor). 
Calculate the protein concentrations for each lysate sample using the standard samples as a 
reference and slope and intercept equation. 
Calculate the volume of sample lysate needed to achieve 150 µg of protein for each sample. 
Calculate the volume of Array Diluent Buffer needed to achieve a final volume of 200 µl. 
 
Phosphoarray: Assay Procedure Part 1 
50. Work at room temperature in open laboratory. Keep reagents on ice. 
51. Thaw lysates at room temperature then keep on ice. 
52. Use PathScan® RTK Signalling Antibody Array Kit (Chemiluminescent Readout) (Cell Signalling 
Technology #7982). 1 slide for 8 samples or 2 slides for 16 samples. 
53. Bring glass slides and blocking buffer to room temperature before use. 
54. Assemble cassette. Marker needs to be in top right corner when assembled cassette is placed flat 
on bench. 
55. Add 150 µl Array Blocking Buffer to each well using multipipetter. 
56. Cover with sealing tape and incubate on rocker for 15 min at room temperature. 
57. Prepare diluted sample lysates as follows: 
Meanwhile, label Eppendorf tubes 1-8. 
Add calculated volume of Array Diluent Buffer to each tube (as per Bradford Assay 
calculations). 
Add calculated volume of each sample lysate to each tube (as per Bradford Assay calculations). 
Vortex. 
58. Decant the cassette wells by gently flicking out the liquid into a sink. 
59. Add 150 µl of each diluted sample lysate to each corresponding well and cover with sealing tape. 
60. Incubate overnight on rocker at 4°C. 
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61. Return unused lysate to -80°C freezer. 
 
Phosphoarray: Assay Procedure Part 2 
62. Work at room temperature in open laboratory. Keep reagents on ice (NB double for 2 slides). 
63. Prepare (1X) Array Wash Buffer as follows (NB double for 2 slides): 
Add 30ml of distilled water to a Falcon Tube. 
Add 1.5ml of (20X) Array Wash Buffer. 
Vortex. 
64. Take cassette off the rocker and decant the wells. 
65. Add 200 µl (1X) Array Wash Buffer to each well using multipipetter. 
66. Cover and incubate on rocker for 5 min at room temperature. 
67. Repeat steps 64 to 66 a further 3 times.  
68. Prepare (1X) Detection Antibody Cocktail as follows (NB double for 2 slides): 
Add 1215 µl of Array Diluent Buffer to an Eppendorf tube. 
Add 135 µl of (10X) Detection Antibody Cocktail. 
Vortex. 
69. Take cassette off the rocker and decant the wells. 
70. Add 150 µl of (1X) Detection Antibody Cocktail to each well.  
71. Cover and incubate on rocker for 1 hour at room temperature. 
72. Take cassette off the rocker and decant the wells. 
73. Add 200 µl of (1X) Array Wash Buffer to each well.  
74. Cover and incubate on rocker for 5 min at room temperature. 
75. Repeat steps 72 to 73 a further 3 times. 
76. Prepare (1X) HRP-linked Streptavidin as follows (NB double for 2 slides): 
Add 1215 µl Array Diluent Buffer to an Eppendorf tube. 
Add 135 µl (10X) HRP-linked Streptavidin. 
Vortex. 
77. Take cassette off the rocker and decant the wells. 
78. Add 150 µl of (1X) HRP-linked Streptavidin to each well.  
79. Cover and incubate on rocker for 30 min at room temperature. 
80. Take cassette off the rocker and decant the wells. 
81. Add 200 µl of (1X) Array Wash Buffer to each well using multipipetter. 
82. Cover and incubate on rocker for 5 min at room temperature. 
83. Repeat steps 80 to 82 a further 3 times. 
84. Take cassette off the rocker and decant the wells. 
85. Dismantle cassette by pulling the bottom of the metal clips away from the centre of the slide, then 
peeling the slide and gasket apart. 
86. Place the slide face up in a plastic dish (e.g. pipette tip box cover). When using two slides keep left 
and right positions consistent to prevent confusion. 
87. Wash briefly with 10ml (1X) Array Wash Buffer. 
88. Prepare (1X) LumiGLO/Peroxide reagent immediately before use as follows: 
Add 9 ml of distilled water to an Eppendorf tube. 
Add 500 µl of (20X) LumiGLO. 
Add 500 µl of (20X) Peroxide. 
Vortex. 
89. Decant Array Wash Buffer and cover slide with (1X) LumiGLO/Peroxide reagent. 
90. Transfer slide to sheet protector and sandwich inside it, ensuring that it is still covered by (1X) 
LumiGLO/Peroxide reagent (add a small amount on top of the slide). When folding the top sheet 
over, take care not to trap air bubbles. 




Phosphoarray: Chemiluminescent Film Image Capture 
92. Work in a dark room at room temperature. 
93. Lay film on top of the slide(s) for varying exposures between 20-50 seconds.  
94. Develop the film using the automated film developer. 
95. Label the film with the date, experiment number, array numbers, and exposure time 
 
Phosphoarray: Lightbox and Digital Camera Image Digitisation 
96. Use a lightbox and digital camera rig set up as below. 
 
 
Height setting on camera rig: 51.5 cm (this allows autofocus at the nearest distance to the film) 
 
97. Illuminate with the fluorescent backlight only. 
98. Use a Nikon D70 digital camera with the following settings: 
Dimensions 3040 x 2014 
Bit depth 48 
Flash No 
Exposure time 1/10 s 
Aperture Various from f22 to f16 
Max. aperture 4.44 
Focal length 70.00 mm 
Focal length (EQ35mm) 105 mm 
ISO 200 
Digital zoom ratio 1.00 
Exposure bias -1/3 
Metering mode Spot 
Exposure mode Manual exposure 
White balance Manual 





Gain control None 
Scene capture type Standard 
Light source Cool white fluorescent (W 3800–4500K) 
Software Ver.1.02  
DPI 300.00 
Sensing method One-chip colour area sensor 
Custom image processing Normal process 
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Lens 18.00 - 70.00 mm f/3.5 - 4.5 
Image Quality RAW 
99. Centre the image take multiple images at different exposures. Keep the speed at 1/10s and adjust 
the aperture from f22 to f12. Retain the image where the histogram is as far to the right as 




100. Download the photos into Zoner Photo Studio v17 (Zoner Inc., Kennesaw GA). 
101. Check that the blowout indicator does not encroach onto the slide. In the example below, blue 
highlights areas of blowout, a warning symbol on the histogram indicates image blowout, and 














Phosphoarray: Image and Data Analysis 
103. Use ImageQuant TL 2005 (GE Healthcare Life Sciences, Pittsburg PA) for each array as 
follows: 
Open the image and check orientation. 
Draw grid over array spots (adjust spot shape and size to fit the array). 
Label each cell according to target map and key (see above). 
Select a rectangle on the edge of the slide as the background. 
Select all the positive controls and normalise their mean value to 100% (exclude any spots that 
look like they haven’t produced a strong full signal) 
Export data table as CSV file. 
104. Duplicate the arx file and open to use the previous settings and labels. 
105. Import the CSV file into the database for analysis. 
 
Cytokine Multiplex: MAGPIX Cleaning, Calibration and Verification 
106. If there have been recent problems with the system, clean the probe tip as follows: 
Turn off MAGPIX machine (Luminex Corporation, Austin, TX) and open maintenance hatch.  
Unscrew and remove probe tip.  
Flush through with distilled water using syringe.  
Submerge in distilled water in Falcon tube and immerse in sonicator for 10 minutes.  
Flush through the probe again with distilled water. 
Replace probe tip back into machine. 
Tighten screw connector until it clicks. 
Turn MAGPIX back on. 
107. Clean the reagent wells as follows: 
Eject the tray and remove the reagent wells. 
Clean out any residue with distilled water, soak if necessary, then dry. 
108. Check drive fluid (left-hand chamber) as follows: 
Check level. 
Check the vent in the cap is not crusted over. 
109. Check the waste chamber (right-hand chamber, orange connector) as follows: 
Empty if full, taking care not to wet the sensor filter. 
Swap for spare chamber if sensor wet. 
110. Calibrate the probe height as folllows: 
Ensure reagent wells are clean and dry. 
Install a clean and dry 8-well strip. 
Put 2 calibration discs in a centre well of the 96-well plate that will be used. 
Use the xPONENT software (Luminex Corporation, Austin, TX) to select the test well and run 
the calibration program. 
111. If there have been recent problems with the system: 
Disconnect and remove the drive fluid chamber 
Add 25 ml of 1M NaOH solution to a bottle. 
Add 225 ml of distilled water. 
Mix then pour into a clean chamber and connect to the drive fluid port. 
Use a custom maintenance program to prime the system 4 times. 
112. Clean the system as follows: 
Select the Enhanced Start-up Routine program. 
Add the relevant reagents to the reagent wells (half-filled) as indicated by the program. 
Run. 
113. If there have been recent problems with the system: 
Repeat the Enhanced Start-up Routine. 
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Watch the probe whilst it is at the Clean step. It will pause for a few minutes, and then will drop 
down. At this point turn the power off. 
Leave the system to soak like this for 1 hour, or overnight if experiencing continuing problems. 
Turn the MAGPIX back on and allow it to reset. 
Replace and reconnect the drive fluid chamber with drive fluid in it. 
Use a custom maintenance program to prime the system 4 times. 
114. Flush the system as follows: 
Select the Daily Fluidics Prep program. 
Check the relevant reagents are in the correct reagent wells as indicated by the program. 
Run the program 4 times. 
115. Calibrate and verify the system as follows: 
Use the MAGPIX Calibration Kit (Luminex Corporation, Austin, TX, #MPX-PVER-K25) and 
MAGPIX Performance Verification Kit (Luminex Corporation, Austin, TX, #MPX-CAL-K25) 
kits. 
Vortex the beads well. 
Check the calibration and verification lot numbers on the box correspond with what is specified 
in the program. If not available, load the correct lxl file from the kit’s included CD, using the Lot 
Management screen. 
Add 6 drops of the beads to the correct test wells as indicated by the program (vortex again just 
before using each vial). 
116. Shutdown the system. 
 
Cytokine Multiplex: Protocol and Batch Setup 





Curve: Fit all standards 
118. Enter settings for the beads (only required once) as follows: 
Select the correct beads according to their region for the 30 targets. 
Add the target name to the label. 
Units: pg/ml (for majority at least) 
Bead count: 50 
Fit: Logistic 5P 
119. Enter standard and control details (required for each different kit batch number) 
120. Create a new batch from the protocol. 
121. Select the sample wells, in singlet, and label. 
 
Cytokine Multiplex: Plate Setup and Incubation 
122. Remove the 30-plex Milliplex MAP Kit (EMD Millipore, Billerica, MA, #HCYTMAG-60K-
PX30) from the fridge 1 hour before use to allow to warm to room temperature. Work at room 
temperature on the open bench. 
123. Retrieve the samples from the freezer and thaw at room temperature. 
124. Centrifuge the samples at 7,000 rpm for 5 min. 
125. Prepare 1X Wash Buffer as follows: 
Pour 30ml 10X Wash Buffer into a bottle. 
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Add 270 ml distilled water. 
Mix.** 
126. Reconstitute the Standard and Controls 1 and 2 as follows: 
Tap the vials on the table to encourage powder to settle. 
Open rubber stopper from glass vial slowly and half-way only. 
Add in 250 µl of distilled water. 
Leave to sit for 10 minutes. 
Vortex.†† 
127. Prepare the Standards as follows: 
Label 6 Eppendorf tubes 2,000, 400, 80, 16, 3.2 and 0 pg/ml. 
Add 200 µl of Assay Buffer to each tube. 
Add 50 µl of the 10,000 pg/ml reconstituted standard to the 2,000 pg/ml tube. 
Vortex. 
Repeat the 1 in 5 serial dilution with the remaining tubes in descending order of concentration 
until 3.2 pg/ml (i.e. do not add to the 0 pg/ml background). 
128. Prepare the Antibody-Immobilized Beads as follows: 
Sonicate the Bead Bottle and the RANTES bottle for 30 seconds. 
Vortex for 1 minute. 
Add 70 µl of RANTES to the Bead Bottle. 
Vortex. 
129. Wash the plate as follows: 
Add 200 µl of 1X Wash Buffer to each well of the plate using a multipipette. 
Place on plate shaker for 10 minutes at 500 rpm. 
Decant by tapping out smartly onto paper towels. 
130. Lay out the plate as follows: 
 
 1 2 3 4 5 6 7 8 9 10 11 12 




Control Sample Sample Sample Sample Sample Sample Sample Sample Sample 




Control Sample Sample Sample Sample Sample Sample Sample Sample Sample 
C 3.2 Standard 
2,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
D 3.2 Standard 
2,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
E 16 Standard 
10,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
F 16 Standard 
10,000 
Standard Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
G 80 Standard 
QC-1 
Control Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
H 80 Standard 
QC-1 
Control Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
 
Add 25 µl of Standards or Controls to the corresponding standard/control wells. 
Add 25 µl of Culture Medium (as in step 20) to each standard/control wells. 
Add 25 µl of Assay Buffer to the sample wells using a multipipette. 
Add 25 µl of each Sample to the sample wells. 
Vortex the Beads. 
Add 25 µl of Beads to all the wells using a multipipette (reverse pipette in the reagent tray each 
                                               
 
** After use store 1X Wash Buffer at 2-8°C for 1 month. 
†† After use store Standard and Controls at -20°C for 1 month (discard the diluted standards). 
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time to keep the beads in suspension). 
Cover plate with sealing tape and foil. 
131. Incubate the plate on a plate shaker at 500 rpm overnight (16-18h) at 4°C. 
 
Cytokine Multiplex: MAGPIX System Initialization 
132. Reset the probe height as in step 110. 
133. Select the system initialization program, add the correct reagents to the reagent wells and run. 
 
Cytokine Multiplex: Antibody Detection and Plate Reading 
134. Allow plate to warm to room temperature on the plate shaker at 500 rpm for 30 minutes. 
135. Decant wells as follows: 
Place plate on hand-held magnet 
Leave for 1 minute to allow beads to settle (rest foil cover over to protect from light). 
KEEP MAGNET AND PLATE TOGETHER. 
Decant the wells into sink with a swift motion. 
Return to bench and separate plate and magnet. 
136. Wash as follows: 
Add 200 µl Wash Buffer to each well using a multipipette. 
Place on plate shaker at 500 rpm for 1 minute (rest foil cover on top). 
137. Decant wells with hand-held magnet as before. 
138. Repeat wash and decant steps 136 to 137. 
139. Add 25 µl Detection Antibodies to each well using a multipipette. 
140. Cover plate with sealing tape and foil. 
141. Incubate at room temperature on a plate shaker at 500 rpm for 1 hour. 
142. DO NOT DECANT. 
143. Add 25 µl Streptavidin-Phycoerythrin to each well using a multipipette. 
144. Cover plate with sealing tape and foil. 
145. Incubate at room temperature on a plate shaker at 500 rpm for 30 minutes. 
146. Decant wells with hand-held magnet as before. 
147. Wash as follows: 
Add 200 µl Wash Buffer to each well using a multipipette. 
Place on plate shaker at 500 rpm for 1 minute (rest foil cover on top). 
148. Decant wells with hand-held magnet as before. 
149. Repeat wash and decant steps 147 to 148. 
150. Add 100 µl Drive Fluid to each well using a multipipette.‡‡ 
151. Incubate at room temperature on a plate shaker at 500 rpm for 10 minutes. 
 
                                               
 
‡‡ If required, the plate can be stored at 4°C (preferably on a plate shaker at 500 rpm) for up to 48 
hours. Storage for up to 1 week can still yield results but variability is likely to be higher. 
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Cytokine Multiplex: Plate Reading 
152. Place the plate onto the tray. 
153. Add the appropriate reagents for the Post-Batch Routine. 
154. Select the correct pending batch and run. 
 
Cytokine Multiplex: Results Analysis 
155. Open the batch. 
156. With each of the 30 analytes, review the % recovery of the standards. If it is <70% or >130%, 
review the plot to judge if it is skewing the curve. If it is, invalidate the point and re-analyse to 
see if the curve fit is better and the % recovery values are closer to 100%. Then review the % 
recovery of the controls to see if they are within the 70-130% range. If not, then the curve fit is 
poor. 
157. Then review the test results. If concentrations appear outside the standard curve 3.2-10,000 
pg/ml, the absolute values need to be treated with caution. Also to be borne in mind are the 
minimum detectable concentrations for each analyte (listed in the protocol book). Analytes that 
are giving low values would require a more sensitive assay for more accurate quantification. 




APPENDIX 6 MILLIPLEX MAP HUMAN CYTOKINE/CHEMOKINE 
MAGNETIC BEAD PANEL ASSAY SENSITIVITIES 
Table 37 Assay sensitivities for Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel. Min 
DC, minimum detectable concentration; SD, standard deviation; CV, coefficient of variation. 
Cytokine  Min DC, pg/ml  Min DC + 2SD, pg/ml Intra-assay CV, %  Inter-assay CV, % 
EGF  2.8 4.6 2.3 5.8 
Eotaxin  4.0 6.8 7.2 10.8 
G-CSF  1.8 3.3 1.8 15.5 
GM-CSF  7.5 15 3.1 10.1 
IFN-α2  2.9 4.8 2.4 13.3 
IFN-γ  0.8 1.1 1.6 12 
IL-10  1.1 1.6 1.6 16.8 
IL-12P40  7.4 12.7 2.8 12.4 
IL-12P70  0.6 1 2.2 16.7 
IL-13  1.3 1.9 2.2 9.2 
IL-15  1.2 1.7 2.7 8.1 
IL-17  0.7 1.2 2.2 7.9 
IL-1RA  8.3 17.1 2.1 10.7 
IL-1α  9.4 12.6 3.3 12.8 
IL-1β  0.8 1 2.3 6.7 
IL-2  1.0 1.6 2.1 6.3 
IL-3  0.7 1 3.4 6.1 
IL-4  4.5 7.1 2.9 14.2 
IL-5  0.5 0.7 2.6 10.8 
IL-6  0.9 1.3 2.0 18.3 
IL-7  1.4 2.4 1.7 16.1 
IL-8  0.4 0.7 1.9 3.5 
IP-10  8.6 14 2.6 15.3 
MCP-1  1.9 3.4 1.5 7.9 
MIP-1α  2.9 6.2 1.9 14.5 
MIP-1β  3.0 4.8 2.4 8.8 
TNF-α  0.7 1.1 2.6 13 
TNF-β  1.5 1.9 1.6 11.4 
RANTES  1.2 1.9 1.9 5 









Percent Classification Efficency (%) Counts (Microsphere Events)






















































Percent Total Misclassification (%) Linearity
Reference
All Regions




Tolerance (≥) Actual StatusReference
All Regions
Tolerance (≤) Actual Status

















 107.4  111.2  0.0
 679.5  101.2  23.5
 3,813.1  476.8  45,665.1
 692.6  985.9  4,529.4
 469.9 135.3  4,722.5
 4,558.1 4,070.8  0.0






















 113.0  117.0  5.5 112.0  116.0
 719.0  110.0  29.4 708.0  104.0  32.0
 7.0
 4,035.0  524.0  51,599.0 3,988.5  499.0  51,958.0
 729.0  1,027.0  5,118.0 726.0  1,019.0  5,218.0
 165.0  4,971.0  531.0 171.0  4,981.0  533.0


















Percent Coefficent of Variation (%)
Tolerance (≤) StatusRegion
CL1 %CV CL2 %CV RP1 %CV







 11.20  9.50 3.88  4.22
 9.50  11.30 3.47  4.80
 9.30  7.20  17.20 2.85  3.46  4.13
 10.00  7.30  17.20 3.74  3.73  5.03
 11.30  6.10  17.20 4.71  3.09  4.58


















Final Result Code: OK












Reference Tolerance % (≤) Actual Status










Fluid 1 Lot Number
Fluid 1 Lot Expiration
Pass








Fluid 2 Lot Number




Kit Lot Number B39085
Final Result Code: OK




Percent Classification Efficency (%) Counts (Microsphere Events)






















































Percent Total Misclassification (%) Linearity
Reference
All Regions




Tolerance (≥) Actual StatusReference
All Regions
Tolerance (≤) Actual Status

















 106.4  108.3  0.0
 646.4  97.5  22.6
 3,777.2  492.3  45,997.0
 655.5  921.6  4,739.2
 489.4 127.9  4,747.2
 4,561.0 3,770.6  0.0






















 112.0  114.0  4.6 110.0  113.0
 684.0  106.0  28.3 676.0  103.0  30.0
 6.0
 3,997.0  541.0  51,974.0 3,980.5  529.0  53,115.5
 690.0  960.0  5,355.0 687.0  958.5  5,426.0
 156.0  4,997.0  553.0 161.0  5,026.0  558.0


















Percent Coefficent of Variation (%)
Tolerance (≤) StatusRegion
CL1 %CV CL2 %CV RP1 %CV







 11.20  9.50 3.49  3.90
 9.50  11.30 3.19  3.90
 9.30  7.20  17.20 2.90  3.32  5.12
 10.00  7.30  17.20 2.74  2.82  4.20
 11.30  6.10  17.20 4.41  2.96  4.49


















Final Result Code: OK












Reference Tolerance % (≤) Actual Status










Fluid 1 Lot Number
Fluid 1 Lot Expiration
Pass








Fluid 2 Lot Number




Kit Lot Number B42348
Final Result Code: OK




Percent Classification Efficency (%) Counts (Microsphere Events)






















































Percent Total Misclassification (%) Linearity
Reference
All Regions




Tolerance (≥) Actual StatusReference
All Regions
Tolerance (≤) Actual Status

















 106.4  108.3  0.0
 646.4  97.5  22.6
 3,777.2  492.3  45,997.0
 655.5  921.6  4,739.2
 489.4 127.9  4,747.2
 4,561.0 3,770.6  0.0






















 112.0  114.0  4.6 111.0  114.0
 684.0  106.0  28.3 674.0  103.0  29.0
 5.0
 3,997.0  541.0  51,974.0 3,994.0  530.0  52,665.0
 690.0  960.0  5,355.0 684.0  959.0  5,390.0
 156.0  4,997.0  553.0 163.0  5,038.0  559.0


















Percent Coefficent of Variation (%)
Tolerance (≤) StatusRegion
CL1 %CV CL2 %CV RP1 %CV







 11.20  9.50 3.35  3.32
 9.50  11.30 3.17  4.09
 9.30  7.20  17.20 2.84  3.52  4.71
 10.00  7.30  17.20 3.49  3.49  5.48
 11.30  6.10  17.20 4.08  2.78  4.38


















Final Result Code: OK
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Fluid 1 Lot Number











Fluid 2 Lot Number




Kit Lot Number B42348
Final Result Code: OK
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Percent Total Misclassification (%) Linearity
Reference
All Regions




Tolerance (≥) Actual StatusReference
All Regions
Tolerance (≤) Actual Status

















 106.4  108.3  0.0
 646.4  97.5  22.6
 3,777.2  492.3  45,997.0
 655.5  921.6  4,739.2
 489.4 127.9  4,747.2
 4,561.0 3,770.6  0.0






















 112.0  114.0  4.6 110.0  113.0
 684.0  106.0  28.3 677.0  103.0  29.0
 5.0
 3,997.0  541.0  51,974.0 3,976.5  530.0  52,596.0
 690.0  960.0  5,355.0 687.0  960.0  5,395.5
 156.0  4,997.0  553.0 161.0  5,021.0  557.0


















Percent Coefficent of Variation (%)
Tolerance (≤) StatusRegion
CL1 %CV CL2 %CV RP1 %CV







 11.20  9.50 3.54  3.17
 9.50  11.30 3.14  4.30
 9.30  7.20  17.20 2.90  3.36  5.08
 10.00  7.30  17.20 2.82  2.80  4.31
 11.30  6.10  17.20 3.97  2.74  4.18


















Final Result Code: OK
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Fluid 1 Lot Number











Fluid 2 Lot Number




Kit Lot Number B42348
Final Result Code: OK
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Percent Total Misclassification (%) Linearity
Reference
All Regions




Tolerance (≥) Actual StatusReference
All Regions
Tolerance (≤) Actual Status

















 106.4  108.3  0.0
 646.4  97.5  22.6
 3,777.2  492.3  45,997.0
 655.5  921.6  4,739.2
 489.4 127.9  4,747.2
 4,561.0 3,770.6  0.0






















 112.0  114.0  4.6 110.0  113.0
 684.0  106.0  28.3 675.0  103.0  30.0
 6.0
 3,997.0  541.0  51,974.0 3,983.5  531.0  52,643.0
 690.0  960.0  5,355.0 682.0  956.0  5,393.0
 156.0  4,997.0  553.0 160.0  5,024.5  561.5


















Percent Coefficent of Variation (%)
Tolerance (≤) StatusRegion
CL1 %CV CL2 %CV RP1 %CV







 11.20  9.50 3.99  4.17
 9.50  11.30 3.36  4.48
 9.30  7.20  17.20 2.91  3.46  5.12
 10.00  7.30  17.20 2.98  2.90  4.54
 11.30  6.10  17.20 4.29  2.86  4.40


















Final Result Code: OK











Reference Tolerance % (≤) Actual Status










Fluid 1 Lot Number
Fluid 1 Lot Expiration
Pass








Fluid 2 Lot Number




Kit Lot Number B42348
Final Result Code: OK
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APPENDIX 8 SUPPLEMENTARY TABLES 
Perineal Disease Activity Index 
Table 38 PDAI by treatment outcome at baseline (t0), follow-up 1 (t1) and follow-up 2 (t2). Range for each 
domain 0 to 4. Range for PDAI 0 to 24. Mean (standard deviation) shown. 
 Treatment 
outcome 
Idiopathic Crohn’s Disease All 
t0 t1 t2 t0 t1 t2 t0 t1 t2 
Discharge 


























































































































































































































Table 39 EQ-5D-5L dimensions by treatment outcome at baseline (t0), follow-up 1 (t1) and follow-up 2 (t2). 







Idiopathic Crohn’s Disease All 
t0 t1 t2 t0 t1 t2 t0 t1 t2 
Mobility 
Unsatisfactory 
1 50% 53% 43% 100% 33% 50% 58% 50% 44% 
2 38% 7% 14% 0% 33% 50% 32% 11% 19% 
3 13% 33% 29% 0% 33% 0% 11% 33% 25% 
4 0% 7% 14% 0% 0% 0% 0% 6% 13% 
5 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Satisfactory 
1 76% 77% 78% 45% 45% 56% 68% 68% 72% 
2 10% 4% 9% 27% 9% 11% 15% 5% 9% 
3 0% 4% 9% 27% 36% 22% 8% 14% 13% 
4 10% 12% 4% 0% 9% 11% 8% 11% 6% 
5 3% 4% 0% 0% 0% 0% 3% 3% 0% 
Self-care 
Unsatisfactory 
1 94% 73% 86% 67% 67% 100% 89% 72% 88% 
2 6% 20% 0% 33% 0% 0% 11% 17% 0% 
3 0% 7% 7% 0% 33% 0% 0% 11% 6% 
4 0% 0% 7% 0% 0% 0% 0% 0% 6% 
5 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Satisfactory 
1 86% 85% 91% 100% 73% 67% 90% 81% 84% 
2 3% 8% 4% 0% 27% 22% 3% 14% 9% 
3 10% 8% 0% 0% 0% 11% 8% 5% 3% 
4 0% 0% 4% 0% 0% 0% 0% 0% 3% 




1 56% 40% 43% 67% 100% 50% 58% 50% 44% 
2 31% 13% 7% 0% 0% 50% 26% 11% 13% 
3 0% 27% 29% 33% 0% 0% 5% 22% 25% 
4 6% 7% 21% 0% 0% 0% 5% 6% 19% 
5 6% 13% 0% 0% 0% 0% 5% 11% 0% 
Satisfactory 
1 79% 81% 91% 36% 36% 44% 68% 68% 78% 
2 7% 0% 0% 18% 9% 0% 10% 3% 0% 
3 0% 4% 4% 36% 36% 22% 10% 14% 9% 
4 7% 15% 0% 0% 18% 22% 5% 16% 6% 




1 25% 27% 29% 67% 0% 50% 32% 22% 31% 
2 38% 27% 7% 0% 67% 0% 32% 33% 6% 
3 31% 27% 14% 33% 33% 0% 32% 28% 13% 
4 6% 20% 43% 0% 0% 50% 5% 17% 44% 
5 0% 0% 7% 0% 0% 0% 0% 0% 6% 
Satisfactory 
1 38% 65% 30% 18% 18% 33% 33% 51% 31% 
2 34% 12% 30% 45% 55% 11% 38% 24% 25% 
3 24% 12% 22% 18% 27% 44% 23% 16% 28% 
4 0% 12% 17% 18% 0% 11% 5% 8% 16% 









Idiopathic Crohn’s Disease All 




1 63% 60% 43% 67% 33% 50% 63% 56% 44% 
2 25% 7% 14% 33% 67% 0% 26% 17% 13% 
3 6% 20% 7% 0% 0% 50% 5% 17% 13% 
4 6% 13% 29% 0% 0% 0% 5% 11% 25% 
5 0% 0% 7% 0% 0% 0% 0% 0% 6% 
Satisfactory 
1 62% 77% 87% 45% 45% 44% 58% 68% 75% 
2 28% 8% 9% 36% 9% 0% 30% 8% 6% 
3 3% 12% 4% 9% 27% 56% 5% 16% 19% 
4 3% 4% 0% 9% 9% 0% 5% 5% 0% 
5 3% 0% 0% 0% 9% 0% 3% 3% 0% 
 
Table 40 EQ VAS and index by treatment outcome at baseline (t0), follow-up 1 (t1) and follow-up 2 (t2). 
Mane (standard deviation) shown.  
 Treatment 
Outcome 
Idiopathic Crohn’s disease All 

























































































Table 41 Fistula tract median cytokine concentrations. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested using 
Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median concentration (IQR), pg/ml  
Median difference  
(99% CI), pg/ml p Idiopathic Crohn’s disease All 
EGF 14.7 (7.2–27.9) 17.4 (7.4–32.2) 15.1 (7.2–30.7) 0.2 (-19.9–21.6) 0.880 
Eotaxin 13.2 (4.9–18.8) 10.7 (7.4–19.3) 12.4 (4.9–19.3) 0.0 (-10.5–8.0) 0.907 
G-CSF 950.6 (56.9–6727.4) 4693.6 (34.1–22402.3) 967.5 (38.7–22402.3) 0.0 (-1406.9–21451.8) 0.647 
GM-CSF 14 (6.2–93.5) 30 (5.6–219) 14.6 (5.6–129.4) 9.1 (-21.0–212.7) 0.423 
IFN-α2 19.7 (8.9–28.2) 16.8 (6.2–30.3) 19.1 (8.3–29.8) 0.0 (-15.7–21.4) 0.991 
IFN-γ 4 (1.6–7.3) 5.7 (1.1–10.9) 4.1 (1.4–8) 1.1 (-3.1–8.4) 0.430 
IL-10 24.7 (6.9–156.9) 29.2 (10.2–141.7) 25.3 (6.9–156.9) 0.4 (-87.9–129.9) 0.908 
IL-12p40 12.4 (4.9–17.2) 8.8 (5.2–27.7) 11.9 (4.9–17.5) 1.0 (-9.2–15.7) 0.843 
IL-12p70 3.7 (1.6–5.4) 2.5 (1.2–11.5) 3.7 (1.4–5.9) 0.7 (-2.9–8.6) 0.676 
IL-13 3.9 (1.6–5.2) 5.2 (0.5–7.3) 4 (0.9–5.6) 0.5 (-3.2–5.1) 0.531 
IL-15 3.7 (2.3–5.5) 4.3 (1.2–5.7) 3.7 (2–5.6) 0.0 (-2.9–3.4) 0.954 
IL-17A 4.1 (2–6.3) 4.3 (1–12.7) 4.2 (1.8–7.2) 1.4 (-3.4–11.1) 0.486 
IL-1RA 31.8 (10.9–299.4) 244.5 (40.5–275) 45.1 (11.2–299.4) 36.3 (-160.1–260.1) 0.223 
IL-1α 10.5 (3.1–35.9) 24 (7.5–30.5) 11.3 (3.1–34) 2.8 (-22.4–26.5) 0.618 
IL-1β 4.4 (1.3–30.7) 4.3 (1–56.2) 4.3 (1.1–39.2) 0.1 (-17.6–55.2) 0.871 
IL-2 1.9 (1.2–2.7) 2.3 (1–3.4) 1.9 (1.1–2.8) 0.3 (-1.2–2.1) 0.493 
IL-3 1.1 (0–1.7) 0.3 (0–1.7) 1.1 (0–1.7) 0.0 (-1.3–0.6) 0.765 
IL-4 9.9 (5.1–12.8) 9.1 (5.8–17.9) 9.6 (5.1–14.1) 0.9 (-6.3–10.4) 0.772 
IL-5 1.1 (0.7–2) 2 (0.8–2.6) 1.2 (0.7–2.2) 0.2 (-1.0–1.7) 0.633 
IL-6 324.6 (83.4–1976.6) 576.5 (29.3–2302.7) 370 (80.8–1989.7) 27.4 (-746.6–2298.1) 0.816 
IL-7 11 (5.4–14.7) 9.5 (7.2–14) 11 (5.5–14.4) 0.2 (-6.8–8.7) 0.880 
IL-8 8063.7 (2622.3–10888.1) 7996.7 (297.2–12641.4) 8030.2 (1907–10965) -8.0 (-7038.2–7703.9) 0.991 
IP-10 16 (6.7–28.4) 22.8 (17.2–80.2) 17.1 (6.9–29.7) 9.9 (-8.5–78.5) 0.117 
MCP-1 540.7 (221.4–959.5) 709.8 (234.7–1052.2) 609.9 (221.4–979) 136.4 (-551.9–1033.2) 0.570 
MIP-1α 16.3 (2.7–86.6) 15.6 (6.2–173.5) 15.9 (2.7–100.8) 4.3 (-22.0–168.4) 0.450 
MIP-1β 9.9 (5.4–30.5) 14.9 (11.1–52.1) 11 (5.4–32.7) 7.8 (-8.6–49.4) 0.186 
RANTES 324.4 (112.1–1048.7) 529.6 (85.9–884.3) 345.9 (96.8–1048.7) 28.9 (-629.8–668.2) 0.790 
TNF-α 8.4 (3.2–21.1) 9.7 (4.1–29.8) 8.7 (3.2–25) 2.3 (-9.6–25.9) 0.423 
TNF-β 1.8 (0.9–2.4) 2.5 (0.7–4.5) 1.8 (0.9–2.7) 0.6 (-1.2–2.7) 0.358 
VEGF 82.2 (38.3–119.7) 107.1 (48.2–161.5) 82.2 (38.3–133.1) 16.8 (-63.4–102.2) 0.593 
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Table 42 Granulation tissue median cytokine concentrations. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested 
using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median concentration (IQR), pg/ml  
Median difference  
(99% CI), pg/ml p Idiopathic Crohn’s disease All 
EGF 34.8 (17.5–66.9) 28.7 (14.6–37.8) 29.5 (17.5–66.9) -6.3 (-51.7–20.3) 0.499 
Eotaxin 14.6 (6–20.3) 11 (7.8–19.3) 14.1 (6–20.3) -1.7 (-11.8–7.4) 0.661 
G-CSF 22402.3 (4777.9–22402.3) 22402.3 (22402.3–22402.3) 22402.3 (5081.8–22402.3) 0.0 (0.0–17624.4) 0.589 
GM-CSF 69.3 (27.3–194.4) 128.5 (23.8–202.6) 80.6 (23.8–202.6) 7.2 (-150.4–158.0) 0.893 
IFN-α2 28.2 (22–35.4) 22.1 (17.8–26.7) 25.8 (19.9–35.4) -5.6 (-17.6–5.8) 0.142 
IFN-γ 12.3 (6.1–18.4) 28.9 (17.1–171.9) 15.2 (7.1–27.3) 17.1 (-1.7–249.5) 0.021 
IL-10 321.5 (139.6–599.9) 155.2 (52.3–512.7) 313.6 (138.7–599.9) -87.3 (-502.6–448.7) 0.343 
IL-12p40 24 (20–34.1) 21.7 (17.9–27.9) 24 (19.2–31.2) -3.4 (-16.4–5.0) 0.248 
IL-12p70 5.7 (4.4–9.6) 8.1 (5–8.5) 5.7 (4.7–9.6) 1.0 (-2.9–4.9) 0.457 
IL-13 6 (4.9–7.6) 6 (4.7–7.3) 6 (4.7–7.4) -0.4 (-3.8–1.8) 0.661 
IL-15 8.8 (6.3–11.6) 7.9 (6.9–11.1) 8.8 (6.9–11.6) -0.8 (-4.6–3.4) 0.686 
IL-17A 13.3 (8–28.8) 18.4 (11.8–47.1) 15.1 (9.7–30.2) 4.2 (-12.1–34.1) 0.543 
IL-1RA 741 (220.9–2233) 541.7 (429.1–597.8) 548.5 (246.7–1512.1) -82.5 (-2372.1–387.9) 0.919 
IL-1α 140.5 (46–549.6) 51 (30.4–141.1) 123.5 (35.6–488.2) -64.5 (-543.7–63.8) 0.221 
IL-1β 302.2 (73.2–977.2) 263.3 (62.9–748.7) 295.1 (70.5–955.5) -52.1 (-872.3–460.7) 0.478 
IL-2 2.8 (2–3.5) 2.5 (2–2.7) 2.7 (2–3.4) -0.4 (-1.5–0.6) 0.208 
IL-3 0 (0–1.2) 0.9 (0–1.2) 0.04 (0–1.2) 0.0 (-0.4–1.1) 0.636 
IL-4 12.1 (10.1–15.9) 11.1 (9.1–13.4) 12 (9.8–15.9) -1.4 (-6.0–3.1) 0.343 
IL-5 2.5 (1.6–2.9) 2.3 (1.3–4.3) 2.3 (1.5–3) -0.1 (-1.5–10.2) 0.813 
IL-6 646.4 (325–1473.2) 1010.2 (523.4–4302.8) 708.7 (325–1954.8) 455.8 (-642.7–4122.4) 0.343 
IL-7 13.4 (11.1–15.5) 10.3 (8.2–13.8) 13.1 (9.5–15.5) -2.3 (-6.9–2.8) 0.234 
IL-8 8281.7 (6444.4–9474.4) 7863.6 (4323.6–9001.2) 8206.2 (6247.9–9474.4) -884.7 (-4689.6–2359.2) 0.436 
IP-10 30.3 (19.8–36.9) 116 (40.5–163.4) 32 (19.9–48.4) 73.7 (-4.7–140.7) 0.026 
MCP-1 744.1 (380–1485.4) 678.6 (349.8–954.1) 711.4 (356.2–1353.3) -137.5 (-851.7–472.1) 0.499 
MIP-1α 61.6 (36–134.2) 43.8 (25.5–60.7) 59.6 (33–123.2) -23.5 (-112.7–16.8) 0.115 
MIP-1β 34.6 (27.8–48.4) 32.5 (24–52.6) 33.5 (24–48.6) -3.8 (-24.7–18.0) 0.840 
RANTES 801.4 (431.1–1590.1) 814.5 (213.2–887.6) 808 (400.5–1358.4) -214.0 (-1624.1–420.1) 0.293 
TNF-α 28.3 (13.3–50.4) 16.5 (10.4–36.3) 26.4 (12.5–39.6) -7.0 (-42.0–11.7) 0.457 
TNF-β 3.2 (2.1–3.8) 2.8 (2.4–3.9) 3.1 (2.3–3.8) 0.0 (-1.5–1.3) 0.973 




Table 43 Internal opening median cytokine concentrations. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested using 
Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median concentration (IQR), pg/ml  
Median difference  
(99% CI), pg/ml p Idiopathic Crohn’s disease All 
EGF 20.5 (15.5–29.1) 28.2 (19.5–35.6) 21 (16.7–30.6) 7.3 (-4.3–17.4) 0.086 
Eotaxin 18 (13.5–22.3) 21.1 (19.9–29.1) 19.4 (14.6–23.2) 5.3 (-1.1–12.1) 0.043 
G-CSF 7214.2 (702.2–22402.3) 22402.3 (3738.8–22402.3) 15547 (1011.9–22402.3) 0.0 (-140.1–20526.7) 0.215 
GM-CSF 34.5 (19.5–123.6) 203.6 (50.6–861.7) 39.8 (23.2–220.3) 47.1 (-17.8–820.8) 0.046 
IFN-α2 37.4 (23.5–54.7) 41.1 (34.5–67) 39.5 (25.9–56.2) 9.5 (-14.1–34.2) 0.190 
IFN-γ 7.4 (4–10.9) 12.6 (8.6–26.5) 8.2 (4.3–13) 6.1 (-0.7–17.5) 0.022 
IL-10 55.6 (21.6–176.3) 67.7 (62.9–191.1) 63.8 (28.1–183.7) 15.0 (-91.3–85.2) 0.531 
IL-12p40 19.2 (9.5–31.2) 29.1 (22.5–43.7) 22.2 (10.6–32.8) 13.0 (-1.9–34.2) 0.026 
IL-12p70 7.4 (4.6–12.7) 28.3 (7.4–50.1) 8 (5–15.3) 19.7 (0.2–40.4) 0.008 
IL-13 8 (3.9–10.5) 7.5 (7.4–9.8) 7.8 (4.5–10.3) 1.0 (-2.9–4.9) 0.601 
IL-15 5 (2.9–6.7) 7.8 (5.5–10.9) 5.6 (3.3–7) 3.1 (-0.1–5.9) 0.015 
IL-17A 4.1 (2.4–7.4) 7.4 (5.1–10.7) 4.9 (2.8–7.9) 3.0 (-0.9–7.6) 0.037 
IL-1RA 516.1 (89.4–883) 128.3 (63.5–423.8) 433.4 (78.2–860.5) -167.2 (-698.0–185.6) 0.246 
IL-1α 24.3 (7.3–46.5) 17.4 (10.1–40) 23.1 (7.5–46.4) -0.8 (-31.7–27.2) 0.926 
IL-1β 20.2 (8.3–88.5) 58.3 (10.7–180.9) 25.1 (8.7–96) 21.6 (-17.0–163.2) 0.171 
IL-2 3.7 (2.1–4.9) 5.7 (4.4–9.2) 3.9 (2.4–5.3) 2.7 (-0.2–6.5) 0.013 
IL-3 1.2 (0–1.7) 1.1 (0–3) 1.2 (0–1.7) 0.2 (-1.1–2.0) 0.527 
IL-4 17.3 (12–25.8) 22.7 (19.1–27.7) 19.2 (12.3–26.3) 4.0 (-5.4–12.8) 0.241 
IL-5 2.1 (1.3–3.7) 3.2 (1.7–3.9) 2.5 (1.4–3.9) 0.5 (-1.3–2.2) 0.390 
IL-6 6362.3 (520.6–9061.3) 6181.2 (2616.5–8509.3) 6181.2 (585.9–9014.4) 270.0 (-3759.2–5723.9) 0.642 
IL-7 18.5 (14–21.8) 21 (18.2–28) 18.9 (14.1–24) 3.5 (-3.5–10.8) 0.186 
IL-8 10811.1 (7768.9–13415.3) 11902.6 (10892.9–13208.8) 11149.9 (8415.8–13403.7) 1441.2 (-2499.2–5565.9) 0.318 
IP-10 26.6 (17–71.2) 33.4 (26.5–104.2) 27.6 (18.5–71.4) 7.9 (-33.7–34.0) 0.236 
MCP-1 1296.8 (566–4265.5) 3390.3 (1300.9–6525.9) 1553.8 (599.4–4721.7) 1064.6 (-935.6–3978.4) 0.137 
MIP-1α 66.6 (18.7–177.2) 93.9 (28.7–302.4) 66.6 (21.6–184.8) 13.1 (-88.6–160.8) 0.501 
MIP-1β 23.4 (10–52.7) 36.8 (16.9–123) 23.4 (11.7–58.8) 9.5 (-22.2–90.9) 0.296 
RANTES 169.3 (96.3–648) 233.8 (221.9–281.4) 222.7 (97.2–593.3) 50.0 (-426.2–184.3) 0.593 
TNF-α 30.9 (20.7–46.1) 25 (15.1–57.3) 29.3 (19.5–46.8) -2.0 (-21.6–30.3) 0.763 
TNF-β 3.2 (1.8–4) 5.2 (3.6–5.7) 3.2 (1.9–4.3) 1.9 (-0.2–3.4) 0.022 




Table 44 Rectal mucosa median cytokine concentrations. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested using 
Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median concentration (IQR), pg/ml  
Median difference  
(99% CI), pg/ml p Idiopathic Crohn’s disease All 
EGF 22.7 (19.7–32.5) 20.8 (13–27.4) 22.6 (18.4–29.7) -4.5 (-15.8–5.6) 0.204 
Eotaxin 17.2 (13.7–25.4) 14.2 (10.5–19.3) 17 (13.4–24.3) -4.2 (-14.4–4.3) 0.156 
G-CSF 3139.5 (931.2–4321.6) 1605.1 (640.7–4377.7) 2941.2 (850.5–4327.8) -184.6 (-2876.9–1611.1) 0.757 
GM-CSF 31.2 (15.7–66.6) 30.2 (19.2–86.4) 30.8 (16.9–74.8) 6.7 (-35.6–80.4) 0.601 
IFN-α2 49.7 (27.5–66) 39 (34.5–67.7) 45.6 (28.1–66.8) -5.4 (-31.5–20.6) 0.601 
IFN-γ 8.4 (6–14.4) 9 (5.3–28.8) 8.8 (6–15.9) 1.6 (-5.7–20.4) 0.651 
IL-10 13.5 (7.8–30.5) 7.2 (5.4–12.3) 12.6 (6.5–27.1) -5.7 (-23.4–4.0) 0.117 
IL-12p40 37.2 (26.6–51.3) 28.7 (20.2–48) 36.9 (25.4–51.3) -8.2 (-28.2–14.9) 0.315 
IL-12p70 18.1 (12–24.4) 15.9 (13–20.8) 17.4 (12–24.4) -1.5 (-12.4–9.8) 0.725 
IL-13 6.9 (3.9–8.6) 4 (3.8–4.4) 5.5 (3.9–8.5) -1.6 (-5.4–1.0) 0.111 
IL-15 6.8 (5.2–9.2) 7.6 (5–9.7) 7 (5.1–9.5) -0.1 (-3.8–3.6) 0.924 
IL-17A 5.5 (3.9–8) 4 (2.8–6.4) 5.3 (3.5–7.7) -1.0 (-4.1–2.7) 0.282 
IL-1RA 72 (50.2–140.4) 84.9 (38.5–115.2) 75.5 (49–136.4) -2.8 (-84.8–60.6) 0.943 
IL-1α 11.4 (6.6–27.5) 13.7 (12.4–35.6) 12.4 (6.7–27.5) 3.5 (-8.6–23.2) 0.327 
IL-1β 20.6 (9.6–51.5) 15.5 (9.7–35.7) 20.5 (9.6–44.2) -3.5 (-35.2–19.2) 0.601 
IL-2 8.4 (5.6–10.9) 5.8 (5.4–7) 7.5 (5.5–10.7) -1.7 (-5.5–2.7) 0.250 
IL-3 0 (0–1.5) 0 (0–1.5) 0.04 (0–1.5) 0.0 (-1.3–0.1) 0.924 
IL-4 18.9 (12.5–24) 14.9 (13.4–20.7) 18.7 (12.6–23.4) -3.6 (-13.9–4.7) 0.293 
IL-5 2.7 (2–4.2) 1.9 (1.7–2.4) 2.6 (1.7–3.9) -0.9 (-2.5–0.2) 0.026 
IL-6 638.3 (176.5–2351.3) 427 (161.7–1314.6) 627.8 (172.5–2089.7) -137.4 (-1469.0–1143.6) 0.536 
IL-7 19.9 (14.8–27.4) 17.8 (14–21.5) 19.2 (14.8–26.2) -3.3 (-12.2–4.6) 0.293 
IL-8 6002.3 (3675.4–8800.5) 4415.4 (1344–8885.9) 5967.9 (3135.8–8843.2) -1194.0 (-5482.3–3315.9) 0.431 
IP-10 30.5 (17.3–42.4) 29 (19.1–106.3) 30.2 (18.2–46.2) 5.2 (-16.5–90.2) 0.601 
MCP-1 1089.2 (556.9–1696.6) 741.4 (535.4–1250) 1017.3 (546.1–1693.4) -241.7 (-1069.0–468.5) 0.377 
MIP-1α 43 (17.5–142.3) 31.4 (3.6–40.3) 37.5 (16.2–118.2) -19.6 (-104.0–22.1) 0.171 
MIP-1β 26.9 (14.9–48.7) 17.9 (14.5–31.9) 26.7 (14.7–47.8) -2.8 (-24.0–16.0) 0.617 
RANTES 94.9 (61.5–130.7) 84.9 (45.3–101) 91 (61.1–127.3) -22.5 (-88.3–28.4) 0.231 
TNF-α 18.6 (12.3–28.4) 12.6 (11–16.5) 17.7 (11.6–27.8) -4.7 (-16.8–5.7) 0.250 
TNF-β 3.8 (2.6–5.9) 3.4 (2.5–4.4) 3.8 (2.6–5.5) -0.4 (-2.5–1.4) 0.489 




Table 45 IL-1RA/IL-1 ratio. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested using Mann-Whitney U (significance 
level 0.01). IQR, interquartile range; CI, confidence interval. 
 
Median IL-1RA/IL-1 ratio (IQR) 
Median difference  
(99% CI), pg/ml p Healthy Controls Idiopathic Crohn’s disease All 
Fistula Tract  7.6 (2.7–16.3) 9.4 (4.9–25.8) 7.8 (2.7–16.8) 2.8 (-8.8–24.7) 0.437 
Granulation Tissue  2.3 (1–4.8) 2.6 (0.7–7.2) 2.5 (1–6.1) 0.3 (-3.3–6.7) 0.787 
Internal Opening  19.0 (4.3–51.2) 3.3 (1.8–7.6) 12.9 (3.3–38.6) -15.0 (-50.5–-0.4) 0.008 
Rectal Mucosa  3.6 (1.5–6.5) 3.7 (2.2–7) 3.6 (1.7–6.7) 0.1 (-3.6–3.5) 0.831 




Table 46 Comparison with healthy controls. Rectal mucosa median cytokine concentrations. Median difference and 99% confidence intervals estimated using Hodges-Lehman 
method; hypotheses tested using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
Median concentration (IQR), pg/ml 
Median difference  
(99% CI), pg/ml p Healthy Controls Crohn’s disease 
EGF 20.7 (18.9–22.5) 20.8 (13–27.4) -0.6 (-14.9–9.7) 0.955 
Eotaxin 20.9 (17.6–21.8) 14.2 (10.5–19.3) -4.8 (-20.8–5.0) 0.145 
G-CSF 2638.8 (2361.9–3843.8) 1605.1 (640.7–4377.7) -388.9 (-3203.1–2748.5) 0.864 
GM-CSF 32.1 (13.7–44) 30.2 (19.2–86.4) 12.6 (-27.9–1868.6) 0.607 
IFN-α2 40.5 (36–50) 39 (34.5–67.7) -1.0 (-33.5–38.4) 0.864 
IFN-γ 11.6 (8.2–12) 9 (5.3–28.8) 0.6 (-9.6–120.4) 1.000 
IL-10 17.5 (10.3–23.7) 7.2 (5.4–12.3) -7.1 (-39.9–178.9) 0.181 
IL-12p40 33.3 (28.7–36.8) 28.7 (20.2–48) -3.7 (-28.6–35.0) 0.607 
IL-12p70 16.2 (14.1–25.7) 15.9 (13–20.8) -0.3 (-13.3–18.6) 0.955 
IL-13 5.9 (3.6–8.1) 4 (3.8–4.4) -1.2 (-7.1–3.6) 0.456 
IL-15 5.9 (5.5–7.6) 7.6 (5–9.7) 0.5 (-4.1–5.4) 0.864 
IL-17A 4.1 (3.3–4.5) 4 (2.8–6.4) 0.5 (-2.3–31.7) 0.776 
IL-1RA 79.6 (68.8–156.2) 84.9 (38.5–115.2) -27.6 (-583.6–93.0) 0.776 
IL-1α 10.8 (8.2–20.2) 13.7 (12.4–35.6) 5.2 (-13.9–35.4) 0.388 
IL-1β 22.7 (11.9–74.7) 15.5 (9.7–35.7) -5.2 (-107.2–31.0) 0.456 
IL-2 6.6 (5.7–7.1) 5.8 (5.4–7) -0.2 (-4.0–8.7) 0.776 
IL-3 0.32 (0.3–0.3) 0.04 (0–1.5) -0.3 (-0.3–1.2) 0.328 
IL-4 22.2 (17.2–27.4) 14.9 (13.4–20.7) -6.4 (-19.4–4.5) 0.066 
IL-5 2.8 (1.9–5.5) 1.9 (1.7–2.4) -0.8 (-4.2–0.6) 0.066 
IL-6 580.6 (496.9–1689.3) 427 (161.7–1314.6) -153.7 (-1591.0–6498.5) 0.776 
IL-7 21.1 (16.5–22) 17.8 (14–21.5) -3.0 (-15.2–6.7) 0.456 
IL-8 6442.8 (5055.5–13929.7) 4415.4 (1344–8885.9) -3420.9 (-12587.9–5579.4) 0.272 
IP-10 23.9 (21.4–27.7) 29 (19.1–106.3) 5.0 (-13.5–498.9) 0.607 
MCP-1 1642.1 (650.4–2045.4) 741.4 (535.4–1250) -646.4 (-3452.8–716.3) 0.272 
MIP-1α 58.2 (25.5–80.5) 31.4 (3.6–40.3) -22.9 (-79.1–103.7) 0.456 
MIP-1β 22.5 (21.2–38.2) 17.9 (14.5–31.9) -4.6 (-23.7–48.6) 0.607 
RANTES 49 (38.1–60.3) 84.9 (45.3–101) 26.0 (-29.0–100.6) 0.224 
TNF-α 20.2 (13.9–35.6) 12.6 (11–16.5) -6.1 (-32.3–21.8) 0.145 
TNF-β 3.8 (2.7–5.4) 3.4 (2.5–4.4) -0.2 (-2.9–2.6) 0.689 





Table 47 Control spots. Median (IQR) pixel intensities of the negative and positive control spots. 
 
Fistula Tract Granulation Tissue Internal Opening Rectal Mucosa 
Negative control spots 19 (12.8–28.1) 19 (10.4–30.3) 16.2 (9.9–28.9) 17.4 (11.4–30.1) 




Table 48 Fistula tract median phosphoprotein pixel intensities. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested 
using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median pixel intensity (IQR), %  
Median difference  
(99% CI), % p Idiopathic Crohn’s disease All 
EGFR/ErbB1 26.7 (15.6–42.3) 41.1 (27.4–48.5) 28.6 (16.2–45.1) 12.1 (-4.4–28.8) 0.057 
HER2/ErbB2 18.1 (9–28.1) 26.6 (15–41.7) 19.3 (12.2–33.2) 7.0 (-8.1–24.1) 0.216 
HER3/ErbB3 37.4 (19.1–48.6) 49.4 (34.5–59.9) 39.1 (22.6–51.4) 15.1 (-1.4–33.9) 0.021 
FGFR1 24.1 (13.2–37.3) 29.7 (21.7–41.6) 25.5 (14.9–37.3) 5.6 (-8.4–19.4) 0.266 
FGFR3 21.8 (14.4–35.1) 22.6 (21.5–33.2) 22.4 (15.8–33.7) 3.5 (-9.2–14.5) 0.291 
FGFR4 27.4 (17.3–47.9) 30.1 (21.2–48.7) 28.1 (17.4–47.9) 4.2 (-13.4–22.2) 0.466 
InsR 10.4 (4.2–19.4) 16.3 (10.1–20.7) 11.9 (6.4–19.4) 4.8 (-4.2–12.8) 0.144 
IGF-IR 7.3 (2.5–17.3) 10.5 (4.1–17.6) 7.4 (3–17.3) 2.8 (-5.0–10.7) 0.332 
TrkA/NTRK1 8.2 (0.9–16.8) 6.7 (1.9–18.7) 7.8 (1.7–17.7) 0.4 (-7.7–9.5) 0.855 
TrkB/NTRK2 10 (3–21.8) 6.5 (4.8–23.8) 9.6 (3.2–23.2) -0.2 (-9.2–7.5) 0.878 
Met/HGFR 1.4 (0–5.8) 1.3 (0–3.8) 1.4 (0–5.6) 0.0 (-3.2–2.6) 0.564 
Ron/MST1R 4.3 (0.2–11) 2.3 (0.7–7.3) 3.8 (0.2–11) -0.1 (-6.4–4.3) 0.802 
Ret 1.6 (0–6) 0.1 (0–1.1) 1.1 (0–5.5) -0.8 (-4.6–0.1) 0.104 
ALK 1 (0–6.1) 0.1 (0–3.1) 0.5 (0–5.3) 0.0 (-4.2–0.1) 0.392 
PDGFR 5.3 (0.3–12.9) 2.4 (0.1–15.7) 4.5 (0.1–13.4) 0.0 (-6.4–6.6) 0.855 
c-Kit/SCFR 10.7 (3.8–19.2) 15.1 (8.1–23.8) 11.1 (4.7–20.9) 4.9 (-4.4–14.9) 0.111 
FLT3/Flk2 3.8 (0.4–8.7) 4 (1.7–6.9) 3.8 (0.7–7.1) 0.2 (-5.0–4.4) 0.795 
M-CSFR/CSF-1R 6.4 (0.9–13.4) 5.8 (1.2–12.8) 5.9 (1.1–13.4) 0.1 (-7.1–6.3) 0.833 
EphA1 1.5 (0–11.8) 1.2 (0.4–8) 1.3 (0–10.9) 0.0 (-6.2–2.2) 0.992 
EphA2 3.3 (0.4–15.6) 4.1 (1.6–12.9) 3.5 (0.4–15.6) 0.0 (-8.4–5.7) 0.810 
EphA3 3.8 (0.4–12.4) 3.1 (0.5–11.5) 3.4 (0.4–12.4) 0.0 (-6.7–4.9) 0.962 
EphB1 2.8 (0.1–8.9) 1.2 (0.1–7.1) 2.2 (0.1–8.7) -0.1 (-6.2–4.2) 0.700 
EphB3 0.2 (0–3.7) 0 (0–1.5) 0.1 (0–2.8) 0.0 (-1.9–0.2) 0.303 
EphB4 2.3 (0–8.2) 2.5 (0–11.5) 2.3 (0–9) 0.0 (-3.2–6.7) 0.582 
Tyro3/Dtk 0 (0–3.3) 0.1 (0–3) 0.015 (0–3.2) 0.0 (-1.1–2.1) 0.647 
Axl 0.3 (0–4.3) 1.4 (0–3.9) 0.4 (0–4.1) 0.0 (-1.2–2.6) 0.843 
Tie2/TEK 9.2 (3.8–17.8) 13.1 (7.1–28.1) 9.6 (4.2–21.6) 5.0 (-4.7–16.9) 0.144 
VEGFR2/KDR 0.7 (0–7.3) 0.9 (0–6.7) 0.7 (0–7.3) 0.0 (-3.8–4.4) 0.852 
Akt/PKB/Rac @Thr308 9.2 (1.2–18.3) 12.8 (0.1–28.9) 9.2 (0.5–22.9) 0.1 (-11.4–22.0) 0.863 
Akt/PKB/Rac @Ser473 0.6 (0–6.2) 1.2 (0–10.4) 0.8 (0–9.1) 0.0 (-2.1–8.3) 0.832 
p44/42 MAPK (ERK1/2) 4.6 (0.5–21.6) 3.6 (0–11.5) 4.6 (0.3–21.3) -0.7 (-15.4–4.9) 0.386 
S6 Ribosomal Protein 1.3 (0–9.6) 0.2 (0–11.5) 1 (0–9.6) 0.0 (-4.5–4.6) 0.742 
c-Abl 0.2 (0–8) 0 (0–6.8) 0.2 (0–8) 0.0 (-4.0–1.8) 0.428 
IRS-1 13.1 (3.5–29.9) 13.3 (3.1–43.7) 13.1 (3.5–30.8) 0.8 (-12.3–26.7) 0.722 
Zap-70 9.1 (1.1–15.4) 9.1 (0.1–20.6) 9.1 (1.1–15.7) 0.1 (-8.8–12.1) 0.773 
Src 17.4 (5.2–24.8) 13.9 (2.2–29.5) 16.6 (4.6–24.8) 0.1 (-12.5–14.3) 0.946 
Lck 4.7 (0.1–13.5) 4.2 (0–20.2) 4.7 (0.1–13.5) 0.0 (-5.9–12.9) 0.893 
Stat1 16.6 (7.8–36.9) 37 (12.3–51.6) 19.7 (7.8–37.4) 13.1 (-8.5–32.6) 0.134 




Table 49 Granulation tissue median phosphoprotein pixel intensities. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses 
tested using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median pixel intensity (IQR), %  
Median difference  
(99% CI), % p Idiopathic Crohn’s disease All 
EGFR/ErbB1 26 (18.2–38.6) 37.3 (23.6–46.9) 28 (18.2–42.2) 7.0 (-9.0–22.8) 0.283 
HER2/ErbB2 17.1 (14.3–29.6) 24.2 (12.2–31.4) 17.6 (14–30.7) 1.8 (-9.5–14.8) 0.650 
HER3/ErbB3 37.5 (24–49.3) 41 (30.8–63) 38.9 (25.3–51.2) 7.7 (-10.8–25.4) 0.248 
FGFR1 23.1 (12.6–34.3) 22.5 (17.2–35.8) 22.8 (14.3–35) 1.7 (-13.9–13.9) 0.810 
FGFR3 33.8 (15.8–45.2) 26.6 (18.1–52.8) 32.4 (16.6–46.3) 4.8 (-16.5–25.1) 0.437 
FGFR4 23 (16.3–46.3) 28.6 (20.3–38.5) 23.6 (17.5–45.7) 4.3 (-12.9–17.7) 0.334 
InsR 9.3 (5.8–15.8) 19.4 (10.1–23.3) 11.7 (6.6–19.8) 5.3 (-3.9–13.7) 0.099 
IGF-IR 7 (3.1–16.2) 13.1 (4.3–18.3) 10.7 (3.3–17.2) 3.5 (-5.5–13.0) 0.248 
TrkA/NTRK1 5.6 (1.5–18.3) 10.4 (6.3–11.7) 8.5 (1.8–17.1) 1.6 (-10.0–8.9) 0.769 
TrkB/NTRK2 6.9 (1.4–19) 7.2 (1.7–13.4) 7 (1.5–17.2) -0.5 (-11.8–7.0) 0.852 
Met/HGFR 0.8 (0–5.4) 2.2 (0–4.6) 1.3 (0–4.8) 0.0 (-3.0–3.8) 0.769 
Ron/MST1R 2.9 (0.1–11.3) 8.2 (0–13.7) 4 (0.1–11.9) 1.6 (-4.4–8.6) 0.538 
Ret 1 (0–6.8) 2.9 (0–6.2) 2.2 (0–6.5) 0.2 (-3.1–4.0) 0.689 
ALK 0.1 (0–4.8) 0.2 (0–0.9) 0.2 (0–3.7) 0.0 (-3.2–0.6) 0.831 
PDGFR 1.7 (0.4–12.7) 6.2 (2–10.4) 4.3 (0.4–11.3) 1.1 (-6.2–6.2) 0.574 
c-Kit/SCFR 8.9 (5.1–20.7) 14.8 (9.5–21.7) 10.1 (5.8–20.9) 4.1 (-7.5–13.7) 0.216 
FLT3/Flk2 3.3 (0.2–10.3) 6.3 (1.9–12.2) 3.5 (0.2–10.9) 1.5 (-4.6–6.4) 0.487 
M-CSFR/CSF-1R 5 (0.7–14.4) 7.8 (0.2–14.7) 6.4 (0.6–14.6) 0.2 (-7.4–8.6) 0.689 
EphA1 2 (0.1–11.8) 5.1 (0–6.8) 2.1 (0.1–10.9) -0.1 (-7.9–5.1) 0.574 
EphA2 4 (1–13.5) 4 (0.7–9) 4 (0.9–13.3) -0.3 (-11.3–4.5) 0.630 
EphA3 3.5 (0.4–9.9) 6 (0.4–9) 4.3 (0.4–9.4) 0.0 (-7.1–6.0) 0.979 
EphB1 4.2 (0.2–9.4) 3.6 (0.4–10.4) 3.9 (0.3–9.9) 0.0 (-6.3–6.2) 0.915 
EphB3 0.2 (0–4.6) 0.6 (0–5.5) 0.2 (0–5) 0.0 (-1.6–2.5) 0.979 
EphB4 1.5 (0–10.6) 0 (0–3.9) 0.9 (0–8.4) -0.9 (-10.0–0.1) 0.138 
Tyro3/Dtk 0.7 (0–3.6) 0 (0–2.5) 0.3 (0–3.1) 0.0 (-2.5–1.4) 0.391 
Axl 0.9 (0–4.8) 0 (0–3.4) 0.8 (0–4.2) 0.0 (-3.8–2.0) 0.422 
Tie2/TEK 13.5 (3–22.3) 10.6 (3.9–14.6) 12.4 (3.5–20.6) -2.1 (-14.1–8.2) 0.538 
VEGFR2/KDR 3.6 (0–9.5) 2.1 (0–7.1) 3.6 (0–7.4) -0.1 (-6.3–3.5) 0.437 
Akt/PKB/Rac @Thr308 8.4 (0.5–19.8) 5.8 (0.1–16.3) 8.3 (0.1–19.3) -1.6 (-14.0–9.4) 0.630 
Akt/PKB/Rac @Ser473 0.7 (0–8.7) 0 (0–4.5) 0.5 (0–8.1) 0.0 (-6.9–0.6) 0.283 
p44/42 MAPK (ERK1/2) 0.4 (0–9.7) 0 (0–3.9) 0.3 (0–8.9) 0.0 (-7.5–2.1) 0.334 
S6 Ribosomal Protein 2.6 (0.1–8.3) 0.2 (0–6.7) 2.5 (0–8) -0.1 (-7.2–2.6) 0.348 
c-Abl 0.9 (0–7.4) 0.1 (0–4.9) 0.8 (0–7.4) -0.2 (-7.2–2.9) 0.308 
IRS-1 20.9 (4–28) 16.4 (5.8–22.4) 18.3 (4.7–27.1) -3.9 (-18.4–11.3) 0.391 
Zap-70 13 (1.5–19.2) 7 (0–14.2) 10.2 (1.1–17) -2.6 (-13.9–6.6) 0.295 
Src 18.2 (4.9–27.2) 10.1 (0–20.2) 17.6 (3.1–23.4) -3.8 (-16.9–7.8) 0.283 
Lck 9.3 (0.7–15.3) 4.5 (0–15.3) 6.4 (0.5–15.3) -0.7 (-11.6–5.9) 0.574 
Stat1 27.8 (6.1–37.2) 40.6 (16.3–63.5) 28.6 (10.2–40.5) 12.5 (-10.4–41.5) 0.153 




Table 50 Internal opening median phosphoprotein pixel intensities. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses 
tested using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median pixel intensity (IQR), %  
Median difference  
(99% CI), % p Idiopathic Crohn’s disease All 
EGFR/ErbB1 35 (22.1–50.8) 43.8 (27–46.5) 37.1 (22.5–49.8) 4.7 (-13.8–22.0) 0.584 
HER2/ErbB2 23.4 (12.7–37.3) 22.4 (19.3–33.1) 23.3 (13.7–34.6) -0.1 (-13.4–13.4) 0.984 
HER3/ErbB3 50.7 (32–64.5) 47.2 (38.1–56.5) 47.8 (32.8–61.7) -0.7 (-17.2–21.6) 0.876 
FGFR1 28.6 (19.7–43.8) 36.3 (15.3–44.7) 31.5 (18.3–43.8) 1.5 (-15.5–20.1) 0.830 
FGFR3 43.5 (22.7–64.6) 36.3 (23.9–59.3) 41 (23.4–60) -1.0 (-23.9–20.1) 0.860 
FGFR4 33.2 (18.6–53) 33.2 (22.5–41.5) 33.2 (20.9–51) 0.0 (-18.2–17.5) 1.000 
InsR 17.8 (8.4–31.8) 20.2 (11.9–25.4) 18.3 (10.3–27.6) 0.4 (-13.6–12.2) 0.876 
IGF-IR 13.6 (5.3–27.7) 16.1 (10.3–20.7) 14 (7.8–26.8) 0.5 (-13.6–11.2) 0.891 
TrkA/NTRK1 12.6 (4.3–25.6) 12.2 (3.2–16.7) 12.2 (4.3–23.2) -2.5 (-15.2–9.1) 0.544 
TrkB/NTRK2 12.7 (3.7–26.7) 9.1 (4.1–17.7) 12.1 (3.7–24.2) -2.7 (-15.4–6.7) 0.481 
Met/HGFR 0.8 (0–7) 0 (0–5.9) 0.6 (0–7) 0.0 (-4.8–0.7) 0.347 
Ron/MST1R 5.7 (0.4–17.2) 3.7 (0.4–10.2) 5.1 (0.4–16.1) -1.0 (-11.8–4.2) 0.563 
Ret 1.5 (0–10.1) 0.4 (0–6.7) 0.8 (0–9.4) 0.0 (-7.8–0.8) 0.545 
ALK 0.1 (0–3.4) 0 (0–4.8) 0.1 (0–3.4) 0.0 (-2.2–0.4) 0.425 
PDGFR 4.5 (0–14.9) 1.2 (0–8.5) 3.3 (0–12.6) -0.8 (-9.4–2.5) 0.352 
c-Kit/SCFR 14 (4.4–27.1) 9.3 (6.2–18.5) 12.7 (5.3–26.6) -1.6 (-17.2–7.7) 0.799 
FLT3/Flk2 4.8 (0.4–16.4) 2.2 (0–9.7) 3.9 (0.2–15.8) -1.6 (-12.9–2.2) 0.188 
M-CSFR/CSF-1R 11.3 (2.7–20.8) 6.7 (2.5–12.1) 8.3 (2.7–19.4) -2.7 (-14.7–4.9) 0.434 
EphA1 3.3 (0.1–11.9) 0.3 (0–3.8) 1.4 (0.1–10.1) -1.0 (-9.4–0.2) 0.120 
EphA2 5 (0.4–16.1) 0.8 (0.2–7.3) 4 (0.4–15.5) -2.7 (-15.1–0.7) 0.139 
EphA3 11.1 (0.8–18.9) 3 (0–7.9) 7.7 (0.4–15.9) -5.8 (-14.9–0.2) 0.031 
EphB1 3.2 (0.2–15.1) 1.1 (0–5.1) 2 (0.1–12.7) -1.1 (-12.1–0.8) 0.163 
EphB3 0.1 (0–8.4) 0 (0–1.3) 0.01 (0–5.7) 0.0 (-4.0–0.0) 0.113 
EphB4 6.9 (0.4–15.9) 0.1 (0–1.9) 3.8 (0–14.4) -4.9 (-15.1–0.0) 0.018 
Tyro3/Dtk 0.9 (0–6.6) 0 (0–0.8) 0.1 (0–5.2) -0.7 (-6.3–0.0) 0.082 
Axl 1.3 (0–8.1) 0 (0–2.2) 0.8 (0–5.9) -0.5 (-5.9–0.0) 0.054 
Tie2/TEK 22.8 (13.9–32) 17.1 (9.4–23.1) 20.6 (13.4–28) -6.2 (-19.4–4.0) 0.108 
VEGFR2/KDR 8.2 (0–16.5) 0.9 (0–3.9) 5.2 (0–14.7) -6.1 (-14.9–0.4) 0.059 
Akt/PKB/Rac @Thr308 37.4 (14.6–48.2) 11.9 (1.6–37.8) 31.9 (10.7–44.1) -14.5 (-36.5–4.7) 0.088 
Akt/PKB/Rac @Ser473 4.2 (0.1–16.1) 0 (0–9.1) 3.1 (0–12.7) -1.4 (-11.4–0.0) 0.044 
p44/42 MAPK (ERK1/2) 12.2 (5–31.1) 3.9 (0.1–21.3) 10.1 (3.8–31.1) -5.0 (-22.4–4.3) 0.108 
S6 Ribosomal Protein 14.5 (2.3–33) 1 (0–6.7) 11.8 (0.6–29.6) -11.4 (-29.6–0.0) 0.014 
c-Abl 5.6 (0–18.8) 0 (0–4.7) 3.7 (0–18) -3.1 (-17.3–0.0) 0.028 
IRS-1 26.1 (10.3–43.6) 7.3 (1–29) 23.3 (7.9–41.2) -13.3 (-33.2–2.2) 0.055 
Zap-70 11.5 (1.7–22.9) 0.1 (0–17.1) 10.3 (0.2–21.4) -8.4 (-19.5–0.0) 0.026 
Src 35.1 (19.6–44.9) 7.5 (0.4–25.7) 31.4 (5.9–43.4) -19.2 (-36.3–1.3) 0.031 
Lck 10.9 (2.1–27.6) 0.8 (0–13.6) 10.4 (0.1–19.5) -6.7 (-16.8–0.9) 0.062 
Stat1 49.3 (28.3–64.5) 33.9 (22.2–44.6) 43.7 (22.6–58.6) -11.3 (-32.7–14.1) 0.225 




Table 51 Rectal mucosa median phosphoprotein pixel intensities. Median difference and 99% confidence intervals estimated using Hodges-Lehman method; hypotheses tested 
using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median pixel intensity (IQR), %  
Median difference  
(99% CI), % p Idiopathic Crohn’s disease All 
EGFR/ErbB1 48.2 (21.3–62.4) 45.4 (33.1–59.6) 48.2 (24.3–62.4) 1.6 (-18.2–25.4) 0.821 
HER2/ErbB2 37.3 (22.7–61.3) 36.3 (27.7–56.2) 37.3 (24.3–60.3) 1.4 (-20.7–24.2) 0.792 
HER3/ErbB3 63.2 (40.1–80.5) 75 (61.5–78.1) 64.9 (42.1–79) 9.7 (-10.2–32.5) 0.300 
FGFR1 40.9 (28.3–58.7) 43.7 (32.6–55.5) 41.5 (28.4–58.7) 3.1 (-15.7–20.8) 0.638 
FGFR3 60.1 (35.4–70.9) 68.4 (51.1–73.1) 60.2 (40.6–70.9) 8.4 (-10.6–30.9) 0.187 
FGFR4 42.7 (23.7–67.9) 46.4 (36.8–55.7) 44.8 (27.1–67.1) 4.8 (-19.8–24.7) 0.611 
InsR 35.9 (18.2–50.4) 42.6 (35–48.4) 38.6 (18.8–50) 7.8 (-10.5–27.8) 0.283 
IGF-IR 29 (14.6–44.6) 42.1 (32.5–49.6) 31.7 (16.1–47.7) 12.3 (-5.0–30.3) 0.077 
TrkA/NTRK1 22.6 (13–40.8) 28.9 (21.3–41.1) 27.2 (13.6–40.8) 4.2 (-13.1–19.8) 0.498 
TrkB/NTRK2 17 (7.7–38.6) 17.9 (8.5–25.9) 17.1 (7.7–34.4) 0.0 (-17.9–12.8) 1.000 
Met/HGFR 7.7 (0–22.7) 8.2 (0.1–16.4) 7.7 (0–22.5) 0.0 (-11.4–10.6) 0.902 
Ron/MST1R 15.2 (4.4–32.3) 21.7 (7.7–32) 16.6 (4.6–32.1) 3.1 (-11.7–18.9) 0.572 
Ret 0.5 (0–8.1) 1.9 (0–15.3) 0.5 (0–9.3) 0.0 (-1.5–11.1) 0.531 
ALK 0.5 (0–8.4) 0.1 (0–2.6) 0.3 (0–7.1) 0.0 (-5.5–0.2) 0.464 
PDGFR 5.5 (0–21.5) 6.8 (2.8–14.2) 5.5 (0–20.2) 0.0 (-10.9–7.6) 1.000 
c-Kit/SCFR 30.6 (18.2–43.1) 33.8 (20.8–40.5) 30.6 (18.2–42.9) 3.1 (-12.9–18.4) 0.658 
FLT3/Flk2 6.9 (0.3–15.5) 4.8 (0.7–16.9) 5.7 (0.3–16.8) 0.0 (-8.0–8.3) 0.917 
M-CSFR/CSF-1R 20.6 (5.3–29.4) 15.9 (9.3–38.1) 19.5 (6.3–29.7) 2.3 (-14.0–16.0) 0.735 
EphA1 13.7 (0.3–27.1) 10.3 (0–19.5) 12.8 (0.3–26.4) -1.4 (-17.2–8.6) 0.258 
EphA2 10 (0.2–28.9) 7.6 (0–19.8) 7.8 (0.1–24.3) -0.9 (-16.9–7.7) 0.376 
EphA3 10.3 (0.4–28.9) 9.6 (0.4–21) 10.2 (0.4–28.5) -1.0 (-17.3–9.1) 0.558 
EphB1 7.9 (0.6–23.6) 5.9 (0–24.7) 7.1 (0.4–23.6) 0.0 (-11.7–12.4) 0.748 
EphB3 0.1 (0–6.2) 0 (0–16.1) 0.1 (0–6.8) 0.0 (-1.5–10.6) 0.937 
EphB4 23.2 (6.2–41.3) 17.1 (0.2–31.4) 21.8 (5.5–36.6) -4.3 (-23.4–14.5) 0.451 
Tyro3/Dtk 9.4 (0.2–19.8) 3.7 (0–15.5) 8.9 (0.1–17.7) -0.4 (-14.2–6.9) 0.422 
Axl 10.9 (0.6–18.6) 6.1 (0–18.1) 9.5 (0.6–18.6) -0.6 (-12.5–9.0) 0.497 
Tie2/TEK 41.6 (24.9–57.9) 38.4 (13–54.4) 41.6 (23.1–57.9) -6.0 (-29.3–17.0) 0.492 
VEGFR2/KDR 14.1 (6.5–28.4) 15.5 (0.3–33.6) 14.1 (6.3–28.6) -0.1 (-14.1–18.9) 0.828 
Akt/PKB/Rac @Thr308 41.4 (22.8–58) 34.1 (7.8–53.5) 39.2 (22.3–57.1) -5.6 (-30.6–18.2) 0.498 
Akt/PKB/Rac @Ser473 11.5 (0.6–23.3) 7.2 (0–14.9) 8.5 (0.1–22.9) -1.0 (-15.9–7.6) 0.363 
p44/42 MAPK (ERK1/2) 23.9 (8.7–39.9) 10.7 (0–54.8) 19.8 (6.5–42.6) -5.9 (-26.7–23.0) 0.309 
S6 Ribosomal Protein 24.9 (10–50.5) 23.1 (9–57.7) 24.9 (10–52.9) 0.0 (-22.0–29.0) 1.000 
c-Abl 9.5 (1.4–21.4) 5.3 (0–23.5) 9 (0.4–21.4) -0.2 (-14.0–9.8) 0.591 
IRS-1 40.9 (24.5–62.6) 25 (9.1–41.3) 35.6 (16.7–61.9) -10.7 (-35.5–16.1) 0.207 
Zap-70 18.7 (3.5–28.1) 6.8 (0.9–18.7) 12.2 (1.7–26.4) -3.9 (-19.6–7.3) 0.336 
Src 35.7 (15.9–49.6) 23.3 (5.7–38.8) 33.1 (11.1–47.6) -8.0 (-30.6–14.0) 0.258 
Lck 14.4 (0.8–24.2) 5.6 (0.6–17.6) 13.3 (0.8–24.1) -1.7 (-15.7–9.4) 0.502 
Stat1 40.8 (22.8–57) 35.8 (18.7–49.9) 39.7 (20–56.8) -3.1 (-24.1–22.8) 0.742 




Table 52 Comparison with healthy controls. Rectal mucosa median phosphoprotein pixel intensities. Median difference and 99% confidence intervals estimated using Hodges-
Lehman method; hypotheses tested using Mann-Whitney U (significance level 0.01). IQR, interquartile range; CI, confidence interval. 
 
 
Median pixel intensity (IQR), %  
Median difference  
(99% CI), % p Healthy Controls Crohn’s disease All 
EGFR/ErbB1 30.5 (27.3–40.6) 45.4 (33.1–59.6) 39.8 (28.3–48.4) 13.3 (-15.2–44.4) 0.213 
HER2/ErbB2 59.2 (55.7–64.5) 36.3 (27.7–56.2) 51.9 (33.2–60.8) -19.2 (-40.0–15.3) 0.125 
HER3/ErbB3 81 (79.3–84.4) 75 (61.5–78.1) 77.2 (62.9–81.4) -6.3 (-29.8–16.6) 0.180 
FGFR1 56.8 (47.6–60.7) 43.7 (32.6–55.5) 48.3 (32.6–60.7) -10.0 (-33.5–18.9) 0.291 
FGFR3 71 (59–76.4) 68.4 (51.1–73.1) 69 (52.5–75.5) -3.4 (-27.5–27.1) 0.682 
FGFR4 51.6 (46.6–58.9) 46.4 (36.8–55.7) 49.3 (37.7–56.7) -4.5 (-26.4–27.1) 0.616 
InsR 67.7 (65.5–76.4) 42.6 (35–48.4) 47.1 (38.4–67.6) -26.3 (-45.0–8.1) 0.032 
IGF-IR 58 (48.5–61.9) 42.1 (32.5–49.6) 47.7 (34.7–59.4) -13.8 (-39.9–19.5) 0.180 
TrkA/NTRK1 62.6 (54.4–69.2) 28.9 (21.3–41.1) 35.2 (23–60.1) -31.3 (-48.0–8.2) 0.013 
TrkB/NTRK2 41.2 (34.1–52.6) 17.9 (8.5–25.9) 22.1 (15.8–38) -22.0 (-40.4–5.2) 0.018 
Met/HGFR 16.7 (14.6–23.1) 8.2 (0.1–16.4) 12.6 (1.7–20.2) -8.3 (-22.9–7.4) 0.125 
Ron/MST1R 34.2 (30.2–39.2) 21.7 (7.7–32) 29.1 (11.4–36.6) -10.5 (-31.7–16.4) 0.102 
Ret 9.7 (8.9–13.6) 1.9 (0–15.3) 8.3 (0–14.4) -5.1 (-13.6–12.2) 0.250 
ALK 3.3 (2.3–4) 0.1 (0–2.6) 1.3 (0–3.4) -2.3 (-4.0–1.1) 0.041 
PDGFR 17.5 (14.9–19.3) 6.8 (2.8–14.2) 10.5 (4.8–18.8) -9.3 (-17.1–6.3) 0.083 
c-Kit/SCFR 55.5 (51.4–61.4) 33.8 (20.8–40.5) 37.3 (29.1–54.5) -20.7 (-40.7–8.2) 0.032 
FLT3/Flk2 12.8 (9–14.8) 4.8 (0.7–16.9) 10 (2.7–16.8) -6.3 (-13.9–8.8) 0.385 
M-CSFR/CSF-1R 39.1 (27.9–41.9) 15.9 (9.3–38.1) 23.9 (11.9–41) -17.5 (-35.0–20.1) 0.102 
EphA1 42.2 (38.9–48.9) 10.3 (0–19.5) 17.4 (8.6–38.9) -30.3 (-48.9–-8.6) 0.001 
EphA2 27.1 (26.9–29.9) 7.6 (0–19.8) 14.5 (7.4–27) -19.2 (-28.5–-0.2) 0.007 
EphA3 32.7 (29.8–33.8) 9.6 (0.4–21) 17.6 (7–32.4) -20.1 (-33.7–1.3) 0.010 
EphB1 46.9 (36.2–50.7) 5.9 (0–24.7) 24.7 (3–46) -34.7 (-50.7–-8.1) <0.001 
EphB3 22.7 (14.5–32.8) 0 (0–16.1) 13.9 (0–21) -16.6 (-32.8–2.5) 0.018 
EphB4 68.3 (57.6–73.9) 17.1 (0.2–31.4) 29.2 (15.4–60.6) -46.1 (-69.6–-9.0) 0.001 
Tyro3/Dtk 35.8 (33.1–38.4) 3.7 (0–15.5) 15.5 (0.2–34.1) -29.2 (-38.4–-2.3) 0.002 
Axl 36.1 (28–39.1) 6.1 (0–18.1) 16.8 (1.5–36.6) -26.5 (-39.1–4.1) 0.018 
Tie2/TEK 70.6 (50.6–73.8) 38.4 (13–54.4) 50.6 (21.5–73.6) -26.4 (-67.2–7.5) 0.053 
VEGFR2/KDR 81.1 (57.7–84.4) 15.5 (0.3–33.6) 33.6 (6.3–75.5) -56.3 (-82.2–-11.5) <0.001 
Akt/PKB/Rac @Thr308 31.1 (28.7–38.2) 34.1 (7.8–53.5) 31.1 (13.7–44.1) 1.4 (-31.0–38.8) 1.000 
Akt/PKB/Rac @Ser473 32.5 (30.4–33.5) 7.2 (0–14.9) 13.1 (0.2–32.8) -24.7 (-33.5–20.6) 0.032 
p44/42 MAPK (ERK1/2) 24.3 (18.5–30.9) 10.7 (0–54.8) 19.1 (0.2–32.7) -13.6 (-30.9–45.4) 0.494 
S6 Ribosomal Protein 62.6 (29.1–67.6) 23.1 (9–57.7) 35.9 (12.2–67.4) -20.9 (-60.9–27.1) 0.180 
c-Abl 30.8 (19.7–33.8) 5.3 (0–23.5) 18.3 (2.7–32.4) -19.2 (-33.8–22.0) 0.067 
IRS-1 73.7 (70.5–81.6) 25 (9.1–41.3) 41.3 (17.3–75) -48.2 (-73.0–9.5) 0.018 
Zap-70 28.1 (24.9–28.8) 6.8 (0.9–18.7) 13.6 (2.8–28.2) -18.1 (-28.2–28.2) 0.041 
Src 29.4 (27.9–33) 23.3 (5.7–38.8) 29.1 (13–34.3) -8.6 (-30.0–46.2) 0.616 
Lck 27.2 (20–29) 5.6 (0.6–17.6) 16.4 (2.2–27.5) -18.2 (-29.0–39.9) 0.041 
Stat1 50.9 (36.3–60.7) 35.8 (18.7–49.9) 41.9 (31.1–53.3) -15.1 (-43.4–30.6) 0.180 
Stat3 40.3 (39.4–42.3) 53.6 (36.1–68.3) 49.1 (39.4–59.7) 13.5 (-31.8–46.4) 0.102 
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Table 53 DCE-MRI measurements by fistula disease duration. Hypotheses tested using T test (significance 
level 0.05). SD, standard deviation; CI, confidence interval; TIC, time-intensity curve. NB these 
measurements have no units. 
 
< 12 months ≥ 12 months Mean diff (95% CI) p 
Mean max enhancement (SD) 762 (292) 641 (507) 121 (-234–475) 0.486 
Mean max relative enhancement (SD) 0.964 (.4121) 0.797 (.4932) 0.167 (-0.226–0.560) 0.387 
Mean wash in rate (SD) 80.8 (26.2) 67.9 (59.6) 12.9 (-26.5–52.2) 0.503 
Mean wash out rate (SD) 6.0 (6.8) 36.2 (42.6) -30.2 (-399.5–339.2) 0.499 
Mean area under TIC (SD) 13961 (6331) 10511 (12607) 3451 (-5085–11987) 0.410 
 
Table 54 DCE-MRI measurements by treatment outcome. Hypotheses tested using T test (significance level 
0.05). SD, standard deviation; CI, confidence interval; TIC, time-intensity curve. NB these measurements 
have no units. 
 
Satisfactory Unsatisfactory Mean diff (95% CI) p 
Mean max enhancement (SD) 649 (124) 870 (508) -221 (-571–129) 0.193 
Mean max relative enhancement (SD) 0.924 (.2020) 1.023 (.5473) -0.100 (-0.561–0.362) 0.653 
Mean wash in rate (SD) 69.3 (21.3) 92.5 (55.2) -23.3 (-70.0–23.5) 0.307 
Mean wash out rate (SD) 23.5 (29.3) 2.9 (4.5) 20.6 (-24.3–65.5) 0.292 




Table 55 DCE-MRI measurements by Parks’ classification. Hypotheses tested using T test (significance 
level 0.05). IS, inter-sphincteric; TS, trans-sphincteric; SS, supra-sphincteric; SD, standard deviation; CI, 
confidence interval; TIC, time-intensity curve. NB these measurements have no units. 
* n = 1 
 IS TS or SS Mean diff (95% CI) p 
Mean max enhancement (SD) 327 (87) 776 (390) 449 (36–863) 0.035 
Mean max relative enhancement (SD) 0.465 (0.164) 0.987 (0.437) 0.522 (0.056–0.988) 0.030 
Mean wash in rate (SD) 38.8 (12.6) 80.6 (44.9) 41.9 (-5.8–89.5) 0.082 
Mean wash out rate (SD) 0.2* 15.3 (21.4) 15.2 (-38.4–68.8) 0.524 
Mean area under TIC (SD) 3986 (3166) 13859 (9595) 9872 (-343–20087) 0.057 
 
Table 56 Clinical by time-intensity curve type: quick enhancement (type 3–5) versus slow enhancement 
(type 2). Data compared with Fisher’s Exact test. 
 Type 3–5 Type 2 p 
Parks’ classification:    
Inter-sphincteric 0 4  
Trans- or supra-sphincteric 3 17 1.000 
Fistula disease duration:    
< 12 months 1 11  
≥ 12 months 2 9 0.590 
Treatment outcome:    
Satisfactory 1 6  
Unsatisfactory 1 10 1.000 
 
